

Key Substance Use and Mental Health Indicators in the United States: Results from the 2025 National Survey on Drug Use and Health



SAMHSA
Substance Abuse and Mental Health
Services Administration

Key Substance Use and Mental Health Indicators in the United States: Results from the 2025 National Survey on Drug Use and Health

Key Substance Use and Mental Health Indicators in the United States: Results from the 2025 National Survey on Drug Use and Health was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) under contract number 75S20322C00001 with SAMHSA, U.S. Department of Health and Human Services (HHS). Elizabeth Crane served as Contracting Officer's Representative, and Carlos Graham served as Alternate Contracting Officer's Representative.

Recommended Citation

Substance Abuse and Mental Health Services Administration. (2026). *Key substance use and mental health indicators in the United States: Results from the 2025 National Survey on Drug Use and Health* (HHS Publication No. PEP26-07-010, NSDUH Series H-61). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/national-releases>

Originating Office

Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857.

Electronic Access

Products may be downloaded at <https://library.samhsa.gov/>.

Disclaimer

Nothing in this document constitutes a direct or indirect endorsement by SAMHSA or HHS of any nonfederal entity's products, services, or policies.

Public Domain Notice

This publication is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, HHS.

Substance Abuse and Mental Health Services Administration
Center for Behavioral Health Statistics and Quality

Publication Number PEP26-07-010, NSDUH Series H-61
Released 2026

Table of Contents

Introduction	1	Substance Use Disorders in the Past Year	24
Survey Background	1	Alcohol Use Disorder	27
Data Presentation and Interpretation.....	1	Drug Use Disorder	28
General Substance Use in the Past Month.....	2	Marijuana (Cannabis) Use Disorder	28
Nicotine Product Use in the Past Month	3	Central Nervous System Stimulant Use Disorder	29
Any Nicotine Product Use	4	Opioid Use Disorder	29
Tobacco Product Use	4	Substance Use Disorder Severity	30
Cigarette Use	5	Symptoms of Generalized Anxiety Disorder in the Past	
Daily Cigarette Use	5	2 Weeks	33
Nicotine Vaping	5	Symptoms of Anxiety among Adolescents.....	33
Underage Nicotine Product Use	6	Substance Use among Adolescents with Moderate or	
Alcohol Use in the Past Month	6	Severe Anxiety Symptoms.....	34
Any Alcohol Use	7	Symptoms of Anxiety among Adults	34
Binge Alcohol Use.....	7	Substance Use among Adults with Moderate or	
Heavy Alcohol Use	7	Severe Anxiety Symptoms.....	34
Underage Alcohol Use.....	8	Major Depressive Episode in the Past Year.....	35
Marijuana Use and Marijuana Vaping in the Past Month	9	MDE and MDE with Severe Impairment among Adolescents	35
Illicit Drug Use in the Past Year.....	10	Co-Occurring MDE and SUD among Adolescents	36
Any Illicit Drug Use	10	Substance Use among Adolescents with an MDE	37
Marijuana Use	11	MDE and MDE with Severe Impairment among Adults	37
Any Marijuana Use.....	11	Co-Occurring MDE and SUD among Adults	38
Modes of Marijuana Use.....	11	Substance Use among Adults with an MDE.....	39
Cocaine Use.....	12	Any or Serious Mental Illness among Adults in the Past Year...40	
Heroin Use	13	Any Mental Illness among Adults	40
Methamphetamine Use.....	13	Serious Mental Illness among Adults.....	41
Hallucinogen Use.....	13	Co-Occurring Mental Illness and SUD among Adults	41
Inhalant Use.....	14	Co-Occurring AMI and SUD	41
Misuse of Prescription Psychotherapeutic Drugs.....	14	Co-Occurring SMI and SUD	42
Prescription Stimulant Misuse	15	Substance Use among Adults, by Mental Illness Status	43
Prescription Tranquilizer or Sedative Misuse	15	Suicidal Thoughts and Behaviors among Adults	44
Prescription Opioid Misuse.....	16	Serious Thoughts of Suicide among Adults	45
Misuse of Subtypes of Prescription Opioids	16	Suicide Plans among Adults	45
Opioid Misuse	17	Suicide Attempts among Adults	46
Central Nervous System Stimulant Misuse	18	Suicidal Thoughts and Behaviors among Adolescents.....	46
Illegally Made Fentanyl Use	20	Serious Thoughts of Suicide among Adolescents	47
Initiation of Substance Use	20	Suicide Plans among Adolescents.....	48
Initiation of Alcohol Use.....	21	Suicide Attempts among Adolescents.....	48
Initiation of Nicotine Vaping	22	Nonsuicidal Self-Harm among Adolescents.....	48
Initiation of Marijuana Use.....	22	Substance Use Treatment in the Past Year	49
Initiation of Cigar Use.....	23	Need for Substance Use Treatment	49
Initiation of Cigarette Use	23	Receipt of Substance Use Treatment.....	50

Receipt of Substance Use Treatment among People Who Were Classified as Needing Substance Use Treatment in the Past Year.....	50	Receipt of Other Services among Adults to Help with Mental Health.....	60
Medications for Alcohol Use Disorder or Opioid Use Disorder.....	51	Any Receipt of Other Services for Mental Health among All Adults Aged 18 or Older.....	60
Receipt of Substance Use Treatment via Telehealth among People with a Substance Use Disorder.....	52	Any Receipt of Other Services for Mental Health among Adults with a Past Year MDE.....	60
Receipt of Other Services for Substance Use.....	52	Any Receipt of Other Services for Mental Health among Adults with AMI.....	60
Any Receipt of Other Services for Substance Use among All People Aged 12 or Older.....	52	Any Receipt of Other Services for Mental Health among Adults with SMI.....	60
Any Receipt of Other Services for Substance Use among People with a Substance Use Disorder.....	52	Receipt of Specific Other Services for Mental Health among Adults with a Past Year MDE.....	60
Receipt of Specific Other Services for Substance Use among People with a Substance Use Disorder.....	52	Receipt of Specific Other Services for Mental Health among Adults with AMI.....	61
No Receipt of Treatment or Other Services for Substance Use among People with a Substance Use Disorder.....	53	Receipt of Specific Other Services for Mental Health among Adults with SMI.....	61
Perceived Unmet Need for Substance Use Treatment.....	53	No Receipt of Treatment or Other Services for Mental Health among Adults with a Past Year MDE.....	61
Perceived Unmet Need for Substance Use Treatment among Adolescents.....	53	No Receipt of Treatment or Other Services for Mental Health among Adults with AMI.....	61
Perceived Unmet Need for Substance Use Treatment among Adults.....	54	No Receipt of Treatment or Other Services for Mental Health among Adults with SMI.....	61
Reasons for Not Receiving Substance Use Treatment.....	54	Perceived Unmet Need for Mental Health Treatment among Adults with Mental Health Conditions.....	62
Reasons for Not Receiving Substance Use Treatment among Adults Aged 18 or Older.....	54	Perceived Unmet Need for Mental Health Treatment among Adults with a Past Year MDE.....	62
Mental Health Treatment in the Past Year.....	55	Perceived Unmet Need for Mental Health Treatment among Adults with AMI.....	62
Mental Health Treatment among Adolescents.....	55	Perceived Unmet Need for Mental Health Treatment among Adults with SMI.....	63
Receipt of Mental Health Treatment among All Adolescents.....	55	Reasons for Not Receiving Mental Health Treatment among Adults with AMI and a Perceived Unmet Need.....	63
Receipt of Mental Health Treatment among Adolescents with an MDE.....	55	Receipt of Treatment for Co-Occurring Mental Health Conditions and Substance Use Disorder.....	63
Receipt of Other Services among Adolescents to Help with Mental Health.....	56	Receipt of Treatment among Adolescents with a Co-Occurring MDE and an SUD.....	64
Any Receipt of Other Services for Mental Health among All Adolescents Aged 12 to 17.....	56	Receipt of Treatment among Adults with Co-Occurring AMI and an SUD.....	64
Any Receipt of Other Services for Mental Health among Adolescents with a Past Year MDE.....	56	Receipt of Treatment among Adults with Co-Occurring SMI and an SUD.....	65
Receipt of Specific Other Services for Mental Health among Adolescents with a Past Year MDE.....	57	Recovery.....	65
No Receipt of Treatment or Other Services for Mental Health among Adolescents with a Past Year MDE.....	57	Endnotes.....	66
Perceived Unmet Need for Mental Health Treatment among Adolescents with a Past Year MDE.....	57	Appendix A: Special Tables of Estimates for Substance Use and Mental Health Indicators in the United States.....	A-1
Reasons for Not Receiving Mental Health Treatment among Adolescents with a Past Year MDE and a Perceived Unmet Need.....	57		
Mental Health Treatment among Adults.....	58		
Receipt of Mental Health Treatment among All Adults.....	58		
Receipt of Mental Health Treatment among Adults with an MDE.....	59		
Receipt of Mental Health Treatment among Adults with AMI.....	59		
Receipt of Mental Health Treatment among Adults with SMI.....	59		

Introduction

Substance use and mental health conditions have significant impacts on individuals, families, communities, and societies.^{1,2,3} The National Survey on Drug Use and Health (NSDUH), conducted annually by the Substance Abuse and Mental Health Services Administration (SAMHSA), provides nationally representative data on the use of tobacco, alcohol, and other substances, including illicit drugs; substance use disorders; receipt of substance use treatment; mental health conditions; and receipt of mental health treatment among the civilian, noninstitutionalized population aged 12 or older in the United States. NSDUH estimates allow researchers, clinicians, policymakers, and the general public to better understand and improve the nation's behavioral health.

Historically, NSDUH collected data via in-person interviews; however, the 2021 to 2025 NSDUHs used multimode data collection, in which respondents completed the survey in person or via the web. Methodological investigations led to the conclusion that estimates based on multimode data collection in 2021 and subsequent years are not comparable with estimates from 2020 or prior years.⁴

This report examines changes in substance use and mental health estimates from 2021 to 2025 for those estimates that can be compared for at least 4 years. *Results from the 2025 National Survey on Drug Use and Health: Detailed Tables* also show comprehensive estimates related to substance use and mental health for 2024 and 2025 and selected estimates for 2021 to 2025.⁵ The *2025 Companion Infographic Report: Results from the 2021 to 2025 National Surveys on Drug Use and Health* shows selected estimates from 2021 to 2025.⁶

Survey Background

NSDUH is an annual survey sponsored by SAMHSA within the U.S. Department of Health and Human Services (HHS). NSDUH covers residents of households and people in noninstitutional group settings (e.g., shelters, boarding houses, college dormitories, halfway houses). The survey excludes people with no fixed address (e.g., people who are homeless and not in shelters), military personnel on active duty, and residents of institutional group settings, such as jails, nursing homes, mental health institutions, and long-term care facilities.

NSDUH employs a probability sample designed to be representative of both the nation as a whole and for each

of the 50 states and the District of Columbia.⁷ The 2025 NSDUH used multimode data collection throughout the year, in which respondents completed the survey in person or via the web. In-person data collection commenced after potential respondents first were given the opportunity to complete the survey via the web. Respondents could choose whether to complete screenings or interviews via the web or in person. Respondents also could transition between data collection modes for screening and interviewing (e.g., completing household screening via the web and the main interview in person).⁸

A full sample was available from all 4 quarters in 2025. Screening was completed for 180,506 addresses, and the final sample consisted of 60,447 completed interviews. Based on information from the household screenings, there were 10,933 interviews from adolescents aged 12 to 17 and 49,514 interviews from adults aged 18 or older.⁹ Overall, 44.3 percent of interviews were completed via the web, and 55.7 percent were completed in person. Weighted response rates for household screening and for interviewing were 15.8 and 53.8 percent, respectively, for an overall response rate of 8.5 percent for people aged 12 or older. The weighted interview response rates were 39.3 percent for adolescents and 55.2 percent for adults.^{10,11}

Further information about the 2025 NSDUH design and methods can be found in the *2025 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions* report.¹¹

Data Presentation and Interpretation

This report focuses on substance use and mental health indicators in the United States based on NSDUH data from 2021 to 2025. All estimates (e.g., percentages and numbers) presented in the report are derived from survey data that are subject to sampling errors and have met the criteria for statistical precision.¹² In addition, the analysis weights for 2021 were adjusted to allow estimates for 2021 to be compared with those in later survey years.⁷ Consequently, estimates for 2021 in this report may differ from previously published estimates.

Estimates of substance use, substance use disorders, and related treatment are presented for people aged 12 or older, including adolescents and adults.¹³ However, estimates of mental health conditions are presented separately for adolescents aged 12 to 17 and adults aged 18 or older because only adults were asked questions to estimate any

mental illness (AMI) or serious mental illness (SMI). Although adolescents and adults in 2025 were asked the same questions about treatment for mental health conditions, estimates are also presented separately for adolescents and adults because estimates are available specifically for treatment among adults with AMI or SMI.

Appendix A contains tables of estimates by age group. Because some estimates in these appendix tables may not be found in the 2025 NSDUH Detailed Tables, the appendix tables include standard errors for the associated estimates.¹⁴

Statistical tests were conducted for comparisons discussed in this report according to procedures described in the 2025 Methodological Summary and Definitions report.¹⁵ Based on results of linear tests of trends involving 4 or more years of data, the report summarizes whether an outcome of interest showed a statistically significant change from the baseline year (e.g., 2021) through 2025. Linear trend testing indicates whether estimates have decreased, increased, or showed no change over the period of interest. Statistically significant differences are described using terms such as “higher,” “lower,” “more likely,” “less likely,” “increased,” or “decreased.” Statements use terms such as “similar,” “did not change,” or “showed no change” when a difference was not statistically significant. When estimates are presented without reference to differences across years or groups, statistical significance is not implied.

General Substance Use in the Past Month


This section provides an overview of estimates according to whether respondents aged 12 or older reported using nicotine products (i.e., tobacco products or vaping nicotine with e-cigarettes or other vaping devices), reported using alcohol, or reported using illicit drugs in the 30 days before the NSDUH interview (i.e., in the past month, also referred to as “current use”). Additional information on tobacco product use, nicotine vaping, alcohol use, and illicit drug use, including prescription drug misuse, is provided in other sections of this report.¹⁴

Past month tobacco use includes any use of these tobacco products: cigarettes, smokeless tobacco (such as snuff, dip, chewing tobacco, or snus), cigars, and pipe tobacco. Past month nicotine vaping refers to the use of an e-cigarette or other vaping device to vaporize (i.e., vape) nicotine. Past month alcohol use refers to having more than a sip or two of any type of alcoholic drink (e.g., a can or a bottle of

beer or hard seltzer, a glass of wine or a wine cooler, a shot of liquor, or a drink with liquor in it). Past month illicit drug use includes any use of marijuana or cannabis products (including smoking, vaping, and other modes of use), cocaine (including crack), heroin, hallucinogens, inhalants, or methamphetamine, as well as misuse of prescription stimulants, tranquilizers or sedatives (e.g., benzodiazepines), or pain relievers. (See the [Misuse of Prescription Psychotherapeutic Drugs](#) section for the definition of “misuse.”)

Among people aged 12 or older in 2025, 56.0 percent (or 162.8 million people) used tobacco, vaped nicotine, used alcohol, or used an illicit drug in the past month; 44.4 percent (or 129.1 million people) drank alcohol in the past month; 16.2 percent (or 46.9 million people) used a tobacco product in the past month; 10.1 percent (or 29.3 million people) vaped nicotine in the past month; and 16.4 percent (or 47.5 million people) used an illicit drug in the past month (Figure 1 and Table A.1B). Estimates for tobacco use, nicotine vaping, alcohol use, or illicit drug use are not mutually exclusive because people could have used more than one type of substance (e.g., tobacco products and alcohol) in the past month.

Figure 1. Past Month Substance Use: Among People Aged 12 or Older; 2025



Rx = prescription.
Note: The estimated numbers of current users of different substances are not mutually exclusive because people could have used more than one type of substance in the past month.

Nicotine Product Use in the Past Month

As noted in the section on [General Substance Use in the Past Month](#), past month tobacco use in NSDUH includes any use of these tobacco products: cigarettes, smokeless tobacco (such as snuff, dip, chewing tobacco, or snus), cigars, and pipe tobacco. Past month nicotine vaping refers to the use of an e-cigarette or other vaping device to vape nicotine. Aggregate estimates for past month (i.e., current) nicotine product use are presented for people who used any of these tobacco products or vaped nicotine (or both) in the past month. The estimates for nicotine vaping in 2025 may be compared with those from the 2022 to 2024 NSDUHs. However, because the nicotine vaping questions were modified for 2022, estimates from 2022 to 2025 should not be compared with estimates from 2021.¹⁶ Estimates for nicotine product use and nicotine vaping in 2022 to 2024 may differ from previously published estimates because of updates to nicotine vaping measures.¹⁷

Among people aged 12 or older in 2025, 22.1 percent (or 64.2 million people) used nicotine products in the past month ([Figure 2](#) and [Table A.1B](#)), including 36.1 million people who smoked cigarettes and 29.3 million people who vaped nicotine. Smaller numbers of people used cigars, smokeless tobacco, or pipe tobacco in the past month.

Among people aged 12 or older in 2025 who used nicotine products in the past month, 54.4 percent used only tobacco products, and 27.0 percent only vaped nicotine products ([Figure 3](#) and [Table A.2B](#)). Among people who used

nicotine products in the past month, the percentage who only vaped nicotine was highest among adolescents aged 12 to 17 (70.8 percent), followed by young adults aged 18 to 25 (49.4 percent), then by adults aged 26 or older (21.2 percent). In contrast, almost two thirds of adults aged 26 or older who used nicotine products in the past month used only tobacco products (62.6 percent), compared with 20.1 percent of young adults and 8.2 percent of adolescents who used nicotine products in that period.

Figure 3. Type of Past Month Nicotine Product Use: Among Past Month Nicotine Product Users Aged 12 or Older; 2025





Figure 2. Past Month Nicotine Product Use: Among People Aged 12 or Older; 2025




Note: The estimated numbers of current users of different nicotine products are not mutually exclusive because people could have used more than one type of nicotine product in the past month.

Any Nicotine Product Use

The percentage of people aged 12 or older who used nicotine products in the past month showed no change from 2022 to 2025 (Figure 4 and Table A.3B).¹⁷ Among adolescents aged 12 to 17 and adults aged 26 or older, the percentages who used nicotine products in the past month also showed no change from 2022 to 2025 (Tables A.4B and A.6B). However, the percentage of young adults aged 18 to 25 who used nicotine products in the past month decreased from 30.0 percent (or 10.4 million people) in 2022 to 27.9 percent (or 10.1 million people) in 2025 (Table A.5B).

In 2025, the percentage of people who used nicotine products in the past month was highest among young adults aged 18 to 25 (27.9 percent or 10.1 million people), followed by adults aged 26 or older (22.9 percent or 52.4 million people), then by adolescents aged 12 to 17 (6.9 percent or 1.8 million people) (Figure 4 and Table A.1B).

Figure 4. Past Month Nicotine Product Use: Among People Aged 12 or Older; 2022-2025



Note: Some 2022-2024 estimates may differ from previously published estimates due to updates to the editing procedures for nicotine vaping.

Figure 4 Table. Past Month Nicotine Product Use: Among People Aged 12 or Older; Percentages, 2022-2025

Age Group	2022	2023	2024	2025	Trend
12 or Older	22.7	22.7	22.1	22.1	No Change
12 to 17	7.3	7.4	6.6	6.9	No Change
18 to 25	30.0	30.0	28.9	27.9	Decreased
26 or Older	23.3	23.4	22.8	22.9	No Change

Note: Some 2022-2024 estimates may differ from previously published estimates due to updates to the editing procedures for nicotine vaping.

Tobacco Product Use

Among people aged 12 or older, the percentage who used tobacco products in the past month decreased from 20.1 percent (or 56.2 million people) in 2021 to 16.2 percent (or 46.9 million people) in 2025 (Figure 5 and Table A.3B). Percentages also decreased from 2021 to 2025


for people in each age group (Tables A.4B, A.5B, and A.6B). For example, the percentage of adults aged 26 or older who used tobacco products in the past month decreased from 22.5 percent (or 49.6 million people) in 2021 to 18.0 percent (or 41.3 million people) in 2025.

In 2025, the percentage of people who used tobacco products in the past month was highest among adults aged 26 or older (18.0 percent or 41.3 million people), followed by young adults aged 18 to 25 (14.1 percent or 5.1 million people), then by adolescents aged 12 to 17 (2.0 percent or 513,000 people) (Figure 5 and Table A.1B).

Among people aged 12 or older in 2025 who used any tobacco product in the past month (regardless of whether they vaped nicotine), the following percentages of people used different types of tobacco products:

- 63.5 percent smoked cigarettes but did not use other tobacco products,
- 13.4 percent smoked cigarettes and used some other type of tobacco product, and
- 23.0 percent used only other tobacco products but not cigarettes (Table A.7B).

Figure 5. Past Month Tobacco Product Use: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 5 Table. Past Month Tobacco Product Use: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	20.1	18.1	17.6	16.7	16.2	Decreased
12 to 17	2.9	2.0	1.9	1.9	2.0	Decreased
18 to 25	17.5	15.4	15.7	14.4	14.1	Decreased
26 or Older	22.5	20.4	19.7	18.7	18.0	Decreased


Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

The remainder of this section on tobacco use focuses on cigarette smoking, because most current tobacco users aged 12 or older were cigarette smokers (i.e., 36.1 million of the 46.9 million current tobacco users aged 12 or older). Information on the use of smokeless tobacco, cigars, and pipe tobacco in the past month among people aged 12 or older and by age group can be found in [Tables A.1B](#), [A.3B](#), [A.4B](#), [A.5B](#), and [A.6B](#).

Cigarette Use

Among people aged 12 or older, the percentage who smoked cigarettes in the past month decreased from 16.0 percent (or 44.8 million people) in 2021 to 12.4 percent (or 36.1 million people) in 2025 ([Figure 6](#) and [Table A.3B](#)). Among young adults aged 18 to 25 and adults aged 26 or older, the percentages who smoked cigarettes in the past month also decreased from 2021 to 2025 ([Tables A.5B](#) and [A.6B](#)). For example, the percentage of adults aged 26 or older who smoked cigarettes in the past month decreased from 18.3 percent (or 40.4 million people) in 2021 to 14.1 percent (or 32.2 million people) in 2025. Among adolescents aged 12 to 17, the percentage who smoked cigarettes in the past month showed no change from 2021 to 2025 ([Table A.4B](#)).

Figure 6. Past Month Cigarette Use: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 6 Table. Past Month Cigarette Use: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	16.0	14.6	13.7	13.1	12.4	Decreased
12 to 17	1.7	1.2	1.3	1.2	1.3	No Change
18 to 25	11.8	10.7	10.6	9.6	9.8	Decreased
26 or Older	18.3	16.7	15.5	15.0	14.1	Decreased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

In 2025, the percentage of people who smoked cigarettes in the past month was highest among adults aged 26 or older (14.1 percent or 32.2 million people), followed by young adults aged 18 to 25 (9.8 percent or 3.5 million people), then by adolescents aged 12 to 17 (1.3 percent or 340,000 people) ([Figure 6](#) and [Table A.1B](#)).

Daily Cigarette Use

Among the 36.1 million current cigarette smokers aged 12 or older in 2025 (see the section on [Cigarette Use](#)), 19.9 million people (or 55.1 percent) were daily cigarette smokers ([Table A.3B](#)). Among people aged 12 or older, the percentage of current cigarette smokers who were daily cigarette smokers decreased from 61.5 percent (or 27.5 million people) in 2021 to 55.1 percent (or 19.9 million people) in 2025. Among young adults aged 18 to 25 and adults aged 26 or older who were current smokers, the percentage who smoked cigarettes daily also decreased from 2021 to 2025 ([Tables A.5B](#) and [A.6B](#)). The trend for daily cigarette smoking among adolescents aged 12 to 17 who were current cigarette smokers was not tested because estimates in some years could not be calculated with sufficient precision ([Table A.4B](#)).¹²

Among current cigarette smokers in 2025, the percentage who smoked cigarettes daily was highest among adults aged 26 or older (60.4 percent), followed by young adults aged 18 to 25 (12.4 percent), then by adolescents aged 12 to 17 (1.9 percent) ([Table A.1B](#)). In 2025, 35.8 percent of current daily cigarette smokers (or 7.1 million people) smoked one or more packs of cigarettes per day ([Table A.3B](#)). The percentage of current daily cigarette smokers who smoked one or more packs of cigarettes per day was higher among adults aged 26 or older (36.2 percent or 7.0 million people) than among young adults aged 18 to 25 (17.1 percent or 74,000 people) ([Tables A.5B](#) and [A.6B](#)). The estimate in 2025 for smoking one or more packs of cigarettes per day in the past month among current daily smokers aged 12 to 17 could not be calculated with sufficient precision ([Table A.4B](#)).¹²


Nicotine Vaping

The percentage of people aged 12 or older who vaped nicotine in the past month increased from 8.3 percent (or 23.5 million people) in 2022 to 10.1 percent (or 29.3 million people) in 2025 ([Figure 7](#) and [Table A.3B](#)).¹⁷ Among adults aged 26 or older, the percentage who vaped nicotine in the past month also increased from 6.0 percent

(or 13.4 million people) in 2022 to 8.6 percent (or 19.6 million people) in 2025 (Table A.6B). The percentages among young adults aged 18 to 25 who vaped nicotine in the past month decreased from 24.0 percent (or 8.4 million people) in 2022 to 22.3 percent (or 8.0 million people) in 2025 (Table A.5B). Among adolescents aged 12 to 17, the percentage who vaped nicotine in the past month showed no change from 2022 to 2025 (Table A.4B).

In 2025, the percentage of people who vaped nicotine in the past month was highest among young adults aged 18 to 25 (22.3 percent or 8.0 million people), followed by adults aged 26 or older (8.6 percent or 19.6 million people), then by adolescents aged 12 to 17 (6.3 percent or 1.6 million people) (Figure 7 and Table A.1B).

Figure 7. Past Month Nicotine Vaping: Among People Aged 12 or Older; 2022-2025



Note: Some 2022-2024 estimates may differ from previously published estimates due to updates to the editing procedures for this measure.

Figure 7 Table. Past Month Nicotine Vaping: Among People Aged 12 or Older; Percentages, 2022-2025

Age Group	2022	2023	2024	2025	Trend
12 or Older	8.3	9.4	9.6	10.1	Increased
12 to 17	6.8	6.8	6.0	6.3	No Change
18 to 25	24.0	24.1	23.7	22.3	Decreased
26 or Older	6.0	7.4	7.8	8.6	Increased

Note: Some 2022-2024 estimates may differ from previously published estimates due to updates to the editing procedures for this measure.

Underage Nicotine Product Use

The percentage of underage people aged 12 to 20 who used nicotine products in the past month decreased from 13.4 percent (or 5.2 million people) in 2022 to 12.1 percent (or 4.8 million people) in 2025 (Table A.8B).¹⁷ In 2025, underage people aged 12 to 20 were more likely to have vaped nicotine (10.6 percent or 4.2 million people) than to have used other types of nicotine products in the past


month. In comparison, 3.4 percent of underage people smoked cigarettes in the past month. Smaller percentages of underage people smoked cigars, used smokeless tobacco, or smoked pipe tobacco in the past month.

Alcohol Use in the Past Month

As noted in the section on General Substance Use in the Past Month, NSDUH asked respondents aged 12 or older about their alcohol use in the 30 days before the interview, including binge alcohol use and heavy alcohol use in that period. Binge drinking for males was defined as drinking five or more drinks¹⁸ on the same occasion on at least 1 day in the past 30 days. Binge drinking for females was defined as drinking four or more drinks on the same occasion on at least 1 day in the past 30 days. This definition of binge alcohol use is consistent with federal definitions.¹⁹ Heavy alcohol use was defined as binge drinking on 5 or more days in the past 30 days based on the thresholds previously described for males and females.

Among the 129.1 million current alcohol users aged 12 or older in 2025, 56.8 million people (or 44.0 percent) were past month binge drinkers (Figure 8). Among past month binge drinkers, 14.5 million people were past month heavy drinkers. The 14.5 million heavy drinkers represent 25.6 percent of current binge drinkers and 11.3 percent of current alcohol users.

Figure 8. Alcohol Use, Binge Alcohol Use, or Heavy Alcohol Use in the Past Month: Among People Aged 12 or Older; 2025




Note: Binge Alcohol Use is defined as drinking five or more drinks (for males) or four or more drinks (for females) on the same occasion on at least 1 day in the past 30 days. Heavy Alcohol Use is defined as binge drinking on the same occasion on 5 or more days in the past 30 days; all heavy alcohol users are also binge alcohol users.

Any Alcohol Use

Among people aged 12 or older, the percentage who used alcohol in the past month decreased from 47.4 percent (or 132.5 million people) in 2021 to 44.4 percent (or 129.1 million people) in 2025 (Figure 9 and Table A.3B). Percentages also decreased from 2021 to 2025 for people in each age group (Tables A.4B, A.5B, and A.6B). For example, the percentage of young adults aged 18 to 25 who used alcohol in the past month decreased from 50.9 percent (or 17.0 million people) in 2021 to 46.2 percent (or 16.7 million people) in 2025.

In 2025, the percentage of people who used alcohol in the past month was higher among adults aged 26 or older (48.4 percent or 110.9 million people) than among young adults aged 18 to 25 (46.2 percent or 16.7 million people). The percentage was lowest among adolescents aged 12 to 17 (5.9 percent or 1.5 million people) (Figure 9 and Table A.1B).

Figure 9. Past Month Alcohol Use: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 9 Table. Past Month Alcohol Use: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	47.4	48.7	47.5	46.6	44.4	Decreased
12 to 17	7.2	6.8	6.9	6.6	5.9	Decreased
18 to 25	50.9	50.2	49.6	47.5	46.2	Decreased
26 or Older	51.5	53.4	51.9	51.0	48.4	Decreased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.


Binge Alcohol Use

Among people aged 12 or older, the percentage who engaged in binge drinking in the past month decreased from 21.7 percent (or 60.6 million people) in 2021 to 19.5 percent (or 56.8 million people) in 2025 (Figure 10

and Table A.3B). Percentages also decreased from 2021 to 2025 for people in each age group (Tables A.4B, A.5B, and A.6B). For example, the percentage of young adults aged 18 to 25 who engaged in binge drinking in the past month decreased from 30.0 percent (or 10.0 million people) in 2021 to 26.7 percent (or 9.6 million people) in 2025.

In 2025, the percentage of people who engaged in binge drinking in the past month was higher among young adults aged 18 to 25 (26.7 percent or 9.6 million people) than among adults aged 26 or older (20.2 percent or 46.4 million people). The percentage was lowest among adolescents aged 12 to 17 (3.0 percent or 753,000 people) (Figure 10 and Table A.1B).

Figure 10. Past Month Binge Alcohol Use: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Note: Binge Alcohol Use is defined as drinking five or more drinks (for males) or four or more drinks (for females) on the same occasion on at least 1 day in the past 30 days.

Figure 10 Table. Past Month Binge Alcohol Use: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	21.7	21.7	21.7	20.1	19.5	Decreased
12 to 17	4.0	3.2	3.9	3.5	3.0	Decreased
18 to 25	30.0	29.5	28.7	26.7	26.7	Decreased
26 or Older	22.5	22.6	22.7	21.0	20.2	Decreased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Note: Binge Alcohol Use is defined as drinking five or more drinks (for males) or four or more drinks (for females) on the same occasion on at least 1 day in the past 30 days.


Heavy Alcohol Use

Among people aged 12 or older, the percentage who were heavy alcohol users in the past month decreased from 5.7 percent (or 16.1 million people) in 2021 to 5.0 percent (or 14.5 million people) in 2025 (Figure 11 and Table A.3B). Among young adults aged 18 to 25 and adults aged 26 or older, the percentages who were heavy alcohol

users in the past month also decreased from 2021 to 2025 (Tables A.5B and A.6B). For example, the percentage of young adults aged 18 to 25 who were heavy alcohol users in the past month decreased from 7.1 percent (or 2.4 million people) in 2021 to 6.3 percent (or 2.3 million people) in 2025. Among adolescents aged 12 to 17, the percentage who were heavy alcohol users in the past month showed no change from 2021 to 2025 (Table A.4B).

In 2025, the percentage of people who were heavy alcohol users was higher among young adults aged 18 to 25 (6.3 percent or 2.3 million people) than among adults aged 26 or older (5.3 percent or 12.2 million people). The percentage was lowest among adolescents aged 12 to 17 (0.3 percent or 81,000 people) (Figure 11 and Table A.1B).

Figure 11. Past Month Heavy Alcohol Use: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.
Note: Heavy Alcohol Use is defined as binge drinking on the same occasion on 5 or more days in the past 30 days; all heavy alcohol users are also binge alcohol users. (Binge Alcohol Use is defined as drinking five or more drinks [for males] or four or more drinks [for females] on the same occasion on at least 1 day in the past 30 days.)

Figure 11 Table. Past Month Heavy Alcohol Use: Among People Aged 12 or Older; Percentages, 2021-2025


Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	5.7	5.7	5.8	5.0	5.0	Decreased
12 to 17	0.4	0.2	0.5	0.4	0.3	No Change
18 to 25	7.1	7.6	6.9	6.0	6.3	Decreased
26 or Older	6.2	6.0	6.2	5.4	5.3	Decreased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.
Note: Heavy Alcohol Use is defined as binge drinking on the same occasion on 5 or more days in the past 30 days; all heavy alcohol users are also binge alcohol users. (Binge Alcohol Use is defined as drinking five or more drinks [for males] or four or more drinks [for females] on the same occasion on at least 1 day in the past 30 days.)

Underage Alcohol Use

The percentage of people aged 12 to 20 who used alcohol in the past month decreased from 15.6 percent (or 6.1 million people) in 2021 to 13.7 percent (or 5.4 million people) in 2025 (Figure 12 and Table A.8B). However, percentages for binge and heavy alcohol use in the past month among underage people showed no change from 2021 to 2025. In 2025, 7.9 percent of underage people (or 3.1 million people) engaged in binge drinking in the past month, and 1.8 percent (or 701,000 people) were heavy alcohol users in that period.

Figure 12. Underage Alcohol Use, Binge Alcohol Use, or Heavy Alcohol Use in the Past Month: Among People Aged 12 to 20; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.
Note: Binge Alcohol Use is defined as drinking five or more drinks (for males) or four or more drinks (for females) on the same occasion on at least 1 day in the past 30 days. Heavy Alcohol Use is defined as binge drinking on the same occasion on 5 or more days in the past 30 days; all heavy alcohol users are also binge alcohol users.

Figure 12 Table. Underage Alcohol Use, Binge Alcohol Use, or Heavy Alcohol Use in the Past Month: Among People Aged 12 to 20; Percentages, 2021-2025

Level of Use	2021	2022	2023	2024	2025	Trend
Alcohol Use	15.6	15.1	14.6	13.3	13.7	Decreased
Binge Alcohol Use	8.6	8.2	8.6	7.6	7.9	No Change
Heavy Alcohol Use	1.6	1.7	1.7	1.5	1.8	No Change

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.
Note: Binge Alcohol Use is defined as drinking five or more drinks (for males) or four or more drinks (for females) on the same occasion on at least 1 day in the past 30 days. Heavy Alcohol Use is defined as binge drinking on the same occasion on 5 or more days in the past 30 days; all heavy alcohol users are also binge alcohol users.

Marijuana Use and Marijuana Vaping in the Past Month

The NSDUH questionnaires from 2022 to 2025 included questions to assess the different ways that people use marijuana. Respondents who reported using marijuana in the past month or past year were asked to report ways they used marijuana in these time periods, such as smoking, vaping, and eating. These NSDUH questionnaires also included questions about the use of cannabidiol (CBD) or hemp products and the use of marijuana or cannabis products that were recommended by a doctor or other health professional (i.e., medical marijuana use); however, presentation of these estimates is beyond the scope of this report. Additional information about the use of CBD can be found in Section 8 of the 2025 Detailed Tables.²⁰

This section presents estimates for any marijuana use in the past month regardless of the mode of use, as well as estimates specifically for marijuana vaping. Estimates for additional modes of marijuana use in the past year are discussed in the [Marijuana Use](#) section.


Among people aged 12 or older, the percentage who used marijuana in the past month increased from 13.2 percent (or 37.0 million people) in 2021 to 15.1 percent (or 43.8 million people) in 2025 ([Figure 13](#) and [Table A.3B](#)). Among adults aged 26 or older, the percentage who used marijuana in the past month also increased from 2021 to 2025 ([Table A.6B](#)). However, the percentages among adolescents aged 12 to 17 and young adults aged 18 to 25 who used marijuana in the past month decreased from 2021 to 2025 ([Tables A.4B](#) and [A.5B](#)). For example, the percentage of adolescents who used marijuana in the past month decreased from 6.1 percent (or 1.6 million people) in 2021 to 5.0 percent (or 1.3 million people) in 2025.

In 2025, the percentage of people who used marijuana in the past month was highest among young adults aged 18 to 25 (23.3 percent or 8.4 million people), followed by adults aged 26 or older (14.9 percent or 34.1 million people), then by adolescents aged 12 to 17 (5.0 percent or 1.3 million people) ([Figure 13](#) and [Table A.1B](#)).

About two fifths (37.1 percent) of current marijuana users aged 12 or older in 2025 vaped marijuana in the past month ([Figure 14](#) and [Table A.9B](#)). Among people in 2025 who used marijuana in the past month, the percentage

who vaped it was highest among adolescents aged 12 to 17 (69.8 percent or 893,000 people), followed by young adults aged 18 to 25 (54.3 percent or 4.6 million people), then by adults aged 26 or older (31.6 percent or 10.8 million people).

Figure 13. Past Month Marijuana Use: Among People Aged 12 or Older; 2021-2025




Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 13 Table. Past Month Marijuana Use: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	13.2	15.0	15.4	15.4	15.1	Increased
12 to 17	6.1	6.4	6.0	6.0	5.0	Decreased
18 to 25	24.6	25.9	25.2	24.1	23.3	Decreased
26 or Older	12.3	14.3	15.0	15.1	14.9	Increased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 14. Type of Past Month Marijuana Use: Among Past Month Marijuana Users Aged 12 or Older; 2025



Illicit Drug Use in the Past Year

Past year illicit drug use includes any use of marijuana or cannabis products (including smoking, vaping, and other modes of use), cocaine (including crack), heroin, hallucinogens, inhalants, and methamphetamine, as well as misuse of prescription stimulants, tranquilizers or sedatives (e.g., benzodiazepines),²¹ or pain relievers (see the section on the [Misuse of Prescription Psychotherapeutic Drugs](#) for the definition of “misuse”). Misuse of prescription pain relievers includes the misuse of pain relievers that are classified as prescription opioids and pain relievers that are not opioids. Misuse of prescription opioids reflects misuse of the subset of prescription pain relievers that were classified as prescription opioids.

This report presents estimates of past year illicit drug use (rather than past month use) because of low prevalence estimates for some illicit drugs (e.g., heroin). Moreover, the 2025 NSDUH collected only past year (rather than past month) data on the misuse of benzodiazepines and specific subtypes of prescription pain relievers (e.g., hydrocodone products).

Among people aged 12 or older in 2025, 69.8 million people used illicit drugs in the past year ([Figure 15](#)). The most commonly used illicit drug in the past year was marijuana, which was used by 61.6 million people. In the past year, 9.1 million people used hallucinogens, and 6.9 million people misused prescription opioids (shown as “Rx Opioid Misuse” in the figure). Smaller numbers of people were past year users or misusers of the other illicit drugs shown in [Figure 15](#).²²

Any Illicit Drug Use


Among people aged 12 or older, the percentage who used illicit drugs in the past year increased from 22.2 percent (or 62.0 million people) in 2021 to 24.0 percent (or 69.8 million people) in 2025 ([Figure 16](#) and [Table A.10B](#)). This increase is largely tied to the increase in marijuana use in the past year (see the next section on [Marijuana Use](#)).

The percentage of people who used illicit drugs in the past year also increased among adults aged 26 or older, from 20.5 percent (or 45.2 million people) in 2021 to 23.5 percent (or 53.8 million people) in 2025 ([Figure 16](#) and [Table A.13B](#)). Percentages decreased from 2021 to 2025 for adolescents aged 12 to 17 and young adults aged 18 to 25 ([Tables A.11B](#) and [A.12B](#)). For example, the percentage of adolescents aged 12 to 17 who used illicit drugs in the past year decreased from 14.6 percent (or 3.8 million people) in 2021 to 11.2 percent (or 2.9 million people) in 2025.

Because the question wording for inhalants changed for 2025 (see the [Inhalant Use](#) section), trends also were evaluated for the use of illicit drugs in the past year excluding inhalants. Those trends were the same as the trends described previously for any use of illicit drugs that included inhalants. Therefore, the change to the questions for inhalants in 2025 was assumed not to have affected overall trends for any illicit drug use in the past year.

In 2025, the percentage of people who used illicit drugs in the past year was highest among young adults aged 18 to 25 (36.3 percent or 13.1 million people), followed by adults aged 26 or older (23.5 percent or 53.8 million people), then by adolescents aged 12 to 17 (11.2 percent or 2.9 million people) ([Figure 16](#) and [Tables A.11B](#), [A.12B](#), and [A.13B](#)).


Figure 15. Past Year Illicit Drug Use: Among People Aged 12 or Older; 2025



Rx = prescription.

Note: The estimated numbers of past year users of different illicit drugs are not mutually exclusive because people could have used more than one type of illicit drug in the past year.

Figure 16. Past Year Illicit Drug Use: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 16 Table. Past Year Illicit Drug Use: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	22.2	24.9	24.9	25.5	24.0	Increased
12 to 17	14.6	14.3	14.7	15.1	11.2	Decreased
18 to 25	39.0	40.9	39.0	38.1	36.3	Decreased
26 or Older	20.5	23.7	23.9	24.8	23.5	Increased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.


Marijuana Use

Any Marijuana Use

Among people aged 12 or older, the percentage who used marijuana in the past year increased from 19.0 percent (or 53.2 million people) in 2021 to 21.2 percent (or 61.6 million people) in 2025 (Figure 17 and Table A.10B). The percentage also increased among adults aged 26 or older, from 17.3 percent (or 38.2 million people) in 2021 to 20.6 percent (or 47.2 million people) in 2025 (Table A.13B). Percentages decreased from 2021 to 2025 for both adolescents aged 12 to 17 and young adults aged 18 to 25 (Tables A.11B and A.12B). For example, the percentage of adolescents aged 12 to 17 who used marijuana in the past year decreased from 10.9 percent (or 2.8 million people) in 2021 to 8.7 percent (or 2.2 million people) in 2025.

In 2025, the percentage of people who used marijuana in the past year was highest among young adults aged 18 to 25 (33.7 percent or 12.2 million people), followed by adults aged 26 or older (20.6 percent or 47.2 million people), then by adolescents aged 12 to 17 (8.7 percent or 2.2 million people) (Figure 17 and Tables A.11B, A.12B, and A.13B).

Figure 17. Past Year Marijuana Use: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 17 Table. Past Year Marijuana Use: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	19.0	22.0	21.8	22.3	21.2	Increased
12 to 17	10.9	11.5	11.2	10.4	8.7	Decreased
18 to 25	36.3	38.2	36.5	35.0	33.7	Decreased
26 or Older	17.3	20.6	20.8	21.7	20.6	Increased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Modes of Marijuana Use

As noted previously for marijuana use in the past month, the NSDUH questionnaires from 2022 to 2025 included questions to assess the variety of methods that people use to consume marijuana or other cannabis products. Estimates for the use of CBD or hemp products are not included in this report. The NSDUH questionnaire presented the following modes of marijuana use to respondents who reported using marijuana in the past year or past month:


- smoking;
- vaping;
- dabbing waxes, shatter, or concentrates;
- eating or drinking;
- putting drops, strips, lozenges, or sprays in their mouth or under their tongue;
- applying lotion, cream, or patches to their skin;
- taking pills; or
- using it in some other way.

Respondents could report that they used marijuana in more than one way in the past year or past month. For example, respondents could report that they smoked marijuana and

vaped it in the past year. Also, if respondents did not report a particular mode of use (e.g., vaping) in the past year but reported it as a mode of use for the past month, then these respondents were inferred to have used marijuana in that specific way in the past year.

Among people aged 12 or older in 2025 who used marijuana in the past year, the most common mode of marijuana use was smoking (74.8 percent or 46.1 million people), followed by eating or drinking (49.2 percent or 30.3 million people); vaping (39.2 percent or 24.2 million people); and dabbing waxes, shatter, or concentrates (14.5 percent or 8.9 million people) (Figure 18 and Table A.14B). Smaller percentages and numbers of people who used marijuana in the past year used it in other ways.

Figure 18. Mode of Past Year Marijuana Use: Among People Aged 12 or Older Who Used Marijuana in the Past Year; 2025



Note: Respondents could indicate multiple modes of marijuana use; thus, these response categories are not mutually exclusive.

¹ Includes applying lotion, cream, or patches to skin; putting drops, strips, lozenges, or sprays in mouth or under tongue; taking pills; or some other way not already listed in this figure.

Smoking also was the most common mode of marijuana use in 2025 among young adults aged 18 to 25 and adults aged 26 or older who used marijuana in the past year (Table A.14B). Among people in these adult age groups who used marijuana in the past year, 82.7 percent of young adults and 72.6 percent of adults aged 26 or older smoked marijuana. However, smoking (79.5 percent) and vaping (74.0 percent) were the two most common modes of marijuana use in 2025 among adolescents aged 12 to 17 who used marijuana in the past year.


Other common modes of marijuana use in 2025 among past year marijuana users varied by age group (Table A.14B). Among adolescents aged 12 to 17 who used marijuana in the past year, about two fifths (36.6 percent) ate or drank marijuana, followed by about one sixth who dabbed waxes, shatter, or concentrates (16.8 percent). Among young

adults aged 18 to 25 who used marijuana in the past year, more than half vaped marijuana (57.4 percent), followed by about half who ate or drank it (46.5 percent), then by about one fourth (23.1 percent) who dabbed waxes, shatter, or concentrates. Among adults aged 26 or older who were past year marijuana users, about half (50.5 percent) ate or drank it, followed by about one third (32.9 percent) who vaped it, then by about one eighth (12.1 percent) who dabbed waxes, shatter, or concentrates. Other modes of marijuana use were less common across all three age groups.

Cocaine Use

Cocaine use includes the use of crack cocaine. Among people aged 12 or older, the percentage who used cocaine in the past year showed no change from 2021 to 2025 (Figure 19 and Table A.10B). In 2025, 1.7 percent of people aged 12 or older (or 4.9 million people) used cocaine in the past year. Percentages also showed no change from 2021 to 2025 for adolescents aged 12 to 17 and adults aged 26 or older (Tables A.11B and A.13B). However, the percentage among young adults aged 18 to 25 decreased from 3.7 percent (or 1.2 million people) in 2021 to 2.6 percent (or 950,000 people) in 2025 (Table A.12B).

Figure 19. Past Year Cocaine Use: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 19 Table. Past Year Cocaine Use: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	1.7	1.9	1.8	1.5	1.7	No Change
12 to 17	0.1	0.2	0.2	0.3	0.2	No Change
18 to 25	3.7	3.7	3.1	2.3	2.6	Decreased
26 or Older	1.6	1.8	1.7	1.5	1.7	No Change

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

In 2025, the percentage of people who used cocaine in the past year was highest among young adults aged 18 to 25 (2.6 percent or 950,000 people), followed by adults aged 26 or older (1.7 percent or 3.9 million people), then by adolescents aged 12 to 17 (0.2 percent or 57,000 people) (Figure 19 and Tables A.11B, A.12B, and A.13B).

Heroin Use

Among people aged 12 or older in 2025, 0.2 percent (or 581,000 people) used heroin in the past year (Figure 15 and Table A.10B). The percentage of people in 2025 who used heroin in the past year was higher among adults aged 26 or older (0.3 percent or 574,000 people) than among young adults aged 18 to 25 (less than 0.1 percent or 6,000 people) and adolescents aged 12 to 17 (less than 0.1 percent or fewer than 1,000 people) (Tables A.11B, A.12B, and A.13B).

Methamphetamine Use

Although methamphetamine is legally available by prescription (Desoxyn®), most methamphetamine used in the United States is produced and distributed illicitly rather than through the pharmaceutical industry. Therefore, the 2021 to 2025 NSDUH questionnaire includes separate sections for methamphetamine use and the use and misuse of prescription stimulants.


Among people aged 12 or older, the percentage who used methamphetamine in the past year showed no change from 2021 to 2025 (Figure 20 and Table A.10B). In 2025, 0.9 percent of people aged 12 or older (or 2.7 million people) used methamphetamine in the past year. Percentages also showed no change from 2021 to 2025 for each age group (Tables A.11B, A.12B, and A.13B).

In 2025, the percentage of people who used methamphetamine in the past year was highest among adults aged 26 or older (1.1 percent or 2.5 million people), followed by young adults aged 18 to 25 (0.4 percent or 145,000 people), then by adolescents aged 12 to 17 (0.1 percent or 32,000 people) (Figure 20 and Tables A.11B, A.12B, and A.13B).

Hallucinogen Use

Several drugs are grouped under the category of hallucinogens, including LSD, PCP, peyote, mescaline, psilocybin mushrooms, “Ecstasy” (MDMA or “Molly”), ketamine, DMT/AMT/“Foxy,” and *Salvia divinorum*.²³ Beginning in 2025, the NSDUH questionnaire included

Figure 20. Past Year Methamphetamine Use: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 20 Table. Past Year Methamphetamine Use: Among People Aged 12 or Older; Percentages, 2021-2025


Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	0.9	1.0	0.9	0.8	0.9	No Change
12 to 17	0.1	0.1	0.2	0.2	0.1	No Change
18 to 25	0.5	0.5	0.3	0.5	0.4	No Change
26 or Older	1.1	1.1	1.1	1.0	1.1	No Change

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

questions about the most recent use of each of these specific hallucinogens, in addition to the most recent use of any hallucinogen.²⁴ Preliminary analysis of 2025 NSDUH data suggested that questionnaire changes for hallucinogens did not affect the comparability of the estimates for the use of hallucinogens in the past year. Therefore, this report presents trends in the past year use of hallucinogens for 2021 to 2025. Estimates for the use of specific hallucinogens (e.g., LSD, psilocybin, Ecstasy) can be found in the 2025 Detailed Tables.²⁰

Among people aged 12 or older, the percentage who used hallucinogens in the past year increased from 2.7 percent (or 7.6 million people) in 2021 to 3.1 percent (or 9.1 million people) in 2025 (Figure 21 and Table A.10B). The percentage also increased among adults aged 26 or older, from 2.1 percent (or 4.7 million people) in 2021 to 2.9 percent (or 6.6 million people) in 2025 (Table A.13B). The percentage decreased among young adults aged 18 to 25, from 7.4 percent (or 2.5 million people) in 2021 to 6.0 percent (or 2.2 million people) in 2025 (Table A.12B). Percentages showed no change from 2021 to 2025 for adolescents aged 12 to 17 (Table A.11B).

Figure 21. Past Year Hallucinogen Use: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 21 Table. Past Year Hallucinogen Use: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025		Trend
12 or Older	2.7	3.0	3.1	3.6	3.1		Increased
12 to 17	1.4	1.4	1.5	1.6	1.4		No Change
18 to 25	7.4	7.7	6.7	6.8	6.0		Decreased
26 or Older	2.1	2.5	2.7	3.4	2.9		Increased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.


In 2025, the percentage of people who used hallucinogens in the past year was highest among young adults aged 18 to 25 (6.0 percent or 2.2 million people), followed by adults aged 26 or older (2.9 percent or 6.6 million people), then by adolescents aged 12 to 17 (1.4 percent or 360,000 people) ([Figure 21](#) and [Tables A.11B](#), [A.12B](#), and [A.13B](#)).

Inhalant Use

Inhalants include volatile solvents (e.g., paint thinners and removers, dry cleaning fluids, degreasers, gasoline, glues, shoe polish, correction fluids, felt-tip markers), aerosols (e.g., spray paints, deodorant and hair sprays, fabric protector sprays, computer keyboard cleaner), gases (e.g., ether, halothane, nitrous oxide, butane, propane), and nitrites (e.g., amyl nitrite, “poppers,” locker room odorizers, Rush). As in prior years, NSDUH respondents in 2025 were instructed not to include accidental inhalation of a substance. For the 2025 NSDUH, respondents were asked to report the use of inhalants “to get high” instead of “for fun or to get high.” This change in the questionnaire wording appeared to have affected the reporting of the use of inhalants in the past year, especially among adolescent respondents aged 12 to 17. Therefore, estimates for the use of inhalants in the past year are presented only for 2025.

In 2025, 0.8 percent of people aged 12 or older (or 2.4 million people) used inhalants in the past year ([Figure 22](#) and [Table A.10B](#)). The percentage of people who used inhalants in the past year was lower among adults aged 26 or older (0.6 percent or 1.4 million people) than among young adults aged 18 to 25 (1.8 percent or 636,000 people) or adolescents aged 12 to 17 (1.4 percent or 360,000 people) ([Tables A.11B](#), [A.12B](#), and [A.13B](#)).

Figure 22. Past Year Inhalant Use: Among People Aged 12 or Older; 2025



Misuse of Prescription Psychotherapeutic Drugs

NSDUH assessed the use and misuse of psychotherapeutic drugs currently or recently available by prescription in the United States, including prescription stimulants, tranquilizers or sedatives (e.g., benzodiazepines), and pain relievers. As discussed in the section on [Prescription Opioid Misuse](#), NSDUH respondents were asked about their misuse of prescription pain relievers, but the specific pain relievers in the NSDUH questionnaire are opioid pain relievers. In NSDUH, misuse of prescription drugs was defined as use in any way not directed by a doctor, including use without a prescription of one’s own; use in greater amounts, more often, or longer than told to take a drug; or use in any other way not directed by a doctor. Misuse of over-the-counter drugs was not included.


Of the prescription drugs presented in [Figure 15](#), prescription opioids were the most commonly misused prescription drug by people aged 12 or older. The 12.8 million people in 2025 who misused prescription psychotherapeutic drugs in the past year included 6.9 million people who misused prescription opioids, 4.2 million people who misused prescription tranquilizers or sedatives, and 3.9 million people who misused prescription stimulants.

Prescription Stimulant Misuse

The 2021 to 2025 NSDUHs assessed the misuse of prescription stimulants in the following categories: amphetamine products, methylphenidate products, anorectic (weight-loss) stimulants, Provigil®, or any other prescription stimulant. The amphetamine and methylphenidate products included in the NSDUH questionnaire are primarily prescribed for the treatment of attention-deficit/hyperactivity disorder (ADHD). Methamphetamine is not included as a prescription stimulant, unless respondents specified the prescription form of methamphetamine (Desoxyn®) as some other stimulant they had misused in the past year.²⁵

Among people aged 12 or older, the percentage who misused prescription stimulants in the past year showed no change from 2021 to 2025 (Figure 23 and Table A.10B). In 2025, 1.4 percent of people aged 12 or older (or 3.9 million people) misused prescription stimulants in the past year. Percentages also showed no change from 2021 to 2025 for adolescents aged 12 to 17 and adults aged 26 or older (Tables A.11B and A.13B). Among young adults aged 18 to 25, however, the percentage who misused prescription stimulants in the past year decreased from 4.1 percent (or 1.4 million people) in 2021 to 2.7 percent (or 978,000 people) in 2025 (Table A.12B).

Figure 23. Past Year Prescription Stimulant Misuse: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 23 Table. Past Year Prescription Stimulant Misuse: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	1.4	1.5	1.4	1.4	1.4	No Change
12 to 17	1.2	0.9	0.9	0.8	0.8	No Change
18 to 25	4.1	3.7	3.1	2.8	2.7	Decreased
26 or Older	1.0	1.3	1.2	1.2	1.2	No Change

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.


In 2025, the percentage of people who misused prescription stimulants in the past year was highest among young adults aged 18 to 25 (2.7 percent or 978,000 people), followed by adults aged 26 or older (1.2 percent or 2.7 million people), then by adolescents aged 12 to 17 (0.8 percent or 216,000 people) (Figure 23 and Tables A.11B, A.12B, and A.13B).

Prescription Tranquilizer or Sedative Misuse

Estimates of the misuse of prescription tranquilizers or sedatives are presented together because prescription drugs in both categories have a common effect on specific activity in the brain. Prescription tranquilizers include benzodiazepine tranquilizers (e.g., as alprazolam, lorazepam, clonazepam, or diazepam products), muscle relaxants, or any other prescription tranquilizer. Prescription sedatives include zolpidem products, eszopiclone products, zaleplon products, benzodiazepine sedatives (e.g., as flurazepam, temazepam products, or triazolam products), barbiturates, or any other prescription sedative.

Among people aged 12 or older, the percentage who misused prescription tranquilizers or sedatives in the past year decreased from 1.7 percent (or 4.8 million people) in 2021 to 1.5 percent (or 4.2 million people) in 2025 (Figure 24

Figure 24. Past Year Prescription Tranquilizer or Sedative Misuse: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 24 Table. Past Year Prescription Tranquilizer or Sedative Misuse: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	1.7	1.7	1.7	1.6	1.5	Decreased
12 to 17	1.0	0.5	0.7	0.7	0.6	No Change
18 to 25	2.7	2.4	1.7	1.6	1.6	Decreased
26 or Older	1.7	1.7	1.8	1.7	1.5	No Change

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

and [Table A.10B](#)). Among young adults aged 18 to 25, the percentage who misused prescription tranquilizers or sedatives in the past year also decreased from 2.7 percent (or 916,000 people) in 2021 to 1.6 percent (or 582,000 people) in 2025 ([Table A.12B](#)). However, the percentages for adolescents aged 12 to 17 and adults aged 26 or older who misused prescription tranquilizers or sedatives in the past year showed no change from 2021 to 2025 ([Tables A.11B](#) and [A.13B](#)).

In 2025, the percentage of people who misused prescription tranquilizers or sedatives in the past year was lower among adolescents aged 12 to 17 (0.6 percent or 141,000 people) than among young adults aged 18 to 25 (1.6 percent or 582,000 people) or adults aged 26 or older (1.5 percent or 3.5 million people) ([Figure 24](#) and [Tables A.11B](#), [A.12B](#), and [A.13B](#)).

Prescription Opioid Misuse

The 2021 to 2025 NSDUHs assessed the misuse of prescription pain relievers in the following categories: products containing hydrocodone, oxycodone, tramadol, codeine, morphine, prescription fentanyl,²⁶ buprenorphine, oxymorphone, and hydromorphone, as well as Demerol®, methadone, or any other prescription pain reliever. Except for “any other prescription pain reliever,” the pain relievers mentioned in the preceding sentence are opioids that are available by prescription in the United States, subsequently referred to as “prescription opioids.”


This section provides estimates for the misuse of prescription opioids, including specific subtypes of prescription opioids. Of an estimated 7.2 million people aged 12 or older in 2025 who misused prescription pain relievers in the past year, 6.9 million people misused prescription opioids, or approximately 96 percent of the people who misused prescription pain relievers.²⁰ Respondents were not counted as having misused prescription opioids in the past year if they reported the misuse of only other prescription pain relievers, and the other prescription pain relievers they misused in the past year were all nonopioids.

The percentage of people aged 12 or older who misused prescription opioids in the past year decreased from 3.0 percent (or 8.5 million people) in 2021 to 2.4 percent (or 6.9 million people) in 2025 ([Figure 25](#) and [Table A.10B](#)). The percentages among young adults aged 18 to 25 and adults aged 26 or older who misused prescription opioids in the past year also decreased from 2021 to 2025 ([Tables A.12B](#) and [A.13B](#)). For example, the percentage

of young adults aged 18 to 25 who misused prescription opioids in the past year decreased from 3.0 percent (or 989,000 people) in 2021 to 2.0 percent (or 733,000 people) in 2025. Among adolescents aged 12 to 17, the percentage who misused prescription opioids in the past year showed no change from 2021 to 2025 ([Table A.11B](#)).

In 2025, the percentage of people who misused prescription opioids in the past year was higher among adults aged 26 or older (2.5 percent or 5.7 million people) than among young adults aged 18 to 25 (2.0 percent or 733,000 people) or adolescents aged 12 to 17 (1.6 percent or 402,000 people) ([Figure 25](#) and [Tables A.11B](#), [A.12B](#), and [A.13B](#)).

Figure 25. Past Year Prescription Opioid Misuse: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 25 Table. Past Year Prescription Opioid Misuse: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	3.0	2.8	2.9	2.6	2.4	Decreased
12 to 17	2.0	1.5	2.0	1.5	1.6	No Change
18 to 25	3.0	3.0	2.4	2.6	2.0	Decreased
26 or Older	3.2	3.0	3.1	2.8	2.5	Decreased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Misuse of Subtypes of Prescription Opioids


The 2025 NSDUH asked respondents to identify specific prescription pain relievers they used in the past year, then asked whether they misused those prescription pain relievers in the past year. As noted previously, the specific pain relievers in the NSDUH questionnaire were prescription opioids. These specific prescription opioids that people misused in the past year were categorized into subtypes. For example, respondents who reported misusing Vicodin® or hydrocodone were classified as misusers of hydrocodone products.

This section presents two ways of examining the misuse of subtypes of prescription opioids in 2025. First, it presents estimates of the misuse of subtypes among people aged 12 or older who misused any prescription opioid in the past year. Then, it presents estimates of the misuse of subtypes of prescription opioids among people who used that opioid subtype for any reason in the past year (i.e., not necessarily misuse). See the [Misuse of Prescription Psychotherapeutic Drugs](#) section for the definition of misuse.

Among the 6.9 million people aged 12 or older in 2025 who misused prescription opioids in the past year, 41.8 percent (or 2.8 million people) misused hydrocodone products in the past year ([Figures 15](#) and [26](#) and [Table A.15B](#)). In addition, 31.7 percent (or 2.1 million people) of past year misusers of prescription opioids misused oxycodone products in the past year, including OxyContin®, Percocet®, Percodan®, Roxicodone®, and generic oxycodone. More than 1 in 4 people aged 12 or older who misused prescription opioids in the past year were misusers of codeine products in the past year (27.8 percent or 1.9 million people). These products also have been commonly prescribed opioids.²⁷

Although hydrocodone products were the most commonly misused prescription opioid subtype in the past year, 8.6 percent of people aged 12 or older in 2025 who used hydrocodone products for any reason in the past year misused them in that period ([Figure 27](#) and [Table A.15B](#)).


Figure 26. Past Year Prescription Opioid Subtype Misuse: Among People Aged 12 or Older Who Misused Any Prescription Opioid in the Past Year; 2025



Note: Respondents could indicate misuse of prescription opioids in multiple subtypes; thus, these response categories are not mutually exclusive.

Among people aged 12 or older in 2025 who used buprenorphine products for any reason in the past year, 18.5 percent misused them and 81.5 percent did not ([Figure 27](#) and [Table A.15B](#)). Stated another way, about four fifths of past year buprenorphine users did *not* misuse it in that period. Data from the 2015 to 2019 NSDUHs indicated that adults aged 18 or older who misused buprenorphine products were more likely to have used them without a prescription of their own compared with adults who misused prescription opioids other than buprenorphine products.²⁸

Figure 27. Past Year Prescription Opioid Subtype Misuse: Among People Aged 12 or Older Who Were Past Year Users of Specific Prescription Opioid Subtypes; 2025



* Low precision; no estimate reported.
Note: Respondents could indicate misuse of prescription opioids in multiple subtypes; thus, these response categories are not mutually exclusive.


Opioid Misuse

Opioids are a group of chemically similar drugs that include heroin and prescription opioids, such as hydrocodone (e.g., Vicodin®), oxycodone (e.g., OxyContin®), codeine, and morphine. In this report, opioid misuse includes the misuse of prescription opioids or the use of heroin. Respondents were not counted as having misused opioids in the past year if they reported only the misuse of other prescription pain relievers, and the other pain relievers they misused in the past year were all nonopioids.

In this report, opioid misuse does not include use of illegally made fentanyl (IMF). For additional information on estimates of opioid misuse that do include use of IMF, see Section 1 of the 2025 Detailed Tables.²⁰

Among people aged 12 or older in 2025, 2.4 percent (or 7.1 million people) misused opioids in the past year (Figure 28 and Table A.10B). The vast majority of these people who misused opioids in the past year misused prescription opioids (Table A.16AB), but they did not use heroin. Specifically, 6.9 million people misused prescription opioids in the past year, of whom 6.5 million people did not use heroin. An estimated 382,000 people misused prescription opioids and used heroin in the past year.

Figure 28. Type of Past Year Opioid Misuse: Among Past Year Opioid Misusers Aged 12 or Older; 2025




Note: These estimates do not include illegally made fentanyl.

Note: The numbers for the interior pieces may not add to the number for the whole circle due to rounding.

Among people aged 12 or older, the percentage who misused opioids in the past year decreased from 3.2 percent (or 9.1 million people) in 2021 to 2.4 percent (or 7.1 million people) in 2025 (Figure 29 and Table A.10B). The percentages of young adults aged 18 to 25 and adults aged 26 or older who misused opioids in the past year also decreased from 2021 to 2025 (Tables A.12B and A.13B). For example, the percentage of young adults aged 18 to 25 who misused opioids in the past year decreased from 3.0 percent (or 1.0 million people) in 2021 to 2.0 percent (or 736,000 people) in 2025. Among adolescents aged 12 to 17, the percentage who misused opioids in the past year showed no change from 2021 to 2025 (Table A.11B).

In 2025, the percentage of people who misused opioids in the past year was higher among adults aged 26 or older (2.6 percent or 5.9 million people) than among young adults aged 18 to 25 (2.0 percent or 736,000 people) or adolescents aged 12 to 17 (1.6 percent or 403,000 people) (Figure 29 and Tables A.11B, A.12B, and A.13B).

Figure 29. Past Year Opioid Misuse: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Note: Estimates include the use of heroin or the misuse of prescription opioids in the past year. Estimates for 2021-2023 may differ from previously published estimates because they do not include the misuse of only nonopioid pain relievers.

Figure 29 Table. Past Year Opioid Misuse: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	3.2	3.0	3.0	2.7	2.4	Decreased
12 to 17	2.0	1.5	2.0	1.5	1.6	No Change
18 to 25	3.0	3.0	2.4	2.6	2.0	Decreased
26 or Older	3.4	3.1	3.2	2.8	2.6	Decreased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.


Note: Estimates include the use of heroin or the misuse of prescription opioids in the past year. Estimates for 2021-2023 may differ from previously published estimates because they do not include the misuse of only nonopioid pain relievers.

Central Nervous System Stimulant Misuse

Central nervous system (CNS) stimulants are a group of drugs that include cocaine, methamphetamine, and prescription stimulants. These drugs act in similar ways to stimulate the brain. They produce stimulant effects, such as increased alertness, wakefulness, or energy. They also can produce physical side effects of rapid or irregular heartbeat or increased blood pressure and body temperature.^{29,30,31} In this report, CNS stimulant misuse includes the use of cocaine or methamphetamine or the misuse of prescription stimulants.

Of the 9.5 million people aged 12 or older in 2025 who misused CNS stimulants in the past year, most (7.6 million people) misused only one type of CNS stimulant, including 3.4 million people who used cocaine only, 2.6 million who misused prescription stimulants only, and 1.7 million people who used methamphetamine only (Figure 30 and Table A.17AB).³² An estimated 188,000 people used or misused all three CNS stimulants in the past year (2.0 percent of people who misused CNS stimulants).


Figure 30. Past Year Central Nervous System (CNS) Stimulant Misuse: Among People Aged 12 or Older; 2025



Note: The numbers for the interior pieces may not add to the number for the whole circle due to rounding.

Among people aged 12 or older, the percentage who misused CNS stimulants in the past year showed no change from 2021 to 2025 (Figure 31 and Table A.10B).

Figure 31. Past Year Central Nervous System Stimulant Misuse: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 31 Table. Past Year Central Nervous System Stimulant Misuse: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	3.4	3.6	3.4	3.1	3.3	No Change
12 to 17	1.3	1.1	1.1	1.1	0.9	No Change
18 to 25	6.7	6.5	5.6	4.7	4.7	Decreased
26 or Older	3.1	3.5	3.3	3.1	3.3	No Change

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

In 2025, 3.3 percent of people aged 12 or older (or 9.5 million people) misused CNS stimulants in the past year. Percentages also showed no change from 2021 to 2025 for adolescents aged 12 to 17 and adults aged 26 or older (Tables A.11B and A.13B). Among young adults aged 18 to 25, however, the percentage who misused CNS stimulants in the past year decreased from 6.7 percent (or 2.2 million people) in 2021 to 4.7 percent (or 1.7 million people) in 2025 (Table A.12B).

In 2025, the percentage of people who misused CNS stimulants in the past year was highest among young adults aged 18 to 25 (4.7 percent or 1.7 million people), followed by adults aged 26 or older (3.3 percent or 7.6 million people), then by adolescents aged 12 to 17 (0.9 percent or 241,000 people) (Figure 31 and Tables A.11B, A.12B, and A.13B).

Illegally Made Fentanyl Use

The use of IMF is of particular interest because of its involvement in fatal overdoses in the past decade.^{33,34,35} Although the number of drug overdose deaths overall and the number involving IMF or fentanyl analogues, such as carfentanil, started to decline in the United States in late 2023, overdose deaths remain high.³⁶ In 2024, most people who misused any fentanyl product had used IMF; misuse of fentanyl products includes misuse of prescription forms of fentanyl or use of IMF.³⁷

Fentanyl is 50 to 100 times stronger than morphine. Therefore, the risks for overdose or other adverse effects are substantially increased when people use IMF, especially among people whose bodies are not accustomed to the effects of opioids. IMF is sometimes present in products that are sold as heroin or in counterfeit prescription drugs that are made to look like commonly misused prescription opioids. Some people who use IMF are not aware they are doing so.^{38,39,40,41} The physical appearance or taste of a product or the purchase of drugs from a known source are not reliable indicators of whether they contain IMF. A drug product's physical effects can be a better but not completely reliable indicator of whether the product contains IMF, especially if people have had substantial experience using opioids, such as heroin. Because people who used IMF may have been unaware that they used it, caution must be taken in interpreting estimates of IMF use; these estimates are almost certainly an underestimate of true IMF use.

Among people aged 12 or older, the percentage who used IMF in the past year showed no change from 2021 to 2025 (Table A.18B). In 2025, 0.3 percent of people aged 12 or older (or 768,000 people) used IMF in the past year. Percentages also showed no change from 2021 to 2025 for each age group.

In 2025, the percentage of people who used IMF in the past year did not differ significantly by age group. Percentages ranged from 0.1 percent (or 34,000 people) among adolescents aged 12 to 17 to 0.3 percent (or 676,000 people) among adults aged 26 or older. An estimated 0.2 percent of young adults aged 18 to 25 (57,000 people) used IMF in the past year (Table A.18B).

Initiation of Substance Use

NSDUH included questions to measure the initiation of substance use—that is, the first use of particular substances during a person's lifetime.⁴² This report presents estimates for people aged 12 or older who initiated the use or misuse of a particular substance in the 12 months before the NSDUH interview.^{43,44,45} See the section on the [Misuse of Prescription Psychotherapeutic Drugs](#) for the definition of “misuse” of prescription drugs.

This report highlights estimates and trends for past year initiation of the five substances with the largest numbers of people aged 12 or older in 2025 who initiated use in the past year: alcohol use, nicotine vaping, marijuana use, cigar use, and cigarette use. Estimates for initiation of the use or misuse of additional substances are also presented in figures and tables.

It is important to note the relationship between an aggregate measure of substance use (i.e., a measure including a group of substances) and the individual drugs that make up that aggregate measure. For example, crack (an individual drug) is a form of cocaine (a combined measure including crack and other forms of cocaine). If a person first used crack in the past year but first used other forms of cocaine more than 12 months ago, that person would be a past year initiate of crack use but would not be a past year initiate of cocaine use.


These relationships are especially important to consider for the aggregate measure for the initiation of misuse of prescription psychotherapeutic drugs. There is potential for respondents to underreport lifetime (but not past year) misuse of prescription drugs.⁴⁶ This potential for underreporting could affect the accuracy of aggregate initiation estimates that include prescription psychotherapeutics, such as initiation of the use of any illicit drug. Therefore, this report does not present estimates for past year initiation that include prescription psychotherapeutics, such as central nervous system (CNS) stimulant misuse (cocaine, methamphetamine, or prescription stimulants) or any illicit drug use (including prescription drug misuse).⁴⁷

In addition, NSDUH respondents are asked how old they were when they first used or misused a substance. Respondents who first used (or misused) a substance in the past year would need to recall only whether this event happened at their current age or at the age that was 1 year less than their current age. Information on the age when past

year initiates first used alcohol or nicotine products is useful for estimating whether past year initiation of use occurred before age 21 or at age 21 or older.

Figure 32 and Table A.19A provide an overview of the numbers of people aged 12 or older in 2025 who were past year initiates of the use or misuse of the substances discussed in this section. In the past 12 months, 4.3 million people used alcohol for the first time, 4.2 million people vaped nicotine for the first time, 2.4 million people used marijuana for the first time, 1.8 million people tried cigars for the first time, and 1.7 million people tried a cigarette for the first time. Smaller numbers of people initiated the use or misuse of other substances shown in Figure 32.

Figure 32. Past Year Initiates of Substances: Among People Aged 12 or Older; 2025




Rx = prescription.

Initiation of Alcohol Use

Among people aged 12 or older, the percentage who initiated alcohol use in the past year—meaning they had never had more than a sip or two from a drink before the past 12 months—showed no change from 2021 to 2025 (Figure 33 and Table A.20B). In 2025, 1.5 percent of people aged 12 or older (or 4.3 million people) initiated alcohol use in the past year. Percentages also showed no change from 2021 to 2025 for young adults aged 18 to 25 and adults aged 26 or older (Tables A.22B and A.23B). Among adolescents aged 12 to 17, however, the percentage who initiated alcohol use in the past year decreased from 7.1 percent (or 1.8 million people) in 2021 to 6.2 percent (or 1.6 million people) in 2025 (Table A.21B).

Figure 33. Past Year Alcohol Use Initiates: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.


Figure 33 Table. Past Year Alcohol Use Initiates: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	1.5	1.5	1.5	1.5	1.5	No Change
12 to 17	7.1	7.0	7.0	6.4	6.2	Decreased
18 to 25	6.2	6.5	6.7	6.7	7.1	No Change
26 or Older	0.1	0.1	<0.1	0.1	0.1	No Change

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

In 2025, the percentages of people who initiated alcohol use in the past year were higher among young adults aged 18 to 25 (7.1 percent or 2.6 million people) or adolescents aged 12 to 17 (6.2 percent or 1.6 million people) than among adults aged 26 or older (0.1 percent or 117,000 people) (Figure 33 and Tables A.21B, A.22B, and A.23B). Approximately 7 in 10 of the 4.3 million people in 2025 who initiated alcohol use in the past year did so before age 21 (70.1 percent or 3.0 million people) (Figure 34 and Table A.24AB).

Figure 34. Initiation of Use before Age 21 and at Age 21 or Older: Among People Aged 12 or Older Who Were Past Year Initiates of the Substance; 2025




Initiation of Nicotine Vaping

Among people aged 12 or older, the percentage who initiated nicotine vaping in the past year—meaning they had never vaped nicotine before the past 12 months—decreased from 2.1 percent (or 5.9 million people) in 2022 to 1.5 percent (or 4.2 million people) in 2025 (Figure 35 and Table A.20B). Percentages also decreased from 2022 to 2025 for people in each age group (Tables A.21B, A.22B, and A.23B). For example, the percentage of young adults aged 18 to 25 who first vaped nicotine in the past year decreased from 4.1 percent (or 1.4 million people) in 2022 to 2.7 percent (or 982,000 people) in 2025. Note that estimates in 2022 to 2024 for the initiation of nicotine vaping in the past year may differ from previously published estimates because of updates to nicotine vaping measures.¹⁷

In 2025, the percentage of people who initiated nicotine vaping in the past year was highest among adolescents aged 12 to 17 (3.8 percent or 968,000 people), followed by young adults aged 18 to 25 (2.7 percent or 982,000 people), then by adults aged 26 or older (1.0 percent or 2.3 million people) (Figure 35 and Tables A.21B, A.22B, and A.23B). Among the 4.2 million people who initiated nicotine vaping in the past year, about one third (35.9 percent or 1.5 million

Figure 35. Past Year Nicotine Vaping Initiates: Among People Aged 12 or Older; 2022-2025



Note: Some 2022-2024 estimates may differ from previously published estimates due to updates to the editing procedures for this measure.

Figure 35 Table. Past Year Nicotine Vaping Initiates: Among People Aged 12 or Older; Percentages, 2022-2025

Age Group	2022	2023	2024	2025	Trend
12 or Older	2.1	2.0	1.8	1.5	Decreased
12 to 17	5.5	5.4	4.2	3.8	Decreased
18 to 25	4.1	3.9	3.2	2.7	Decreased
26 or Older	1.4	1.3	1.3	1.0	Decreased

Note: Some 2022-2024 estimates may differ from previously published estimates due to updates to the editing procedures for this measure.


people) did so before age 21, and about two thirds (64.1 percent or 2.7 million people) did so at age 21 or older (Figure 34 and Table A.24AB).

Initiation of Marijuana Use

Among people aged 12 or older, the percentage of people who initiated marijuana use in the past year decreased from 1.0 percent (or 2.7 million people) in 2021 to 0.8 percent (or 2.4 million people) in 2025 (Figure 36 and Table A.20B). The percentage of adolescents aged 12 to 17 who initiated marijuana use in the past year also decreased from 3.5 percent (or 913,000 people) in 2021 to 2.4 percent (or 615,000 people) in 2025 (Table A.21B). Percentages showed no change from 2021 to 2025 for young adults aged 18 to 25 and adults aged 26 or older (Tables A.22B and A.23B).

In 2025, the percentage of people who initiated marijuana use in the past year was highest among young adults aged 18 to 25 (3.2 percent or 1.1 million people), followed by adolescents aged 12 to 17 (2.4 percent or 615,000 people), then by adults aged 26 or older (0.3 percent or 593,000 people) (Figure 36 and Tables A.21B, A.22B, and A.23B).

Figure 36. Past Year Marijuana Use Initiates: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 36 Table. Past Year Marijuana Use Initiates: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	1.0	1.3	1.2	1.0	0.8	Decreased
12 to 17	3.5	4.8	4.5	3.5	2.4	Decreased
18 to 25	3.5	3.4	3.5	2.9	3.2	No Change
26 or Older	0.3	0.6	0.5	0.4	0.3	No Change


Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Initiation of Cigar Use

Among people aged 12 or older, the percentage who initiated cigar use in the past year showed no change from 2021 to 2025 (Figure 37 and Table A.20B). Percentages also showed no change from 2021 to 2025 for adolescents aged 12 to 17 and young adults aged 18 to 25 (Tables A.21B and A.22B). Among adults aged 26 or older, the percentage who initiated cigar use in the past year increased from 0.1 percent (or 315,000 people) in 2021 to 0.4 percent (or 829,000 people) in 2025 (Table A.23B).

In 2025, the percentage of people who initiated cigar use in the past year was highest among young adults aged 18 to 25 (2.3 percent or 823,000 people), followed by adolescents aged 12 to 17 (0.7 percent or 185,000 people), then by adults aged 26 or older (0.4 percent or 829,000 people) (Figure 37 and Tables A.21B, A.22B, and A.23B). About two thirds of the 1.8 million people who initiated cigar use in the past year did so at age 21 or older (68.6 percent or 1.3 million people) (Figure 34 and Table A.24AB).

Figure 37. Past Year Cigar Use Initiates: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 37 Table. Past Year Cigar Use Initiates: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	0.5	0.6	0.7	0.5	0.6	No Change
12 to 17	1.1	0.9	0.9	0.9	0.7	No Change
18 to 25	2.4	2.4	3.1	2.5	2.3	No Change
26 or Older	0.1	0.2	0.3	0.2	0.4	Increased


Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Initiation of Cigarette Use

Among people aged 12 or older, the percentage who initiated cigarette use in the past year increased from 0.4 percent (or 1.2 million people) in 2021 to 0.6 percent (or 1.7 million people) in 2025 (Figure 38 and Table A.20B). The percentage also increased among young adults aged 18 to 25, from 2.2 percent (or 736,000 people) in 2021 to 3.2 percent (or 1.1 million people) in 2025 (Table A.22B). Percentages showed no change from 2021 to 2025 for adolescents aged 12 to 17 and adults aged 26 or older (Tables A.21B and A.23B).

In 2025, the percentage of people who initiated cigarette use in the past year was highest among young adults aged 18 to 25 (3.2 percent or 1.1 million people), followed by 1.4 percent of adolescents aged 12 to 17 (or 363,000 people), then by 0.1 percent of adults aged 26 or older (or 152,000 people) (Figure 38 and Tables A.21B, A.22B, and A.23B). Nearly two thirds of the 1.7 million people who initiated cigarette use in the past year did so before age 21 (65.7 percent or 1.1 million people) (Figure 34 and Table A.24AB).

Figure 38. Past Year Cigarette Use Initiates: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 38 Table. Past Year Cigarette Use Initiates: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	0.4	0.5	0.5	0.5	0.6	Increased
12 to 17	1.5	1.7	1.7	1.3	1.4	No Change
18 to 25	2.2	2.3	2.8	2.9	3.2	Increased
26 or Older	<0.1	0.1	<0.1	0.1	0.1	No Change

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Substance Use Disorders in the Past Year

Substance use disorders (SUDs) are characterized by impairment caused by the recurrent use of alcohol or other drugs (or both), such as health problems; disability; or failure to meet major responsibilities at work, school, or home. NSDUH has included a series of questions to estimate the percentage of the population aged 12 or older who had at least one SUD in the past 12 months (subsequently referred to as “an SUD” or “a past year SUD”). The SUD questions assess the presence of an SUD in the past 12 months based on criteria specified in the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition (DSM-5).^{48,49} Respondents were asked about their SUD symptoms for any alcohol or drugs they used in the 12 months prior to the survey. Drugs include marijuana, cocaine (including crack), heroin, hallucinogens, inhalants, methamphetamine, and *any* use of prescription stimulants, tranquilizers or sedatives (e.g., benzodiazepines), and pain relievers. The DSM-5 SUD criteria for prescription drugs apply to people who used prescription drugs for any reason in the past year. Therefore, NSDUH respondents in 2025 who reported *any* use of prescription psychotherapeutic drugs (i.e., pain relievers, tranquilizers, stimulants, or sedatives) in the past year (i.e., not just misuse of prescription drugs) were asked the respective SUD questions for that category of prescription drugs. Beginning with the 2024 NSDUH, however, respondents were not counted as having an opioid use disorder if the prescription pain relievers they reported using in the past year were not opioids, and they did not use heroin in the past year.

In addition, questions about the use of illegally made fentanyl (IMF) have appeared after SUD questions in the NSDUH questionnaire since 2022. For this reason, overall SUD, drug use disorder, and opioid use disorder measures do not capture disorders arising solely from the use of IMF. As discussed in the [Illegally Made Fentanyl Use](#) section, however, the estimate of IMF use in the past year among people aged 12 or older was low in 2025 (0.3 percent or 768,000 people). For data from people who used IMF in the past year to affect SUD estimates in NSDUH, respondents would need to have used only IMF or to have attributed their SUD symptoms to IMF and not to their use of other substances. Fewer than 15 respondents in 2025 reported using IMF in the past year but did not report using alcohol or other drugs in the past year.

DSM-5 includes the following SUD criteria (as measured in the 2025 NSDUH):

1. The substance is often taken in larger amounts or over a longer period than intended.
2. There is a persistent desire or unsuccessful efforts to cut down or control substance use.
3. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects.
4. There is a craving, or a strong desire or urge, to use the substance.
5. There is recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home.
6. There is continued substance use despite having persistent or recurrent social or interpersonal problems caused by or exacerbated by the effects of the substance.
7. Important social, occupational, or recreational activities are given up or reduced because of substance use.
8. There is recurrent substance use in situations in which it is physically hazardous.
9. Substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance.
10. There is a need for markedly increased amounts of the substance to achieve intoxication or the desired effect, or markedly diminished effect with continued use of the same amount of the substance (i.e., tolerance).
11. For substances other than hallucinogens and inhalants that have a withdrawal criterion, there are two components of withdrawal symptoms, either of which meet the overall criterion for withdrawal symptoms:
 - a. There is a required number of withdrawal symptoms that occur when substance use is cut back or stopped following a period of prolonged use.⁵⁰
 - b. The substance or a related substance is used to get over or avoid withdrawal symptoms.⁵¹

Table 1 shows how these 11 DSM-5 SUD criteria apply to substances in NSDUH. For prescription opioids, tranquilizers, stimulants, and sedatives, Table 1 also shows how these criteria apply if respondents misused prescription drugs or if they simply used but did not misuse prescription drugs in the past year. For consistency with the DSM-5 criteria, NSDUH respondents were classified as having an SUD in the past year if they met two or more of the applicable criteria for a given substance in the 12-month period before the interview. NSDUH does not measure whether respondents met criteria for an SUD prior to the past 12 months. Thus, some respondents could have received treatment for SUDs that occurred more than 12 months before the interview, but they did not have active SUD symptoms in the past 12 months.

For alcohol, marijuana, cocaine, heroin, and methamphetamine in Table 1, respondents were classified as having an SUD in the past year if they met 2 or more of the 11 criteria in the 12-month period before the interview. However, respondents were classified as having a hallucinogen use disorder or an inhalant use disorder if they met 2 or more of the first 10 criteria in the past 12 months; the withdrawal criterion does not apply to hallucinogens and inhalants.

For the use or misuse of prescription drugs in Table 1, the number of applicable DSM-5 criteria for classifying respondents as having an SUD depends on whether respondents misused prescription drugs, or they used prescription drugs in the past year, but they did *not* misuse them. If respondents misused prescription drugs in the past year, they were classified as having an SUD if they met

Table 1. DSM-5 SUD Criteria for Substances and Types of Use in the 2025 NSDUH

Criterion ¹	Alcohol	Marijuana	Cocaine ²	Heroin ³	Hallucinogens	Inhalants	Methamphetamine ²	Rx Opioids, Use but Not Misuse ³	Rx Opioids, Misuse ³	Rx Tranquilizers, Use but Not Misuse ⁴	Rx Tranquilizers, Misuse ⁴	Rx Stimulants, Use but Not Misuse ²	Rx Stimulants, Misuse ²	Rx Sedatives, Use but Not Misuse ⁴	Rx Sedatives, Misuse ⁴
1: Substance is often taken in larger amounts, longer than intended	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
2: Unsuccessful efforts to cut down/control use	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
3: A great deal of time is spent obtaining, using, recovering	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
4: Craving/strong urge to use	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
5: Recurrent use resulting in failure to fulfill major role obligations at work/school/home	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
6: Continued use despite social problems	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
7: Important social/occupational/recreational activities given up or reduced because of use	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
8: Recurrent use in physically hazardous situations	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
9: Continued use despite physical, psychological problems	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
10: Increased amount of substance is needed to achieve same effect	●	●	●	●	●	●	●	—	●	—	●	—	●	—	●
11a: Withdrawal symptoms ⁵	●	●	●	●	—	—	●	—	●	—	●	—	●	—	●
11b: The same or related substance is taken to avoid withdrawal symptoms	●	●	●	●	—	—	●	—	●	—	●	—	●	—	●

● = criterion applies; — = criterion does not apply.
DSM-5 = *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition; Rx = prescription;
SUD = substance use disorder.
¹ The criterion wording is based on the 2025 NSDUH questions.

² These substances contribute to central nervous system stimulant use disorder.
³ These substances contribute to opioid use disorder.
⁴ These substances contribute to Rx tranquilizer or Rx sedative use disorder.
⁵ Withdrawal symptoms and requirements differ by substance.

2 or more of the 11 criteria shown in [Table 1](#). However, if respondents used prescription drugs in the past year but did not misuse them, they were classified as having an SUD if they met two or more of the first *nine* criteria shown in [Table 1](#). Criteria 10 (tolerance) and 11 (withdrawal) do not apply to respondents who used but did not misuse these prescription drugs in the past year; tolerance and withdrawal can occur as normal physiological adaptations when people use these prescription drugs appropriately under medical supervision.⁵²

Substances and types of use or misuse that are included in selected SUD measures in the 2025 NSDUH are as follows:

- Any SUD in the past year includes data from past year users of alcohol, marijuana, cocaine (including crack), heroin, hallucinogens, inhalants, and methamphetamine, and *any* past year users of prescription psychotherapeutic drugs.⁵³
- Alcohol use disorder includes only data from past year users of alcohol.⁵³
- Drug use disorder includes data from past year users of marijuana,⁵³ cocaine, heroin, hallucinogens, inhalants, and methamphetamine, and *any* past year users of prescription psychotherapeutic drugs. It does not include people who had only an alcohol use disorder in the past year.

In addition, NSDUH asked respondents about SUD symptoms that respondents specifically attributed to their


use in the past year of cocaine, heroin, methamphetamine, prescription pain relievers, prescription tranquilizers, prescription stimulants, and prescription sedatives. However, DSM-5 groups these substances into a smaller set of categories for classifying people as having SUDs.

- Cocaine, methamphetamine, and prescription stimulants are included in an overall category for stimulants (referred to in NSDUH as CNS stimulants to differentiate between stimulants that are available by prescription and those that are not).
- Heroin and prescription pain relievers that are opioids are included in an overall category for opioids.
- Prescription tranquilizers and sedatives are included in an overall category for sedatives, hypnotics, and anxiolytics (referred to in NSDUH as prescription tranquilizer or sedative use disorder).

Therefore, this report does not focus on SUDs arising from the use of specific substances, such as heroin or prescription opioids. Rather, the report focuses on estimates for CNS stimulant use disorder, opioid use disorder, and prescription tranquilizer or sedative use disorder that align with DSM-5 categories.

In 2025, 44.6 million people aged 12 or older (or 15.3 percent of the population) had an SUD in the past year, including 25.7 million people who had an alcohol use disorder and 26.0 million people who had a drug use disorder ([Figure 39](#) and [Tables A.25AB](#) and [A.26B](#)). People

Figure 39. Past Year Substance Use Disorder (SUD): Among People Aged 12 or Older; 2025



CNS = central nervous system.

Note: The estimated numbers of people with SUDs are not mutually exclusive because people could have an SUD for more than one substance.

¹ Includes data from all past year users of marijuana, cocaine, heroin, hallucinogens, inhalants, methamphetamine, or prescription psychotherapeutic drugs (i.e., pain relievers, tranquilizers, stimulants, or sedatives). See footnote 3 for more information about opioid use disorder.

² Includes data from all past year users of cocaine, methamphetamine, or prescription stimulants.


³ Includes data from all past year users of heroin or prescription opioids. Respondents were not included if they used only nonopioid pain relievers.

who had an SUD in the past year tended to have an alcohol use disorder only or a drug use disorder only. About 1 in 6 people with a past year SUD (16.0 percent or 7.1 million people) had both an alcohol use disorder and a drug use disorder in the past year.

Among people aged 12 or older, the percentage who had a past year SUD decreased from 16.7 percent (or 46.8 million people) in 2021 to 15.3 percent (or 44.6 million people) in 2025 (Figure 40 and Table A.26B). Percentages also decreased from 2021 to 2025 for each age group (Tables A.27B, A.28B, and A.29B). For example, the percentage of young adults aged 18 to 25 who had a past year SUD decreased from 26.2 percent (or 8.8 million people) in 2021 to 23.8 percent (or 8.6 million people) in 2025.

In 2025, the percentage of people who had a past year SUD was highest among young adults aged 18 to 25 (23.8 percent or 8.6 million people), followed by adults aged 26 or older (14.9 percent or 34.1 million people), then by adolescents aged 12 to 17 (7.4 percent or 1.9 million people) (Figure 40 and Tables A.27B, A.28B, and A.29B).

Figure 40. Past Year Substance Use Disorder: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 40 Table. Past Year Substance Use Disorder: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	16.7	17.3	17.1	16.8	15.3	Decreased
12 to 17	9.2	8.7	8.5	7.8	7.4	Decreased
18 to 25	26.2	27.8	27.1	25.9	23.8	Decreased
26 or Older	16.2	16.6	16.6	16.4	14.9	Decreased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.


Alcohol Use Disorder

Respondents who used alcohol on 6 or more days in the past 12 months were classified as having an alcohol use disorder if they met two or more of the DSM-5 criteria for alcohol use disorder. Relevant criteria for alcohol use disorder can be found in the 2025 Methodological Summary and Definitions report.¹¹

Among people aged 12 or older, the percentage who had a past year alcohol use disorder decreased from 10.6 percent (or 29.7 million people) in 2021 to 8.9 percent (or 25.7 million people) in 2025 (Figure 41 and Table A.26B). Percentages also decreased from 2021 to 2025 for each age group (Tables A.27B, A.28B, and A.29B). For example, the percentage of young adults aged 18 to 25 who had a past year alcohol use disorder decreased from 15.5 percent (or 5.2 million people) in 2021 to 13.1 percent (or 4.7 million people) in 2025.

In 2025, the percentage of people who had a past year alcohol use disorder was highest among young adults aged 18 to 25 (13.1 percent or 4.7 million people), followed by adults aged 26 or older (8.9 percent or 20.3 million people), then by adolescents aged 12 to 17 (2.8 percent or 710,000 people) (Figure 41 and Tables A.27B, A.28B, and A.29B).

Figure 41. Past Year Alcohol Use Disorder: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 41 Table. Alcohol Use Disorder in the Past Year: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	10.6	10.5	10.2	9.7	8.9	Decreased
12 to 17	3.7	2.9	2.9	3.0	2.8	Decreased
18 to 25	15.5	16.4	15.1	14.4	13.1	Decreased
26 or Older	10.7	10.4	10.3	9.7	8.9	Decreased


Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Drug Use Disorder

This section presents overall estimates for drug use disorder, then provides estimates for selected specific drugs. As discussed previously, drug use disorder was defined as meeting DSM-5 SUD criteria for one or more of the following drugs that were used in the past year: marijuana, cocaine, heroin, hallucinogens, inhalants, methamphetamine, or prescription psychotherapeutic drugs (i.e., stimulants, tranquilizers or sedatives, and pain relievers). Measures for prescription drug use disorders for 2025 were based on data from *all* past year users of prescription drugs, not just misusers. Relevant SUD definitions and criteria for specific drugs can be found in [Table 1](#) and in the 2025 Methodological Summary and Definitions report.¹¹

Among people aged 12 or older, the percentage who had a past year drug use disorder showed no change from 2021 to 2025. In 2025, 8.9 percent of people aged 12 or older (or 26.0 million people) had a past year drug use disorder ([Figure 42](#) and [Table A.26B](#)). Percentages for young adults aged 18 to 25 and adults aged 26 or older also showed no change from 2021 to 2025 ([Tables A.28B](#) and [A.29B](#)). Among adolescents aged 12 to 17, the percentage who had a past year drug use disorder decreased from 7.3 percent (or

Figure 42. Past Year Drug Use Disorder: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 42 Table. Past Year Drug Use Disorder: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	8.7	9.7	9.6	9.8	8.9	No Change
12 to 17	7.3	7.0	6.9	6.6	5.9	Decreased
18 to 25	16.6	18.6	18.0	17.8	15.9	No Change
26 or Older	7.7	8.5	8.6	8.9	8.2	No Change

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

1.9 million people) in 2021 to 5.9 percent (or 1.5 million people) in 2025 ([Table A.27B](#)).


In 2025, the percentage of people who had a past year drug use disorder was highest among young adults aged 18 to 25 (15.9 percent or 5.7 million people), followed by adults aged 26 or older (8.2 percent or 18.7 million people), then by adolescents aged 12 to 17 (5.9 percent or 1.5 million people) ([Figure 42](#) and [Tables A.27B](#), [A.28B](#), and [A.29B](#)).

Marijuana (Cannabis) Use Disorder

Among people aged 12 or older, the percentage who had a past year marijuana (cannabis) use disorder increased from 6.0 percent (or 16.7 million people) in 2021 to 6.7 percent (or 19.3 million people) in 2025 ([Figure 43](#) and [Table A.26B](#)). The percentage of people who had a past year marijuana use disorder also increased among adults aged 26 or older, from 4.7 percent (or 10.4 million people) in 2021 to 5.7 percent (or 13.1 million people) in 2025 ([Table A.29B](#)). Percentages showed no change from 2021 to 2025 for adolescents aged 12 to 17 and young adults aged 18 to 25 ([Tables A.27B](#) and [A.28B](#)).

In 2025, the percentage of people who had a past year marijuana use disorder was highest among young adults aged

Figure 43. Past Year Marijuana Use Disorder: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 43 Table. Past Year Marijuana Use Disorder: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	6.0	6.7	6.8	7.1	6.7	Increased
12 to 17	5.2	5.1	4.7	4.7	4.4	No Change
18 to 25	14.7	16.5	16.6	15.8	14.1	No Change
26 or Older	4.7	5.4	5.5	6.1	5.7	Increased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.


18 to 25 (14.1 percent or 5.1 million people), followed by adults aged 26 or older (5.7 percent or 13.1 million people), then by adolescents aged 12 to 17 (4.4 percent or 1.1 million people) (Figure 43 and Tables A.27B, A.28B, and A.29B).

Central Nervous System Stimulant Use Disorder

Central nervous system (CNS) stimulant use disorder included data from people who used cocaine, methamphetamine, or prescription stimulants in the past year. NSDUH respondents were counted as having a CNS stimulant use disorder if they met two or more of the DSM-5 criteria shown in Table 1 for cocaine, methamphetamine, or prescription stimulants in the past year, including situations in which respondents met SUD criteria for more than one of these substances. Respondents were not counted as having a CNS stimulant use disorder if they did not meet the full SUD criteria individually for cocaine, methamphetamine, or prescription stimulants.

Among people aged 12 or older, the percentage who had a past year CNS stimulant use disorder showed no change from 2021 to 2025 (Figure 44 and Table A.26B). In 2025, 1.5 percent of people aged 12 or older (or 4.5 million people) had a past year CNS stimulant use disorder.

Figure 44. Past Year Central Nervous System (CNS) Stimulant Use Disorder: Among People Aged 12 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 44 Table. Past Year Central Nervous System (CNS) Stimulant Use Disorder: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	1.5	1.6	1.5	1.5	1.5	No Change
12 to 17	1.1	1.0	1.0	0.8	0.8	No Change
18 to 25	1.9	2.2	1.5	2.1	1.6	No Change
26 or Older	1.5	1.6	1.6	1.5	1.6	No Change

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Percentages also showed no change from 2021 to 2025 for each age group (Tables A.27B, A.28B, and A.29B).


In 2025, the percentage of people who had a past year CNS stimulant use disorder was higher among young adults aged 18 to 25 and adults aged 26 or older (1.6 percent for each age group, or 591,000 young adults and 3.7 million adults aged 26 or older) than among adolescents aged 12 to 17 (0.8 percent or 213,000 people) (Figure 44 and Tables A.27B, A.28B, and A.29B).

Opioid Use Disorder

Opioid use disorder included data from people who used heroin or prescription opioids in the past year. NSDUH respondents were counted as having an opioid use disorder if they met two or more of the DSM-5 criteria shown in Table 1 for heroin or prescription opioids in the past year, including situations in which respondents met SUD criteria for both substances. Respondents were not counted as having an opioid use disorder if they did not meet the full SUD criteria individually for heroin or prescription opioids. As noted previously, respondents also were not counted as having an opioid use disorder if the prescription pain relievers they reported using in the past year were not opioids, and they did not use heroin in the past year. Additionally, questions about the use of IMF were asked in the 2025 NSDUH following the SUD questions; hence, the opioid use disorder estimates do not capture symptoms that arose solely from the use of IMF in the past year. However, fewer than 30 respondents in 2025 reported use of IMF in the past year but did not report use of heroin or any use of prescription opioids in that period.

Among people aged 12 or older, the percentage who had a past year opioid use disorder decreased from 1.9 percent (or 5.2 million people) in 2021 to 1.4 percent (or 4.0 million people) in 2025 (Figure 45 and Table A.26B). The percentage of people who had a past year opioid use disorder also decreased among adults aged 26 or older, from 2.1 percent (or 4.6 million people) in 2021 to 1.5 percent (or 3.4 million people) in 2025 (Table A.29B). Percentages showed no change from 2021 to 2025 for adolescents aged 12 to 17 and young adults aged 18 to 25 (Tables A.27B and A.28B).

In 2025, the percentage of people who had a past year opioid use disorder was higher among adults aged 26 or older (1.5 percent or 3.4 million people) than among young adults

Figure 45. Past Year Opioid Use Disorder: Among People Aged 12 or Older; 2021-2025

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Note: Estimates for 2021-2023 may differ from previously published estimates for opioid use disorder because they do not include the use of only nonopioid pain relievers.

Figure 45 Table. Past Year Opioid Use Disorder: Among People Aged 12 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
12 or Older	1.9	2.0	1.8	1.7	1.4	Decreased
12 to 17	0.9	0.9	0.9	1.0	0.8	No Change
18 to 25	1.2	1.1	1.0	1.0	0.9	No Change
26 or Older	2.1	2.3	2.0	1.9	1.5	Decreased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.


Note: Estimates for 2021-2023 may differ from previously published estimates for opioid use disorder because they do not include the use of only nonopioid pain relievers.

aged 18 to 25 (0.9 percent or 337,000 people) or adolescents aged 12 to 17 (0.8 percent or 207,000 people) ([Figure 45](#) and [Tables A.27B](#), [A.28B](#), and [A.29B](#)).

Substance Use Disorder Severity

The DSM-5 SUD criteria include a severity level classification. People who meet two or three criteria are considered to have a “mild” disorder, those who meet four or five criteria are considered to have a “moderate” disorder, and those who meet six or more criteria are considered to have a “severe” disorder. For SUD measures that were aggregated across more than one substance (e.g., any SUD, drug use disorder), mild SUD meant that people had only mild SUDs. Moderate SUD meant that people had at least one moderate SUD but did not have severe SUDs. Severe SUD meant that people had a severe SUD for at least one substance.

Highlights from [Figure 46](#) and [Table A.30B](#) for severity levels among people aged 12 or older in 2025 who had a past year SUD, drug use disorder, marijuana use disorder, or alcohol use disorder include the following:

Figure 46. Substance Use Disorder (SUD) Severity Level for Specific Substances in the Past Year: Among People Aged 12 or Older with a Specific SUD; 2025

Note: The percentages may not add to 100 percent due to rounding.

Note: There are 11 criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, that apply to these substances. People who meet two or three criteria are considered to have a “mild” disorder, those who meet four or five criteria are considered to have a “moderate” disorder, and those who meet six or more criteria are considered to have a “severe” disorder.

¹ Includes data from all past year users of marijuana, cocaine, heroin, hallucinogens, inhalants, methamphetamine, and prescription psychotherapeutic drugs (i.e., pain relievers, tranquilizers, stimulants, or sedatives).


- Among the 44.6 million people aged 12 or older who had a past year SUD ([Figure 39](#) and [Table A.25AB](#)), most (54.1 percent) had a mild disorder, and about 1 in 5 (22.5 percent) had a severe disorder.
 - A similar pattern occurred among each age group.
 - Percentages of people with a past year SUD who had a severe disorder did not differ significantly by age group and ranged from 22.0 percent among adults aged 26 or older to 25.1 percent among adolescents aged 12 to 17.
- The percentages for severity among people aged 12 or older who had a past year drug use disorder followed a general pattern similar to that for any SUD in that period.
 - Among the 26.0 million people aged 12 or older who had a drug use disorder ([Figure 39](#) and [Table A.25AB](#)), most (53.0 percent) had a mild disorder, and about 1 in 5 (22.1 percent) had a severe disorder.

- Among people with a past year drug use disorder, percentages who had a severe disorder were higher among adolescents aged 12 to 17 (28.1 percent) and young adults aged 18 to 25 (25.3 percent) than among adults aged 26 or older (20.6 percent).
 - The percentages for severity among people who had a marijuana use disorder in the past year followed a general pattern similar to that for any SUD among people aged 12 or older, young adults aged 18 to 25, and adults aged 26 or older.
 - Among the 19.3 million people aged 12 or older who had a marijuana use disorder (Figure 39), most (53.4 percent) had a mild disorder, and about 1 in 6 (18.0 percent) had a severe disorder.
 - A slightly different pattern occurred among adolescents aged 12 to 17. Among adolescents who had a marijuana use disorder, about one third (35.7 percent) had a mild disorder, and one third (33.4 percent) had a severe disorder.
 - Among all people who had a marijuana use disorder, the percentage who had a severe disorder was highest among adolescents aged 12 to 17 (33.4 percent), followed by young adults aged 18 to 25 (25.3 percent), then by adults aged 26 or older (13.8 percent).
 - The percentages for severity among people aged 12 or older who had a past year alcohol use disorder followed a general pattern similar to that for any SUD in that period.
 - Among the 25.7 million people aged 12 or older with a past year alcohol use disorder (Figure 39 and Table A.25AB), most (57.6 percent) had a mild disorder, compared with about 1 in 5 (20.7 percent) who had a severe disorder.
 - Among people with a past year alcohol use disorder, percentages who had a severe disorder did not differ significantly by age group and ranged from 14.5 percent among adolescents aged 12 to 17 to 21.6 percent among adults aged 26 or older.
- In summary, the majority of people aged 12 or older who had an SUD, a drug use disorder, an alcohol use disorder, or a marijuana use disorder had a mild disorder, and only about 1 in 5 people with these disorders had a severe disorder.

These patterns differ from those described next for people with a CNS stimulant use disorder due to their misuse of CNS stimulants and for people with an opioid use disorder due to their misuse of opioids.

Among the estimated 4.5 million people aged 12 or older in 2025 who had a CNS stimulant use disorder in the past year (Figure 39), about 2 in 5 (40.7 percent) had a mild disorder, and about 2 in 5 (39.1 percent) had a severe disorder (Figure 47 and Table A.31B).

Figure 47. Central Nervous System (CNS) Stimulant Use Disorder Severity Level in the Past Year: Among People Aged 12 or Older with a CNS Stimulant Use Disorder; 2025



SUD = substance use disorder.

Note: As shown in Table 1, the number of criteria for CNS stimulant use disorder differed for people who misused prescription stimulants in the past year or who used but did not misuse them. Regardless of the total number of criteria used for classifying people as having a prescription stimulant use disorder, people who meet two or three criteria are considered to have a “mild” disorder, those who meet four or five criteria are considered to have a “moderate” disorder, and those who meet six or more criteria are considered to have a “severe” disorder.

¹ Past Year Misuse of CNS Stimulants is defined as the use of cocaine or methamphetamine or the misuse of prescription stimulants.


- Among people who had a CNS stimulant use disorder in the past year that was due to their misuse of CNS stimulants in the past year (i.e., use of cocaine or methamphetamine⁵⁴ or misuse of prescription stimulants), 29.8 percent had a mild disorder, and about half (47.9 percent) had a severe disorder (Table A.31B).

- In comparison, among people whose CNS stimulant use disorder was due only to their use but not misuse of prescription stimulants in the past year, 82.5 percent had a mild disorder, and 5.4 percent had a severe disorder ([Table A.31B](#)).

Among the estimated 4.0 million people aged 12 or older in 2025 who had an opioid use disorder in the past year ([Figure 39](#)), about 3 in 5 (58.9 percent) had a mild disorder, and about 1 in 5 (20.3 percent) had a severe disorder ([Figure 48](#) and [Table A.31B](#)).

- Among people who had an opioid use disorder in the past year that was due to their misuse of opioids in the past year (i.e., use of heroin⁵⁴ or misuse of prescription opioids), 32.0 percent had a mild disorder, and 38.4 percent had a severe disorder ([Table A.31B](#)).
- In comparison, among people whose opioid use disorder was due only to their use but not misuse of prescription opioids in the past year, 82.6 percent had a mild disorder, and 4.3 percent had a severe disorder ([Table A.31B](#)).

Figure 48. Opioid Use Disorder Severity Level in the Past Year: Among People Aged 12 or Older with an Opioid Use Disorder; 2025



SUD = substance use disorder.
Note: The percentages may not add to 100 percent due to rounding.
Note: As shown in [Table 1](#), the number of criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, for opioid use disorder differed for people who misused prescription opioids in the past year or who used but did not misuse them. Regardless of the total number of criteria used for classifying people as having an opioid use disorder, people who meet two or three criteria are considered to have a “mild” disorder, those who meet four or five criteria are considered to have a “moderate” disorder, and those who meet six or more criteria are considered to have a “severe” disorder.
¹ Past Year Misuse of Opioids is defined as the use of heroin or the misuse of prescription opioids.

Symptoms of Generalized Anxiety Disorder in the Past 2 Weeks

The seven-item GAD-7 scale has been included in the NSDUH questionnaire since 2024 for adolescents aged 12 to 17 and adults aged 18 or older. The GAD-7 is a validated self-report measure that is used to screen for generalized anxiety disorder (GAD) and assess the severity of symptoms of GAD in the past 2 weeks.⁵⁵ Although the GAD-7 captures recent symptoms, it does not estimate the prevalence of GAD because diagnostic criteria for GAD require a longer pattern of symptoms and impairment.⁴⁸ Symptoms assessed in the GAD-7 questions include feeling nervous or on edge, excessively worrying about different things, having difficulty controlling thoughts of worry, having trouble relaxing, being restless, feeling irritable, and feeling that something awful might happen. As shown in Table 2, GAD-7 scores range from 0 to 21, with higher scores indicating greater symptom severity. NSDUH respondents with scores of 0 to 4 were classified as having no or minimal symptoms of GAD, 5 to 9 as having mild symptoms, 10 to 14 as having moderate symptoms, and 15 to 21 as having severe symptoms.⁵⁶

Symptoms of Anxiety among Adolescents

Among adolescents aged 12 to 17 in 2025, about 1 in 5 (18.0 percent or 4.6 million people) had moderate or severe symptoms of GAD, including 10.6 percent (or 2.7 million people) who had moderate symptoms and 7.4 percent (or 1.9 million people) who had severe symptoms (Figure 49 and Table A.32B). The majority of adolescents (58.4 percent or 14.9 million people) had no or minimal symptoms, and the remainder had mild symptoms (23.6 percent or about 6.0 million people).

Figure 49. Generalized Anxiety Disorder (GAD) Symptom Severity in the Past 2 Weeks: Among Adolescents Aged 12 to 17; 2025




Table 2. GAD-7 Questions, Response Categories, and Score Classification

GAD-7 Questions					
Over the last 2 weeks, how often have you been bothered by...		Not at all	Several days	More than half the days	Nearly every day
1. Feeling nervous, anxious, or on edge?		0	1	2	3
2. Not being able to stop or control worrying?		0	1	2	3
3. Worrying too much about different things?		0	1	2	3
4. Having trouble relaxing?		0	1	2	3
5. Being so restless that it is hard to sit still?		0	1	2	3
6. Becoming easily annoyed or irritable?		0	1	2	3
7. Feeling afraid as if something awful might happen?		0	1	2	3
TOTAL SCORE					

GAD-7 Score

0 to 4
No or minimal symptoms

5 to 9
Mild symptoms

10 to 14
Moderate symptoms


15 to 21
Severe symptoms

GAD-7 = seven-item screener for generalized anxiety disorder (GAD) and severity of symptoms of GAD.
Note: Numbers ranging from 0 to 3 for each question are for scoring purposes. Response choices in the questionnaire ranged from 1 (Not at all) to 4 (Nearly every day).
Note: All respondents who had missing data for the individual GAD-7 questions had their responses statistically imputed. Thus, there were no missing values for the variables associated with the GAD-7 questions that were used in analysis.

Substance Use among Adolescents with Moderate or Severe Anxiety Symptoms

In 2025, adolescents aged 12 to 17 who had moderate or severe symptoms of anxiety in the past 2 weeks were more likely to have used some substances in the past year or past month compared with their counterparts who had no or minimal symptoms in the past 2 weeks. Adolescents with moderate or severe symptoms were more likely than adolescents with no or minimal symptoms to have used illicit drugs in the past year (17.7 vs. 8.2 percent), used marijuana in the past year (12.9 vs. 6.7 percent), or misused opioids (i.e., used heroin or misused prescription opioids) in the past year (2.6 vs. 1.0 percent) (Figure 50 and Table A.33B). Adolescents who had moderate or severe symptoms were more likely than those with no or minimal symptoms to have engaged in binge alcohol use in the past month (4.8 vs. 2.4 percent). In addition, adolescents with moderate or severe symptoms were more likely than those with no or minimal symptoms of anxiety to have used nicotine products in the past month (11.0 vs. 5.2 percent). Adolescents with moderate or severe symptoms of anxiety also were more likely than those with no or minimal symptoms to have used most of the other substances in the past year or past month that are shown in Table A.33B.

Figure 50. Past Year or Past Month Substance Use: Among Adolescents Aged 12 to 17; by Severity of Anxiety Symptoms in the Past 2 Weeks, 2025




⁺ Difference between this estimate and the estimate for adolescents with no or minimal anxiety symptoms is statistically significant at the .05 level.
Note: Generalized anxiety disorder (GAD) symptom severity is based on the GAD-7 scale. GAD-7 scores indicate the following: 0 to 4 = no or minimal symptoms of GAD, 5 to 9 = mild symptoms, 10 to 14 = moderate symptoms, 15 to 21 = severe symptoms. The Moderate or Severe category includes respondents with a GAD-7 score of 10 or greater.

Symptoms of Anxiety among Adults

Among adults aged 18 or older in 2025, 6.6 percent (or 17.5 million people) had moderate or severe symptoms of GAD in the past 2 weeks, including 4.2 percent (or 11.2 million people) who had moderate symptoms and 2.4 percent (or 6.3 million people) who had severe symptoms (Figure 51 and Table A.34B). About 8 in 10 adults (79.1 percent or 209.6 million people) had no or minimal symptoms, and the remainder had mild symptoms (14.3 percent or about 37.9 million people).

Figure 51. Generalized Anxiety Disorder (GAD) Symptom Severity in the Past 2 Weeks: Among Adults Aged 18 or Older; 2025



Note: GAD symptom severity is based on the GAD-7 scale. GAD-7 scores indicate the following: 0 to 4 = no or minimal symptoms of GAD, 5 to 9 = mild symptoms, 10 to 14 = moderate symptoms, 15 to 21 = severe symptoms. The Moderate or Severe category includes respondents with a GAD-7 score of 10 or greater.


In 2025, the percentage of adults who had moderate or severe symptoms was highest among young adults aged 18 to 25 (12.2 percent or 4.4 million people), followed by adults aged 26 to 49 (8.1 percent or 8.5 million people), then by adults aged 50 or older (3.7 percent or 4.6 million people) (Figure 51 and Table A.34B).

Substance Use among Adults with Moderate or Severe Anxiety Symptoms

In 2025, adults aged 18 or older who had moderate or severe symptoms of anxiety in the past 2 weeks were more likely to have used some substances in the past year or past month compared with their counterparts who had no or minimal symptoms. Adults with moderate or severe symptoms were more likely than adults with no or minimal

symptoms to have used illicit drugs in the past year (47.8 vs. 21.0 percent), used marijuana in the past year (42.1 vs. 18.4 percent), or misused opioids (i.e., used heroin or misused prescription opioids) in the past year (7.6 vs. 1.8 percent) (Figure 52 and Table A.35B). Adults who had moderate or severe symptoms were more likely than those with no or minimal symptoms to have engaged in binge alcohol use in the past month (25.5 vs. 20.0 percent). In addition, adults with moderate or severe symptoms were more likely than those with no or minimal symptoms to have used nicotine products in the past month (37.4 vs. 21.4 percent). Adults with moderate or severe symptoms also were more likely than those with no or minimal symptoms of anxiety in the past 2 weeks to have used most of the other substances in the past year or past month that are shown in Table A.35B. For example, 5.0 percent of adults (or 875,000 people) with moderate or severe symptoms of anxiety misused prescription tranquilizers or sedatives in the past year, compared with 1.0 percent of adults (or 2.0 million people) with no or minimal symptoms.

Figure 52. Past Year or Past Month Substance Use: Among Adults Aged 18 or Older; by Severity of Anxiety Symptoms, 2025



⁺ Difference between this estimate and the estimate for adults with no or minimal anxiety symptoms is statistically significant at the .05 level.

Note: Generalized anxiety disorder (GAD) symptom severity is based on the GAD-7 scale. GAD-7 scores indicate the following: 0 to 4 = no or minimal symptoms of GAD, 5 to 9 = mild symptoms, 10 to 14 = moderate symptoms, 15 to 21 = severe symptoms. The Moderate or Severe category includes respondents with a GAD-7 score of 10 or greater.

Major Depressive Episode in the Past Year

NSDUH respondents were classified as having had a major depressive episode (MDE) in the past 12 months if (1) they had at least one period of 2 weeks or longer in the past year when, for most of the day nearly every day, they felt depressed or lost interest or pleasure in daily activities; and (2) they also had problems with sleeping, eating, energy, concentration, self-worth, or having recurrent thoughts of death or recurrent suicidal ideation. The MDE questions are based on diagnostic criteria from the DSM-5, which requires the presence of five or more symptoms during the same 2-week period.⁴⁸ The wording for some depression questions asked of adolescent respondents aged 12 to 17 differed from the wording for similar questions asked of adult respondents aged 18 or older. Therefore, the MDE estimates for adolescents and adults are not directly comparable and are presented separately.^{14,57,58}

NSDUH also collected data on whether an MDE in the past year caused respondents to experience severe impairment in four major life activities or role domains. These domains were defined separately for adolescents aged 12 to 17 and adults aged 18 or older to reflect the different roles associated with the two age groups. Adolescents were classified as having an MDE with severe impairment if their depression caused severe problems with their ability to (1) do chores at home, (2) do well at work or school, (3) get along with their family, or (4) have a social life. Adults aged 18 or older were classified as having an MDE with severe impairment if their depression caused severe problems with their ability to (1) manage tasks at home, (2) manage tasks at work, (3) have relationships with others, or (4) have a social life.


Web-based interviewing affected the number of adult respondents aged 18 or older in 2025 who provided usable information on their substance use⁵⁹ but did not complete the mental health or later questions (i.e., “break-offs”). To reduce the potential for bias, missing data for measures of MDE and MDE with severe impairment among adults aged 18 or older were statistically imputed for 2021 to 2025.⁶⁰

MDE and MDE with Severe Impairment among Adolescents

Among adolescents aged 12 to 17 in 2025, 15.1 percent (or 3.7 million people) had a past year MDE (Figure 53 and Table A.36B). An estimated 11.0 percent of adolescents in 2025 (or 2.7 million people) had a past year MDE with

severe impairment. Among adolescents who had a past year MDE, about three fourths (73.8 percent) had an MDE with severe impairment.

Figure 53. Major Depressive Episode (MDE) or MDE with Severe Impairment in the Past Year: Among Adolescents Aged 12 to 17; 2025




Note: Adolescent respondents with unknown MDE data were excluded; therefore, the sum of the interior pieces may not add to the whole.

Among adolescents aged 12 to 17, the percentage who had a past year MDE decreased from 20.8 percent (or 5.2 million people) in 2021 to 15.1 percent (or 3.7 million people) in 2025 (Figure 54 and Table A.36B). Similarly, the percentage of adolescents who had a past year MDE with severe impairment decreased from 15.2 percent (or 3.8 million people) in 2021 to 11.0 percent (or 2.7 million people) in 2025.

Co-Occurring MDE and SUD among Adolescents

NSDUH provides information on whether adolescents aged 12 to 17 had both a past year MDE and a past year substance use disorder (SUD) (i.e., drug use disorder, alcohol use disorder, or both). However, NSDUH does not capture information to measure whether criteria for an MDE and an SUD were met at the same point in time during the past 12 months. Among adolescents aged 12 to 17 in 2025, 20.1 percent (or 5.0 million people) had either an MDE or an SUD in the past year (Figure 55 and Table A.37AB). Among the 1.9 million adolescents who had an SUD in the past year, about one third (604,000 people) also had a past

Figure 54. Major Depressive Episode (MDE) or MDE with Severe Impairment in the Past Year: Among Adolescents Aged 12 to 17; 2021-2025




Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 54 Table. Major Depressive Episode (MDE) or MDE with Severe Impairment in the Past Year: Among Adolescents Aged 12 to 17; Percentages, 2021-2025

MDE	2021	2022	2023	2024	2025	Trend
MDE	20.8	19.5	18.1	15.4	15.1	Decreased
MDE with Severe Impairment	15.2	14.6	13.5	11.3	11.0	Decreased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 55. Past Year Major Depressive Episode (MDE) or Substance Use Disorder (SUD): Among Adolescents Aged 12 to 17; 2025




Note: Adolescent respondents with unknown MDE data were excluded; therefore, the sum of the interior pieces may not add to the whole.

year MDE. Among the 3.7 million adolescents who had a past year MDE, however, most (3.1 million people) did not have an SUD because most adolescents did not use alcohol or drugs in the past year and therefore did not have an SUD.

Among adolescents aged 12 to 17, the percentage who had an MDE and SUD in the past year decreased from 4.1 percent (or 1.0 million people) in 2021 to 2.5 percent (or 604,000 people) in 2025 (Figure 56 and Table A.38B). The percentage of adolescents who had an MDE with severe impairment and an SUD in the past year also decreased from 3.1 percent (or 781,000 people) in 2021 to 1.9 percent of adolescents (or 467,000 people) in 2025.

Figure 56. Co-Occurring Past Year Major Depressive Episode (MDE) and Substance Use Disorder (SUD) or Co-Occurring Past Year MDE with Severe Impairment and SUD: Among Adolescents Aged 12 to 17; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 56 Table. Co-Occurring Past Year Major Depressive Episode (MDE) and Substance Use Disorder (SUD) or Co-Occurring Past Year MDE with Severe Impairment and SUD: Among Adolescents Aged 12 to 17; Percentages, 2021-2025

MDE and SUD	2021	2022	2023	2024	2025	Trend
Co-Occurring MDE and SUD	4.1	3.7	3.4	3.2	2.5	Decreased
Co-Occurring MDE with Severe Impairment and SUD	3.1	3.0	2.9	2.5	1.9	Decreased


Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Substance Use among Adolescents with an MDE

In 2025, adolescents aged 12 to 17 who had a past year MDE were more likely to have used some substances in the past year or past month compared with their counterparts who did not have an MDE in the past year. Adolescents with

a past year MDE were more likely than adolescents without a past year MDE to have used illicit drugs in the past year (21.7 vs. 9.1 percent), used marijuana in the past year (17.5 vs. 7.0 percent), or misused opioids (i.e., used heroin or misused prescription opioids) in the past year (2.7 vs. 1.2 percent) (Figure 57 and Table A.39B). Adolescents with a past year MDE also were more likely than those without a past year MDE to have engaged in binge alcohol use in the past month (4.8 vs. 2.6 percent) or to have used nicotine products in the past month (13.0 vs. 5.7 percent). In addition, adolescents with a past year MDE were more likely than those without a past year MDE to have used most of the other substances in the past year or past month that are shown in Table A.39B.

Figure 57. Past Year or Past Month Substance Use: Among Adolescents Aged 12 to 17; by Past Year Major Depressive Episode (MDE) Status, 2025




+ Difference between this estimate and the estimate for adolescents without MDE is statistically significant at the .05 level.
Note: Adolescent respondents with unknown MDE data were excluded.

MDE and MDE with Severe Impairment among Adults

Among adults aged 18 or older, the percentage who had a past year MDE decreased from 8.5 percent (or 21.6 million people) in 2021 to 7.4 percent (or 19.7 million people) in 2025 (Figure 58 and Table A.40B). In addition, among young adults aged 18 to 25, the percentage who had a past year MDE decreased from 19.3 percent (or 6.4 million people) in 2021 to 14.2 percent (or 5.1 million people) in 2025. Among adults aged 26 to 49 and adults aged 50 or older, however, the percentages who had a past year MDE showed no change from 2021 to 2025. In 2025, the percentage of adults aged 18 or older who had a past year MDE was highest among young adults aged 18 to 25

Figure 58. Major Depressive Episode (MDE) in the Past Year: Among Adults Aged 18 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 58 Table. Major Depressive Episode (MDE) in the Past Year: Among Adults Aged 18 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
18 or Older	8.5	8.8	8.5	8.2	7.4	Decreased
18 to 25	19.3	20.1	17.5	15.9	14.2	Decreased
26 to 49	9.6	9.7	10.2	10.0	9.1	No Change
50 or Older	4.5	4.6	4.5	4.4	4.0	No Change


Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

(14.2 percent or 5.1 million people), followed by adults aged 26 to 49 (9.1 percent or 9.6 million people), then by adults aged 50 or older (4.0 percent or 4.9 million people).

The percentage of adults aged 18 or older who had a past year MDE with severe impairment also decreased from 5.9 percent (or 14.9 million people) in 2021 to 5.2 percent (or 13.8 million people) in 2025 (Figure 59 and Table A.40B). Among young adults aged 18 to 25 and adults aged 50 or older, the percentages who had a past year MDE with severe impairment also decreased from 2021 to 2025. For example, the percentage of young adults who had a past year MDE with severe impairment decreased from 13.8 percent (or 4.6 million people) in 2021 to 10.2 percent (or 3.7 million people) in 2025. Among adults aged 26 to 49, the percentages who had a past year MDE with severe impairment showed no change from 2021 to 2025.

In 2025, the percentage of adults aged 18 or older who had a past year MDE with severe impairment was highest among young adults aged 18 to 25 (10.2 percent or 3.7 million people), followed by adults aged 26 to 49 (6.7 percent or 7.0 million people), then by adults aged 50 or older (2.5 percent or 3.1 million people) (Figure 59 and Table A.40B).

Figure 59. Major Depressive Episode (MDE) with Severe Impairment in the Past Year: Among Adults Aged 18 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 59 Table. Major Depressive Episode (MDE) with Severe Impairment in the Past Year: Among Adults Aged 18 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
18 or Older	5.9	6.2	5.9	5.6	5.2	Decreased
18 to 25	13.8	14.7	12.9	11.5	10.2	Decreased
26 to 49	6.6	6.9	7.4	7.0	6.7	No Change
50 or Older	3.0	3.1	2.7	2.6	2.5	Decreased


Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Co-Occurring MDE and SUD among Adults

NSDUH provides information on whether adults aged 18 or older had both a past year MDE and a past year SUD (i.e., drug use disorder, alcohol use disorder, or both). However, NSDUH does not capture information to measure whether criteria for an MDE and an SUD were met at the same point in time during the past 12 months. Among adults aged 18 or older in 2025, 20.8 percent (or 55.1 million people) had either an MDE or an SUD in the past year, including 2.8 percent (or 7.3 million people) who had an MDE and an SUD in the past year (Figure 60 and Tables A.41A and A.41B). The percentage of adults aged 18 or older who had either an MDE or an SUD in the past year was highest among young adults aged 18 to 25 (32.2 percent or 11.6 million people), followed by adults aged 26 to 49 (25.7 percent or 27.1 million people), then by adults aged 50 or older (13.2 percent or 16.3 million people).

Among the 42.7 million adults aged 18 or older in 2025 who had an SUD in the past year (Figure 60), most (35.4 million people) did not have a past year MDE (Table A.41A). Likewise, among the 19.7 million adults who had a past year MDE, most (12.4 million people) did not have a past year SUD.

Figure 60. Past Year Major Depressive Episode (MDE) or Substance Use Disorder (SUD): Among Adults Aged 18 or Older; 2025




Among adults aged 18 or older, the percentage who had an MDE and an SUD in the past year decreased from 3.2 percent (or 8.2 million people) in 2021 to 2.8 percent (or 7.3 million people) in 2025 (Figure 61 and Table A.42B). The percentage of young adults aged 18 to 25 who had an MDE and an SUD in the past year also decreased from 7.5 percent (or 2.5 million people) in 2021 to 5.7 percent (or 2.1 million people) in 2025. The percentages of adults aged 26 to 49 or aged 50 or older who had an MDE and an SUD in the past year showed no change from 2021 to 2025.

In 2025, the percentage of adults aged 18 or older who had an MDE and an SUD in the past year was highest among young adults aged 18 to 25 (5.7 percent or 2.1 million people), followed by adults aged 26 to 49 (3.7 percent or 3.9 million people), then by adults aged 50 or older (1.1 percent or 1.3 million people) (Figure 61 and Table A.42B).

The percentage of adults who had an MDE with severe impairment and an SUD in the past year decreased from 2.5 percent (or 6.4 million people) in 2021 to 2.1 percent (or 5.5 million people) in 2025. The percentage of adults who had an MDE with severe impairment and an SUD in the past year also decreased from 2021 to 2025 for young adults aged 18 to 25 and adults aged 50 or older. For example, the percentage of young adults aged 18 to 25 who had an MDE and an SUD in the past year decreased from 5.7 percent (or 1.9 million people) in 2021 to 4.4 percent (or 1.6 million people) in 2025. Among adults aged 26 to 49, the percentages showed no change from 2021 to 2025 (Table A.42B).

Figure 61. Co-Occurring Past Year Major Depressive Episode (MDE) and Substance Use Disorder (SUD): Among Adults Aged 18 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 61 Table. Co-Occurring Past Year Major Depressive Episode (MDE) and Substance Use Disorder (SUD): Among Adults Aged 18 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
18 or Older	3.2	3.6	3.4	3.4	2.8	Decreased
18 to 25	7.5	8.9	7.9	7.2	5.7	Decreased
26 to 49	4.1	4.2	4.4	4.4	3.7	No Change
50 or Older	1.3	1.7	1.4	1.4	1.1	No Change


Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

In 2025, the percentage of adults in 2025 who had an MDE with severe impairment and an SUD in the past year was highest among young adults aged 18 to 25 (4.4 percent or 1.6 million people), followed by adults aged 26 to 49 (2.9 percent or 3.0 million people), then by adults aged 50 or older (0.7 percent or 891,000 people) (Table A.42B).

Substance Use among Adults with an MDE

In 2025, adults aged 18 or older who had a past year MDE were more likely to have used some substances in the past year or past month compared with their counterparts who did not have an MDE in the past year. Adults with a past year MDE were more likely than adults without a past year MDE to have used illicit drugs in the past year (49.6 vs. 23.3 percent), used marijuana in the past year (43.8 vs. 20.7 percent), or misused opioids (i.e., used heroin or misused prescription opioids) in the past year (6.1 vs. 2.2 percent) (Figure 62 and Table A.43B). Adults with a past year MDE also were more likely than those without a past year MDE to have engaged in binge alcohol use in the past month (25.9 vs. 20.7 percent). In addition, adults with a past year MDE were more likely than those without a past year MDE to have used nicotine products in the past month

Figure 62. Past Year or Past Month Substance Use: Among Adults Aged 18 or Older; by Past Year Major Depressive Episode (MDE) Status, 2025



⁺ Difference between this estimate and the estimate for adults without MDE is statistically significant at the .05 level.

(33.0 vs. 22.8 percent). Adults with a past year MDE also were more likely than those without a past year MDE to have used most of the other substances in the past year or past month that are shown in [Table A.43B](#).

Any or Serious Mental Illness among Adults in the Past Year


NSDUH provides estimates of any mental illness (AMI) and serious mental illness (SMI) for adults aged 18 or older. Beginning with the 2025 NSDUH, adults aged 18 or older were classified as having AMI if they had any mental, behavioral, or emotional disorder in the past year of sufficient duration to meet criteria from the DSM-5, excluding developmental disorders and SUDs.⁶¹ The Mental Illness Calibration Study (MICS) was conducted as part of the 2023 and 2024 NSDUHs and included clinical interviews to assess whether adult respondents met clinical criteria for specific mental disorders based on DSM-5 criteria. The MICS was used to develop model-based estimates to predict whether adults in 2021 to 2025 had AMI or SMI according to DSM-5 criteria. Consequently, estimates of AMI and SMI in 2021 to 2024 that are presented in this report may differ from previously published estimates, which were developed using the previous Mental Health Surveillance Study in 2007 to 2012 based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition (DSM-IV).^{62,63}

Adults aged 18 or older who were classified as having AMI were further classified as having SMI if they had any mental, behavioral, or emotional disorder that substantially interfered with or limited one or more major life activities.⁶⁴ Statistical prediction models that were developed using the MICS clinical interview data from a subset of NSDUH adult respondents aged 18 or older in 2023 and 2024 were used to classify whether respondents in the adult samples for 2021 to 2025 had AMI or SMI in the past year. Source variables were statistically imputed for the prediction models used to estimate AMI or SMI.⁶⁵

Any Mental Illness among Adults

Among adults aged 18 or older, the percentage who had AMI in the past year showed no change from 2021 to 2025 ([Figure 63](#) and [Table A.44B](#)). In 2025, 20.6 percent of adults aged 18 or older (or 54.6 million people) had AMI in the past year. Percentages of adults aged 26 to 49 or 50 or older who had AMI in the past year also showed no change from 2021 to 2025. The percentage of young adults aged 18 to 25 who had AMI in the past year decreased from 33.2 percent (or 11.1 million people) in 2021 to 28.6 percent (or 10.3 million people) in 2025.

Figure 63. Any Mental Illness (AMI) in the Past Year: Among Adults Aged 18 or Older; 2021-2025



Note: Some 2021-2024 estimates may differ from previously published estimates due to updates that were made to the mental illness model beginning in 2025.

Figure 63 Table. Any Mental Illness (AMI) in the Past Year: Among Adults Aged 18 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
18 or Older	21.0	21.3	20.9	21.5	20.6	No Change
18 to 25	33.2	35.2	32.7	31.9	28.6	Decreased
26 to 49	26.2	27.1	27.0	27.7	27.1	No Change
50 or Older	13.1	12.3	12.3	13.2	12.8	No Change

Note: Some 2021-2024 estimates may differ from previously published estimates due to updates that were made to the mental illness model beginning in 2025.


In 2025, the percentage of adults aged 18 or older who had AMI in the past year was highest among young adults aged 18 to 25 (28.6 percent or 10.3 million people), followed by adults aged 26 to 49 (27.1 percent or 28.5 million people), then by adults aged 50 or older (12.8 percent or 15.8 million people) (Figure 63 and Table A.44B).

Serious Mental Illness among Adults

Among adults aged 18 or older, the percentage who had SMI in the past year decreased from 7.9 percent (or 20.1 million people) in 2021 to 6.9 percent (or 18.2 million people) in 2025 (Figure 64 and Table A.44B). Among young adults aged 18 to 25, the percentage who had SMI in the past year also decreased from 16.8 percent (or 5.6 million people) in 2021 to 12.1 percent (or 4.4 million people) in 2025. Among adults aged 26 to 49 and adults aged 50 or older, however, the percentages who had SMI in the past year showed no change from 2021 to 2025.

In 2025, the percentage of adults aged 18 or older who had SMI in the past year was highest among young adults aged 18 to 25 (12.1 percent or 4.4 million people), followed by adults aged 26 to 49 (9.6 percent or 10.1 million people), then by adults aged 50 or older (3.0 percent or 3.7 million people) (Figure 64 and Table A.44B).

Figure 64. Serious Mental Illness (SMI) in the Past Year: Among Adults Aged 18 or Older; 2021-2025



Note: Some 2021-2024 estimates may differ from previously published estimates due to updates that were made to the mental illness model beginning in 2025.

Figure 64 Table. Serious Mental Illness (SMI) in the Past Year: Among Adults Aged 18 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
18 or Older	7.9	8.4	7.9	7.8	6.9	Decreased
18 to 25	16.8	17.6	15.3	14.1	12.1	Decreased
26 to 49	10.0	10.3	10.6	10.3	9.6	No Change
50 or Older	3.5	4.1	3.5	3.8	3.0	No Change

Note: Some 2021-2024 estimates may differ from previously published estimates due to updates that were made to the mental illness model beginning in 2025.


Co-Occurring Mental Illness and SUD among Adults

NSDUH provides information on whether adults aged 18 or older who had an SUD in the past year could also be classified as having AMI or SMI in the past year. However, statistical prediction models for classifying whether adult respondents had AMI or SMI in the past year cannot establish whether adults met criteria for AMI or SMI and an SUD at the same point in time during the past 12 months.

Co-Occurring AMI and SUD

Among adults aged 18 or older in 2025, 29.8 percent (or 78.9 million people) had either AMI or an SUD in the past year (Figure 65 and Tables A.45A and A.45B). Among the 42.7 million adults who had an SUD in the past year, about two fifths also had AMI (18.5 million people) in the past year. The 18.5 million adults who had AMI and an SUD in the past year also represent about one third of the 54.6 million adults who had AMI.

Figure 65. Any Mental Illness (AMI) or Substance Use Disorder (SUD) in the Past Year: Among Adults Aged 18 or Older; 2025




In 2025, the percentage of adults aged 18 or older who had AMI or an SUD in the past year was highest among young adults aged 18 to 25 (41.2 percent or 14.9 million people), followed by adults aged 26 to 49 (37.4 percent or 39.4 million people), then by adults aged 50 or older (19.9 percent or 24.6 million people) (Tables A.45A and A.45B).

Among adults aged 18 or older, the percentage who had AMI and an SUD in the past year showed no change from 2021 to 2025 (Figure 66 and Table A.46B). In 2025, 7.0 percent of adults (or 18.5 million people) had AMI and an SUD in the past year. Percentages of adults aged 26 to 49

and 50 or older who had AMI and an SUD in the past year also showed no change from 2021 to 2025. Among young adults aged 18 to 25, however, the percentage who had AMI and an SUD in the past year decreased from 13.3 percent (or 4.4 million people) in 2021 to 11.1 percent (or 4.0 million people) in 2025.

The percentage of adults aged 18 or older in 2025 who had AMI and an SUD in the past year was highest among young adults aged 18 to 25 (11.1 percent or 4.0 million people), followed by adults aged 26 to 49 (10.0 percent or 10.5 million people), then by adults aged 50 or older (3.2 percent or 3.9 million people) (Figure 66 and Table A.46B).

Figure 66. Co-Occurring Past Year Any Mental Illness (AMI) and Substance Use Disorder (SUD): Among Adults Aged 18 or Older; 2021-2025



Note: Some 2021-2024 estimates may differ from previously published estimates due to updates that were made to the mental illness model beginning in 2025.

Figure 66 Table. Co-Occurring Past Year Any Mental Illness (AMI) and Substance Use Disorder (SUD): Among Adults Aged 18 or Older; Percentages, 2021-2025


Age Group	2021	2022	2023	2024	2025	Trend
18 or Older	7.4	8.0	7.6	7.7	7.0	No Change
18 to 25	13.3	14.7	13.7	13.0	11.1	Decreased
26 to 49	10.0	10.8	10.4	10.9	10.0	No Change
50 or Older	3.5	3.6	3.4	3.3	3.2	No Change

Note: Some 2021-2024 estimates may differ from previously published estimates due to updates that were made to the mental illness model beginning in 2025.

Co-Occurring SMI and SUD

Among adults aged 18 or older in 2025, 20.0 percent (or 53.1 million people) had either SMI or an SUD in the past year (Figure 67 and Tables A.45A and A.45B). Among the 18.2 million adults who had SMI, about two fifths (7.8 million people) also had an SUD. Among the 42.7 million adults who had an SUD in the past year, however, most (34.9 million people) did not have SMI.

Figure 67. Serious Mental Illness (SMI) or Substance Use Disorder (SUD) in the Past Year: Among Adults Aged 18 or Older; 2025




In 2025, the percentage of adults aged 18 or older who had either SMI or an SUD in the past year was highest among young adults aged 18 to 25 (30.5 percent or 11.0 million people), followed by adults aged 26 to 49 (25.6 percent or 26.9 million people), then by adults aged 50 or older (12.3 percent or 15.2 million people) (Tables A.45A and A.45B).

Among adults aged 18 or older, the percentage who had SMI and an SUD in the past year decreased from 3.5 percent (or 8.8 million people) in 2021 to 2.9 percent (or 7.8 million people) in 2025 (Figure 68 and Table A.46B). Among young adults aged 18 to 25, the percentage who had SMI and an SUD in the past year also decreased from 7.6 percent (or 2.5 million people) in 2021 to 5.4 percent (or 2.0 million people) in 2025. However, among adults aged 26 to 49 and adults aged 50 or older, the percentages who had SMI and an SUD in the past year showed no change from 2021 to 2025.

In 2025, the percentage of adults aged 18 or older who had SMI and an SUD in the past year was highest among young adults aged 18 to 25 (5.4 percent or 2.0 million people), followed by adults aged 26 to 49 (4.4 percent or 4.6 million people), then by adults aged 50 or older (1.0 percent or 1.2 million people) (Figure 68 and Table A.46B).

Figure 68. Co-Occurring Past Year Serious Mental Illness (SMI) and Substance Use Disorder (SUD): Among Adults Aged 18 or Older; 2021-2025



Note: Some 2021-2024 estimates may differ from previously published estimates due to updates that were made to the mental illness model beginning in 2025.

Figure 68 Table. Co-Occurring Past Year Serious Mental Illness (SMI) and Substance Use Disorder (SUD): Among Adults Aged 18 or Older; Percentages, 2021-2025


Age Group	2021	2022	2023	2024	2025	Trend
18 or Older	3.5	3.8	3.6	3.5	2.9	Decreased
18 to 25	7.6	8.5	7.6	6.9	5.4	Decreased
26 to 49	4.6	4.8	5.0	5.0	4.4	No Change
50 or Older	1.3	1.7	1.2	1.3	1.0	No Change

Note: Some 2021-2024 estimates may differ from previously published estimates due to updates that were made to the mental illness model beginning in 2025.

Substance Use among Adults, by Mental Illness Status

This section discusses how the prevalence of substance use among adults aged 18 or older differed based on past year mental illness status. In 2025, about one fourth of adults aged 18 or older (25.3 percent or 66.9 million people) used illicit drugs in the past year (Table A.47B). Among adults aged 18 or older in 2025, those with SMI or AMI in the past year were more likely than those without mental illness in the past year to have used illicit drugs in the past year (53.0 percent for SMI and 43.3 percent for AMI vs. 20.6 percent for adults with no mental illness), used marijuana in the past year (46.8 and 38.7 percent vs. 18.2 percent), or misused opioids (i.e., used heroin or misused prescription opioids) in the past year (7.3 and 5.2 percent vs. 1.8 percent) (Figure 69).

Figure 69. Past Year or Past Month Substance Use: Among Adults Aged 18 or Older; by Level of Mental Illness, 2025



+ Difference between this estimate and the estimate for adults without mental illness is statistically significant at the .05 level.

In addition, adults aged 18 or older in 2025 with SMI or AMI in the past year were more likely than adults aged 18 or older with no mental illness in the past year to have engaged in binge alcohol use in the past month (26.6 and 25.3 percent vs. 20.0 percent) (Figure 69 and Table A.47B). Adults with SMI or AMI in the past year were more likely to have used nicotine products in the past month than adults with no mental illness in the past year (37.5 and 33.0 percent vs. 21.1 percent). Adults with SMI or AMI in the past year also were more likely than those without mental illness in the past year to have used the other substances in the past year or past month that are shown in Table A.47B.

Suicidal Thoughts and Behaviors among Adults

Suicide is a leading cause of death and an important public health problem in the United States.^{66,67} Data from the National Vital Statistics System (NVSS) indicated that in 2024, 48,824 people in the United States died by suicide. This number was slightly lower than the 49,316 deaths by suicide in 2023, but it was greater than the numbers in 2018 to 2021.⁶⁸

In the United States, one person dies by suicide every 11 minutes.⁶⁹ In 2024, suicide replaced coronavirus disease 2019 (COVID-19) as the 10th leading cause of death among people of all ages in the United States, moving from the 11th leading cause of death in 2023. Suicide was the second leading cause of death in 2024 among people aged 10 to 34 and was among the top five leading causes of death among people aged 35 to 54.⁶⁷ However, people who die by suicide represent a fraction of those who consider or attempt suicide. In 2023, for example, nearly 47,700 adults aged 18 or older died by suicide, compared with 1.5 million adults in the civilian, noninstitutionalized population who were estimated to have made a nonfatal suicide attempt,⁷⁰ or about 31 nonfatal


suicide attempts for every death by suicide among adults.⁷¹ Moreover, 1 in 5 people who make a nonfatal suicide attempt will make a future attempt.⁷²

NSDUH respondents aged 18 or older were asked if at any time during the past 12 months they had thought seriously about trying to kill themselves (serious thoughts of suicide). Adults aged 18 or older also were asked whether they made a plan to kill themselves (suicide plan) or tried to kill themselves (suicide attempt) in the past 12 months, regardless of whether they had serious thoughts of suicide in that period.

In 2025, 13.9 million adults aged 18 or older (5.3 percent) had serious thoughts of suicide in the past year, 4.9 million (1.8 percent) made a suicide plan, and 2.3 million (0.9 percent) attempted suicide ([Figure 70](#) and [Table A.48AB](#)). An estimated 1.9 million adults (0.7 percent) had serious thoughts of suicide, made a suicide plan, and attempted suicide in the past year. Additional highlights from [Figure 70](#) include the following:

- Among the 13.9 million adults aged 18 or older who had serious thoughts of suicide in the past year, most (9.4 million adults) had serious thoughts of suicide only.

Figure 70. Adults Aged 18 or Older Who Had Serious Thoughts of Suicide, Made a Suicide Plan, or Attempted Suicide in the Past Year; 2025




Note: The numbers for the interior pieces may not add to the number for the whole circle due to rounding.

- Among the 4.9 million adults aged 18 or older who made a suicide plan in the past year, about two fifths attempted suicide (i.e., 1.9 million adults had serious thoughts of suicide, made a suicide plan, and attempted suicide, in addition to 88,000 adults who made a suicide plan and attempted suicide but did not have serious thoughts of suicide).
- Attempting suicide without first having serious thoughts of suicide or making a suicide plan was relatively uncommon but was estimated to have occurred (i.e., 139,000 adults).

Serious Thoughts of Suicide among Adults

Among adults aged 18 or older, the percentage who had serious thoughts of suicide in the past year showed no change from 2021 to 2025 (Figure 71 and Table A.49B). In 2025, 5.3 percent of adults aged 18 or older (or 13.9 million people) had serious thoughts of suicide in the past year. Among young adults aged 18 to 25, the percentage who had serious thoughts of suicide in the past year decreased from 13.4 percent (or 4.5 million people) in 2021 to 10.8 percent (or 3.9 million people) in 2025. However, the percentages of adults who had serious thoughts of suicide in the past year increased from 5.5 percent (or 5.6 million people) in 2021

Figure 71. Had Serious Thoughts of Suicide in the Past Year: Among Adults Aged 18 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 71 Table. Had Serious Thoughts of Suicide in the Past Year: Among Adults Aged 18 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
18 or Older	4.9	5.2	5.0	5.5	5.3	No Change
18 to 25	13.4	13.6	12.2	12.6	10.8	Decreased
26 to 49	5.5	5.5	5.9	6.1	6.2	Increased
50 or Older	2.0	2.4	2.1	2.9	2.9	Increased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.


to 6.2 percent (or 6.5 million people) in 2025 among adults aged 26 to 49 and from 2.0 percent (or 2.4 million people) in 2021 to 2.9 percent (or 3.5 million people) in 2025 among adults aged 50 or older.

In 2025, the percentage of adults aged 18 or older who had serious thoughts of suicide in the past year was highest among young adults aged 18 to 25 (10.8 percent or 3.9 million people), followed by adults aged 26 to 49 (6.2 percent or 6.5 million people), then by adults aged 50 or older (2.9 percent or 3.5 million people) (Figure 71 and Table A.49B).

Suicide Plans among Adults

Among adults aged 18 or older, the percentage who had made any suicide plans in the past year increased from 1.4 percent (or 3.6 million people) in 2021 to 1.8 percent (or 4.9 million people) in 2025 (Figure 72 and Table A.49B). Percentages also increased from 2021 to 2025 among adults aged 26 to 49 and adults aged 50 or older. For example, the percentage of adults aged 50 or older who made a suicide plan in the past year increased from 0.3 percent (or 405,000 people) in 2021 to 1.1 percent (or 1.3 million people) in 2025. Among young adults aged 18 to 25, the percentage who made a suicide plan in the past year

Figure 72. Made a Suicide Plan in the Past Year: Among Adults Aged 18 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 72 Table. Made a Suicide Plan in the Past Year: Among Adults Aged 18 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
18 or Older	1.4	1.5	1.4	1.8	1.8	Increased
18 to 25	5.2	4.9	4.2	4.2	4.0	Decreased
26 to 49	1.4	1.3	1.6	1.8	2.0	Increased
50 or Older	0.3	0.6	0.5	1.1	1.1	Increased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.


decreased from 5.2 percent (or 1.7 million people) in 2021 to 4.0 percent (or 1.4 million people) in 2025.

In 2025, the percentage of adults aged 18 or older who made a suicide plan in the past year was highest among young adults aged 18 to 25 (4.0 percent or 1.4 million people), followed by adults aged 26 to 49 (2.0 percent or 2.1 million people), then by adults aged 50 or older (1.1 percent or 1.3 million people) (Figure 72 and Table A.49B).

Suicide Attempts among Adults

Among adults aged 18 or older, the percentage who attempted suicide in the past year increased from 0.7 percent (or 1.8 million people) in 2021 to 0.9 percent (or 2.3 million people) in 2025 (Figure 73 and Table A.49B). Among adults aged 26 to 49 and adults aged 50 or older, the percentages who attempted suicide in the past year also increased from 2021 to 2025. Among adults aged 50 or older, for example, the percentage who attempted suicide in the past year increased from 0.2 percent (or 188,000 people) in 2021 to 0.5 percent (or 656,000 people) in 2025. Among young adults aged 18 to 25, the percentage who attempted suicide in the past year decreased from 2.8 percent (or 947,000 people) in 2021 to 1.9 percent (or 672,000 people) in 2025.

Figure 73. Attempted Suicide in the Past Year: Among Adults Aged 18 or Older; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 73 Table. Attempted Suicide in the Past Year: Among Adults Aged 18 or Older; Percentages, 2021-2025

Age Group	2021	2022	2023	2024	2025	Trend
18 or Older	0.7	0.6	0.6	0.8	0.9	Increased
18 to 25	2.8	2.1	2.0	2.0	1.9	Decreased
26 to 49	0.7	0.5	0.6	0.8	0.9	Increased
50 or Older	0.2	0.3	0.2	0.6	0.5	Increased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

In 2025, the percentage of adults aged 18 or older who attempted suicide in the past year was highest among young adults aged 18 to 25 (1.9 percent or 672,000 people), followed by adults aged 26 to 49 (0.9 percent or 956,000 people), then by adults aged 50 or older (0.5 percent or 656,000 people) (Figure 73 and Table A.49B).

Suicidal Thoughts and Behaviors among Adolescents


Trends in suicidal thoughts and behaviors have been increasing among adolescents^{73,74,75,76} and remain a major public health concern in the United States.⁷⁷ In 2024, suicide was the second leading cause of death among adolescents aged 10 to 14.⁶⁷ In addition, 1 in 5 high school students in 2023 seriously considered attempting suicide, 1 in 6 made a suicide plan, and nearly 1 in 10 attempted suicide in the past year.⁷⁶ Generally speaking, adolescent populations exposed to adverse childhood experiences (ACEs) are at particular risk of suicide and related behaviors.^{78,79}

Questions were included in the 2021 to 2025 NSDUHs to better understand suicidal thoughts and behaviors among adolescents aged 12 to 17. Adolescent respondents were asked if they seriously thought about trying to kill themselves, if they made plans to kill themselves, and if they had tried to kill themselves in the past 12 months. Unlike the questions for adults, the questions for adolescent respondents included the response options “I’m not sure” and “I don’t want to answer.”

In 2025, 2.6 million adolescents aged 12 to 17 (10.3 percent) had serious thoughts of suicide in the past year, 1.3 million (5.1 percent) made a suicide plan, and 738,000 (2.9 percent) attempted suicide (Figure 74 and Table A.50AB). An estimated 622,000 adolescents (2.4 percent) had serious thoughts of suicide, made a suicide plan, and attempted suicide in the past year. Additional highlights from Figure 74 include the following:

- Nearly half of the 2.6 million adolescents aged 12 to 17 who had serious thoughts of suicide in the past year also made a suicide plan or attempted suicide, or both.

Figure 74. Adolescents Aged 12 to 17 Who Had Serious Thoughts of Suicide, Made a Suicide Plan, or Attempted Suicide in the Past Year; 2025




- Among the 1.3 million adolescents aged 12 to 17 who made a suicide plan, 656,000 adolescents did not attempt suicide (543,000 made a suicide plan and had serious thoughts of suicide but did not attempt suicide, and 113,000 made a suicide plan only). An estimated 633,000 adolescents who made a suicide plan also attempted suicide (622,000 made a suicide plan, had serious thoughts of suicide, and attempted suicide, and 11,000 made a suicide plan and attempted suicide but did not have serious thoughts of suicide).
- Attempting suicide without first having serious thoughts of suicide or making a suicide plan was relatively uncommon among adolescents aged 12 to 17 but was estimated to have occurred (i.e., 24,000 adolescents).

Serious Thoughts of Suicide among Adolescents

Among adolescents aged 12 to 17 in 2025, 10.4 percent (or 2.6 million people) had serious thoughts of suicide in the past year (Figures 74 and 75 and Table A.51B). However, 7.2 percent of adolescents in 2025 (or 1.8 million people) were unsure or did not know whether they had serious thoughts of suicide, and 6.6 percent (or 1.7 million people) did not want to report whether they had these thoughts. These response options in 2025 correspond to approximately 13.8 percent of adolescents overall (or 3.5 million people).


Figure 75. Had Serious Thoughts of Suicide, Made a Suicide Plan, or Attempted Suicide in the Past Year: Among Adolescents Aged 12 to 17; 2025



Therefore, estimates of adolescents who had serious thoughts of suicide in the past year are likely to be conservative. This information suggests that some adolescents could have had these thoughts but did not feel comfortable disclosing that information.

Among adolescents aged 12 to 17, the percentage who had serious thoughts of suicide in the past year decreased from 12.9 percent (or 3.4 million people) in 2021 to 10.4 percent (or 2.6 million people) in 2025 ([Figure 76](#) and [Table A.52B](#)).

Figure 76. Had Serious Thoughts of Suicide, Made a Suicide Plan, or Attempted Suicide in the Past Year: Among Adolescents Aged 12 to 17; 2021-2025



Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Figure 76 Table. Had Serious Thoughts of Suicide, Made a Suicide Plan, or Attempted Suicide in the Past Year: Among Adolescents Aged 12 to 17; Percentages, 2021-2025

Suicidal Thoughts or Behaviors	2021	2022	2023	2024	2025	Trend
Had Serious Thoughts of Suicide	12.9	13.4	12.3	10.1	10.4	Decreased
Made a Suicide Plan	6.2	6.5	5.6	4.6	5.1	Decreased
Attempted Suicide	3.6	3.7	3.3	2.7	2.9	Decreased

Note: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons.

Suicide Plans among Adolescents

In 2025, 5.1 percent of adolescents aged 12 to 17 (or 1.3 million people) made a suicide plan in the past year ([Figures 74](#) and [76](#) and [Table A.51B](#)). Adolescent respondents who reported that they were not sure or did not know whether they made a suicide plan corresponded to a population estimate of 3.0 percent (or 762,000 people). Adolescent respondents who did not want to report whether they made a suicide plan corresponded to a population estimate of 5.6 percent (or 1.4 million people). Therefore, estimates of adolescents who made a suicide plan in the past year are likely to be conservative.

Among adolescents aged 12 to 17, the percentage who had made a suicide plan in the past year decreased from 6.2 percent (or 1.6 million people) in 2021 to 5.1 percent (or 1.3 million people) in 2025 ([Figure 76](#) and [Table A.52B](#)).

Suicide Attempts among Adolescents

In 2025, 2.9 percent of adolescents aged 12 to 17 (or 738,000 people) attempted suicide in the past year ([Figures 74](#) and [76](#) and [Table A.51B](#)). Adolescent respondents who reported that they were not sure or did not know whether they attempted suicide corresponded to a population estimate of 1.8 percent (or 463,000 people). Adolescent respondents who did not want to report whether they attempted suicide corresponded to a population estimate of 5.0 percent (or 1.3 million people). Therefore, estimates of adolescents who attempted suicide in the past year are likely to be conservative.

Among adolescents aged 12 to 17, the percentage who attempted suicide in the past year decreased from 3.6 percent (or 940,000 people) in 2021 to 2.9 percent (or 738,000 people) in 2025 ([Figure 76](#) and [Table A.52B](#)).

Nonsuicidal Self-Harm among Adolescents

Nonsuicidal self-harm, also referred to as nonsuicidal self-injury, describes deliberate, self-inflicted damage to one's body tissue without suicidal intent, most commonly through behaviors such as cutting, scratching, burning, or hitting oneself.⁸⁰ Lifetime prevalence estimates range from 10 to 23 percent, with onset typically occurring between the ages of 12 and 14. Nonsuicidal self-harm is an important risk factor for suicidal behavior, with previous longitudinal research indicating that it predicts concurrent and future suicide attempts. Moreover, more than half of adolescents who engaged in these behaviors had a history of suicide attempts. These behaviors occur across demographic groups and are more commonly reported among adolescents than adults.⁸⁰

Beginning in 2025, NSDUH added an item to assess nonsuicidal self-harm among adolescents aged 12 to 17. Respondents were asked whether, during the past 12 months, they intentionally harmed themselves without trying to kill themselves, such as by cutting, burning, or bruising themselves. In addition to the standard "Yes" and "No" response options, adolescents could select "I'm not sure" or "I don't want to answer" when answering the question.

In 2025, 11.2 percent of adolescents aged 12 to 17 (or 2.8 million people) engaged in nonsuicidal self-harm in the past year ([Table A.53B](#)). However, 2.9 percent of adolescents in 2025 (or 735,000 people) were unsure or did not know whether they had intentionally harmed themselves without

trying to kill themselves, and 5.6 percent (or 1.4 million people) did not want to report whether they had engaged in these behaviors. These response options in 2025 correspond to approximately 8.5 percent of adolescents overall (or 2.2 million people). Therefore, these 2025 estimates of adolescents who engaged in nonsuicidal self-harm in the past year are likely to be conservative.

Substance Use Treatment in the Past Year

Substance use treatment is intended to help people address problems associated with their use of alcohol or drugs, including medical problems associated with the use of alcohol or drugs.⁸¹ NSDUH provides two principal measures related to substance use treatment in the past year: (a) the need for substance use treatment and (b) the receipt of substance use treatment. The survey also collected information on the types of settings where people received treatment and barriers associated with people needing substance use treatment but not receiving it.¹⁴

This report presents estimates for the receipt of substance use treatment only for 2025 because of changes to the questionnaire during the 2024 NSDUH for the receipt of substance use treatment in inpatient or outpatient locations.^{82,83} Consequently, 4 years of comparable data are not available to assess trends in the receipt of substance use treatment.

People were classified as having received substance use treatment if they received treatment in the past year for the use of alcohol or drugs in an inpatient location;⁸⁴ in an outpatient location;⁸⁵ via telehealth; or in a prison, jail, or juvenile detention center. People also were classified as having received substance use treatment if they received prescription medication to reduce or stop their use of alcohol or to reduce or stop their use of heroin or prescription pain relievers. Respondents who used heroin or prescription pain relievers in their lifetime were shown a list of medications that are prescribed to treat opioid use disorder. For this reason, respondents who used prescription pain relievers but not heroin in their lifetime and who reported receiving prescription medications in the past year to reduce or stop their use of drugs were assumed to have received medication for the use of opioids.⁸⁶

Since 2022, NSDUH also has collected information on the receipt of other services, such as support services from a support group or from a peer support specialist or recovery coach, services in an emergency room or department,


or withdrawal management services. A question about treatment with overdose reversal medicine such as Narcan[®] or naloxone was added to the 2024 NSDUH questionnaire. These other services were not classified as “substance use treatment.”⁸⁷

Need for Substance Use Treatment

People were classified as needing substance use treatment in the past year if they had an SUD or if they received substance use treatment in the past year. As noted in the [Substance Use Disorders in the Past Year](#) section, NSDUH did not measure whether respondents met criteria for an SUD more than 12 months before the interview. Therefore, the definition of the need for substance use treatment took into account that people may not have met criteria for an SUD in the past year because they were receiving treatment.

Based on this definition, 16.3 percent of people aged 12 or older in 2025 (or 47.2 million people) needed substance use treatment in the past year ([Figure 77](#) and [Table A.54AB](#)). The 47.2 million people who needed substance use treatment included 44.6 million people who had an SUD in the past year and 2.7 million people who did not have an SUD in the past year but who received substance use treatment in the past year.

Figure 77. Need for Substance Use Treatment in the Past Year: Among People Aged 12 or Older; 2025



Note: Need for Substance Use Treatment is defined as having a substance use disorder in the past year or receiving substance use treatment in the past year.

In 2025, the percentage of people needing substance use treatment was highest among young adults aged 18 to 25 (24.3 percent or 8.8 million people), followed by adults aged 26 or older (15.9 percent or 36.4 million people), then by adolescents aged 12 to 17 (8.1 percent or 2.1 million people) ([Figure 77](#) and [Table A.54AB](#)).

Receipt of Substance Use Treatment

NSDUH respondents in 2025 who used alcohol or drugs in their lifetime were asked substance use treatment questions. Most questions asked whether respondents received professional counseling, medication, or other treatment for their alcohol or drug use in specific locations in the 12 months prior to the survey interview (i.e., in the past year). Respondents also were asked if they received treatment in the past 12 months via telehealth or if they received prescription medication to reduce or stop their use of alcohol or drugs. Receipt of substance use treatment was defined previously. Note that locations or types of substance use treatment are not mutually exclusive. For example, people could have received substance use treatment in an outpatient setting and in an inpatient setting. As noted previously, the following “other services” were not classified as “substance use treatment”: support services from a support group or from a peer support specialist or recovery coach, services in an emergency room, withdrawal management services, or treatment with overdose reversal medicine.

Among people aged 12 or older in 2025, 2.6 percent (or 7.6 million people) received substance use treatment in the past year (Figure 78 and Table A.55AB). An estimated


4.4 million people aged 12 or older (or 1.5 percent) received outpatient substance use treatment. Of the 4.4 million people who received outpatient substance use treatment, most (4.1 million people or 92.2 percent)⁸⁸ received treatment in an outpatient setting other than a general medical clinic or doctor’s office. Additionally, 1.2 percent (or 3.6 million people) received treatment via telehealth. Smaller numbers of people received other treatment shown in Figure 78.

In 2025, the percentage of adults aged 26 or older who received substance use treatment in the past year (2.7 percent or 6.2 million people) was higher than the percentage among adolescents aged 12 to 17 (1.8 percent or 470,000 people) (Table A.54AB). An estimated 2.3 percent of young adults aged 18 to 25 (or 845,000 people) received substance use treatment in the past year.

Receipt of Substance Use Treatment among People Who Were Classified as Needing Substance Use Treatment in the Past Year

Among people aged 12 or older in 2025 who were classified as needing substance use treatment in the past year, about 1 in 6 (16.0 percent or 7.6 million people) received substance use treatment in the past year (Figure 79 and Table A.54AB). Among people in different age groups in 2025 who needed substance use treatment in the past year, young adults aged 18 to 25 (9.6 percent or 845,000 people) were least likely to have received substance use treatment in the past year, followed by adults aged 26 or older (17.1 percent or 6.2 million people), then by adolescents aged 12 to 17 (22.8 percent or 470,000 people).

Figure 78. Types and Locations of Substance Use Treatment Received in the Past Year: Among People Aged 12 or Older; 2025




Note: Types of substance use treatment and locations where people received substance use treatment are not mutually exclusive because respondents could report that they received treatment in more than one setting in the past year.

Note: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medication for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

Note: Because respondents who used prescription pain relievers or heroin in their lifetime were shown a list of medications that are prescribed to treat opioid use disorder, respondents who used prescription pain relievers but not heroin in their lifetime and who reported use of these medications were assumed to have received medication for opioid use disorder.

Figure 79. Received Substance Use Treatment in the Past Year: Among People Aged 12 or Older Who Needed Substance Use Treatment in the Past Year; 2025



Note: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medication for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

Note: Need for Substance Use Treatment is defined as having a substance use disorder in the past year or receiving substance use treatment in the past year.

An estimated 1.1 percent of people aged 12 or older in 2025 who did not have an SUD in the past year (or 2.7 million people) received substance use treatment in the past year ([Table A.54AB](#)). As noted previously, these people were classified as needing substance use treatment and included people who may have had an SUD in the past year had they not been receiving treatment.

Among the estimated 44.6 million people aged 12 or older in 2025 who had an SUD in the past year ([Figure 39](#)), 11.0 percent (or 4.9 million people) ([Table A.54AB](#)) received substance use treatment in the past year, and 89.0 percent (or 39.7 million people) did *not* receive substance use treatment in the past year.

Among people who needed substance use treatment because they had an SUD in the past year, the percentage who received treatment was lowest among people with a mild SUD (4.1 percent or 980,000 people), followed by people with a moderate SUD (9.7 percent or 1.0 million people), then by people with a severe SUD (28.9 percent or 2.9 million people) ([Table A.54AB](#)). Although the percentage who received substance use treatment was highest among people with a severe SUD, nearly three fourths of this group did *not* receive substance use treatment in the past year.

Medications for Alcohol Use Disorder or Opioid Use Disorder

Prescription medications are approved by the U.S. Food and Drug Administration for the treatment of alcohol use disorder or opioid use disorder. These medications are often used in combination with counseling and other behavioral therapies to provide a whole-patient approach to the treatment of these disorders. This section uses the terms “medication for alcohol use disorder (MAUD)” and “medication for opioid use disorder (MOUD)” to discuss treatment with these medications. However, MAUD and MOUD do *not* include the use of medications that are prescribed to manage withdrawal symptoms or administered to stop a drug overdose. Also, NSDUH respondents may have met criteria for an alcohol use disorder or an opioid use disorder more than 12 months before the interview, but they were not classified as having a disorder in the past year because they were receiving MAUD or MOUD.

In 2025, NSDUH respondents aged 12 or older who reported lifetime alcohol use were asked to report whether they used medication in the past year that was prescribed to them to help reduce or stop their use of alcohol. Respondents also were informed that use of

these medications for alcohol use differed from the use of medications to stop an overdose. Examples of medications shown to respondents that are prescribed as a part of MAUD included acamprosate (also known as Campral®), disulfiram (also known as Antabuse®), naltrexone pills (also known as ReVia® or Trexan®), and injectable naltrexone (also known as Vivitrol®).

Questions on MOUD were asked of respondents aged 12 or older who reported ever using heroin or prescription pain relievers. These respondents were asked whether they used medication in the past year that was prescribed to them to help reduce or stop their drug use. Respondents also were informed that use of these medications for drug use differed from the use of medications to stop an overdose. Examples of medications shown to respondents that are prescribed as a part of MOUD included methadone, buprenorphine or buprenorphine-naloxone pills or film taken by mouth (also known as Suboxone®, Zubsolv®, Bunavail®, or Subutex®), injectable buprenorphine (also known as Sublocade®), buprenorphine implants (also known as Probuphine®), naltrexone pills (also known as ReVia® or Trexan®), and injectable naltrexone (also known as Vivitrol®). Because the drugs listed in the questionnaire are approved for treating opioid use disorder, respondents who used prescription pain relievers but not heroin in their lifetime and who reported receiving prescription medication in the past year to help reduce or stop their use of drugs were assumed to have received MOUD for their use of prescription opioids.

Medications for Alcohol Use Disorder

Among people aged 12 or older in 2025, 0.4 percent (or 1.1 million people) received MAUD in the past year ([Table A.55AB](#)). Among the 25.7 million people aged 12 or older with a past year alcohol use disorder (see the section on [Alcohol Use Disorder](#)), 2.6 percent (or 679,000 people) received MAUD in the past year.

Medications for Opioid Use Disorder

Among people aged 12 or older in 2025, 0.7 percent (or 2.1 million people) received MOUD in the past year ([Table A.55AB](#)). Among the 4.0 million people aged 12 or older with a past year opioid use disorder (see the section on [Opioid Use Disorder](#)), 15.7 percent (or 623,000 people) received MOUD in the past year.

Receipt of Substance Use Treatment via Telehealth among People with a Substance Use Disorder

Among people aged 12 or older in 2025 who had an SUD in the past year, 5.7 percent (or 2.5 million people) received substance use treatment via telehealth in the past year ([Table A.56AB](#)). Percentages of people with an SUD in the past year who received substance use treatment via telehealth in the past year ranged from 3.6 percent of young adults aged 18 to 25 (or 308,000 people) to 8.9 percent of adolescents aged 12 to 17 (or 167,000 people). An estimated 6.0 percent of adults aged 26 or older who had an SUD in the past year (or 2.1 million people) received substance use treatment via telehealth.

Receipt of Other Services for Substance Use

As noted previously, in addition to collecting information on substance use treatment, the 2025 NSDUH collected information on the receipt of other services for people's use of alcohol or drugs. These other services include support services from a support group or from a peer support specialist or recovery coach, services in an emergency room, withdrawal management services, or treatment with overdose reversal medicine such as Narcan® or naloxone. NSDUH does not classify these other services as "substance use treatment."

However, people could have received both substance use treatment and other services in the past year for their use of alcohol or drugs. Therefore, this section presents estimates for the following:

- any receipt of other services,
- receipt of substance use treatment and other services, and
- receipt of other services but not substance use treatment.

Any Receipt of Other Services for Substance Use among All People Aged 12 or Older

In 2025, 2.7 percent of people aged 12 or older (or 7.9 million people) received other services in the past year for their use of alcohol or drugs ([Table A.57AB](#)), including 1.5 percent (or 4.5 million people) who received both substance use treatment and other services and 1.2 percent (or 3.4 million people) who received other services but not substance use treatment. Among the estimated 7.9 million people who received other services, more than half (56.4 percent) also received substance use treatment, and the remainder (43.6 percent) received only other services.

Any Receipt of Other Services for Substance Use among People with a Substance Use Disorder

Among the estimated 44.6 million people aged 12 or older in 2025 who had an SUD in the past year ([Figure 39](#)), 9.6 percent (or 4.3 million people) received other services in the past year for their use of alcohol or drugs ([Table A.57AB](#)), including 6.9 percent (or 3.1 million people) who received both substance use treatment and other services and 2.6 percent (or 1.2 million people) who received other services but not substance use treatment. Among the estimated 4.3 million people who had an SUD and received other services, about three fourths (72.5 percent) also received substance use treatment, and about one fourth (27.5 percent) received only other services.

Receipt of Specific Other Services for Substance Use among People with a Substance Use Disorder

Among people aged 12 or older in 2025 who had an SUD in the past year, estimates for the receipt of specific other services in the past year to help them with their use of alcohol or drugs were as follows:

- 6.4 percent (or 2.9 million people) participated in a support group,
- 3.5 percent (or 1.6 million people) received services from a peer support specialist or recovery coach,
- 2.8 percent (or 1.3 million people) were seen in an emergency room,
- 2.2 percent (or 989,000 people) received withdrawal management services, and
- 0.9 percent (or 406,000 people) received overdose reversal medicine ([Tables A.58A](#) and [A.58B](#)).

Among people aged 12 or older in 2025 who had an SUD in the past year, most of those who received withdrawal management services or received services from a peer support specialist or recovery coach also received substance use treatment (97.3 and 92.4 percent, respectively) ([Table A.58B](#)). In addition, about three fourths of those who participated in a support group (72.8 percent) or were seen in an emergency room (72.7 percent) received substance use treatment. The percentages of people with an SUD who received overdose reversal medicine and did or did not receive substance use treatment could not be calculated with sufficient precision.¹²

No Receipt of Treatment or Other Services for Substance Use among People with a Substance Use Disorder

Previous sections discussed whether people received substance use treatment or other services in the past year for their alcohol or drug use. This section complements the information in those other sections by presenting estimates for people who had an SUD in the past year but received neither substance use treatment nor other services.

Among the estimated 44.6 million people aged 12 or older in 2025 who had an SUD in the past year (Figure 39), 86.4 percent (or 38.5 million people) received neither substance use treatment nor other services to help with their substance use (Table A.59AB). In each age group, about 80 percent or more of people who had an SUD received neither treatment nor other services for their substance use. Young adults aged 18 to 25 were most likely not to have received treatment or other services (90.6 percent or 7.8 million people), followed by adults aged 26 or older (85.7 percent or 29.2 million people), then by adolescents aged 12 to 17 (80.5 percent or 1.5 million people).

As discussed in the next section on the perceived unmet need for substance use treatment, people who had an SUD but received neither substance use treatment nor other services could perceive an unmet need for any professional counseling, medication, or other treatment for their alcohol or drug use but would not have a perceived unmet need for additional help.

Perceived Unmet Need for Substance Use Treatment

NSDUH respondents in 2025 who used alcohol or drugs in their lifetime and did not receive substance use treatment in the past year (i.e., inpatient or outpatient treatment; MAUD or MOUD; telehealth treatment; or treatment in a prison, jail, or juvenile detention center) were asked whether they sought professional counseling, medication, or other treatment in the past year for their alcohol or drug use. Those who did not report seeking treatment were asked whether they thought they should get treatment. Respondents who did not receive substance use treatment in the past year but sought or thought they should get treatment were classified as having a perceived unmet need for treatment. Respondents who received other services (i.e., support services from a support group or from a peer support specialist or recovery coach, services in an emergency room, or withdrawal management services)^{87,89}


but not substance use treatment were asked if they sought or thought they should get additional professional counseling, medication, or other treatment in the past 12 months for their use of alcohol or drugs; these respondents also were classified as having a perceived unmet need for treatment.

This section presents estimates separately for the perceived unmet need for substance use treatment among adolescents aged 12 to 17 and among adults aged 18 or older. Factors affecting the perception of need for substance use treatment, including how people interpret whether they sought substance use treatment, could differ for adolescents and adults, even if adolescent and adult respondents were asked the same questions about perceived unmet need.

Perceived Unmet Need for Substance Use Treatment among Adolescents

Among the 1.6 million adolescents aged 12 to 17 in 2025 who had an SUD in the past year and did not receive substance use treatment, 95.1 percent (or 1.4 million people) did not perceive that they needed treatment (Figure 80 and Table A.60AB). That is, they did not seek treatment and did not think they should get it. The estimated 4.9 percent of adolescents with an SUD in the past year who did not receive treatment but had a perceived unmet need for treatment corresponds to 74,000 people and includes 0.7 percent (or 11,000 people) who sought treatment and 4.2 percent (or 63,000 people) who did not seek treatment but thought they should get it.

Figure 80. Perceptions of Need for Substance Use Treatment: Among Adolescents Aged 12 to 17 with a Past Year Substance Use Disorder Who Did Not Receive Substance Use Treatment in the Past Year; 2025




Note: Adolescents with unknown information for perceptions of need for substance use treatment were excluded; therefore, the sum of the interior pieces does not add to the whole.

Perceived Unmet Need for Substance Use Treatment among Adults

Among the 38.1 million adults aged 18 or older in 2025 who had an SUD in the past year and did not receive substance use treatment, 94.5 percent (or 34.9 million people) did not perceive that they needed treatment ([Figure 81](#) and [Table A.60AB](#)). That is, they did not seek treatment and did not think they should get it. The estimated 5.5 percent of adults with an SUD in the past year who did not receive treatment but had a perceived unmet need for treatment corresponds to 2.0 million people and includes 0.5 percent (or 187,000 people) who sought treatment and 5.0 percent (or 1.9 million people) who did not seek treatment but thought they should get it.

Figure 81. Perceptions of Need for Substance Use Treatment: Among Adults Aged 18 or Older with a Past Year Substance Use Disorder Who Did Not Receive Substance Use Treatment in the Past Year; 2025



Note: Adults with unknown information for perceptions of need for substance use treatment were excluded; therefore, the sum of the interior pieces does not add to the whole.

Reasons for Not Receiving Substance Use Treatment

In 2025, questions about reasons for people not receiving substance use treatment were asked only of respondents who reported receiving no treatment in the past year⁸⁹ and who reported either seeking treatment or thinking they should get treatment. For each reason for not receiving treatment, respondents were asked whether that reason was “one of the reasons” or “not one of the reasons” they did not seek or get treatment. If respondents received other services but not treatment to help with their substance use, they were asked whether these were reasons for them not getting additional

professional counseling, medication, or other treatment for their alcohol or drug use. Respondents could report more than one reason for not seeking or getting treatment (or additional treatment).

As noted in previous sections, among people who were classified as having an SUD in the past year and who did not receive substance use treatment in the past year, only 4.9 percent of adolescents aged 12 to 17 and 5.5 percent of adults aged 18 or older perceived an unmet need for treatment ([Table A.60AB](#)). For people who perceived an unmet need for treatment, information on common reasons for not receiving substance use treatment is important for identifying and addressing barriers to the receipt of treatment.

This section presents estimates only among adults aged 18 or older because estimates among adolescents aged 12 to 17 could not be calculated with sufficient precision.¹² Additionally, even if adolescent and adult respondents were asked the same questions about why they did not receive substance use treatment, adolescent respondents may not have sufficient knowledge to report whether health insurance coverage or cost were important reasons for them not receiving treatment.

Reasons for Not Receiving Substance Use Treatment among Adults Aged 18 or Older

Among adults aged 18 or older in 2025 with a past year SUD who perceived an unmet need for treatment, the following were the four most common reasons for not receiving substance use treatment:

- thinking they should have been able to handle their alcohol or drug use on their own (82.5 percent),
- not being ready to stop or cut back on using alcohol or drugs (68.4 percent),
- not being ready to start treatment (67.7 percent), and
- not having enough time for treatment (54.3 percent) ([Table A.61B](#)).

Percentages for additional reasons were not necessarily significantly different from one another. Therefore, ranking of these reasons should not be assumed. Nevertheless, the following were additional common reasons for not receiving substance use treatment:

- being worried about what people would think or say if they got treatment (41.4 percent);

- not knowing how or where to get treatment (40.5 percent);
- thinking that treatment would cost too much (39.2 percent);
- thinking bad things would happen if people knew they were in treatment, such as losing their job, home, or children (34.9 percent);
- not being able to find a treatment program or healthcare professional they wanted to go to (32.7 percent);
- thinking treatment would not help them (31.5 percent); and
- not having enough health insurance coverage to pay for the costs of treatment (30.4 percent) ([Table A.61B](#)).

Mental Health Treatment in the Past Year

NSDUH includes questions to estimate the receipt of treatment in the United States to help people with their mental health, emotions, or behavior. Questions apply to the receipt of mental health treatment among the adolescent and adult populations. These questions allow for the estimation of mental health treatment among adolescents aged 12 to 17 overall and among adolescents with a past year MDE. These questions also allow for the estimation of mental health treatment among adults aged 18 or older overall and among adults with an MDE, AMI, or SMI in the past year.¹⁴

This report presents estimates for the receipt of mental health treatment only for 2025 because of changes to the questionnaire during the 2024 NSDUH for the receipt of mental health treatment in inpatient or outpatient locations.^{90,91} Consequently, 4 years of comparable data are not available to assess trends in the receipt of mental health treatment.

Since 2022, NSDUH also has collected information on the receipt of other services, such as support services from a support group or from a peer support specialist or recovery coach, or services in an emergency room or department. These other services were not classified as “mental health treatment.”⁹²

In sections that present estimates for adolescents aged 12 to 17, estimates are presented for all adolescents. For sections for adults aged 18 or older, estimates are presented for all adults and among adults aged 18 to 25, 26 to 49, or 50 or older. For adolescents and adults, locations or types of mental health treatment are not mutually exclusive.

For example, people could have received mental health treatment in an outpatient setting and taken prescription medication in the past year for their mental health.

Mental Health Treatment among Adolescents

The 2025 NSDUH included questions for adolescents aged 12 to 17 that asked about the receipt of professional counseling, medication, or other treatment they may have received for their mental health. Adolescent respondents were asked whether they received professional counseling, medication, or other treatment for their mental health in an inpatient location;⁹³ in an outpatient location;⁹⁴ via telehealth; or in a prison, jail, or juvenile detention center in the 12 months prior to the survey interview (i.e., in the past year). Respondents also were asked if they took medication in the past year that was prescribed to help with their mental health. Adolescent respondents who reported receiving any of these types of treatment were classified as having received mental health treatment in the past year.

This section first presents estimates for the receipt of mental health treatment in the past year among all adolescents aged 12 to 17, followed by estimates for the receipt of mental health treatment among adolescents who had an MDE in the past year. Measures for AMI or SMI were not created for adolescents.


Receipt of Mental Health Treatment among All Adolescents

In 2025, 27.6 percent of adolescents aged 12 to 17 (or 7.0 million people) received mental health treatment in the past year ([Figure 82](#) and [Table A.62B](#)). An estimated 20.3 percent of adolescents (or 5.2 million people) received mental health treatment in an outpatient setting, 13.3 percent (or 3.4 million people) took prescription medication to help with their mental health, and 13.0 percent (or 3.3 million people) received mental health treatment via telehealth. Smaller percentages of adolescents received mental health treatment in the other locations shown in [Figure 82](#).

Receipt of Mental Health Treatment among Adolescents with an MDE

As noted in the section on [MDE and MDE with Severe Impairment among Adolescents](#), an estimated 3.7 million adolescents aged 12 to 17 in 2025 had a past year MDE. Of these adolescents with a past year MDE, 57.7 percent (or 2.1 million people) received mental health treatment in the past year ([Figure 83](#) and [Table A.62B](#)), including 48.4 percent (or 1.8 million people) who received mental health treatment in an outpatient setting, 32.8 percent (or


Figure 82. Types and Locations of Mental Health Treatment in the Past Year: Among Adolescents Aged 12 to 17; 2025



Note: Types of mental health treatment and locations where people received mental health treatment are not mutually exclusive because respondents could report that they received treatment in more than one setting in the past year.

Note: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

Figure 83. Types and Locations of Mental Health Treatment in the Past Year: Among Adolescents Aged 12 to 17 with a Past Year Major Depressive Episode (MDE); 2025



Note: Adolescents with unknown past year MDE data were excluded.

Note: Types of mental health treatment and locations where people received mental health treatment are not mutually exclusive because respondents could report that they received treatment in more than one setting in the past year.

Note: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

1.2 million people) who received mental health treatment via telehealth, and 28.7 percent (or 1.1 million people) who took prescription medication to help with their mental health. However, about 42.3 percent of adolescents with a past year MDE (or 1.6 million people) did *not* receive mental health treatment in the past year ([Table A.63AB](#)).

Receipt of Other Services among Adolescents to Help with Mental Health

As noted previously, in addition to collecting information on mental health treatment, the 2025 NSDUH collected information on the receipt of other services to help people with their mental health. These other services include support services from a support group or from a peer support specialist or recovery coach, or services in an emergency room. These other services were not classified as “mental health treatment.”

However, adolescents could have received mental health treatment and other services in the past year to help with their mental health. Therefore, this section presents estimates for the following:

- any receipt of other services,
- receipt of mental health treatment and other services, and
- receipt of other services but not mental health treatment.

Any Receipt of Other Services for Mental Health among All Adolescents Aged 12 to 17

In 2025, 9.8 percent of adolescents aged 12 to 17 (or 2.5 million people) received other services in the past year for their mental health ([Table A.64AB](#)), including 7.5 percent (or 1.9 million people) who received mental health treatment and other services and 2.3 percent (or 597,000 people) who received other services but not mental health treatment. Among the estimated 2.5 million adolescents who received other services, therefore, about three fourths (76.1 percent) also received mental health treatment, and about one fourth (23.9 percent) received only other services.

Any Receipt of Other Services for Mental Health among Adolescents with a Past Year MDE

Among the estimated 3.7 million adolescents aged 12 to 17 in 2025 who had an MDE in the past year (see the section on [MDE and MDE with Severe Impairment among Adolescents](#)), 22.2 percent (or 822,000 people) received other services in the past year to help with their mental health ([Table A.64AB](#)), including 20.1 percent (or 744,000 people) who received mental health treatment and other services and 2.1 percent (or 78,000 people) who received other services but not mental health treatment. Among the estimated 822,000 adolescents who had an

MDE and received other services, therefore, the vast majority (90.5 percent) also received mental health treatment, and 9.5 percent received only other services.

Receipt of Specific Other Services for Mental Health among Adolescents with a Past Year MDE

Among adolescents aged 12 to 17 in 2025 who had an MDE in the past year, estimates for the receipt of specific other services in the past year to help them with their mental health were as follows:

- 16.3 percent (or 603,000 people) participated in a support group,
- 7.9 percent (or 292,000 people) received services from a peer support specialist or recovery coach, and
- 6.2 percent (or 231,000 people) were seen in an emergency room ([Tables A.65A](#) and [A.65B](#)).

Among the 822,000 adolescents aged 12 to 17 in 2025 who had an MDE and received specific other services in the past year, the vast majority (744,000 people) also received mental health treatment in that period ([Table A.64AB](#)). For example, among the 231,000 adolescents who had an MDE and were seen in an emergency room in the past year, 99.4 percent (or 229,000 people) also received mental health treatment ([Tables A.65A](#) and [A.65B](#)).

No Receipt of Treatment or Other Services for Mental Health among Adolescents with a Past Year MDE

Previous sections discussed whether adolescents aged 12 to 17 received mental health treatment or other services in the past year to help with their mental health. This section complements the information in those other sections by presenting estimates for adolescents who had an MDE in the past year but received neither mental health treatment nor other services. Among the estimated 3.7 million adolescents aged 12 to 17 in 2025 who had an MDE in the past year (see the section on [MDE and MDE with Severe Impairment among Adolescents](#)), 40.2 percent (or 1.5 million people) received neither mental health treatment nor other services to help with their mental health ([Table A.66AB](#)).

Perceived Unmet Need for Mental Health Treatment among Adolescents with a Past Year MDE

This section discusses estimates of perceived unmet need for mental health treatment among adolescents aged 12 to 17 with an MDE in the past year who did not receive mental health treatment in the past year. Adolescents in 2025 who did not receive mental health treatment in the past year were asked whether they sought treatment or thought they should get treatment for their mental health. These questions were asked only if adolescents did not report receipt of any mental health treatment as defined previously.

Adolescent NSDUH respondents aged 12 to 17 in 2025 were classified as having a perceived unmet need for mental health treatment if they did not receive mental health treatment in the past year, but they sought treatment or thought they should get treatment in the past 12 months to help with their mental health. Respondents also were classified as having a perceived unmet need for mental health treatment if they received other services in the past 12 months to help with their mental health but not mental health treatment, and they sought or thought they should get additional professional counseling, medication, or other treatment for their mental health.

As noted previously, 1.6 million adolescents aged 12 to 17 in 2025 had a past year MDE and did not receive mental health treatment in the past year ([Table A.63AB](#)). Of these 1.6 million adolescents, 41.7 percent (or 651,000 people) perceived an unmet need for mental health treatment, including 6.8 percent (or 107,000 people) who sought treatment and 34.8 percent (or 544,000 people) who did not seek treatment but thought they should get it.

Reasons for Not Receiving Mental Health Treatment among Adolescents with a Past Year MDE and a Perceived Unmet Need

Adolescents aged 12 to 17 in 2025 who had a perceived unmet need for mental health treatment in the past year were asked to report their reasons for not receiving treatment. These questions on reasons for not receiving treatment were the same for adolescents and for adults aged 18 or older. However, reasons for not receiving treatment could differ between adolescents and adults who had a perceived unmet need for treatment; therefore, these reasons are presented separately for adolescents and adults.

Among the 651,000 adolescents aged 12 to 17 in 2025 with a past year MDE who perceived an unmet need for mental health treatment ([Table A.63AB](#)), the most common reason for not receiving treatment was that they thought they should have been able to handle their mental health, emotions, or behavior on their own (87.4 percent) ([Table A.67B](#)). Percentages for additional reasons were not necessarily significantly different from one another. Therefore, ranking of these reasons should not be assumed. Nevertheless, the following were additional common reasons for not receiving treatment among adolescents with a past year MDE and a perceived unmet need for mental health treatment:

- being worried about what people would think or say if they got treatment (62.8 percent),
- being worried that information they shared would not be kept private (57.2 percent),
- not thinking treatment would help them (53.9 percent),
- not knowing how or where to get treatment (43.2 percent),
- thinking their family, friends, or religious group would not like it if they got treatment (41.7 percent),
- thinking no one would care if they got better (41.4 percent), and
- not being ready to start treatment (41.1 percent).

Mental Health Treatment among Adults

Adult respondents aged 18 or older in 2025 were asked whether they received professional counseling, medication, or other treatment for their mental health in an inpatient location;⁹³ in an outpatient location;⁹⁴ via telehealth; or in a prison, jail, or juvenile detention center in the 12 months prior to the survey interview (i.e., in the past year). Respondents also were asked if they took medication in the past year that was prescribed to help with their mental health. Adult respondents who reported receiving any of these types of treatment were classified as having received mental health treatment in the past year.


This section first presents estimates for the receipt of mental health treatment in the past year among all adults aged 18 or older, followed by estimates for the receipt of mental health treatment among adults who had an MDE, AMI, or SMI in the past year. Estimates are also presented for the receipt of mental health treatment among adults by age group.

Receipt of Mental Health Treatment among All Adults

In 2025, 21.6 percent of adults aged 18 or older (or 57.3 million people) received any of the types of mental health treatment in the past year that were described previously ([Figure 84](#) and [Table A.68B](#)). An estimated 16.2 percent of adults (or 43.1 million people) took prescription medication to help with their mental health, and equal percentages received mental health treatment in an outpatient setting and received treatment via telehealth (both 12.3 percent or 32.6 million people). Smaller percentages of adults received mental health treatment in the other locations shown in [Figure 84](#).

The percentage of adults in 2025 who received any mental health treatment in the past year was lower among adults aged 50 or older (17.1 percent or 21.2 million people) than among young adults aged 18 to 25 (24.5 percent or 8.8 million people) or adults aged 26 to 49 (25.9 percent or 27.3 million people) ([Table A.68B](#)).

Figure 84. Types and Locations of Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older; 2025



Note: Types of mental health treatment and locations where people received mental health treatment are not mutually exclusive because respondents could report that they received treatment in more than one setting in the past year.

Note: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

Receipt of Mental Health Treatment among Adults with an MDE

As noted in the section on [MDE and MDE with Severe Impairment among Adults](#), an estimated 19.7 million adults aged 18 or older in 2025 had a past year MDE. Of these adults with a past year MDE, 65.9 percent (or 13.0 million people) received any of the types of mental health treatment in the past year that were described previously ([Table A.69B](#)). Among adults who had an MDE in the past year, 51.7 percent (or 10.2 million people) took prescription medication to help with their mental health, 47.6 percent (or 9.4 million people) received mental health treatment in an outpatient setting, and 44.7 percent (or 8.8 million people) received mental health treatment via telehealth. However, about one third of adults who had an MDE in the past year did not receive any mental health treatment in that period.


In 2025, about three fifths of young adults aged 18 to 25 with an MDE in the past year received any mental health treatment in the past year (59.1 percent or 3.0 million people) ([Table A.69B](#)). In comparison, 68.6 percent of adults aged 26 to 49 (or 6.6 million people) and 67.6 percent of adults aged 50 or older (or 3.3 million people) with a past year MDE received any mental health treatment in the past year.

Receipt of Mental Health Treatment among Adults with AMI

Among the 54.6 million adults aged 18 or older in 2025 with AMI in the past year ([Figure 65](#)), 50.9 percent (or 27.8 million people) received any of the types of mental health treatment in the past year that were described previously ([Figure 85](#) and [Table A.70B](#)). Among adults who had AMI in the past year, 39.5 percent (or 21.6 million people) took prescription medication to help with their mental health, 34.2 percent (or 18.7 million people) received outpatient mental health treatment, and 32.8 percent (or 17.9 million people) received mental health treatment via telehealth. However, nearly half of adults who had AMI did not receive any mental health treatment in the past year.

As noted previously, about half of adults aged 18 or older in 2025 who had AMI in the past year received any of these types of treatment in the past year ([Figure 85](#) and [Table A.70B](#)). Percentages of adults with AMI who received any mental health treatment in the past year did not differ significantly by age group and ranged from 48.1 percent of adults aged 50 or older (or 7.6 million people) to

Figure 85. Mental Health Treatment Received in the Past Year: Among Adults Aged 18 or Older with Any Mental Illness (AMI) or Serious Mental Illness (SMI) in the Past Year; 2025



Note: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

52.8 percent of adults aged 26 to 49 (or 15.0 million people). An estimated 49.7 percent of young adults aged 18 to 25 (or 5.1 million people) with AMI received any mental health treatment.

Receipt of Mental Health Treatment among Adults with SMI

Among the 18.2 million adults aged 18 or older in 2025 with SMI in the past year ([Figure 67](#)), 67.7 percent (or 12.3 million people) received any of the types of mental health treatment in the past year that were mentioned previously ([Figure 85](#) and [Table A.71B](#)). Among adults who had SMI in the past year, 54.1 percent (or 9.8 million people) took prescription medication to help with their mental health, 50.1 percent (or 9.1 million people) received outpatient mental health treatment, and 46.0 percent (or 8.4 million people) received mental health treatment via telehealth. In addition, 7.9 percent of adults who had SMI (or 1.4 million people) received inpatient mental health treatment. However, about 30 percent of adults who had SMI did not receive any mental health treatment in the past year.

Among adults aged 18 or older in 2025 who had SMI in the past year, the percentage who received mental health treatment in the past year was lower among young adults aged 18 to 25 (63.0 percent or 2.8 million people) than among adults aged 26 to 49 (68.5 percent or 6.9 million people) or adults aged 50 or older (71.2 percent or 2.6 million people) ([Figure 85](#) and [Table A.71B](#)).

Receipt of Other Services among Adults to Help with Mental Health

As noted previously, the 2025 NSDUH also collected information on the receipt of other services to help people with their mental health, such as support services from a support group or from a peer support specialist or recovery coach, or services in an emergency room. These other services were not classified as “mental health treatment.”

However, adults could have received mental health treatment and other services in the past year to help with their mental health. Therefore, this section presents estimates for the following:

- any receipt of other services,
- receipt of mental health treatment and other services, and
- receipt of other services but not mental health treatment.

Any Receipt of Other Services for Mental Health among All Adults Aged 18 or Older

In 2025, 5.8 percent of adults aged 18 or older (or 15.5 million people) received other services in the past year to help with their mental health ([Table A.72AB](#)), including 4.1 percent (or 10.9 million people) who received mental health treatment and other services and 1.7 percent (or 4.6 million people) who received other services but not mental health treatment. Among the estimated 15.5 million adults who received other services, therefore, about 7 in 10 (70.6 percent) also received mental health treatment, and about 3 in 10 (29.4 percent) received only other services.

Any Receipt of Other Services for Mental Health among Adults with a Past Year MDE

Among the estimated 19.7 million adults aged 18 or older in 2025 who had an MDE in the past year (see the section on [MDE and MDE with Severe Impairment among Adults](#)), 18.7 percent (or 3.7 million people) received other services in the past year to help with their mental health ([Table A.72AB](#)), including 17.3 percent (or 3.4 million people) who received mental health treatment and other services and 1.4 percent (or 284,000 people) who received other services but not mental health treatment. Among the estimated 3.7 million adults who had an MDE and received other services, therefore, about 12 in 13 (92.3 percent) also received mental health treatment, and about 1 in 13 (7.7 percent) received only other services.

Any Receipt of Other Services for Mental Health among Adults with AMI

As noted in the section on [Any Mental Illness among Adults](#), among the estimated 54.6 million adults aged 18 or older in 2025 with AMI in the past year, 14.9 percent (or 8.1 million people) received other services in the past year to help with their mental health ([Table A.72AB](#)), including 12.4 percent (or 6.8 million people) who received mental health treatment and other services and 2.4 percent (or 1.3 million people) who received other services but not mental health treatment. Among the estimated 8.1 million adults with AMI and who received other services, therefore, about 5 in 6 (83.6 percent) also received mental health treatment, and about 1 in 6 (16.4 percent) received only other services.

Any Receipt of Other Services for Mental Health among Adults with SMI

As noted in the section on [Serious Mental Illness among Adults](#), among the estimated 18.2 million adults aged 18 or older in 2025 with SMI in the past year, 21.1 percent (or 3.8 million people) received other services in the past year to help with their mental health ([Table A.72AB](#)), including 19.7 percent (or 3.6 million people) who received mental health treatment and other services and 1.4 percent (or 247,000 people) who received other services but not mental health treatment. Among the estimated 3.8 million adults with SMI who received other services, therefore, about 19 in 20 (93.6 percent) also received mental health treatment, and about 1 in 20 (6.4 percent) received only other services.

Receipt of Specific Other Services for Mental Health among Adults with a Past Year MDE

Among adults aged 18 or older in 2025 who had an MDE in the past year, estimates for the receipt of specific other services in the past year to help them with their mental health were as follows:

- 14.2 percent (or 2.8 million people) participated in a support group,
- 6.1 percent (or 1.2 million people) were seen in an emergency room, and
- 5.2 percent (or 1.0 million people) received services from a peer support specialist or recovery coach ([Tables A.73A](#) and [A.73B](#)).

Among adults aged 18 or older who had a past year MDE and participated in a support group, received services from a peer support specialist or recovery coach, or were seen in an emergency room in the past year, the vast majority also received mental health treatment in that period (91.7, 95.1, and 95.6 percent, respectively) ([Table A.73B](#)).

Receipt of Specific Other Services for Mental Health among Adults with AMI

Among adults aged 18 or older in 2025 with AMI in the past year, estimates for the receipt of specific other services in the past year to help them with their mental health were as follows:

- 11.5 percent (or 6.3 million people) participated in a support group,
- 4.6 percent (or 2.5 million people) received services from a peer support specialist or recovery coach, and
- 4.3 percent (or 2.4 million people) were seen in an emergency room ([Tables A.73A](#) and [A.73B](#)).

Most adults aged 18 or older in 2025 with AMI in the past year who participated in a support group, received services from a peer support specialist or recovery coach, or were seen in an emergency room in the past year also received mental health treatment in that period (82.0, 96.3, and 83.7 percent, respectively) ([Table A.73B](#)).

Receipt of Specific Other Services for Mental Health among Adults with SMI

Among adults aged 18 or older in 2025 with SMI in the past year, estimates for the receipt of specific other services in the past year to help them with their mental health were as follows:

- 16.0 percent (or 2.9 million people) participated in a support group,
- 8.1 percent (or 1.5 million people) were seen in an emergency room, and
- 6.2 percent (or 1.1 million people) received services from a peer support specialist or recovery coach ([Tables A.73A](#) and [A.73B](#)).

The vast majority of adults aged 18 or older in 2025 with SMI in the past year who participated in a support group, received services from a peer support specialist or recovery coach, or were seen in an emergency room in the past year also received mental health treatment in that period (93.9, 96.1, and 92.9 percent, respectively) ([Table A.73B](#)).

No Receipt of Treatment or Other Services for Mental Health among Adults with a Past Year MDE

Previous sections discussed whether adults received mental health treatment or other services in the past year to help with their mental health. This section complements the information in those other sections by presenting estimates for adults who had an MDE in the past year but received neither mental health treatment nor other services. Among the estimated 19.7 million adults aged 18 or older in 2025 who had an MDE in the past year (see the section on [MDE and MDE with Severe Impairment among Adults](#)), about a third (32.7 percent or 6.4 million people) received neither mental health treatment nor other services in the past year to help with their mental health ([Table A.74AB](#)). In each age group, about 30 percent or more of adults who had an MDE received neither treatment nor other services for their mental health.

No Receipt of Treatment or Other Services for Mental Health among Adults with AMI

Previous sections discussed whether adults received mental health treatment or other services in the past year to help with their mental health. This section complements the information in those other sections by presenting estimates for adults with AMI in the past year but who received neither mental health treatment nor other services. Among the estimated 54.6 million adults aged 18 or older in 2025 with AMI in the past year (as noted in the section on [Any Mental Illness among Adults](#)), about half (46.7 percent or 25.5 million people) received neither mental health treatment nor other services in the past year to help with their mental health ([Table A.74AB](#)). In each age group, about 45 percent or more of adults with AMI received neither treatment nor other services for their mental health.

No Receipt of Treatment or Other Services for Mental Health among Adults with SMI

Previous sections discussed whether adults received mental health treatment or other services in the past year for their mental health. This section complements the information in those other sections by presenting estimates for adults with SMI in the past year but who received neither mental health treatment nor other services. Among the estimated 18.2 million adults aged 18 or older in 2025 with SMI in the past year (see the section on [Serious Mental Illness among Adults](#)), about a third (31.0 percent or 5.6 million people) received neither mental health treatment nor other

services in the past year to help with their mental health ([Table A.74AB](#)). In each age group, about 30 percent or more of people with SMI received neither treatment nor other services for their mental health.

Perceived Unmet Need for Mental Health Treatment among Adults with Mental Health Conditions

This section discusses estimates of perceived unmet need for mental health treatment among adults aged 18 or older with an MDE, AMI, or SMI in the past year who did not receive mental health treatment in the past year. The section also discusses the reasons adults aged 18 or older with AMI did not receive treatment in the past year if they had a perceived unmet need.

Adults who did not receive mental health treatment in the past year were asked whether they sought treatment or thought they should get treatment for their mental health. These questions were asked only if adults did not report any receipt of inpatient or outpatient mental health treatment; use of prescription medication to help with mental health; treatment via telehealth; or treatment in a prison, jail, or juvenile detention center.

Adult NSDUH respondents aged 18 or older in 2025 were classified as having a perceived unmet need for mental health treatment if they did not receive mental health treatment in the past year, but they sought treatment or thought they should get treatment in the past 12 months to help with their mental health. Respondents also were classified as having a perceived unmet need for mental health treatment if they received other services in the past 12 months to help with their mental health but not mental health treatment, and they sought or thought they should get additional professional counseling, medication, or other treatment for their mental health.

Perceived Unmet Need for Mental Health Treatment among Adults with a Past Year MDE


As noted in the section on [MDE and MDE with Severe Impairment among Adults](#), an estimated 19.7 million adults aged 18 or older in 2025 had a past year MDE. Of these adults with a past year MDE, about one third (or 6.7 million people) did not receive mental health treatment in the past year ([Table A.75A](#)). Among these 6.7 million adults with a past year MDE who did not receive mental health treatment, 36.9 percent (or 2.4 million people) perceived an unmet need for mental health treatment in the past year ([Table A.75B](#)). The percentage of adults in 2025 with a past

year MDE who did not receive mental health treatment in the past year and who had a perceived unmet need for treatment was higher among young adults aged 18 to 25 (48.1 percent or 989,000 people) than among adults aged 26 to 49 (35.5 percent or 1.0 million people) or adults aged 50 or older (24.7 percent or 385,000 people).

Perceived Unmet Need for Mental Health Treatment among Adults with AMI

Of the 54.6 million adults aged 18 or older in 2025 who had AMI in the past year ([Figure 65](#)), slightly less than half (26.9 million people) did not receive mental health treatment in the past year ([Table A.76A](#)). Among these 26.9 million adults with AMI in the past year who did not receive mental health treatment, 21.4 percent (or 5.6 million people) perceived an unmet need for mental health treatment in the past year ([Figure 86](#) and [Table A.76B](#)). The percentage of adults in 2025 with AMI in the past year who did not receive treatment in the past year and who had a perceived unmet need for mental health treatment was highest among young adults aged 18 to 25 (35.9 percent or 1.8 million people), followed by adults aged 26 to 49 (22.3 percent or 2.9 million people), then by adults aged 50 or older (10.7 percent or 857,000 people).

Figure 86. Perceived Unmet Need for Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with Any Mental Illness (AMI) or Serious Mental Illness (SMI) in the Past Year Who Did Not Receive Mental Health Treatment; 2025



* Low precision; no estimate reported.
Note: Adults with unknown information for perceptions of need for mental health treatment were excluded.
Note: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

Perceived Unmet Need for Mental Health Treatment among Adults with SMI

Of the 18.2 million adults aged 18 or older in 2025 who had SMI in the past year (Figure 67), about one third (5.9 million people) did not receive mental health treatment in the past year (Table A.77A). Among these 5.9 million adults with SMI in the past year who did not receive mental health treatment, 40.5 percent (or 2.3 million people) perceived an unmet need for mental health treatment in the past year (Figure 86 and Table A.77B). Percentages of adults in 2025 with SMI in the past year who did not receive mental health treatment and who had a perceived unmet need for treatment were 55.8 percent among young adults aged 18 to 25 (or 889,000 people) and 36.6 percent among adults aged 26 to 49 (or 1.1 million people). Estimates among adults with SMI who did not receive treatment and who had a perceived unmet need for mental health treatment could not be calculated with sufficient precision for adults aged 50 or older.¹²

Reasons for Not Receiving Mental Health Treatment among Adults with AMI and a Perceived Unmet Need

Among adults aged 18 or older in 2025 who had AMI in the past year and a perceived unmet need for mental health treatment in the past year, the most common reason for not receiving treatment was that they thought they should have been able to handle their mental health, emotions, or behavior on their own (72.9 percent) (Table A.78B). The second most common reason for not receiving treatment was thinking treatment would cost too much (61.4 percent).

Percentages for additional reasons were not necessarily significantly different from one another. Therefore, ranking of these reasons should not be assumed. Nevertheless, the following were additional common reasons for not receiving treatment among adults with AMI in the past year and a perceived unmet need for mental health treatment:

- not having enough time for treatment (48.3 percent),
- not being ready to start treatment (47.7 percent),
- not knowing how or where to get treatment (44.9 percent),
- not finding a treatment program or a healthcare professional they wanted to go to (43.2 percent),
- health insurance not paying enough of the costs for treatment (40.3 percent), and
- not having health insurance coverage for mental health treatment (39.0 percent).

In addition, Table 6.40B in the 2025 Detailed Tables contains estimates for adults who had SMI in the past year and had a perceived unmet need for mental health treatment.²⁰ Common reasons for not getting mental health treatment among adults who had SMI and a perceived unmet need for treatment were generally similar to those among adults who had AMI and a perceived unmet need for treatment.

Receipt of Treatment for Co-Occurring Mental Health Conditions and Substance Use Disorder

The relationship between SUDs and mental disorders is known to be bidirectional.²⁵ The presence of a mental disorder may contribute to the development or exacerbation of an SUD. Likewise, the presence of an SUD may contribute to the development or exacerbation of a mental disorder. The combined presence of SUDs and mental disorders (hereafter referred to as co-occurring disorders) results in more profound functional impairment; worse treatment outcomes; higher morbidity and mortality; increased treatment costs; and higher risk for homelessness, incarceration, and suicide than if people had only one of these disorders.^{25,96,97,98,99} Current treatment guidelines often recommend that people with co-occurring disorders receive treatment for both disorders.^{25,98,99}

This section presents estimates of the receipt of treatment among adolescents aged 12 to 17 and adults aged 18 or older with co-occurring mental health conditions and SUDs. Estimates are first presented for whether people with co-occurring mental health conditions and an SUD received any treatment for their use of alcohol or drugs or their mental health, or if people received no treatment. If people with co-occurring mental health conditions and an SUD received treatment for either their substance use or their mental health conditions, estimates are presented for the following:

- mental health treatment but not substance use treatment,
- substance use treatment but not mental health treatment, or
- both substance use treatment and mental health treatment.


Estimates for adults aged 18 or older are presented overall and by age group.

Receipt of Treatment among Adolescents with a Co-Occurring MDE and an SUD

Among the 604,000 adolescents aged 12 to 17 in 2025 with a co-occurring MDE and an SUD in the past year (Figure 87), 75.4 percent (or 455,000 people) received either substance use treatment or mental health treatment in the past year (Table A.79B). However, about 1 in 4 adolescents with a co-occurring MDE and an SUD in the past year (24.6 percent or 148,000 people) did not receive treatment for either condition. An estimated 60.2 percent of adolescents with a co-occurring MDE and an SUD in the past year (or 364,000 people) received only mental health treatment, and 14.3 percent (or 86,000 people) received both substance use treatment and mental health treatment. A smaller percentage received only substance use treatment.

Among the 455,000 adolescents aged 12 to 17 in 2025 with a co-occurring MDE and an SUD who received either substance use treatment or mental health treatment in the past year (Figure 87), most received only mental health treatment (79.9 percent), and 18.9 percent received both types of treatment.⁸⁸ The remainder received only substance use treatment.⁸⁸

Figure 87. Receipt of Substance Use Treatment or Mental Health Treatment in the Past Year: Among Adolescents Aged 12 to 17 with Past Year Substance Use Disorder (SUD) and Major Depressive Episode (MDE); 2025




MH Tx = mental health treatment; SU Tx = substance use treatment.
Note: Adolescents with unknown past year MDE data were excluded.
Note: The numbers for the subdivisions may not add to the number for the whole division due to rounding.
Note: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/ counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.
Note: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

Receipt of Treatment among Adults with Co-Occurring AMI and an SUD

Among the 18.5 million adults aged 18 or older in 2025 with co-occurring AMI and an SUD in the past year (Figure 88), 57.4 percent (or 10.6 million people) received either substance use treatment or mental health treatment in the past year (Table A.80B). However, about 2 in 5 adults aged 18 or older with co-occurring AMI and an SUD in the past year (42.6 percent or 7.9 million people) did not receive treatment for either condition. An estimated 41.8 percent of adults aged 18 or older with co-occurring AMI and an SUD in the past year (or 7.7 million people) received only mental health treatment, and 12.7 percent (or 2.3 million people) received both types of treatment. A smaller percentage received only substance use treatment.

Among the 10.6 million adults aged 18 or older in 2025 with co-occurring AMI and an SUD who received either substance use treatment or mental health treatment in the past year (Figure 88), most received only mental health treatment (72.9 percent), and 22.1 percent received both types of treatment.⁸⁸ The remainder received only substance use treatment.⁸⁸

Figure 88. Receipt of Substance Use Treatment or Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with Past Year Substance Use Disorder (SUD) and Any Mental Illness (AMI); 2025



MH Tx = mental health treatment; SU Tx = substance use treatment.
Note: The numbers and percentages for the subdivisions may not add to the percentage for the whole division due to rounding.
Note: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/ counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.
Note: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

Percentages of adults aged 18 or older in 2025 with co-occurring AMI and an SUD in the past year who received either substance use treatment or mental health treatment in the past year ranged from 55.7 percent of adults aged 50 or older (or 2.2 million people) to 58.5 percent of adults aged 26 to 49 (or 6.1 million people) (Table A.80B). An estimated 56.1 percent of young adults aged 18 to 25 with co-occurring AMI and an SUD in the past year (or 2.3 million people) received either type of treatment.

Receipt of Treatment among Adults with Co-Occurring SMI and an SUD

Among the 7.8 million adults aged 18 or older in 2025 with co-occurring SMI and an SUD in the past year (Figure 89), 71.3 percent (or 5.6 million people) received either substance use treatment or mental health treatment in the past year (Table A.80B). However, about 3 in 10 adults aged 18 or older with co-occurring SMI and an SUD in the past year (28.7 percent or 2.2 million people) did not receive treatment for either condition. An estimated 51.9 percent of adults aged 18 or older with co-occurring SMI and an SUD in the past year (or 4.0 million people) received only mental

health treatment, and 16.4 percent (or 1.3 million people) received both types of treatment. A smaller percentage received only substance use treatment.

Among the 5.6 million adults aged 18 or older in 2025 with co-occurring SMI and an SUD who received either substance use treatment or mental health treatment in the past year (Figure 89), most received only mental health treatment (72.7 percent), and 23.1 percent received both types of treatment.⁸⁸ The remainder received only substance use treatment.⁸⁸

Among adults aged 18 or older in 2025 with co-occurring SMI and an SUD in the past year, 65.5 percent of young adults aged 18 to 25 (or 1.3 million people) and 73.8 percent of adults aged 26 to 49 (or 3.4 million people) received either substance use treatment or mental health treatment in the past year (Table A.80B). Percentages could not be calculated with sufficient precision for adults aged 50 or older with co-occurring SMI and an SUD in the past year.¹²


Recovery

Respondents aged 18 or older were asked whether they thought they ever had a problem with their use of drugs or alcohol or whether they ever had a problem with their mental health. Respondents who reported that they ever had a problem with their drug or alcohol use were asked whether they considered themselves (at the time they were interviewed) to be in recovery or to have recovered from their drug or alcohol use problem. Similarly, respondents aged 18 or older who reported that they ever had a problem with their mental health were asked whether they considered themselves (at the time they were interviewed) to be in recovery or to have recovered from their mental health issue.

Among adults aged 18 or older in 2025, 11.6 percent (or 30.6 million people) perceived that they ever had a problem with their use of drugs or alcohol (Table A.81B). Among the 30.6 million adults in 2025 who perceived that they ever had a substance use problem, 73.0 percent (or 22.3 million people) considered themselves to be in recovery or to have recovered from their drug or alcohol use problem (Table A.82B).

In 2025, 8.0 percent of young adults aged 18 to 25 (or 2.9 million people) and 12.2 percent of adults aged 26 or older (or 27.7 million people) perceived that they ever had a problem with their use of drugs or alcohol (Table A.81B).

Figure 89. Receipt of Substance Use Treatment or Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with Past Year Substance Use Disorder (SUD) and Serious Mental Illness (SMI); 2025



MH Tx = mental health treatment; SU Tx = substance use treatment.
Note: The numbers for the subdivisions may not add to the number for the whole division due to rounding.
Note: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.
Note: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

Among adults who perceived that they ever had a problem with their use of drugs or alcohol, about two thirds of young adults (63.4 percent or 1.8 million people) and about three fourths of adults aged 26 or older (74.0 percent or 20.5 million people) considered themselves to be in recovery or to have recovered from their drug or alcohol use problem (Table A.82B).

In 2025, 24.3 percent of adults aged 18 or older (or 63.8 million people) perceived that they ever had a problem with their mental health (Table A.81B). Among the 63.8 million adults in 2025 who perceived that they ever had a problem with their mental health, 69.4 percent (or 44.1 million people) considered themselves to be in recovery or to have recovered from their mental health issue (Table A.82B).

In 2025, 35.5 percent of young adults aged 18 to 25 (or 12.7 million people) and 22.5 percent of adults aged 26 or older (or 51.1 million people) perceived that they ever had a problem with their mental health (Table A.81B). Among adults who perceived that they ever had a problem with their mental health, 66.4 percent of young adults (or 8.4 million people) and 70.2 percent of adults aged 26 or older (or 35.7 million people) considered themselves to be in recovery or to have recovered from their mental health issue (Table A.82B).

Endnotes

1. Hasin, D. S., & Grant, B. F. (2015). The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: Review and summary of findings. *Social Psychiatry and Psychiatric Epidemiology*, 50, 1609-1640. <https://doi.org/10.1007/s00127-015-1088-0>
2. Bitsko, R. H., Claussen, A. H., Lichstein, J., Black, L. I., Jones, S. E., Danielson, M. L., Hoenig, J. M., Davis Jack, S. P., Brody, D. J., Gyawali, S., Maenner, M. J., Warner, M., Holland, K. M., Perou, R., Crosby, A. E., Blumberg, S. J., Avenevoli, S., Kaminski, J. W., & Ghandour, R. M. (2022). Mental health surveillance among children – United States, 2013-2019. *MMWR Supplements*, 71(2), 1-42. <https://doi.org/10.15585/mmwr.su7102a1>
3. Global Burden of Diseases, Injuries, and Risk Factors Study 2021 U.S. Burden of Disease Collaborators. (2024). The burden of diseases, injuries, and risk factors by state in the USA, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. *Lancet*, 404, 2314-2340. [https://doi.org/10.1016/s0140-6736\(24\)01446-6](https://doi.org/10.1016/s0140-6736(24)01446-6)
4. Chapter 6 of CBHSQ (2022) discusses these methodological investigations for the 2021 NSDUH in greater detail. See the following reference: Center for Behavioral Health Statistics and Quality. (2022). *2021 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/report/2021-methodological-summary-and-definitions>
5. This report occasionally presents estimated numbers of people with a specific characteristic (e.g., estimated numbers of substance users). Some of these estimated numbers are not included in figures or tables in this report but may be found in the 2025 Detailed Tables. See the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Detailed tables*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/national-releases>
6. Center for Behavioral Health Statistics and Quality. (2026). *2025 Companion infographic report: Results from the 2021 to 2025 National Surveys on Drug Use and Health* (SAMHSA Publication No. PEP26-07-011). <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/national-releases>
7. Details about the sample design, weighting, and interviewing results for the 2025 NSDUH (and prior years, where applicable) are provided in Sections 2.1, 2.3.4, and 3.3.1 of CBHSQ (2026). In particular, Table 2.1 in CBHSQ (2026) provides sample design information on the targeted numbers of completed interviews by age group. See the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
8. Details about the multimode data collection procedures for the 2025 NSDUH are provided in Section 2.2.1 of CBHSQ (2026). See the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
9. Ages reported in household screenings were used in the response rate calculations. Numbers of adolescent respondents aged 12 to 17 and adult respondents aged 18 or older changed slightly based on final ages from the interview data (10,898 adolescents and 49,549 adults).

10. Overall response rates are not calculated for adolescents or adults because the screening response rate is not specific to age groups.
11. Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
12. For a discussion of the criteria for suppressing (i.e., not publishing) unreliable estimates, see Section 3.2.2 in the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
13. Estimates presented in this report have been weighted to reflect characteristics of the civilian, noninstitutionalized population aged 12 or older in the United States. The calculation of NSDUH weights for analysis includes a step that yields weights consistent with population totals obtained from the U.S. Census Bureau based on the most recently available decennial census.
14. See the following reference for population estimates cited in this report that do not appear in the report figures or the appendix tables: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Detailed tables*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/national-releases>
15. See Section 3.2.3 in the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
16. For more information on the change to the nicotine vaping questions for 2022, see Section 3.4.11 in the following reference: Center for Behavioral Health Statistics and Quality. (2023). *2022 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/report/2022-methodological-summary-and-definitions>
17. For more information on updates to the procedures for estimating nicotine vaping in 2022 to 2024, see Section 3.4.4 in the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
18. In the 2025 NSDUH, a “drink” was defined as a can or bottle of beer or hard seltzer, a glass of wine or a wine cooler, a shot of liquor, or a drink with liquor in it. Times when respondents had only a sip or two from a drink were not considered to be alcohol consumption.
19. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines binge drinking as a pattern of drinking that brings blood alcohol concentration (BAC) levels to 0.08 percent or higher, or 0.08 grams per deciliter (g/dL) or higher. For a typical adult, this pattern corresponds to consuming four or more drinks for women and five or more drinks for men in about 2 hours. See the following reference: National Institute on Alcohol Abuse and Alcoholism. (2026). *Alcohol's effects on health*. <https://www.niaaa.nih.gov/alcohol-effects-health/alcohol-drinking-patterns>
20. Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Detailed tables*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/national-releases>
21. The 2025 NSDUH questionnaire included separate sections for prescription tranquilizer misuse and prescription sedative misuse. Data from these sections were combined to produce aggregate estimates for the misuse of any prescription tranquilizer or sedative.
22. The estimated numbers of past year users of different illicit drugs are not mutually exclusive because people could have used more than one type of illicit drug in the past year.
23. LSD = lysergic acid diethylamide; PCP = phencyclidine; MDMA = methylenedioxymethamphetamine; DMT = dimethyltryptamine; AMT = alpha-methyltryptamine; Foxy = N, N-diisopropyl-5-methoxytryptamine (5-MeO-DIPT). Definitions for these hallucinogens also are included in Appendix A of the following reference: Center for Behavioral Health Statistics and Quality. (2026). *Results from the 2025 National Survey on Drug Use and Health: Detailed tables*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/national-releases>
24. In the 2021 to 2023 NSDUHs, respondents who reported that they used LSD, PCP, Ecstasy, ketamine, DMT/AMT/“Foxy,” or *Salvia divinorum* in their lifetime were asked when they last used these specific hallucinogens. In addition to questions about the most recent use of these hallucinogens, a recency question has been included for psilocybin since 2024. Recency questions were added for peyote and mescaline in 2025.
25. No respondents in 2025 specified Desoxyn® as some other stimulant they misused, and it has been mentioned only rarely as a stimulant in other years. Desoxyn® is grouped with the other amphetamines because it is chemically similar to other prescription amphetamines (e.g., Adderall®).
26. Examples of forms of fentanyl presented to NSDUH respondents in the pain relievers section of the interview are available by prescription.
27. U.S. Centers for Disease Control and Prevention. (2025, June). *Basics about prescription opioids*. <https://www.cdc.gov/rx-awareness/information/index.html>
28. Han, B., Jones, C. M., Einstein, E. B., & Compton, W. M. (2021). Trends in and characteristics of buprenorphine misuse among adults in the US. *JAMA Network Open*, 4(10), e2129409. <https://doi.org/10.1001/jamanetworkopen.2021.29409>
29. National Institute on Drug Abuse. (2024, September). *Cocaine*. <https://nida.nih.gov/research-topics/cocaine>
30. National Institute on Drug Abuse. (2024, November). *Methamphetamine*. <https://nida.nih.gov/research-topics/methamphetamine>
31. National Institute on Drug Abuse. (2023, June). *Misuse of prescription drugs research report: What classes of prescription drugs are commonly misused?* <https://nida.nih.gov/publications/research-reports/misuse-prescription-drugs/what-classes-prescription-drugs-are-commonly-misused>
32. Individual estimated numbers of people who used cocaine only, misused prescription stimulants only, or used methamphetamine only sum to more than 7.6 million people because of rounding.

33. U.S. Centers for Disease Control and Prevention. (2025, June). *Understanding the opioid overdose epidemic*. <https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html>
34. Spencer, M. R., Warner, M., Cisewski, J. A., Miniño, A., Dodds, D., Perera, J., & Ahmad, F. B. (2023, May). *Estimates of drug overdose deaths involving fentanyl, methamphetamine, cocaine, heroin, and oxycodone: United States, 2021*. Vital Statistics Rapid Release (Report No. 27). National Center for Health Statistics. <https://doi.org/10.15620/cdc:125504>
35. Zibbell, J. E., Aldridge, A., Grabenauer, M., Heller, D., Duhart Clarke, S., Pressley, D., & Smiley-McDonald, H. (2023). Associations between opioid overdose deaths and drugs confiscated by law enforcement and submitted to crime laboratories for analysis, United States, 2014–2019: An observational study. *The Lancet Regional Health–Americas*, 25. <https://doi.org/10.1016/j.lana.2023.100569>
36. Tanz, L. J., Stewart, A., Gladden, R. M., Ko, J. Y., Owens, L., & O'Donnell, J. (2024). Detection of illegally manufactured fentanyl and carfentanil in drug overdose deaths—United States, 2021–2024. *Morbidity and Mortality Weekly Report*, 73(48), 1099–1105. <https://www.cdc.gov/mmwr/volumes/73/wr/pdfs/mm7348a2-H.pdf>
37. Center for Behavioral Health Statistics and Quality. (2025). *Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drug Use and Health* (HHS Publication No. PEP25-07-007, NSDUH Series H-60). <https://www.samhsa.gov/data/report/2024-nsduh-annual-national-report>
38. Carroll, J. J., Marshall, B. D. L., Rich, J. D., & Green, T. C. (2017). Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study. *International Journal of Drug Policy*, 46, 136–145. <https://doi.org/10.1016/j.drugpo.2017.05.023>
39. Macmadu, A., Carroll, J. J., Hadland, S. E., Green, T. C., & Marshall, B. D. L. (2017). Prevalence and correlates of fentanyl-contaminated heroin exposure among young adults who use prescription opioids non-medically. *Addictive Behaviors*, 68, 35–38. <https://doi.org/10.1016/j.addbeh.2017.01.014>
40. McKnight, C., & Des Jarlais, D. C. (2018). Being “hooked up” during a sharp increase in the availability of illicitly manufactured fentanyl: Adaptations of drug using practices among people who use drugs (PWUD) in New York City. *International Journal of Drug Policy*, 60, 82–88. <https://doi.org/10.1016/j.drugpo.2018.08.004>
41. Stevens, C., Li, T., Ton, E., Zou, J., Douglas, E., & Jones, P. (2021). Longitudinal opioid surveillance project involving toxicologic analysis of postmortem specimens from 9 counties in Michigan suggests the discovery of new high-intensity drug trafficking areas. *American Journal of Forensic Medicine and Pathology*, 42(3), 216–224. <https://doi.org/10.1097/PAF.0000000000000675>
42. To measure initiation for most substances, NSDUH respondents who reported they ever used a particular substance were asked to report their age when they first used it. To measure initiation of prescription drug misuse (i.e., misuse of prescription pain relievers, prescription tranquilizers, prescription stimulants, and prescription sedatives), NSDUH respondents who reported they misused a particular prescription drug in the past 12 months were asked to report their age when they first misused it. Respondents who reported first use (or misuse in the case of prescription drugs) of a substance within a year of their current age also were asked to report the year and month when they first used (or misused) it.
43. Estimates relating to the periods prior to the 12-month reference period have not been considered here because of concerns about their validity resulting from recall bias. See the following reference: Gfroerer, J., Hughes, A., Chromy, J., Heller, D., & Packer, L. (2004, July). Estimating trends in substance use based on reports of prior use in a cross-sectional survey. In S. B. Cohen & J. M. Lepkowski (Eds.), *Eighth Conference on Health Survey Research Methods: Conference proceedings [Peachtree City, GA]* (HHS Publication No. PHS 04-1013, pp. 29–34). U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics.
44. For substances other than prescription psychotherapeutic drugs, respondents who had ever used the substance (e.g., marijuana) were asked to report when they first used the substance, and respondents who reported first use within a year of their current age were asked to report the year and month when they first used it. Thus, past year initiates of the use of substances other than prescription psychotherapeutic drugs reported their first use within 12 months of the interview date.
45. Assessing whether respondents in the 2025 NSDUH had initiated misuse of a prescription psychotherapeutic drug in the past 12 months differed from assessing whether respondents had initiated the use of other substances in that period because the psychotherapeutic drug categories (e.g., prescription pain relievers) include many different types of prescription drugs in a given category (e.g., pain relievers containing hydrocodone, such as Vicodin®, Lortab®, Norco®, or generic hydrocodone). Respondents in 2025 were asked questions about initiation of misuse only for the specific prescription drugs they misused in the past 12 months, including their age when they first misused a drug and (if the first misuse occurred within a year of the current age) the year and month of first misuse for that drug. Respondents who reported they initiated misuse in the past 12 months for all of the specific prescription drugs in a given category they misused in that period were asked a follow-up question to establish whether they had ever misused prescription drugs in that category more than 12 months before being interviewed. Respondents who answered this follow-up question as “no” were classified as being past year initiates of the misuse of any prescription drug in the overall category. This answer meant respondents had never misused any prescription drug in that category more than 12 months prior to the interview date.
46. Field testing in 2012 and 2013 for the prescription drug questions in the 2025 NSDUH questionnaire indicated a higher prevalence of the past year misuse of prescription drugs but a lower prevalence of lifetime misuse compared with the main survey questionnaire at the time. The conclusion was that the emphasis on the past year misuse of prescription drugs can result in underreporting of lifetime misuse of prescription drugs. For more information, see the following references:

- Center for Behavioral Health Statistics and Quality. (2014). *National Survey on Drug Use and Health: 2012 Questionnaire Field Test final report*. <https://www.samhsa.gov/data/report/nsduh-2012-questionnaire-field-test-report>
- Center for Behavioral Health Statistics and Quality. (2014). *National Survey on Drug Use and Health: 2013 Dress Rehearsal final report*. <https://www.samhsa.gov/data/report/nsduh-2013-dress-rehearsal-final-report>
47. More information about the methods for measuring and estimating the initiation of substance use and prescription drug misuse in NSDUH can be found in Section 3.4.7 of the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
48. American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). <https://doi.org/10.1176/appi.books.9780890425596>
49. For more information about the DSM-5 criteria for SUDs, see Section 3.4.8 in the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
50. For alcohol, for example, withdrawal symptoms include (but are not limited to) trouble sleeping, hands trembling, hallucinations (seeing, feeling, or hearing things that are not really there), or feeling anxious.
51. For alcohol use disorder, for example, this criterion involves the use of alcohol, sedatives, or tranquilizers to get over or avoid alcohol withdrawal symptoms.
52. Hasin, D. S., O'Brien, C. P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W. M., Crowley, T., Ling, W., Petry, N. M., Schuckit, M., & Grant, B. F. (2013). DSM-5 criteria for substance use disorders: Recommendations and rationale. *American Journal of Psychiatry*, 170(8), 834-851. <https://doi.org/10.1176/appi.ajp.2013.12060782>
53. NSDUH respondents in 2025 were asked the respective questions for alcohol use disorder or marijuana use disorder if they reported use of these substances on 6 or more days in the past year. Respondents were asked the respective SUD questions for cocaine, heroin, hallucinogens, inhalants, methamphetamine, and prescription psychotherapeutic drugs if they reported any use in the past year.
54. Estimates in 2025 for CNS stimulant use disorder and opioid use disorder include data from a small number of respondents (fewer than 15 each) who reported in a later section of the interview that they used methamphetamine with a needle in the past 12 months or that they smoked, sniffed, or used heroin with a needle in the past year despite having previously reported that they last used these substances more than 12 months ago. For more information, see Section 3.4.6 in the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
55. Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. *Archives of Internal Medicine*, 166(10), 1092-1097. <https://doi.org/10.1001/archinte.166.10.1092>
56. Terlizzi, E. P., & Villarroel, M. A. (2020). *Symptoms of generalized anxiety disorder among adults: United States, 2019* (NCHS Data Brief No. 378). National Center for Health Statistics. <https://www.cdc.gov/nchs/products/databriefs/db378.htm>
57. Adolescents were first asked whether they ever had a period in their lifetime lasting several days or longer when any of the following was true for most of the day: (a) feeling sad, empty, or depressed; (b) feeling very discouraged or hopeless about how things were going in their lives; or (c) losing interest and becoming bored with most things they usually enjoy. Adolescents who reported any of these problems were asked further questions about their experience with the nine symptoms of MDE in their lifetime. Adolescents were classified as having an MDE in their lifetime if they experienced at least five of the nine symptoms in the same 2-week period in their lifetime; at least one of the symptoms needed to be having a depressed mood or loss of interest or pleasure in activities that had been enjoyable. Adolescents who reported gaining weight without trying were asked if their weight gain occurred because they were growing; this question was not asked of adult respondents. Adolescent respondents who had a lifetime MDE were asked if they had a period of 2 weeks or longer in the past 12 months when they felt depressed or lost interest or pleasure in previously enjoyable activities, and they reported having some of their other MDE symptoms. These adolescents were classified as having a past year MDE.
58. Adults were first asked whether they ever had a period in their lifetime lasting several days or longer when any of the following was true for most of the day: (a) feeling sad, empty, or depressed; (b) feeling discouraged about how things were going in their lives; or (c) losing interest in most things they usually enjoy. Adults who reported any of these problems were asked further questions about their experience with the nine symptoms of MDE in their lifetime. Adults were classified as having an MDE in their lifetime if they experienced at least five of the nine symptoms in the same 2-week period in their lifetime; at least one of the symptoms needed to be having a depressed mood or loss of interest or pleasure in activities that had been enjoyable. Adult respondents who had a lifetime MDE were asked if they had a period of 2 weeks or longer in the past 12 months when they felt depressed or lost interest or pleasure in previously enjoyable activities, and they reported having some of their other MDE symptoms. These adults were classified as having a past year MDE.
59. Details about the criteria for defining a NSDUH interview as usable are provided in Section 2.3.1 of CBHSQ (2026). See the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
60. Details about imputation procedures, including imputation of adult MDE data, are provided in Sections 2.3.3 and 3.4.13 of CBHSQ (2026). See the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>

61. Follow-up clinical interviews for classifying whether adults had a mental, behavioral, or emotional disorder in the past year used the Structured Clinical Interview for the DSM-5, Research Version, (SCID-5-RV). See the following reference: First, M. B., Williams, J. B. W., Karg, R. S., & Spitzer, R. L. (2015). *Structured clinical interview for DSM-5—research version* (SCID-5 for DSM-5, Research Version; SCID-5-RV). American Psychiatric Association.
62. American Psychiatric Association. (1994). *Diagnostic and statistical manual of mental disorders* (4th ed.).
63. For more information on the MICS and creation of estimates for AMI and SMI based on DSM-5 criteria, see Section 3.4.10 in the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
64. Clinical interviewers in the MICS assessed respondents' level of functional impairment according to the Global Assessment of Functioning (GAF) scale. A GAF score of 50 or lower was considered to indicate severe or worse impairment because of a mental disorder. See the following reference: Endicott, J., Spitzer, R. L., Fleiss, J. L., & Cohen, J. (1976). The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. *Archives of General Psychiatry*, 33, 766-771. <https://doi.org/10.1001/archpsyc.1976.01770060086012>
65. Details about imputation procedures, including imputation of source variables for predicting AMI or SMI among adults, are provided in Sections 2.3.3 and 3.4.10 of CBHSQ (2026). See the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
66. Curtin, S. C., Garnett, M. F., & Ahmad, F. B. (2023). *Provisional estimates of suicide by demographic characteristics: United States, 2022*. Vital Statistics Rapid Release (Report No. 34). National Center for Health Statistics. <https://doi.org/10.15620/cdc:133702>
67. U.S. Centers for Disease Control and Prevention. (2024). *Web-based Injury Statistics Query and Reporting System: WISQARS leading causes of death visualization tool*. <https://wisqars.cdc.gov/lcd/?o=LCD&y1=2024&y2=2024&ct=10&cc=ALL&g=00&s=0&r=0&ry=2&e=0&ar=lcd1age&at=groups&ag=lcd1age&a1=0&a2=199>
68. Xu, J., Murphy, S. L., Kochanek, K. D., & Arias, E. (2026). *Mortality in the United States, 2024* (NCHS Data Brief No. 548). National Center for Health Statistics. <https://www.cdc.gov/nchs/products/databriefs/db548.htm>
69. U.S. Centers for Disease Control and Prevention. (2026, May). *Suicide prevention: Suicide data and statistics*. <https://www.cdc.gov/suicide/data/index.html>
70. U.S. Centers for Disease Control and Prevention, National Center for Health Statistics. National Vital Statistics System, Provisional Mortality on CDC WONDER Online Database, released in 2026. Data are from the final Multiple Cause of Death Files, 2018-2024, and from provisional data for years 2025 and later, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Retrieved March 11, 2026, from <https://wonder.cdc.gov/mcd-icd10-provisional.html>
71. Center for Behavioral Health Statistics and Quality. (2024). *2023 National Survey on Drug Use and Health: Detailed tables*. <https://www.samhsa.gov/data/report/2023-nsduh-detailed-tables>
72. de la Torre-Luque, A., Pemau, A., Ayad-Ahmed, W., Borges, G., Fernandez-Sevillano, J., Garrido-Torres, N., Garrido-Sanchez, L., Garriga, M., Gonzalez-Ortega, I., Gonzalez-Pinto, A., Grande, I., Guinovart, M., Hernandez-Calle, D., Jimenez-Treviño, L., Lopez-Sola, C., Mediavilla, R., Perez-Aranda, A., Ruiz-Veguilla, M., Seijo-Zazo, E., ... & SURVIVE Consortium. (2023). Risk of suicide attempt repetition after an index attempt: A systematic review and meta-analysis. *General Hospital Psychiatry*, 81, 51-56. <https://doi.org/10.1016/j.genhosppsych.2023.01.007>
73. Wang, J., Sumner, S. A., Simon, T. R., Crosby, A. E., Annor, F. B., Gaylor, E., Xu, L., & Holland, K. M. (2020). Trends in the incidence and lethality of suicidal acts in the United States, 2006 to 2015. *JAMA Psychiatry*, 77(7), 684-693. <https://doi.org/10.1001/jamapsychiatry.2020.0596>
74. Miron, O., Yu, K.-H., Wilf-Miron, R., & Kohane, I. S. (2019). Suicide rates among adolescents and young adults in the United States, 2000-2017. *JAMA*, 321(23), 2362-2364. <https://doi.org/10.1001/jama.2019.5054>
75. Curtin, S. C. (2020, September). State suicide rates among adolescents and young adults aged 10–24: United States, 2000–2018. *National Vital Statistics Reports*, 69(11). <https://www.cdc.gov/nchs/data/nvstr/nvstr69/nvstr-69-11-508.pdf>
76. U.S. Centers for Disease Control and Prevention. (2024). *Youth Risk Behavior Survey data summary & trends report: 2013–2023*. <https://www.cdc.gov/yrb/dstr/index.html>
77. Mojtabai, R., & Olfson, M. (2020). National trends in mental health care for US adolescents. *JAMA Psychiatry*, 77(7), 703-714. <https://doi.org/10.1001/jamapsychiatry.2020.0279>
78. Examples of ACEs include abuse, neglect, and negative family interactions. ACEs can occur anytime from birth to age 17.
79. Swedo, E. A., Pampati, S., Anderson, K. N., Thorne, E., McKinnon, I. I., Brener, N. D., Stinson, J., Mpofu, J. J., & Holditch-Nielsen, P. (2024). Adverse childhood experiences and health conditions and risk behaviors among high school students — Youth Risk Behavior Survey, United States, 2023. *Morbidity and Mortality Weekly Report Supplement*, 73(Suppl. 4), 39-49. <https://doi.org/10.15585/mmwr.su7304a5>
80. Apicella, M., Pontillo, M., Maglio, G., Di Vincenzo, C., Della Santa, G., Andracchio, E., & Vicari, S. (2025). Non-suicidal self-injury in adolescents: A clinician's guide to understanding the phenomenon, diagnostic challenges, and evidence-based treatments. *Frontiers in Psychiatry*, 16, 1605508. <https://doi.org/10.3389/fpsyt.2025.1605508>
81. Respondents were eligible to be asked the substance use treatment questions if they reported lifetime use of alcohol, marijuana, cocaine (including crack), heroin, hallucinogens, inhalants, or methamphetamine, or the lifetime misuse of prescription psychotherapeutic drugs (i.e., pain relievers, tranquilizers, stimulants, or sedatives). Respondents who were lifetime users of tobacco products or other substances (e.g., kratom) but who did not report lifetime use or misuse of the substances mentioned in the previous sentence were not asked the substance use treatment questions. Thus, substance use treatment questions in NSDUH do not cover treatment for the use of nicotine products.

82. Details about the changes to the inpatient and outpatient substance use treatment questions for the 2024 NSDUH are provided in Section 3.4.8 of CBHSQ (2025). See the following reference: Center for Behavioral Health Statistics and Quality. (2025). *2024 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/report/2024-methodological-summary-and-definitions>
83. Details about the recent redesign of the substance use treatment questions for the 2022 NSDUH are provided in CBHSQ (2023). See the following reference: Center for Behavioral Health Statistics and Quality. (2023). *Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health* (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). <https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report>
84. Inpatient treatment locations were places where people stayed overnight or longer to receive treatment for their alcohol or drug use. Locations included hospitals where people stayed as inpatients, residential drug or alcohol rehabilitation or treatment centers, residential mental health treatment centers, or some other place where people stayed overnight or longer to receive treatment.
85. Outpatient treatment locations were places where people received treatment for their alcohol or drug use without needing to stay overnight. Locations included outpatient drug or alcohol rehabilitation or treatment centers; outpatient mental health treatment centers; the office of a therapist, psychologist, psychiatrist, or substance use treatment professional; general medical clinics or doctor's offices; hospitals where people received treatment as outpatients; school health or counseling centers; or some other place where people received treatment as outpatients.
86. Question TXDRRX in the NSDUH questionnaire asks about the use of prescription medication to cut back or stop the use of "drugs," but respondents were not asked TXDRRX unless they reported using heroin or prescription pain relievers in their lifetime. Because NSDUH respondents are asked this question if they reported using prescription pain relievers in their lifetime, respondents who used only nonopioid prescription pain relievers in their lifetime cannot be identified. As noted in the text, however, the drugs listed in TXDRRX are prescribed for the treatment of opioid use disorder.
87. For more information about other services not being classified as "substance use treatment," see Section 3.4.9 in the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
88. These estimates (or selected estimates being cited) were calculated from special analyses but are not included in the appendix tables or in the 2025 Detailed Tables.
89. Respondents in 2025 who did not receive substance use treatment and received overdose reversal medicine but did not receive support services from a support group or from a peer support specialist or recovery coach, services in an emergency room, or withdrawal management services were not asked if they sought or thought they should get additional professional counseling, medication, or other treatment in the past 12 months for their use of alcohol or drugs.
90. Details about the changes to the mental health treatment questions for the 2024 NSDUH are provided in Section 3.4.10 of CBHSQ (2025). See the following reference: Center for Behavioral Health Statistics and Quality. (2025). *2024 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/report/2024-methodological-summary-and-definitions>
91. Details about the recent redesign of the mental health treatment questions for the 2022 NSDUH are provided in CBHSQ (2023). See the following reference: Center for Behavioral Health Statistics and Quality. (2023). *Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health* (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). <https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report>
92. For more information about other services not being classified as "mental health treatment," see Section 3.4.11 in the following reference: Center for Behavioral Health Statistics and Quality. (2026). *2025 National Survey on Drug Use and Health: Methodological summary and definitions*. <https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/methodology>
93. Inpatient treatment locations were places where people stayed overnight or longer to receive mental health treatment. Locations included hospitals where people stayed as inpatients, residential mental health treatment centers, residential drug or alcohol rehabilitation or treatment centers, or some other place where people stayed overnight or longer to receive treatment.
94. Outpatient treatment locations were places where people received mental health treatment without needing to stay overnight. Locations included outpatient mental health treatment centers; outpatient drug or alcohol rehabilitation or treatment centers; the office of a therapist, psychologist, psychiatrist, or substance use treatment professional; general medical clinics or doctor's offices; hospitals where people received treatment as outpatients; school health or counseling centers; or some other place where people received treatment as outpatients.
95. Substance Abuse and Mental Health Services Administration. (2020). *Substance use disorder treatment for people with co-occurring disorders*. Treatment Improvement Protocol (TIP) Series, No. 42 (SAMHSA Publication No. PEP20-02-01-004). https://library.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-02-01_004.pdf
96. Scott, K. D., & Gorey, K. M. (2025). Concurrent disorders and treatment outcomes: A meta-analysis. *Journal of Dual Diagnosis*, 21(3), 251-265. <https://doi.org/10.1080/15504263.2025.2515015>
97. Substance Abuse and Mental Health Services Administration. (2013). *Behavioral health, United States, 2012* (HHS Publication No. (SMA) 13-4797). <https://www.samhsa.gov/data/sites/default/files/2012-BHUS.pdf>
98. Avery, J. D., & Hankins, D. (2022). Co-occurring substance use disorders and mental illness. In J. D. Avery & D. Hankins (Eds.), *Addiction medicine: A case and evidence-based guide* (pp. 123-129). Springer. https://doi.org/10.1007/978-3-030-86430-9_12
99. Karapareddy, V. (2019). A review of integrated care for concurrent disorders: Cost effectiveness and clinical outcomes. *Journal of Dual Diagnosis*, 15(1), 56-66. <https://doi.org/10.1080/15504263.2018.1518553>

Appendix A: Special Tables of Estimates for Substance Use and Mental Health Indicators in the United States

**Table A.1B Tobacco Product Use or Nicotine Vaping, Alcohol Use, or Illicit Drug Use in the Past Month:
Among People Aged 12 or Older; by Age Group, 2025**

Substance	12 or Older		12 to 17		18 to 25		26 or Older	
GENERAL SUBSTANCE USE								
Nicotine Products, Alcohol, or Illicit Drugs ^{1,2,3,4}	56.0	(0.41)	11.9	(0.47)	57.2	(0.80)	60.8	(0.50)
NICOTINE PRODUCTS ^{1,2}	22.1	(0.34)	6.9	(0.37)	27.9	(0.69)	22.9	(0.41)
Tobacco Products ¹	16.2	(0.30)	2.0	(0.21)	14.1	(0.49)	18.0	(0.37)
Cigarettes	12.4	(0.27)	1.3	(0.19)	9.8	(0.42)	14.1	(0.34)
Daily Cigarette Smoking ⁵	55.1	(1.09)	1.9	(1.17)	12.4	(1.13)	60.4	(1.17)
Smoked 1+ Packs of Cigarettes per Day ⁶	35.8	(1.54)	*	(*)	17.1	(3.77)	36.2	(1.58)
Smokeless Tobacco	2.5	(0.11)	0.4	(0.08)	3.4	(0.27)	2.6	(0.13)
Cigars	3.4	(0.14)	0.5	(0.09)	3.8	(0.23)	3.6	(0.17)
Pipe Tobacco	0.6	(0.06)	0.2	(0.05)	0.7	(0.12)	0.7	(0.07)
Nicotine Vaping ²	10.1	(0.23)	6.3	(0.36)	22.3	(0.63)	8.6	(0.25)
ALCOHOL	44.4	(0.43)	5.9	(0.34)	46.2	(0.86)	48.4	(0.52)
Binge Alcohol Use	19.5	(0.32)	3.0	(0.23)	26.7	(0.79)	20.2	(0.37)
Heavy Alcohol Use	5.0	(0.17)	0.3	(0.07)	6.3	(0.36)	5.3	(0.20)
ILLCIT DRUGS ^{3,4}	16.4	(0.30)	5.8	(0.34)	24.4	(0.66)	16.3	(0.35)
Marijuana	15.1	(0.29)	5.0	(0.32)	23.3	(0.66)	14.9	(0.34)
Marijuana Vaping ⁷	5.6	(0.16)	3.5	(0.28)	12.7	(0.49)	4.7	(0.18)

* Low precision; no estimate reported.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

¹ Nicotine product use includes use of tobacco products (cigarettes, smokeless tobacco [such as snuff, dip, chewing tobacco, or snus], cigars, or pipe tobacco) or nicotine vaping. Use of tobacco products does not include nicotine vaping because people could have used a vaping device to vape nicotine-containing products other than tobacco.

² Nicotine vaping refers to using an e-cigarette or other vaping device to vape nicotine or tobacco.

³ Illicit Drug Use includes the misuse of prescription psychotherapeutics (pain relievers, tranquilizers, stimulants, or sedatives) or the use of marijuana, cocaine (including crack), heroin, hallucinogens, inhalants, or methamphetamine.

⁴ These estimates do not include illegally made fentanyl.

⁵ Percentages for daily cigarette smoking are among past month cigarette smokers.

⁶ Percentages for smoking one or more packs of cigarettes per day are among daily cigarette smokers in the past month. Respondents with missing data for the number of cigarettes smoked per day were excluded from the analysis.

⁷ Marijuana vaping refers to using vape pens, dab pens, tabletop vaporizers, or portable vaporizers to vape marijuana.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.2B Type of Nicotine Product Use in the Past Month: Among Past Month Nicotine Product Users Aged 12 or Older; by Age Group, 2025

Nicotine Product Use ¹	12 or Older	12 to 17	18 to 25	26 or Older
Only Nicotine Vaping ²	27.0 (0.67)	70.8 (2.49)	49.4 (1.28)	21.2 (0.72)
Nicotine Vaping and Tobacco Products ^{2,3}	18.6 (0.60)	21.1 (2.29)	30.5 (1.16)	16.2 (0.66)
Nicotine Vaping and Only Cigarettes ²	11.0 (0.46)	10.8 (1.77)	17.0 (0.96)	9.9 (0.50)
Nicotine Vaping, Cigarettes, and Other Tobacco Products ^{2,4}	4.3 (0.30)	4.3 (1.02)	6.8 (0.55)	3.8 (0.35)
Nicotine Vaping and Only Other Tobacco Products ^{2,4}	3.3 (0.22)	6.0 (1.19)	6.7 (0.59)	2.6 (0.24)
Only Tobacco Products ³	54.4 (0.83)	8.2 (1.31)	20.1 (1.11)	62.6 (0.92)

NOTE: Estimates shown are percentages with standard errors included in parentheses. Percentages for Only Nicotine Vaping, Nicotine Vaping and Tobacco Products, and Only Tobacco Products in an age group category may not add to 100 percent due to rounding.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

¹ Nicotine product use refers to using tobacco or nicotine vaping.

² Nicotine vaping refers to using an e-cigarette or other vaping device to vape nicotine or tobacco.

³ Tobacco products include cigarettes, smokeless tobacco (such as snuff, dip, chewing tobacco, or snus), cigars, or pipe tobacco. Use of any tobacco product does not include nicotine vaping because people could have used a vaping device to vape nicotine-containing products other than tobacco.

⁴ Other tobacco products include smokeless tobacco (such as snuff, dip, chewing tobacco, or snus), cigars, or pipe tobacco.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.3B Use of Selected Substances in the Past Month: Among People Aged 12 or Older; 2021-2025

Substance	2021	2022	2023	2024	2025	Trend
NICOTINE PRODUCTS^{1,2}	--	22.7 (0.37)	22.7 (0.32)	22.1 (0.32)	22.1 (0.34)	No Change
Tobacco Products	20.1 (0.38)	18.1 (0.35)	17.6 (0.30)	16.7 (0.29)	16.2 (0.30)	Decreased
Cigarettes	16.0 (0.36)	14.6 (0.32)	13.7 (0.28)	13.1 (0.27)	12.4 (0.27)	Decreased
Daily Cigarette Smoking ³	61.5 (1.02)	58.7 (1.01)	58.9 (0.98)	59.0 (1.02)	55.1 (1.09)	Decreased
Smoked 1+ Packs of Cigarettes per Day ⁴	42.4 (1.46)	39.8 (1.33)	39.6 (1.33)	37.7 (1.35)	35.8 (1.54)	Decreased
Smokeless Tobacco	2.7 (0.14)	2.2 (0.11)	2.5 (0.12)	2.3 (0.11)	2.5 (0.11)	No Change
Cigars	3.7 (0.16)	3.7 (0.14)	3.8 (0.14)	3.3 (0.13)	3.4 (0.14)	Decreased
Pipe Tobacco	0.7 (0.06)	0.6 (0.06)	0.7 (0.06)	0.6 (0.06)	0.6 (0.06)	No Change
Nicotine Vaping ^{1,2}	--	8.3 (0.18)	9.4 (0.20)	9.6 (0.19)	10.1 (0.23)	Increased
ALCOHOL	47.4 (0.44)	48.7 (0.42)	47.5 (0.42)	46.6 (0.40)	44.4 (0.43)	Decreased
Binge Alcohol Use	21.7 (0.34)	21.7 (0.31)	21.7 (0.30)	20.1 (0.29)	19.5 (0.32)	Decreased
Heavy Alcohol Use	5.7 (0.20)	5.7 (0.16)	5.8 (0.16)	5.0 (0.16)	5.0 (0.17)	Decreased
MARIJUANA	13.2 (0.30)	15.0 (0.28)	15.4 (0.28)	15.4 (0.28)	15.1 (0.29)	Increased

-- Not available or not comparable with the estimate in 2022-2025 due to methodological or questionnaire changes.

Decreased = the linear trend test showed a statistically significant decrease from the baseline year to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from the baseline year to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from the baseline year to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

¹ The baseline year for this measure is 2022.

² Estimates for 2022 to 2024 may differ from previously published estimates because of updates to nicotine vaping measures. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

³ Percentages for daily cigarette smoking are among past month cigarette smokers.

⁴ Percentages for smoking one or more packs of cigarettes per day are among daily cigarette smokers in the past month. Respondents with missing data for the number of cigarettes smoked per day were excluded from the analysis.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.4B Use of Selected Substances in the Past Month: Among Adolescents Aged 12 to 17; 2021-2025

Substance	2021	2022	2023	2024	2025	Trend
NICOTINE PRODUCTS^{1,2}	--	7.3 (0.34)	7.4 (0.33)	6.6 (0.30)	6.9 (0.37)	No Change
Tobacco Products	2.9 (0.29)	2.0 (0.18)	1.9 (0.17)	1.9 (0.17)	2.0 (0.21)	Decreased
Cigarettes	1.7 (0.22)	1.2 (0.15)	1.3 (0.15)	1.2 (0.14)	1.3 (0.19)	No Change
Daily Cigarette Smoking ³	* (*)	3.1 (1.30)	* (*)	3.8 (1.37)	1.9 (1.17)	Not Tested
Smoked 1+ Packs of Cigarettes per Day ⁴	* (*)	* (*)	* (*)	* (*)	* (*)	Not Tested
Smokeless Tobacco	0.6 (0.12)	0.2 (0.05)	0.3 (0.06)	0.5 (0.08)	0.4 (0.08)	No Change
Cigars	0.8 (0.16)	0.7 (0.10)	0.4 (0.07)	0.5 (0.09)	0.5 (0.09)	No Change
Pipe Tobacco	0.3 (0.08)	0.2 (0.07)	0.2 (0.05)	0.1 (0.03)	0.2 (0.05)	No Change
Nicotine Vaping ^{1,2}	--	6.8 (0.33)	6.8 (0.32)	6.0 (0.29)	6.3 (0.36)	No Change
ALCOHOL	7.2 (0.44)	6.8 (0.32)	6.9 (0.37)	6.6 (0.36)	5.9 (0.34)	Decreased
Binge Alcohol Use	4.0 (0.33)	3.2 (0.22)	3.9 (0.29)	3.5 (0.22)	3.0 (0.23)	Decreased
Heavy Alcohol Use	0.4 (0.11)	0.2 (0.05)	0.5 (0.10)	0.4 (0.06)	0.3 (0.07)	No Change
MARIJUANA	6.1 (0.39)	6.4 (0.32)	6.0 (0.32)	6.0 (0.32)	5.0 (0.32)	Decreased

* Low precision; no estimate reported.

-- Not available or not comparable with the estimate in 2022-2025 due to methodological or questionnaire changes.

Decreased = the linear trend test showed a statistically significant decrease from the baseline year to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from the baseline year to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from the baseline year to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

¹ The baseline year for this measure is 2022.

² Estimates for 2022 to 2024 may differ from previously published estimates because of updates to nicotine vaping measures. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

³ Percentages for daily cigarette smoking are among past month cigarette smokers.

⁴ Percentages for smoking one or more packs of cigarettes per day are among daily cigarette smokers in the past month. Respondents with missing data for the number of cigarettes smoked per day were excluded from the analysis.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.5B Use of Selected Substances in the Past Month: Among Young Adults Aged 18 to 25; 2021-2025

Substance	2021	2022	2023	2024	2025	Trend
NICOTINE PRODUCTS^{1,2}	--	30.0 (0.62)	30.0 (0.62)	28.9 (0.61)	27.9 (0.69)	Decreased
Tobacco Products	17.5 (0.56)	15.4 (0.48)	15.7 (0.47)	14.4 (0.44)	14.1 (0.49)	Decreased
Cigarettes	11.8 (0.47)	10.7 (0.42)	10.6 (0.39)	9.6 (0.37)	9.8 (0.42)	Decreased
Daily Cigarette Smoking ³	27.0 (1.76)	26.7 (1.75)	25.4 (1.64)	19.5 (1.52)	12.4 (1.13)	Decreased
Smoked 1+ Packs of Cigarettes per Day ⁴	23.3 (2.74)	17.5 (2.62)	23.3 (2.64)	16.8 (2.93)	17.1 (3.77)	No Change
Smokeless Tobacco	3.0 (0.22)	2.4 (0.19)	2.8 (0.21)	3.3 (0.20)	3.4 (0.27)	Increased
Cigars	5.6 (0.34)	5.3 (0.31)	5.3 (0.28)	4.9 (0.27)	3.8 (0.23)	Decreased
Pipe Tobacco	1.1 (0.15)	1.1 (0.13)	1.1 (0.14)	0.9 (0.12)	0.7 (0.12)	Decreased
Nicotine Vaping ^{1,2}	--	24.0 (0.57)	24.1 (0.59)	23.7 (0.57)	22.3 (0.63)	Decreased
ALCOHOL	50.9 (0.81)	50.2 (0.76)	49.6 (0.77)	47.5 (0.72)	46.2 (0.86)	Decreased
Binge Alcohol Use	30.0 (0.76)	29.5 (0.63)	28.7 (0.64)	26.7 (0.63)	26.7 (0.79)	Decreased
Heavy Alcohol Use	7.1 (0.39)	7.6 (0.37)	6.9 (0.35)	6.0 (0.28)	6.3 (0.36)	Decreased
MARIJUANA	24.6 (0.71)	25.9 (0.64)	25.2 (0.58)	24.1 (0.56)	23.3 (0.66)	Decreased

-- Not available or not comparable with the estimate in 2022-2025 due to methodological or questionnaire changes.

Decreased = the linear trend test showed a statistically significant decrease from the baseline year to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from the baseline year to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from the baseline year to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

¹ The baseline year for this measure is 2022.

² Estimates for 2022 to 2024 may differ from previously published estimates because of updates to nicotine vaping measures. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

³ Percentages for daily cigarette smoking are among past month cigarette smokers.

⁴ Percentages for smoking one or more packs of cigarettes per day are among daily cigarette smokers in the past month. Respondents with missing data for the number of cigarettes smoked per day were excluded from the analysis.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.6B Use of Selected Substances in the Past Month: Among Adults Aged 26 or Older; 2021-2025

Substance	2021	2022	2023	2024	2025	Trend
NICOTINE PRODUCTS^{1,2}	--	23.3 (0.44)	23.4 (0.39)	22.8 (0.39)	22.9 (0.41)	No Change
Tobacco Products	22.5 (0.46)	20.4 (0.43)	19.7 (0.37)	18.7 (0.36)	18.0 (0.37)	Decreased
Cigarettes	18.3 (0.43)	16.7 (0.39)	15.5 (0.35)	15.0 (0.33)	14.1 (0.34)	Decreased
Daily Cigarette Smoking ³	65.3 (1.09)	62.4 (1.10)	62.9 (1.03)	63.3 (1.10)	60.4 (1.17)	Decreased
Smoked 1+ Packs of Cigarettes per Day ⁴	43.3 (1.51)	40.8 (1.37)	40.3 (1.38)	38.4 (1.39)	36.2 (1.58)	Decreased
Smokeless Tobacco	2.9 (0.17)	2.4 (0.13)	2.7 (0.15)	2.4 (0.13)	2.6 (0.13)	No Change
Cigars	3.8 (0.19)	3.8 (0.16)	3.9 (0.17)	3.3 (0.15)	3.6 (0.17)	No Change
Pipe Tobacco	0.7 (0.08)	0.6 (0.08)	0.7 (0.08)	0.6 (0.07)	0.7 (0.07)	No Change
Nicotine Vaping ^{1,2}	--	6.0 (0.20)	7.4 (0.21)	7.8 (0.21)	8.6 (0.25)	Increased
ALCOHOL	51.5 (0.53)	53.4 (0.51)	51.9 (0.50)	51.0 (0.48)	48.4 (0.52)	Decreased
Binge Alcohol Use	22.5 (0.40)	22.6 (0.36)	22.7 (0.36)	21.0 (0.35)	20.2 (0.37)	Decreased
Heavy Alcohol Use	6.2 (0.24)	6.0 (0.19)	6.2 (0.20)	5.4 (0.20)	5.3 (0.20)	Decreased
MARIJUANA	12.3 (0.34)	14.3 (0.32)	15.0 (0.32)	15.1 (0.33)	14.9 (0.34)	Increased

-- Not available or not comparable with the estimate in 2022-2025 due to methodological or questionnaire changes.

Decreased = the linear trend test showed a statistically significant decrease from the baseline year to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from the baseline year to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from the baseline year to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

¹ The baseline year for this measure is 2022.

² Estimates for 2022 to 2024 may differ from previously published estimates because of updates to nicotine vaping measures. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

³ Percentages for daily cigarette smoking are among past month cigarette smokers.

⁴ Percentages for smoking one or more packs of cigarettes per day are among daily cigarette smokers in the past month. Respondents with missing data for the number of cigarettes smoked per day were excluded from the analysis.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.7B Type of Tobacco Product Use in the Past Month: Among Past Month Tobacco Product Users Aged 12 or Older; by Age Group, 2025

Tobacco Product Use¹	12 or Older	12 to 17	18 to 25	26 or Older
Only Cigarettes	63.5 (0.92)	49.6 (4.79)	50.5 (1.81)	65.3 (1.01)
Cigarettes and Other Tobacco Products ²	13.4 (0.61)	16.8 (3.92)	18.6 (1.27)	12.8 (0.68)
Only Other Tobacco Products ²	23.0 (0.82)	33.6 (4.58)	30.9 (1.70)	22.0 (0.89)

NOTE: Estimates shown are percentages with standard errors included in parentheses. Percentages in an age group category may not add to 100 percent due to rounding.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

¹ Tobacco products include cigarettes, smokeless tobacco (such as snuff, dip, chewing tobacco, or snus), cigars, or pipe tobacco. Use of any tobacco product does not include nicotine vaping because people could have used a vaping device to vape nicotine-containing products other than tobacco.

² Other tobacco products include smokeless tobacco (such as snuff, dip, chewing tobacco, or snus), cigars, or pipe tobacco.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.8B Use of Selected Substances in the Past Month: Among People Aged 12 to 20; 2021-2025

Substance	2021	2022	2023	2024	2025	Trend
NICOTINE PRODUCTS^{1,2}	--	13.4 (0.41)	13.1 (0.42)	11.7 (0.38)	12.1 (0.42)	Decreased
Tobacco Products	5.7 (0.29)	5.0 (0.28)	4.8 (0.28)	4.3 (0.23)	5.0 (0.28)	Decreased
Cigarettes	3.6 (0.24)	3.1 (0.22)	3.3 (0.21)	3.0 (0.20)	3.4 (0.24)	No Change
Daily Cigarette Smoking ³	19.4 (3.05)	16.5 (2.67)	14.2 (1.96)	11.1 (1.84)	5.8 (1.22)	Decreased
Smoked 1+ Packs of Cigarettes per Day ⁴	11.0 (3.43)	* (*)	14.2 (4.41)	* (*)	* (*)	Not Tested
Smokeless Tobacco	1.0 (0.12)	0.8 (0.11)	0.8 (0.11)	0.9 (0.10)	1.0 (0.12)	No Change
Cigars	1.9 (0.19)	1.9 (0.17)	1.5 (0.14)	1.3 (0.13)	1.3 (0.12)	Decreased
Pipe Tobacco	0.5 (0.08)	0.4 (0.08)	0.5 (0.11)	0.3 (0.08)	0.3 (0.06)	Decreased
Nicotine Vaping ^{1,2}	--	12.2 (0.39)	11.7 (0.40)	10.5 (0.36)	10.6 (0.38)	Decreased
ALCOHOL	15.6 (0.50)	15.1 (0.45)	14.6 (0.49)	13.3 (0.44)	13.7 (0.53)	Decreased
Binge Alcohol Use	8.6 (0.40)	8.2 (0.36)	8.6 (0.38)	7.6 (0.33)	7.9 (0.40)	No Change
Heavy Alcohol Use	1.6 (0.17)	1.7 (0.18)	1.7 (0.17)	1.5 (0.14)	1.8 (0.17)	No Change

* Low precision; no estimate reported.

-- Not available or not comparable with the estimate in 2022-2025 due to methodological or questionnaire changes.

Decreased = the linear trend test showed a statistically significant decrease from the baseline year to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from the baseline year to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from the baseline year to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

¹ The baseline year for this measure is 2022.

² Estimates for 2022 to 2024 may differ from previously published estimates because of updates to nicotine vaping measures. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

³ Percentages for daily cigarette smoking are among past month cigarette smokers.

⁴ Percentages for smoking one or more packs of cigarettes per day are among daily cigarette smokers in the past month. Respondents with missing data for the number of cigarettes smoked per day were excluded from the analysis.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.9B Type of Marijuana Use in the Past Month: Among Past Month Marijuana Users Aged 12 or Older; by Age Group, 2025

Marijuana Use	12 or Older	12 to 17	18 to 25	26 or Older
Marijuana Vaping ¹	37.1 (0.84)	69.8 (2.63)	54.3 (1.44)	31.6 (0.98)
Marijuana Use but Not Marijuana Vaping ¹	62.9 (0.84)	30.2 (2.63)	45.7 (1.44)	68.4 (0.98)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: The 2025 NSDUH collected data on the variety of methods that people used to consume marijuana in the past month. Estimates shown focus on whether marijuana vaping was a method of past month consumption among past month marijuana users.

¹ Marijuana vaping refers to using vape pens, dab pens, tabletop vaporizers, or portable vaporizers to vape marijuana.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.10B Type of Illicit Drug Use in the Past Year: Among People Aged 12 or Older; 2021-2025

Drug	2021	2022	2023	2024	2025	Trend
ILLCIT DRUGS¹	22.2 (0.36)	24.9 (0.35)	24.9 (0.32)	25.5 (0.35)	24.0 (0.35)	Increased
Marijuana	19.0 (0.36)	22.0 (0.33)	21.8 (0.31)	22.3 (0.34)	21.2 (0.33)	Increased
Cocaine	1.7 (0.09)	1.9 (0.10)	1.8 (0.09)	1.5 (0.08)	1.7 (0.10)	No Change
Crack	0.4 (0.05)	0.3 (0.04)	0.4 (0.05)	0.3 (0.04)	0.3 (0.05)	No Change
Heroin	0.4 (0.05)	0.4 (0.04)	0.2 (0.03)	0.2 (0.03)	0.2 (0.03)	Decreased
Hallucinogens	2.7 (0.12)	3.0 (0.12)	3.1 (0.10)	3.6 (0.13)	3.1 (0.13)	Increased
Inhalants ²	--	--	--	--	0.8 (0.07)	Not Tested
Methamphetamine	0.9 (0.09)	1.0 (0.08)	0.9 (0.07)	0.8 (0.06)	0.9 (0.08)	No Change
Misuse of Prescription Psychotherapeutics	5.2 (0.18)	5.0 (0.15)	5.1 (0.15)	4.8 (0.14)	4.4 (0.15)	Decreased
Pain Relievers	3.2 (0.14)	3.0 (0.12)	3.0 (0.12)	2.8 (0.11)	2.5 (0.12)	Decreased
Prescription Opioids ³	3.0 (0.14)	2.8 (0.11)	2.9 (0.11)	2.6 (0.11)	2.4 (0.11)	Decreased
Stimulants	1.4 (0.08)	1.5 (0.07)	1.4 (0.07)	1.4 (0.07)	1.4 (0.07)	No Change
Tranquilizers or Sedatives	1.7 (0.09)	1.7 (0.09)	1.7 (0.09)	1.6 (0.09)	1.5 (0.10)	Decreased
Tranquilizers	1.5 (0.09)	1.5 (0.08)	1.4 (0.08)	1.3 (0.08)	1.3 (0.09)	Decreased
Sedatives	0.3 (0.03)	0.3 (0.04)	0.4 (0.05)	0.3 (0.04)	0.3 (0.06)	No Change
Benzodiazepines	1.4 (0.08)	1.3 (0.08)	1.3 (0.08)	1.2 (0.07)	1.1 (0.08)	Decreased
Misuse of Opioids ^{1,4}	3.2 (0.15)	3.0 (0.12)	3.0 (0.12)	2.7 (0.11)	2.4 (0.11)	Decreased
Misuse of Central Nervous System Stimulants	3.4 (0.14)	3.6 (0.13)	3.4 (0.13)	3.1 (0.11)	3.3 (0.14)	No Change

-- Not available or not comparable with the estimate in 2025 due to methodological or questionnaire changes.

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

¹ These estimates do not include illegally made fentanyl.

² Changes were made to the inhalant questions in 2025. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

³ Respondents who reported the misuse of only nonopioid pain relievers were not counted as having misused prescription opioids.

⁴ Estimates include the use of heroin or the misuse of prescription opioids in the past year. Estimates for 2021-2023 may differ from previously published estimates because they do not include the misuse of only nonopioid pain relievers.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.11B Type of Illicit Drug Use in the Past Year: Among Adolescents Aged 12 to 17; 2021-2025

Drug	2021	2022	2023	2024	2025	Trend
ILLICIT DRUGS¹	14.6 (0.58)	14.3 (0.45)	14.7 (0.46)	15.1 (0.51)	11.2 (0.46)	Decreased
Marijuana	10.9 (0.51)	11.5 (0.42)	11.2 (0.41)	10.4 (0.41)	8.7 (0.42)	Decreased
Cocaine	0.1 (0.04)	0.2 (0.05)	0.2 (0.06)	0.3 (0.07)	0.2 (0.07)	No Change
Crack	<0.1 (0.01)	<0.1 (<0.01)	<0.1 (0.02)	<0.1 (0.02)	<0.1 (0.03)	No Change
Heroin	<0.1 (<0.01)	<0.1 (0.01)	<0.1 (0.02)	<0.1 (0.02)	<0.1 (<0.01)	No Change
Hallucinogens	1.4 (0.18)	1.4 (0.14)	1.5 (0.16)	1.6 (0.16)	1.4 (0.19)	No Change
Inhalants ²	--	--	--	--	1.4 (0.16)	Not Tested
Methamphetamine	0.1 (0.05)	0.1 (0.02)	0.2 (0.07)	0.2 (0.09)	0.1 (0.06)	No Change
Misuse of Prescription Psychotherapeutics	3.5 (0.32)	2.5 (0.19)	3.0 (0.23)	2.5 (0.20)	2.4 (0.22)	Decreased
Pain Relievers	2.1 (0.24)	1.6 (0.14)	2.2 (0.21)	1.6 (0.17)	1.7 (0.19)	No Change
Prescription Opioids ³	2.0 (0.23)	1.5 (0.14)	2.0 (0.19)	1.5 (0.15)	1.6 (0.19)	No Change
Stimulants	1.2 (0.16)	0.9 (0.12)	0.9 (0.12)	0.8 (0.12)	0.8 (0.13)	No Change
Tranquilizers or Sedatives	1.0 (0.20)	0.5 (0.08)	0.7 (0.10)	0.7 (0.10)	0.6 (0.12)	No Change
Tranquilizers	0.8 (0.20)	0.4 (0.07)	0.5 (0.07)	0.5 (0.09)	0.5 (0.11)	No Change
Sedatives	0.2 (0.05)	0.1 (0.04)	0.3 (0.07)	0.2 (0.07)	0.1 (0.04)	No Change
Benzodiazepines	0.8 (0.19)	0.4 (0.07)	0.4 (0.07)	0.4 (0.08)	0.5 (0.11)	No Change
Misuse of Opioids ^{1,4}	2.0 (0.23)	1.5 (0.14)	2.0 (0.19)	1.5 (0.15)	1.6 (0.19)	No Change
Misuse of Central Nervous System Stimulants	1.3 (0.16)	1.1 (0.13)	1.1 (0.14)	1.1 (0.16)	0.9 (0.14)	No Change

-- Not available or not comparable with the estimate in 2025 due to methodological or questionnaire changes.

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

NOTE: Standard errors that round to 0.00 percent are presented as <0.01.

¹ These estimates do not include illegally made fentanyl.

² Changes were made to the inhalant questions in 2025. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

³ Respondents who reported the misuse of only nonopioid pain relievers were not counted as having misused prescription opioids.

⁴ Estimates include the use of heroin or the misuse of prescription opioids in the past year. Estimates for 2021-2023 may differ from previously published estimates because they do not include the misuse of only nonopioid pain relievers.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.12B Type of Illicit Drug Use in the Past Year: Among Young Adults Aged 18 to 25; 2021-2025

Drug	2021	2022	2023	2024	2025	Trend
ILLCIT DRUGS¹	39.0 (0.77)	40.9 (0.71)	39.0 (0.69)	38.1 (0.65)	36.3 (0.77)	Decreased
Marijuana	36.3 (0.76)	38.2 (0.71)	36.5 (0.70)	35.0 (0.64)	33.7 (0.74)	Decreased
Cocaine	3.7 (0.33)	3.7 (0.26)	3.1 (0.25)	2.3 (0.18)	2.6 (0.24)	Decreased
Crack	0.2 (0.09)	0.1 (0.04)	0.2 (0.06)	0.1 (0.04)	0.1 (0.02)	No Change
Heroin	0.2 (0.05)	0.2 (0.04)	0.1 (0.02)	0.1 (0.04)	<0.1 (0.01)	Decreased
Hallucinogens	7.4 (0.40)	7.7 (0.36)	6.7 (0.33)	6.8 (0.33)	6.0 (0.37)	Decreased
Inhalants ²	--	--	--	--	1.8 (0.24)	Not Tested
Methamphetamine	0.5 (0.12)	0.5 (0.09)	0.3 (0.06)	0.5 (0.08)	0.4 (0.10)	No Change
Misuse of Prescription Psychotherapeutics	7.9 (0.40)	7.3 (0.35)	6.0 (0.30)	5.8 (0.31)	5.3 (0.30)	Decreased
Pain Relievers	3.1 (0.26)	3.2 (0.22)	2.5 (0.19)	2.7 (0.24)	2.1 (0.20)	Decreased
Prescription Opioids ³	3.0 (0.25)	3.0 (0.21)	2.4 (0.17)	2.6 (0.23)	2.0 (0.20)	Decreased
Stimulants	4.1 (0.31)	3.7 (0.26)	3.1 (0.23)	2.8 (0.21)	2.7 (0.25)	Decreased
Tranquilizers or Sedatives	2.7 (0.24)	2.4 (0.19)	1.7 (0.14)	1.6 (0.16)	1.6 (0.17)	Decreased
Tranquilizers	2.6 (0.23)	2.2 (0.18)	1.5 (0.13)	1.5 (0.15)	1.4 (0.17)	Decreased
Sedatives	0.4 (0.08)	0.3 (0.06)	0.3 (0.06)	0.2 (0.05)	0.3 (0.08)	No Change
Benzodiazepines	2.5 (0.23)	2.1 (0.18)	1.4 (0.13)	1.4 (0.14)	1.3 (0.16)	Decreased
Misuse of Opioids ^{1,4}	3.0 (0.25)	3.0 (0.21)	2.4 (0.17)	2.6 (0.23)	2.0 (0.20)	Decreased
Misuse of Central Nervous System Stimulants	6.7 (0.40)	6.5 (0.35)	5.6 (0.33)	4.7 (0.26)	4.7 (0.32)	Decreased

-- Not available or not comparable with the estimate in 2025 due to methodological or questionnaire changes.

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

¹ These estimates do not include illegally made fentanyl.

² Changes were made to the inhalant questions in 2025. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

³ Respondents who reported the misuse of only nonopioid pain relievers were not counted as having misused prescription opioids.

⁴ Estimates include the use of heroin or the misuse of prescription opioids in the past year. Estimates for 2021-2023 may differ from previously published estimates because they do not include the misuse of only nonopioid pain relievers.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.13B Type of Illicit Drug Use in the Past Year: Among Adults Aged 26 or Older; 2021-2025

Drug	2021	2022	2023	2024	2025	Trend
ILLICIT DRUGS¹	20.5 (0.42)	23.7 (0.41)	23.9 (0.37)	24.8 (0.42)	23.5 (0.41)	Increased
Marijuana	17.3 (0.40)	20.6 (0.39)	20.8 (0.35)	21.7 (0.40)	20.6 (0.39)	Increased
Cocaine	1.6 (0.10)	1.8 (0.11)	1.7 (0.11)	1.5 (0.09)	1.7 (0.12)	No Change
Crack	0.4 (0.06)	0.4 (0.05)	0.4 (0.06)	0.3 (0.05)	0.4 (0.06)	No Change
Heroin	0.5 (0.06)	0.4 (0.05)	0.3 (0.04)	0.2 (0.04)	0.3 (0.04)	Decreased
Hallucinogens	2.1 (0.13)	2.5 (0.13)	2.7 (0.12)	3.4 (0.16)	2.9 (0.14)	Increased
Inhalants ²	--	--	--	--	0.6 (0.07)	Not Tested
Methamphetamine	1.1 (0.11)	1.1 (0.10)	1.1 (0.09)	1.0 (0.08)	1.1 (0.10)	No Change
Misuse of Prescription Psychotherapeutics	5.0 (0.21)	5.0 (0.17)	5.2 (0.18)	4.9 (0.17)	4.5 (0.19)	No Change
Pain Relievers	3.3 (0.18)	3.1 (0.14)	3.2 (0.14)	2.9 (0.14)	2.6 (0.14)	Decreased
Prescription Opioids ³	3.2 (0.17)	3.0 (0.14)	3.1 (0.14)	2.8 (0.13)	2.5 (0.14)	Decreased
Stimulants	1.0 (0.08)	1.3 (0.08)	1.2 (0.08)	1.2 (0.08)	1.2 (0.08)	No Change
Tranquilizers or Sedatives	1.7 (0.11)	1.7 (0.11)	1.8 (0.11)	1.7 (0.10)	1.5 (0.12)	No Change
Tranquilizers	1.5 (0.10)	1.5 (0.10)	1.5 (0.10)	1.4 (0.09)	1.3 (0.11)	No Change
Sedatives	0.3 (0.04)	0.4 (0.05)	0.4 (0.07)	0.3 (0.05)	0.4 (0.07)	No Change
Benzodiazepines	1.3 (0.10)	1.3 (0.09)	1.4 (0.10)	1.2 (0.09)	1.2 (0.10)	No Change
Misuse of Opioids ^{1,4}	3.4 (0.18)	3.1 (0.14)	3.2 (0.14)	2.8 (0.13)	2.6 (0.14)	Decreased
Misuse of Central Nervous System Stimulants	3.1 (0.15)	3.5 (0.16)	3.3 (0.15)	3.1 (0.14)	3.3 (0.16)	No Change

-- Not available or not comparable with the estimate in 2025 due to methodological or questionnaire changes.

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

¹ These estimates do not include illegally made fentanyl.

² Changes were made to the inhalant questions in 2025. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

³ Respondents who reported the misuse of only nonopioid pain relievers were not counted as having misused prescription opioids.

⁴ Estimates include the use of heroin or the misuse of prescription opioids in the past year. Estimates for 2021-2023 may differ from previously published estimates because they do not include the misuse of only nonopioid pain relievers.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.14B Mode of Marijuana Use in the Past Year: Among Past Year Marijuana Users Aged 12 or Older; by Age Group, 2025

Mode of Marijuana Use	12 or Older		12 to 17		18 to 25		26 or Older	
Smoking	74.8	(0.69)	79.5	(2.01)	82.7	(0.93)	72.6	(0.87)
Vaping ¹	39.2	(0.70)	74.0	(2.02)	57.4	(1.17)	32.9	(0.82)
Dabbing Waxes, Shatter, or Concentrates	14.5	(0.52)	16.8	(1.56)	23.1	(1.04)	12.1	(0.58)
Eating or Drinking	49.2	(0.80)	36.6	(2.32)	46.5	(1.24)	50.5	(0.99)
Applying Lotion, Cream, or Patches to Skin	7.0	(0.42)	2.4	(0.75)	3.6	(0.43)	8.1	(0.53)
Putting Drops, Strips, Lozenges, or Sprays in Mouth or under Tongue	4.3	(0.30)	2.1	(0.69)	2.6	(0.33)	4.9	(0.38)
Taking Pills	2.2	(0.24)	3.2	(1.02)	1.4	(0.21)	2.4	(0.31)
Some Other Way ²	0.8	(0.16)	3.2	(1.11)	0.5	(0.22)	0.8	(0.20)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Respondents could indicate multiple modes of marijuana use; thus, these response categories are not mutually exclusive.

¹ Marijuana vaping refers to using vape pens, dab pens, tabletop vaporizers, or portable vaporizers to vape marijuana.

² Some Other Way includes write-in responses not already listed in this table or responses with insufficient information that could allow them to be placed in another category.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.15B Misuse of Specific Prescription Opioid Subtypes in the Past Year: Among People Aged 12 or Older, among Past Year Misusers of Prescription Opioids Aged 12 or Older, and among All Past Year Users of Prescription Opioid Subtypes Aged 12 or Older; 2025

Prescription Opioid Subtype	Past Year Misuse among People Aged 12 or Older		Past Year Misuse among Past Year Misusers of Prescription Opioids¹		Past Year Misuse among All Past Year Users of Specific Prescription Opioid Subtypes	
Hydrocodone Products	1.0	(0.07)	41.8	(2.55)	8.6	(0.62)
Oxycodone Products	0.7	(0.07)	31.7	(2.51)	10.2	(0.93)
Tramadol Products	0.4	(0.05)	15.8	(1.87)	7.0	(0.84)
Codeine Products	0.7	(0.05)	27.8	(2.07)	10.7	(0.88)
Morphine Products	0.2	(0.04)	7.2	(1.55)	9.7	(2.06)
Fentanyl Products ²	0.2	(0.04)	8.1	(1.52)	17.8	(3.21)
Buprenorphine Products	0.2	(0.03)	9.6	(1.37)	18.5	(2.49)
Oxymorphone Products	0.1	(0.02)	2.4	(0.78)	14.1	(4.48)
Demerol [®]	<0.1	(0.01)	1.3	(0.62)	*	(*)
Hydromorphone Products	<0.1	(<0.01)	0.4	(0.14)	2.1	(0.72)
Methadone	0.1	(0.02)	3.2	(0.90)	14.6	(3.95)

* Low precision; no estimate reported.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

NOTE: Standard errors that round to 0.00 percent are presented as <0.01.

NOTE: Percentages for misuse in the past year among people aged 12 or older and among past year misusers of prescription opioids are not mutually exclusive because people could have misused prescription opioids in more than one subtype.

NOTE: Respondents with unknown prescription drug subtype information were excluded from the respective analyses.

¹ Misuse of prescription opioids includes data from respondents who reported opioid subtypes other than those in the questionnaire.

² Estimates in this row do not include use of only illegally made fentanyl.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.16AB Type of Opioid Misuse in the Past Year: Among Past Year Opioid Misusers Aged 12 or Older; 2025

Opioid Misuse	Number in Thousands ¹		Percentage ²	
Opioid Misuse	7,080	(344)	100.0	(0.00)
Prescription Opioid Misuse	6,881	(341)	97.2	(0.63)
Heroin Use	581	(97)	8.2	(1.33)
Prescription Opioid Misuse but Not Heroin Use	6,499	(332)	91.8	(1.33)
Heroin Use but Not Prescription Opioid Misuse	199	(45)	2.8	(0.63)
Prescription Opioid Misuse and Heroin Use	382	(84)	5.4	(1.15)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: These estimates do not include illegally made fentanyl.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.17AB Type of Central Nervous System (CNS) Stimulant Misuse in the Past Year: Among Past Year CNS Stimulant Misusers Aged 12 or Older; 2025

CNS Stimulant Misuse	Number in Thousands ¹		Percentage ²	
CNS Stimulant Misuse	9,486	(425)	100.0	(0.00)
Cocaine Use	4,937	(300)	52.0	(2.08)
Methamphetamine Use	2,653	(236)	28.0	(2.01)
Prescription Stimulant Misuse	3,940	(221)	41.5	(1.96)
USED OR MISUSED ONLY ONE TYPE OF CNS STIMULANT				
Cocaine Use (No Methamphetamine Use or Prescription Stimulant Misuse)	3,358	(252)	35.4	(1.98)
Methamphetamine Use (No Cocaine Use or Prescription Stimulant Misuse)	1,709	(204)	18.0	(1.86)
Prescription Stimulant Misuse (No Cocaine Use or Methamphetamine Use)	2,563	(175)	27.0	(1.67)
USED OR MISUSED TWO TYPES OF CNS STIMULANTS				
Cocaine Use and Methamphetamine Use (No Prescription Stimulant Misuse)	479	(82)	5.0	(0.84)
Cocaine Use and Prescription Stimulant Misuse (No Methamphetamine Use)	912	(105)	9.6	(1.06)
Methamphetamine Use and Prescription Stimulant Misuse (No Cocaine Use)	277	(59)	2.9	(0.62)
USED OR MISUSED ALL THREE TYPES OF CNS STIMULANTS (Cocaine Use, Methamphetamine Use, and Prescription Stimulant Misuse)	188	(46)	2.0	(0.48)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.18B Illegally Made Fentanyl Use in the Past Year: Among People Aged 12 or Older; by Age Group, 2022-2025

Illegally Made Fentanyl	2022	2023	2024	2025	Trend
ILLEGALLY MADE FENTANYL, 12 OR OLDER	0.2 (0.03)	0.2 (0.02)	0.2 (0.03)	0.3 (0.04)	No Change
12 to 17	0.1 (0.03)	0.1 (0.05)	0.1 (0.06)	0.1 (0.06)	No Change
18 to 25	0.1 (0.04)	0.2 (0.05)	0.3 (0.07)	0.2 (0.04)	No Change
26 or Older	0.3 (0.04)	0.2 (0.03)	0.2 (0.04)	0.3 (0.06)	No Change

Decreased = the linear trend test showed a statistically significant decrease from 2022 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2022 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2022 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2022-2025.

Table A.19A Initiation of Specific Substance Use in the Past Year: Among People Aged 12 or Older; by Age Group, 2025

Substance	12 or Older	12 to 17	18 to 25	26 or Older
ILLICIT DRUGS	nr	nr	nr	nr
Marijuana	2,352 (134)	615 (56)	1,143 (94)	593 (78)
Cocaine	479 (72)	41 (18)	234 (40)	203 (54)
Crack	62 (25)	9 (9)	6 (5)	46 (22)
Heroin	5 (3)	<1 (<1)	1 (1)	3 (3)
Hallucinogens	1,216 (118)	204 (36)	520 (66)	491 (95)
Inhalants	542 (69)	194 (28)	306 (59)	42 (23)
Methamphetamine	114 (32)	16 (10)	11 (4)	87 (30)
Misuse of Prescription Psychotherapeutics	nr	nr	nr	nr
Pain Relievers	1,280 (144)	164 (30)	190 (29)	926 (140)
Stimulants	691 (76)	95 (22)	272 (44)	324 (58)
Tranquilizers or Sedatives	nr	nr	nr	nr
Tranquilizers	573 (87)	36 (13)	98 (22)	439 (83)
Sedatives	132 (50)	11 (5)	47 (19)	74 (46)
NICOTINE PRODUCTS	nr	nr	nr	nr
Cigarettes	1,661 (120)	363 (44)	1,146 (97)	152 (52)
Daily Cigarette Smoking	233 (40)	37 (14)	107 (20)	90 (32)
Smokeless Tobacco	1,097 (102)	116 (19)	591 (79)	390 (59)
Cigars	1,837 (156)	185 (25)	823 (75)	829 (133)
Nicotine Vaping	4,249 (231)	968 (73)	982 (84)	2,299 (203)
ALCOHOL	4,258 (192)	1,590 (95)	2,551 (146)	117 (44)

nr = not reported due to measurement issues.

NOTE: Estimates shown are numbers in thousands with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates that round to 0 are presented as <1.

NOTE: Standard errors that round to 0 are presented as <1.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.20B Initiation of Specific Substance Use in the Past Year: Among People Aged 12 or Older; 2021-2025

Substance	2021	2022	2023	2024	2025	Trend
ILLICIT DRUGS	nr	nr	nr	nr	nr	nr
Marijuana	1.0 (0.06)	1.3 (0.07)	1.2 (0.06)	1.0 (0.05)	0.8 (0.05)	Decreased
Cocaine	0.2 (0.03)	0.2 (0.02)	0.2 (0.02)	0.1 (0.02)	0.2 (0.02)	No Change
Heroin	<0.1 (<0.01)	<0.1 (0.01)	<0.1 (<0.01)	<0.1 (<0.01)	<0.1 (<0.01)	Decreased
Hallucinogens	0.5 (0.04)	0.5 (0.04)	0.5 (0.03)	0.6 (0.04)	0.4 (0.04)	No Change
Inhalants	--	--	--	--	0.2 (0.02)	Not Tested
Methamphetamine	<0.1 (0.01)	0.1 (0.02)	<0.1 (0.01)	<0.1 (0.01)	<0.1 (0.01)	No Change
Misuse of Prescription Psychotherapeutics	nr	nr	nr	nr	nr	nr
Pain Relievers	0.6 (0.07)	0.5 (0.04)	0.5 (0.04)	0.5 (0.04)	0.4 (0.05)	No Change
Stimulants	0.3 (0.03)	0.3 (0.03)	0.3 (0.03)	0.2 (0.02)	0.2 (0.03)	No Change
Tranquilizers	0.3 (0.05)	0.3 (0.03)	0.2 (0.02)	0.2 (0.03)	0.2 (0.03)	Decreased
Sedatives	0.1 (0.02)	0.1 (0.01)	0.1 (0.02)	0.1 (0.02)	<0.1 (0.02)	No Change
NICOTINE PRODUCTS	nr	nr	nr	nr	nr	nr
Cigarettes	0.4 (0.04)	0.5 (0.03)	0.5 (0.03)	0.5 (0.03)	0.6 (0.04)	Increased
Daily Cigarette Smoking	0.1 (0.03)	0.1 (0.01)	0.1 (0.02)	0.1 (0.01)	0.1 (0.01)	No Change
Smokeless Tobacco	0.2 (0.03)	0.2 (0.02)	0.3 (0.03)	0.4 (0.03)	0.4 (0.03)	Increased
Cigars	0.5 (0.04)	0.6 (0.05)	0.7 (0.05)	0.5 (0.04)	0.6 (0.05)	No Change
Nicotine Vaping ^{1,2}	--	2.1 (0.09)	2.0 (0.08)	1.8 (0.08)	1.5 (0.08)	Decreased
ALCOHOL	1.5 (0.06)	1.5 (0.06)	1.5 (0.06)	1.5 (0.06)	1.5 (0.06)	No Change

-- Not available or not comparable with the estimate in 2025 due to methodological or questionnaire changes; nr = not reported due to measurement issues.

Decreased = the linear trend test showed a statistically significant decrease from the baseline year to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from the baseline year to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from the baseline year to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

NOTE: Standard errors that round to 0.00 percent are presented as <0.01.

¹ The baseline year for this measure is 2022.

² Estimates for 2022 to 2024 may differ from previously published estimates because of updates to nicotine vaping measures. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.21B Initiation of Specific Substance Use in the Past Year: Among Adolescents Aged 12 to 17; 2021-2025

Substance	2021	2022	2023	2024	2025	Trend
ILLICIT DRUGS	nr	nr	nr	nr	nr	nr
Marijuana	3.5 (0.28)	4.8 (0.28)	4.5 (0.28)	3.5 (0.26)	2.4 (0.22)	Decreased
Cocaine	0.1 (0.03)	0.1 (0.05)	0.1 (0.03)	0.1 (0.04)	0.2 (0.07)	No Change
Heroin	<0.1 (<0.01)	* (*)	<0.1 (0.02)	<0.1 (0.02)	<0.1 (<0.01)	Not Tested
Hallucinogens	0.8 (0.14)	0.9 (0.12)	1.0 (0.12)	0.9 (0.13)	0.8 (0.14)	No Change
Inhalants	--	--	--	--	0.8 (0.11)	Not Tested
Methamphetamine	0.1 (0.04)	<0.1 (0.02)	0.1 (0.03)	0.1 (0.02)	0.1 (0.04)	No Change
Misuse of Prescription Psychotherapeutics	nr	nr	nr	nr	nr	nr
Pain Relievers	0.6 (0.14)	0.7 (0.10)	0.8 (0.10)	0.6 (0.10)	0.6 (0.12)	No Change
Stimulants	0.6 (0.12)	0.4 (0.09)	0.4 (0.07)	0.2 (0.05)	0.4 (0.08)	Decreased
Tranquilizers	0.3 (0.08)	0.2 (0.05)	0.2 (0.04)	0.2 (0.06)	0.1 (0.05)	No Change
Sedatives	0.1 (0.03)	0.1 (0.04)	0.2 (0.06)	0.1 (0.02)	<0.1 (0.02)	No Change
NICOTINE PRODUCTS	nr	nr	nr	nr	nr	nr
Cigarettes	1.5 (0.22)	1.7 (0.18)	1.7 (0.18)	1.3 (0.13)	1.4 (0.17)	No Change
Daily Cigarette Smoking	0.1 (0.05)	0.1 (0.04)	0.1 (0.03)	0.1 (0.04)	0.1 (0.05)	No Change
Smokeless Tobacco	0.5 (0.10)	0.4 (0.08)	0.4 (0.08)	0.7 (0.11)	0.5 (0.08)	No Change
Cigars	1.1 (0.19)	0.9 (0.11)	0.9 (0.14)	0.9 (0.12)	0.7 (0.10)	No Change
Nicotine Vaping ^{1,2}	--	5.5 (0.30)	5.4 (0.31)	4.2 (0.26)	3.8 (0.28)	Decreased
ALCOHOL	7.1 (0.38)	7.0 (0.35)	7.0 (0.35)	6.4 (0.32)	6.2 (0.34)	Decreased

* Low precision; no estimate reported; -- Not available or not comparable with the estimate in 2025 due to methodological or questionnaire changes; nr = not reported due to measurement issues.

Decreased = the linear trend test showed a statistically significant decrease from the baseline year to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from the baseline year to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from the baseline year to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

NOTE: Standard errors that round to 0.00 percent are presented as <0.01.

¹ The baseline year for this measure is 2022.

² Estimates for 2022 to 2024 may differ from previously published estimates because of updates to nicotine vaping measures. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.22B Initiation of Specific Substance Use in the Past Year: Among Young Adults Aged 18 to 25; 2021-2025

Substance	2021	2022	2023	2024	2025	Trend
ILLICIT DRUGS	nr	nr	nr	nr	nr	nr
Marijuana	3.5 (0.28)	3.4 (0.24)	3.5 (0.23)	2.9 (0.21)	3.2 (0.25)	No Change
Cocaine	0.8 (0.15)	1.1 (0.15)	0.8 (0.11)	0.8 (0.12)	0.6 (0.11)	No Change
Heroin	<0.1 (0.02)	0.1 (0.03)	<0.1 (0.01)	0.1 (0.02)	<0.1 (<0.01)	No Change
Hallucinogens	2.2 (0.22)	2.0 (0.18)	1.9 (0.16)	1.7 (0.16)	1.4 (0.18)	Decreased
Inhalants	--	--	--	--	0.8 (0.16)	Not Tested
Methamphetamine	0.1 (0.02)	0.2 (0.07)	<0.1 (0.01)	0.1 (0.04)	<0.1 (0.01)	No Change
Misuse of Prescription Psychotherapeutics	nr	nr	nr	nr	nr	nr
Pain Relievers	0.8 (0.13)	0.8 (0.12)	0.6 (0.08)	0.7 (0.12)	0.5 (0.08)	No Change
Stimulants	1.0 (0.16)	0.8 (0.12)	0.8 (0.13)	0.7 (0.10)	0.8 (0.12)	No Change
Tranquilizers	0.7 (0.11)	0.5 (0.09)	0.4 (0.07)	0.3 (0.07)	0.3 (0.06)	Decreased
Sedatives	0.1 (0.05)	0.1 (0.03)	0.1 (0.02)	<0.1 (0.03)	0.1 (0.05)	No Change
NICOTINE PRODUCTS	nr	nr	nr	nr	nr	nr
Cigarettes	2.2 (0.23)	2.3 (0.19)	2.8 (0.22)	2.9 (0.21)	3.2 (0.25)	Increased
Daily Cigarette Smoking	0.4 (0.09)	0.5 (0.09)	0.6 (0.09)	0.5 (0.10)	0.3 (0.05)	No Change
Smokeless Tobacco	0.6 (0.14)	0.7 (0.11)	1.4 (0.19)	1.4 (0.15)	1.6 (0.21)	Increased
Cigars	2.4 (0.23)	2.4 (0.19)	3.1 (0.23)	2.5 (0.20)	2.3 (0.20)	No Change
Nicotine Vaping ^{1,2}	--	4.1 (0.24)	3.9 (0.25)	3.2 (0.24)	2.7 (0.23)	Decreased
ALCOHOL	6.2 (0.36)	6.5 (0.30)	6.7 (0.34)	6.7 (0.33)	7.1 (0.37)	No Change

-- Not available or not comparable with the estimate in 2025 due to methodological or questionnaire changes; nr = not reported due to measurement issues.

Decreased = the linear trend test showed a statistically significant decrease from the baseline year to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from the baseline year to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from the baseline year to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

NOTE: Standard errors that round to 0.00 percent are presented as <0.01.

¹ The baseline year for this measure is 2022.

² Estimates for 2022 to 2024 may differ from previously published estimates because of updates to nicotine vaping measures. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.23B Initiation of Specific Substance Use in the Past Year: Among Adults Aged 26 or Older; 2021-2025

Substance	2021	2022	2023	2024	2025	Trend
ILLICIT DRUGS	nr	nr	nr	nr	nr	nr
Marijuana	0.3 (0.05)	0.6 (0.07)	0.5 (0.06)	0.4 (0.05)	0.3 (0.03)	No Change
Cocaine	0.1 (0.02)	<0.1 (0.02)	0.1 (0.02)	0.1 (0.02)	0.1 (0.02)	No Change
Heroin	<0.1 (<0.01)	<0.1 (0.01)	<0.1 (<0.01)	* (*)	<0.1 (<0.01)	Not Tested
Hallucinogens	0.2 (0.03)	0.2 (0.04)	0.3 (0.03)	0.4 (0.05)	0.2 (0.04)	No Change
Inhalants	--	--	--	--	<0.1 (0.01)	Not Tested
Methamphetamine	<0.1 (0.01)	<0.1 (0.03)	<0.1 (0.01)	<0.1 (0.01)	<0.1 (0.01)	No Change
Misuse of Prescription Psychotherapeutics	nr	nr	nr	nr	nr	nr
Pain Relievers	0.6 (0.09)	0.4 (0.05)	0.4 (0.05)	0.5 (0.05)	0.4 (0.06)	No Change
Stimulants	0.1 (0.03)	0.2 (0.03)	0.2 (0.03)	0.1 (0.03)	0.1 (0.03)	No Change
Tranquilizers	0.3 (0.05)	0.2 (0.04)	0.2 (0.03)	0.2 (0.03)	0.2 (0.04)	No Change
Sedatives	0.1 (0.02)	<0.1 (0.01)	0.1 (0.03)	0.1 (0.02)	<0.1 (0.02)	No Change
NICOTINE PRODUCTS	nr	nr	nr	nr	nr	nr
Cigarettes	<0.1 (0.02)	0.1 (0.02)	<0.1 (0.01)	0.1 (0.02)	0.1 (0.02)	No Change
Daily Cigarette Smoking	0.1 (0.03)	<0.1 (0.01)	<0.1 (0.02)	<0.1 (0.01)	<0.1 (0.01)	No Change
Smokeless Tobacco	0.1 (0.02)	0.1 (0.02)	0.1 (0.03)	0.2 (0.02)	0.2 (0.03)	Increased
Cigars	0.1 (0.03)	0.2 (0.05)	0.3 (0.06)	0.2 (0.03)	0.4 (0.06)	Increased
Nicotine Vaping ^{1,2}	--	1.4 (0.10)	1.3 (0.09)	1.3 (0.08)	1.0 (0.09)	Decreased
ALCOHOL	0.1 (0.03)	0.1 (0.02)	<0.1 (0.02)	0.1 (0.02)	0.1 (0.02)	No Change

* Low precision; no estimate reported; -- Not available or not comparable with the estimate in 2025 due to methodological or questionnaire changes; nr = not reported due to measurement issues.

Decreased = the linear trend test showed a statistically significant decrease from the baseline year to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from the baseline year to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from the baseline year to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

NOTE: Standard errors that round to 0.00 percent are presented as <0.01.

¹ The baseline year for this measure is 2022.

² Estimates for 2022 to 2024 may differ from previously published estimates because of updates to nicotine vaping measures. See Chapter 3 of the [2025 Methodological Summary and Definitions](#) for details.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.24AB First Use before Age 21 or at Age 21 or Older: Alcohol, Nicotine Vaping, Cigars, or Cigarettes: Among People Aged 12 or Older Who Initiated Use of Specific Substances in the Past Year; 2025

Substance	Number of Past Year Initiates ¹		Percentage of Past Year Initiates ²	
ALCOHOL	4,258	(192)	100.0	(0.00)
First Use before Age 21	2,987	(142)	70.1	(2.01)
First Use at Age 21 or Older	1,271	(113)	29.9	(2.01)
NICOTINE VAPING	4,249	(231)	100.0	(0.00)
First Use before Age 21	1,527	(99)	35.9	(2.40)
First Use at Age 21 or Older	2,722	(213)	64.1	(2.40)
CIGARS	1,837	(156)	100.0	(0.00)
First Use before Age 21	576	(58)	31.4	(3.24)
First Use at Age 21 or Older	1,261	(144)	68.6	(3.24)
CIGARETTES	1,661	(120)	100.0	(0.00)
First Use before Age 21	1,091	(93)	65.7	(3.36)
First Use at Age 21 or Older	570	(72)	34.3	(3.36)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.25AB Type of Substance Use Disorder in the Past Year: Among People Aged 12 or Older with a Past Year Substance Use Disorder; 2025

Type of Substance Use Disorder	Number in Thousands ¹		Percentage ²	
SUBSTANCE USE DISORDER	44,576	(992)	100.0	(0.00)
Drugs	25,969	(723)	58.3	(0.94)
Alcohol	25,746	(690)	57.8	(0.93)
Both Drugs and Alcohol	7,139	(314)	16.0	(0.62)
Drugs Only (No Alcohol Use Disorder)	18,830	(603)	42.2	(0.93)
Alcohol Only (No Drug Use Disorder)	18,607	(580)	41.7	(0.94)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Substance use disorder estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.26B Substance Use Disorder for Specific Substances in the Past Year: Among People Aged 12 or Older; 2021-2025

Disorder	2021	2022	2023	2024	2025	Trend
SUBSTANCE USE DISORDER	16.7 (0.30)	17.3 (0.27)	17.1 (0.27)	16.8 (0.28)	15.3 (0.28)	Decreased
DRUGS	8.7 (0.22)	9.7 (0.22)	9.6 (0.22)	9.8 (0.23)	8.9 (0.22)	No Change
Marijuana (Cannabis)	6.0 (0.18)	6.7 (0.17)	6.8 (0.18)	7.1 (0.19)	6.7 (0.18)	Increased
Central Nervous System Stimulants	1.5 (0.09)	1.6 (0.09)	1.5 (0.09)	1.5 (0.08)	1.5 (0.09)	No Change
Cocaine	0.5 (0.06)	0.5 (0.05)	0.4 (0.04)	0.4 (0.04)	0.5 (0.05)	No Change
Methamphetamine	0.6 (0.06)	0.6 (0.07)	0.6 (0.06)	0.5 (0.05)	0.6 (0.06)	No Change
Prescription Stimulants	0.5 (0.04)	0.6 (0.05)	0.6 (0.05)	0.6 (0.04)	0.6 (0.05)	No Change
Opioids ¹	1.9 (0.10)	2.0 (0.12)	1.8 (0.10)	1.7 (0.10)	1.4 (0.09)	Decreased
Heroin	0.4 (0.05)	0.3 (0.04)	0.2 (0.03)	0.2 (0.03)	0.2 (0.03)	Decreased
Prescription Opioids	1.7 (0.10)	1.8 (0.11)	1.7 (0.10)	1.6 (0.10)	1.3 (0.08)	Decreased
Prescription Tranquilizers or Sedatives	0.8 (0.07)	0.8 (0.07)	0.8 (0.06)	0.7 (0.06)	0.6 (0.06)	Decreased
Prescription Tranquilizers	0.6 (0.06)	0.6 (0.06)	0.6 (0.05)	0.5 (0.05)	0.5 (0.06)	Decreased
Prescription Sedatives	0.3 (0.05)	0.3 (0.04)	0.3 (0.04)	0.3 (0.04)	0.2 (0.02)	Decreased
Hallucinogens	0.2 (0.03)	0.2 (0.03)	0.2 (0.02)	0.2 (0.02)	0.2 (0.03)	No Change
Inhalants	0.1 (0.02)	0.1 (0.02)	0.1 (0.02)	0.1 (0.02)	0.1 (0.02)	No Change
ALCOHOL	10.6 (0.26)	10.5 (0.22)	10.2 (0.20)	9.7 (0.20)	8.9 (0.21)	Decreased

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Substance use disorder estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

¹ Estimates for 2021-2023 may differ from previously published estimates for opioid use disorder because they do not include the use of only nonopioid pain relievers. Estimates for opioid use disorder also do not include illegally made fentanyl.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.27B Substance Use Disorder for Specific Substances in the Past Year: Among Adolescents Aged 12 to 17; 2021-2025

Disorder	2021	2022	2023	2024	2025	Trend
SUBSTANCE USE DISORDER	9.2 (0.48)	8.7 (0.39)	8.5 (0.37)	7.8 (0.35)	7.4 (0.39)	Decreased
DRUGS	7.3 (0.42)	7.0 (0.35)	6.9 (0.34)	6.6 (0.33)	5.9 (0.36)	Decreased
Marijuana (Cannabis)	5.2 (0.38)	5.1 (0.29)	4.7 (0.28)	4.7 (0.28)	4.4 (0.32)	No Change
Central Nervous System Stimulants	1.1 (0.17)	1.0 (0.12)	1.0 (0.14)	0.8 (0.12)	0.8 (0.11)	No Change
Cocaine	<0.1 (0.02)	<0.1 (0.01)	0.2 (0.06)	0.1 (0.02)	<0.1 (0.02)	No Change
Methamphetamine	0.1 (0.04)	<0.1 (0.01)	0.1 (0.04)	<0.1 (0.03)	<0.1 (0.01)	No Change
Prescription Stimulants	1.0 (0.17)	1.0 (0.12)	0.9 (0.13)	0.7 (0.12)	0.8 (0.11)	No Change
Opioids ¹	0.9 (0.14)	0.9 (0.11)	0.9 (0.10)	1.0 (0.13)	0.8 (0.13)	No Change
Heroin	<0.1 (<0.01)	<0.1 (0.01)	* (*)	<0.1 (0.02)	<0.1 (<0.01)	Not Tested
Prescription Opioids	0.9 (0.14)	0.9 (0.11)	0.9 (0.10)	1.0 (0.13)	0.8 (0.13)	No Change
Prescription Tranquilizers or Sedatives	0.5 (0.10)	0.5 (0.10)	0.5 (0.09)	0.5 (0.09)	0.2 (0.06)	Decreased
Prescription Tranquilizers	0.4 (0.09)	0.3 (0.06)	0.3 (0.07)	0.3 (0.08)	0.1 (0.03)	Decreased
Prescription Sedatives	0.2 (0.06)	0.2 (0.08)	0.3 (0.06)	0.2 (0.05)	0.2 (0.05)	No Change
Hallucinogens	0.2 (0.06)	0.3 (0.07)	0.2 (0.05)	0.3 (0.08)	0.3 (0.08)	No Change
Inhalants	0.4 (0.09)	0.3 (0.08)	0.3 (0.07)	0.3 (0.08)	0.4 (0.08)	No Change
ALCOHOL	3.7 (0.31)	2.9 (0.22)	2.9 (0.23)	3.0 (0.23)	2.8 (0.23)	Decreased

* Low precision; no estimate reported.

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

NOTE: Standard errors that round to 0.00 percent are presented as <0.01.

NOTE: Substance use disorder estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

¹ Estimates for 2021-2023 may differ from previously published estimates for opioid use disorder because they do not include the use of only nonopioid pain relievers. Estimates for opioid use disorder also do not include illegally made fentanyl.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.28B Substance Use Disorder for Specific Substances in the Past Year: Among Young Adults Aged 18 to 25; 2021-2025

Disorder	2021	2022	2023	2024	2025	Trend
SUBSTANCE USE DISORDER	26.2 (0.68)	27.8 (0.66)	27.1 (0.59)	25.9 (0.55)	23.8 (0.63)	Decreased
DRUGS	16.6 (0.57)	18.6 (0.54)	18.0 (0.52)	17.8 (0.50)	15.9 (0.52)	No Change
Marijuana (Cannabis)	14.7 (0.56)	16.5 (0.52)	16.6 (0.50)	15.8 (0.48)	14.1 (0.50)	No Change
Central Nervous System Stimulants	1.9 (0.19)	2.2 (0.20)	1.5 (0.13)	2.1 (0.18)	1.6 (0.17)	No Change
Cocaine	0.8 (0.14)	0.8 (0.11)	0.6 (0.08)	0.8 (0.11)	0.6 (0.10)	No Change
Methamphetamine	0.4 (0.10)	0.2 (0.04)	0.2 (0.05)	0.3 (0.06)	0.2 (0.08)	No Change
Prescription Stimulants	1.2 (0.14)	1.4 (0.16)	0.9 (0.11)	1.2 (0.13)	1.0 (0.13)	No Change
Opioids ¹	1.2 (0.16)	1.1 (0.13)	1.0 (0.13)	1.0 (0.12)	0.9 (0.13)	No Change
Heroin	0.2 (0.06)	0.1 (0.03)	<0.1 (0.02)	0.1 (0.03)	<0.1 (0.01)	Decreased
Prescription Opioids	1.1 (0.16)	1.1 (0.13)	1.0 (0.13)	0.9 (0.11)	0.9 (0.13)	No Change
Prescription Tranquilizers or Sedatives	0.9 (0.14)	0.8 (0.10)	0.7 (0.10)	0.7 (0.09)	0.7 (0.12)	No Change
Prescription Tranquilizers	0.7 (0.12)	0.7 (0.09)	0.5 (0.09)	0.6 (0.08)	0.5 (0.11)	No Change
Prescription Sedatives	0.3 (0.08)	0.2 (0.06)	0.2 (0.05)	0.3 (0.06)	0.2 (0.06)	No Change
Hallucinogens	0.6 (0.11)	0.7 (0.11)	0.4 (0.07)	0.3 (0.06)	0.4 (0.07)	Decreased
Inhalants	0.3 (0.09)	0.3 (0.08)	0.1 (0.03)	0.2 (0.06)	0.1 (0.03)	No Change
ALCOHOL	15.5 (0.54)	16.4 (0.52)	15.1 (0.48)	14.4 (0.43)	13.1 (0.49)	Decreased

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

NOTE: Substance use disorder estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

¹ Estimates for 2021-2023 may differ from previously published estimates for opioid use disorder because they do not include the use of only nonopioid pain relievers. Estimates for opioid use disorder also do not include illegally made fentanyl.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.29B Substance Use Disorder for Specific Substances in the Past Year: Among Adults Aged 26 or Older; 2021-2025

Disorder	2021	2022	2023	2024	2025	Trend
SUBSTANCE USE DISORDER	16.2 (0.35)	16.6 (0.32)	16.6 (0.31)	16.4 (0.33)	14.9 (0.33)	Decreased
DRUGS	7.7 (0.26)	8.5 (0.27)	8.6 (0.25)	8.9 (0.27)	8.2 (0.26)	No Change
Marijuana (Cannabis)	4.7 (0.20)	5.4 (0.19)	5.5 (0.20)	6.1 (0.21)	5.7 (0.21)	Increased
Central Nervous System Stimulants	1.5 (0.11)	1.6 (0.11)	1.6 (0.10)	1.5 (0.09)	1.6 (0.12)	No Change
Cocaine	0.5 (0.07)	0.5 (0.06)	0.5 (0.05)	0.4 (0.05)	0.5 (0.06)	No Change
Methamphetamine	0.7 (0.08)	0.8 (0.08)	0.8 (0.08)	0.6 (0.07)	0.8 (0.08)	No Change
Prescription Stimulants	0.4 (0.05)	0.5 (0.05)	0.5 (0.05)	0.5 (0.05)	0.5 (0.06)	No Change
Opioids ¹	2.1 (0.13)	2.3 (0.15)	2.0 (0.12)	1.9 (0.12)	1.5 (0.11)	Decreased
Heroin	0.4 (0.06)	0.4 (0.05)	0.3 (0.04)	0.2 (0.03)	0.2 (0.04)	Decreased
Prescription Opioids	1.8 (0.12)	2.1 (0.14)	1.9 (0.12)	1.8 (0.12)	1.4 (0.10)	Decreased
Prescription Tranquilizers or Sedatives	0.8 (0.08)	0.9 (0.08)	0.8 (0.07)	0.8 (0.07)	0.6 (0.08)	Decreased
Prescription Tranquilizers	0.6 (0.07)	0.7 (0.07)	0.7 (0.06)	0.5 (0.06)	0.5 (0.07)	No Change
Prescription Sedatives	0.3 (0.06)	0.3 (0.04)	0.3 (0.05)	0.3 (0.05)	0.2 (0.03)	Decreased
Hallucinogens	0.1 (0.03)	0.1 (0.03)	0.1 (0.02)	0.1 (0.02)	0.1 (0.03)	No Change
Inhalants	0.1 (0.02)	0.1 (0.02)	0.1 (0.02)	0.1 (0.02)	0.1 (0.02)	No Change
ALCOHOL	10.7 (0.30)	10.4 (0.27)	10.3 (0.24)	9.7 (0.24)	8.9 (0.25)	Decreased

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Substance use disorder estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

¹ Estimates for 2021-2023 may differ from previously published estimates for opioid use disorder because they do not include the use of only nonopioid pain relievers. Estimates for opioid use disorder also do not include illegally made fentanyl.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.30B Substance Use Disorder Severity Level for Any Substance Use Disorder, Drug Use Disorder, Marijuana Use Disorder, or Alcohol Use Disorder in the Past Year: Among People Aged 12 or Older with a Specific Substance Use Disorder, by Age Group; 2025

Age Group and Disorder	Any Substance Use Disorder		Mild Substance Use Disorder		Moderate Substance Use Disorder		Severe Substance Use Disorder	
TOTAL								
Any Substance	15.3	(0.28)	54.1	(0.88)	23.4	(0.74)	22.5	(0.76)
Drugs	8.9	(0.22)	53.0	(1.15)	25.0	(0.98)	22.1	(0.94)
Marijuana (Cannabis)	6.7	(0.18)	53.4	(1.31)	28.6	(1.11)	18.0	(0.96)
Alcohol	8.9	(0.21)	57.6	(1.23)	21.7	(1.05)	20.7	(0.99)
12 TO 17								
Any Substance	7.4	(0.39)	49.4	(2.66)	25.5	(2.23)	25.1	(2.25)
Drugs	5.9	(0.36)	46.4	(3.03)	25.4	(2.53)	28.1	(2.66)
Marijuana (Cannabis)	4.4	(0.32)	35.7	(3.43)	31.0	(3.12)	33.4	(3.27)
Alcohol	2.8	(0.23)	59.5	(4.07)	26.0	(3.86)	14.5	(2.71)
18 TO 25								
Any Substance	23.8	(0.63)	49.0	(1.38)	26.9	(1.23)	24.1	(1.18)
Drugs	15.9	(0.52)	45.7	(1.62)	29.1	(1.56)	25.3	(1.38)
Marijuana (Cannabis)	14.1	(0.50)	43.9	(1.76)	30.8	(1.68)	25.3	(1.53)
Alcohol	13.1	(0.49)	60.5	(1.91)	22.0	(1.52)	17.5	(1.45)
26 OR OLDER								
Any Substance	14.9	(0.33)	55.6	(1.09)	22.4	(0.94)	22.0	(0.93)
Drugs	8.2	(0.26)	55.7	(1.52)	23.7	(1.28)	20.6	(1.19)
Marijuana (Cannabis)	5.7	(0.21)	58.6	(1.77)	27.6	(1.52)	13.8	(1.15)
Alcohol	8.9	(0.25)	56.9	(1.50)	21.5	(1.28)	21.6	(1.23)

NOTE: Estimates shown are percentages with standard errors included in parentheses. Percentages may not add to 100 percent due to rounding. Estimates for mild, moderate, and severe substance use disorder are row percentages among people who had any disorder for that substance.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Substance use disorder estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.31B Substance Use Disorder Severity Level for Specific Substances in the Past Year: Among People Aged 12 or Older with a Specific Substance Use Disorder; 2025

Disorder	Any Substance Use Disorder		Mild Substance Use Disorder		Moderate Substance Use Disorder		Severe Substance Use Disorder	
SUBSTANCE USE DISORDER	15.3	(0.28)	54.1	(0.88)	23.4	(0.74)	22.5	(0.76)
DRUGS	8.9	(0.22)	53.0	(1.15)	25.0	(0.98)	22.1	(0.94)
Marijuana (Cannabis)	6.7	(0.18)	53.4	(1.31)	28.6	(1.11)	18.0	(0.96)
Central Nervous System Stimulants	1.5	(0.09)	40.7	(2.80)	20.2	(2.65)	39.1	(2.89)
Cocaine Use, Methamphetamine Use, or Prescription Stimulant Misuse	1.2	(0.09)	29.8	(2.94)	22.3	(3.21)	47.9	(3.41)
Use but Not Misuse of Prescription Stimulants Only	0.3	(0.03)	82.5	(3.65)	12.1	(2.99)	5.4	(2.23)
Opioids	1.4	(0.09)	58.9	(3.11)	20.8	(2.81)	20.3	(2.46)
Heroin Use or Prescription Opioid Misuse	0.6	(0.05)	32.0	(3.63)	29.5	(4.38)	38.4	(4.19)
Use but Not Misuse of Prescription Opioids Only	0.7	(0.07)	82.6	(3.82)	13.1	(3.65)	4.3	(1.69)
Prescription Tranquilizers or Sedatives	0.6	(0.06)	69.3	(4.67)	9.9	(1.93)	20.8	(4.51)
Prescription Tranquilizer or Sedative Misuse	0.3	(0.05)	*	(*)	13.2	(3.35)	*	(*)
Use but Not Misuse of Prescription Tranquilizers or Sedatives Only	0.3	(0.04)	84.5	(3.78)	6.2	(1.83)	9.3	(3.47)
Hallucinogens	0.2	(0.03)	*	(*)	*	(*)	*	(*)
Inhalants	0.1	(0.02)	*	(*)	*	(*)	*	(*)
ALCOHOL	8.9	(0.21)	57.6	(1.23)	21.7	(1.05)	20.7	(0.99)

* Low precision; no estimate reported.

NOTE: Estimates shown are percentages with standard errors included in parentheses. Percentages may not add to 100 percent due to rounding. Estimates for mild, moderate, and severe substance use disorder are row percentages among people who had any disorder for that substance.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Substance use disorder estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.32B Severity of Symptoms of Generalized Anxiety Disorder (GAD) in the Past 2 Weeks: Among Adolescents Aged 12 to 17; 2025

Severity	12 to 17	
No or Minimal	58.4	(0.70)
Mild	23.6	(0.64)
Moderate or Severe	18.0	(0.57)
Moderate	10.6	(0.47)
Severe	7.4	(0.36)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: GAD symptom severity is based on the GAD-7 scale. GAD-7 scores indicate the following: 0 to 4 = no or minimal symptoms of GAD, 5 to 9 = mild symptoms, 10 to 14 = moderate symptoms, 15 to 21 = severe symptoms. The Moderate or Severe category includes respondents with a GAD-7 score of 10 or greater.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.33B Substance Use in the Past Year or Past Month: Among Adolescents Aged 12 to 17; by Severity of Symptoms of Generalized Anxiety Disorder (GAD) in the Past 2 Weeks, 2025

Period/Substance	12 to 17 ¹		Adolescents with Moderate or Severe Symptoms		Adolescents with No or Minimal Symptoms	
PAST YEAR USE						
Illicit Drugs ²	11.2	(0.46)	17.7	(1.33)	8.2	(0.55)
Marijuana	8.7	(0.42)	12.9	(1.20)	6.7	(0.50)
Cocaine	0.2	(0.07)	0.3	(0.15)	0.1	(0.05)
Heroin	<0.1	(<0.01)	*	(*)	<0.1	(<0.01)
Hallucinogens	1.4	(0.19)	2.6	(0.61)	1.1	(0.20)
Inhalants ³	1.4	(0.16)	3.2	(0.62)	0.8	(0.14)
Methamphetamine	0.1	(0.06)	0.3	(0.13)	*	(*)
Misuse of Prescription Psychotherapeutics	2.4	(0.22)	4.9	(0.69)	1.3	(0.21)
Pain Relievers	1.7	(0.19)	2.8	(0.54)	1.0	(0.19)
Prescription Opioids ⁴	1.6	(0.19)	2.6	(0.53)	1.0	(0.19)
Stimulants	0.8	(0.13)	2.3	(0.50)	0.3	(0.10)
Tranquilizers or Sedatives	0.6	(0.12)	1.2	(0.31)	0.3	(0.11)
Misuse of Opioids ^{2,5}	1.6	(0.19)	2.6	(0.53)	1.0	(0.19)
Misuse of Central Nervous System Stimulants	0.9	(0.14)	2.4	(0.50)	0.3	(0.10)
PAST MONTH USE						
Nicotine Products ^{6,7}	6.9	(0.37)	11.0	(1.09)	5.2	(0.44)
Tobacco Products	2.0	(0.21)	3.3	(0.62)	1.4	(0.22)
Cigarettes	1.3	(0.19)	2.3	(0.56)	0.8	(0.17)
Nicotine Vaping ⁷	6.3	(0.36)	10.2	(1.03)	4.8	(0.43)
Alcohol	5.9	(0.34)	8.9	(0.91)	4.8	(0.39)
Binge Alcohol Use	3.0	(0.23)	4.8	(0.66)	2.4	(0.30)
Heavy Alcohol Use	0.3	(0.07)	0.7	(0.25)	0.2	(0.07)
Marijuana	5.0	(0.32)	8.0	(0.99)	3.7	(0.34)
Marijuana Vaping ⁸	3.5	(0.28)	5.7	(0.92)	2.5	(0.31)

* Low precision; no estimate reported.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

NOTE: Standard errors that round to 0.00 percent are presented as <0.01.

NOTE: GAD symptom severity is based on the GAD-7 scale. GAD-7 scores indicate the following: 0 to 4 = no or minimal symptoms of GAD, 5 to 9 = mild symptoms, 10 to 14 = moderate symptoms, 15 to 21 = severe symptoms. The Moderate or Severe category includes respondents with a GAD-7 score of 10 or greater.

¹ Estimates are for all adolescents aged 12 to 17, including those with mild GAD symptoms in the past 2 weeks.

² These estimates do not include illegally made fentanyl.

³ Changes were made to the inhalant questions in 2025. See Chapter 3 of the [2025 National Survey on Drug Use and Health: Methodological Summary and Definitions](#) for details.

⁴ Respondents who reported the misuse of only nonopioid pain relievers were not counted as having misused prescription opioids.

⁵ Estimates include the use of heroin or the misuse of prescription opioids in the past year.

⁶ Nicotine product use includes use of tobacco products (cigarettes, smokeless tobacco [such as snuff, dip, chewing tobacco, or snus], cigars, or pipe tobacco) or nicotine vaping. Use of tobacco products does not include nicotine vaping because people could have used a vaping device to vape nicotine-containing products other than tobacco.

⁷ Nicotine vaping refers to using an e-cigarette or other vaping device to vape nicotine or tobacco.

⁸ Marijuana vaping refers to using vape pens, dab pens, tabletop vaporizers, or portable vaporizers to vape marijuana.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.34B Severity of Symptoms of Generalized Anxiety Disorder (GAD) in the Past 2 Weeks: Among Adults Aged 18 or Older; by Age Group; 2025

Severity	18 or Older		18 to 25		26 to 49		50 or Older	
No or Minimal	79.1	(0.35)	66.7	(0.67)	74.2	(0.52)	86.9	(0.50)
Mild	14.3	(0.29)	21.1	(0.59)	17.7	(0.45)	9.4	(0.41)
Moderate or Severe	6.6	(0.19)	12.2	(0.44)	8.1	(0.29)	3.7	(0.30)
Moderate	4.2	(0.15)	7.8	(0.37)	5.1	(0.22)	2.4	(0.22)
Severe	2.4	(0.12)	4.3	(0.25)	3.0	(0.18)	1.3	(0.19)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: GAD symptom severity is based on the GAD-7 scale. GAD-7 scores indicate the following: 0 to 4 = no or minimal symptoms of GAD, 5 to 9 = mild symptoms, 10 to 14 = moderate symptoms, 15 to 21 = severe symptoms. The Moderate or Severe category includes respondents with a GAD-7 score of 10 or greater.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.35B Substance Use in the Past Year or Past Month: Among Adults Aged 18 or Older; by Severity of Symptoms of Generalized Anxiety Disorder (GAD) in the Past 2 Weeks, 2025

Period/Substance	18 or Older ¹		Adults with Moderate or Severe Symptoms		Adults with No or Minimal Symptoms	
PAST YEAR USE						
Illicit Drugs ²	25.3	(0.38)	47.8	(1.37)	21.0	(0.39)
Marijuana	22.4	(0.36)	42.1	(1.36)	18.4	(0.37)
Cocaine	1.8	(0.11)	5.0	(0.57)	1.3	(0.11)
Heroin	0.2	(0.04)	0.7	(0.23)	0.1	(0.03)
Hallucinogens	3.3	(0.14)	8.5	(0.70)	2.3	(0.12)
Inhalants ³	0.8	(0.07)	2.4	(0.46)	0.5	(0.06)
Methamphetamine	1.0	(0.09)	3.1	(0.50)	0.6	(0.08)
Misuse of Prescription Psychotherapeutics	4.6	(0.17)	12.9	(0.90)	3.4	(0.17)
Pain Relievers	2.5	(0.13)	7.4	(0.73)	1.9	(0.13)
Prescription Opioids ⁴	2.4	(0.12)	7.3	(0.73)	1.8	(0.13)
Stimulants	1.4	(0.08)	4.5	(0.49)	0.9	(0.07)
Tranquilizers or Sedatives	1.5	(0.11)	5.0	(0.56)	1.0	(0.10)
Misuse of Opioids ^{2,5}	2.5	(0.12)	7.6	(0.74)	1.8	(0.13)
Misuse of Central Nervous System Stimulants	3.5	(0.15)	9.4	(0.76)	2.5	(0.15)
PAST MONTH USE						
Nicotine Products ^{6,7}	23.6	(0.37)	37.4	(1.38)	21.4	(0.40)
Tobacco Products	17.5	(0.33)	27.2	(1.29)	16.2	(0.36)
Cigarettes	13.5	(0.30)	22.6	(1.25)	12.3	(0.32)
Nicotine Vaping ⁷	10.4	(0.24)	21.2	(1.05)	8.6	(0.25)
Alcohol	48.1	(0.47)	50.3	(1.40)	47.5	(0.54)
Binge Alcohol Use	21.1	(0.35)	25.5	(1.14)	20.0	(0.39)
Heavy Alcohol Use	5.5	(0.18)	8.8	(0.82)	4.9	(0.20)
Marijuana	16.0	(0.32)	31.6	(1.33)	13.1	(0.33)
Marijuana Vaping ⁸	5.8	(0.17)	15.2	(0.88)	4.1	(0.17)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: GAD symptom severity is based on the GAD-7 scale. GAD-7 scores indicate the following: 0 to 4 = no or minimal symptoms of GAD, 5 to 9 = mild symptoms, 10 to 14 = moderate symptoms, 15 to 21 = severe symptoms. The Moderate or Severe category includes respondents with a GAD-7 score of 10 or greater.

¹ Estimates are for all adults aged 18 or older, including those with mild GAD symptoms in the past 2 weeks.

² These estimates do not include illegally made fentanyl.

³ Changes were made to the inhalant questions in 2025. See Chapter 3 of the [2025 National Survey on Drug Use and Health: Methodological Summary and Definitions](#) for details.

⁴ Respondents who reported the misuse of only nonopioid pain relievers were not counted as having misused prescription opioids.

⁵ Estimates include the use of heroin or the misuse of prescription opioids in the past year.

⁶ Nicotine product use includes use of tobacco products (cigarettes, smokeless tobacco [such as snuff, dip, chewing tobacco, or snus], cigars, or pipe tobacco) or nicotine vaping. Use of tobacco products does not include nicotine vaping because people could have used a vaping device to vape nicotine-containing products other than tobacco.

⁷ Nicotine vaping refers to using an e-cigarette or other vaping device to vape nicotine or tobacco.

⁸ Marijuana vaping refers to using vape pens, dab pens, tabletop vaporizers, or portable vaporizers to vape marijuana.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.36B Major Depressive Episode (MDE) or MDE with Severe Impairment in the Past Year: Among Adolescents Aged 12 to 17; 2021-2025

MDE	2021	2022	2023	2024	2025	Trend
MDE	20.8 (0.61)	19.5 (0.54)	18.1 (0.52)	15.4 (0.48)	15.1 (0.52)	Decreased
MDE with Severe Impairment ¹	15.2 (0.53)	14.6 (0.50)	13.5 (0.48)	11.3 (0.44)	11.0 (0.48)	Decreased

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. Respondents with unknown past year MDE data were excluded.

¹ Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on an adolescent's life. Impairment is defined as the highest severity level of role impairment across four domains: (1) chores at home, (2) school or work, (3) close relationships with family, and (4) social life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains were considered severe impairment. Respondents with unknown impairment data were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.37AB Substance Use Disorder (SUD) or Major Depressive Episode (MDE) in the Past Year: Among Adolescents Aged 12 to 17; 2025

SUD or MDE	Number in Thousands¹		Percentage²	
SUD or MDE	4,979	(182)	20.1	(0.59)
SUD but No MDE ³	1,176	(83)	4.8	(0.32)
MDE ³ but No SUD	3,102	(137)	12.6	(0.48)
Co-Occurring SUD and MDE³	604	(53)	2.5	(0.21)
Co-Occurring SUD and MDE with Severe Impairment ⁴	467	(49)	1.9	(0.20)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: SUD estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition (DSM-5). See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on SUD.

NOTE: MDE estimates are based on criteria from DSM-5, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

³ Respondents with unknown past year MDE data were excluded.

⁴ Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on an adolescent's life. Impairment is defined as the highest severity level of role impairment across four domains: (1) chores at home, (2) school or work, (3) close relationships with family, and (4) social life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains were considered severe impairment. Respondents with unknown impairment data were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.38B Co-Occurring Substance Use Disorder (SUD) and Major Depressive Episode (MDE) or MDE with Severe Impairment in the Past Year: Among Adolescents Aged 12 to 17; 2021-2025

SUD and MDE	2021	2022	2023	2024	2025	Trend
Co-Occurring SUD and MDE	4.1 (0.32)	3.7 (0.25)	3.4 (0.23)	3.2 (0.25)	2.5 (0.21)	Decreased
Co-Occurring SUD and MDE with Severe Impairment ¹	3.1 (0.30)	3.0 (0.23)	2.9 (0.21)	2.5 (0.21)	1.9 (0.20)	Decreased

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: SUD estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition (DSM-5). See the [2025 Methodological Summary and Definitions](#) for details on who was eligible to receive questions on SUD.

NOTE: MDE estimates are based on criteria from DSM-5, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. Respondents with unknown past year MDE data were excluded.

¹ Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on an adolescent's life. Impairment is defined as the highest severity level of role impairment across four domains: (1) chores at home, (2) school or work, (3) close relationships with family, and (4) social life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains were considered severe impairment. Respondents with unknown impairment data were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.39B Substance Use in the Past Year or Past Month: Among Adolescents Aged 12 to 17; by Past Year Major Depressive Episode (MDE), 2025

Period/Substance	12 to 17 ¹		MDE		No MDE	
PAST YEAR USE						
Illicit Drugs ²	11.2	(0.46)	21.7	(1.45)	9.1	(0.49)
Marijuana	8.7	(0.42)	17.5	(1.33)	7.0	(0.43)
Cocaine	0.2	(0.07)	0.8	(0.30)	<0.1	(0.01)
Heroin	<0.1	(<0.01)	*	(*)	<0.1	(<0.01)
Hallucinogens	1.4	(0.19)	3.4	(0.76)	1.0	(0.17)
Inhalants ³	1.4	(0.16)	3.3	(0.58)	1.0	(0.13)
Methamphetamine	0.1	(0.06)	0.3	(0.17)	<0.1	(<0.01)
Misuse of Prescription Psychotherapeutics	2.4	(0.22)	5.1	(0.75)	1.7	(0.21)
Pain Relievers	1.7	(0.19)	2.9	(0.58)	1.3	(0.18)
Prescription Opioids ⁴	1.6	(0.19)	2.7	(0.56)	1.2	(0.18)
Stimulants	0.8	(0.13)	2.4	(0.50)	0.5	(0.11)
Tranquilizers or Sedatives	0.6	(0.12)	1.6	(0.40)	0.3	(0.09)
Misuse of Opioids ^{2,5}	1.6	(0.19)	2.7	(0.56)	1.2	(0.18)
Misuse of Central Nervous System Stimulants	0.9	(0.14)	2.6	(0.52)	0.5	(0.12)
PAST MONTH USE						
Nicotine Products ^{6,7}	6.9	(0.37)	13.0	(1.19)	5.7	(0.38)
Tobacco Products	2.0	(0.21)	3.8	(0.65)	1.7	(0.20)
Cigarettes	1.3	(0.19)	2.7	(0.57)	1.1	(0.17)
Nicotine Vaping ⁷	6.3	(0.36)	11.9	(1.15)	5.2	(0.37)
Alcohol	5.9	(0.34)	10.6	(1.14)	5.1	(0.35)
Binge Alcohol Use	3.0	(0.23)	4.8	(0.77)	2.6	(0.24)
Heavy Alcohol Use	0.3	(0.07)	0.9	(0.29)	0.2	(0.06)
Marijuana	5.0	(0.32)	9.5	(0.99)	4.1	(0.32)
Marijuana Vaping ⁸	3.5	(0.28)	7.4	(0.90)	2.6	(0.26)

* Low precision; no estimate reported.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

NOTE: Standard errors that round to 0.00 percent are presented as <0.01.

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

¹ Estimates are for all adolescents aged 12 to 17, including those with unknown past year MDE data.

² These estimates do not include illegally made fentanyl.

³ Changes were made to the inhalant questions in 2025. See Chapter 3 of the [2025 National Survey on Drug Use and Health: Methodological Summary and Definitions](#) for details.

⁴ Respondents who reported the misuse of only nonopioid pain relievers were not counted as having misused prescription opioids.

⁵ Estimates include the use of heroin or the misuse of prescription opioids in the past year.

⁶ Nicotine product use includes use of tobacco products (cigarettes, smokeless tobacco [such as snuff, dip, chewing tobacco, or snus], cigars, or pipe tobacco) or nicotine vaping. Use of tobacco products does not include nicotine vaping because people could have used a vaping device to vape nicotine-containing products other than tobacco.

⁷ Nicotine vaping refers to using an e-cigarette or other vaping device to vape nicotine or tobacco.

⁸ Marijuana vaping refers to using vape pens, dab pens, tabletop vaporizers, or portable vaporizers to vape marijuana.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.40B Major Depressive Episode (MDE) or MDE with Severe Impairment in the Past Year: Among Adults Aged 18 or Older; by Age Group, 2021-2025

MDE	2021	2022	2023	2024	2025	Trend
MDE, 18 OR OLDER	8.5 (0.22)	8.8 (0.20)	8.5 (0.20)	8.2 (0.18)	7.4 (0.20)	Decreased
18 to 25	19.3 (0.61)	20.1 (0.55)	17.5 (0.51)	15.9 (0.48)	14.2 (0.48)	Decreased
26 to 49	9.6 (0.33)	9.7 (0.31)	10.2 (0.29)	10.0 (0.30)	9.1 (0.32)	No Change
50 or Older	4.5 (0.29)	4.6 (0.30)	4.5 (0.29)	4.4 (0.28)	4.0 (0.26)	No Change
MDE WITH SEVERE IMPAIRMENT,¹ 18 OR OLDER	5.9 (0.18)	6.2 (0.17)	5.9 (0.17)	5.6 (0.15)	5.2 (0.16)	Decreased
18 to 25	13.8 (0.53)	14.7 (0.51)	12.9 (0.44)	11.5 (0.41)	10.2 (0.42)	Decreased
26 to 49	6.6 (0.27)	6.9 (0.26)	7.4 (0.26)	7.0 (0.25)	6.7 (0.28)	No Change
50 or Older	3.0 (0.25)	3.1 (0.26)	2.7 (0.24)	2.6 (0.22)	2.5 (0.19)	Decreased

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

¹ Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on an adult's life. Impairment is defined as the highest severity level of role impairment across four domains: (1) home management, (2) work, (3) close relationships with others, and (4) social life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains were considered severe impairment.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.41A Substance Use Disorder (SUD) or Major Depressive Episode (MDE) in the Past Year: Among Adults Aged 18 or Older; by Age Group, 2025

SUD or MDE	18 or Older	18 to 25	26 to 49	50 or Older
SUD or MDE	55,068 (1,133)	11,628 (352)	27,120 (672)	16,320 (681)
SUD but No MDE	35,395 (890)	6,511 (254)	17,506 (524)	11,377 (578)
MDE but No SUD	12,370 (451)	3,050 (142)	5,689 (274)	3,631 (289)
Co-Occurring SUD and MDE	7,304 (328)	2,066 (125)	3,925 (227)	1,313 (181)
Co-Occurring SUD and MDE with Severe Impairment ¹	5,497 (269)	1,600 (110)	3,007 (192)	891 (144)

NOTE: Estimates shown are numbers in thousands with standard errors included in parentheses. Numbers may not add to totals due to rounding.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: SUD estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on SUD.

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

¹ Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on an adult's life. Impairment is defined as the highest severity level of role impairment across four domains: (1) home management, (2) work, (3) close relationships with others, and (4) social life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains were considered severe impairment.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.41B Substance Use Disorder (SUD) or Major Depressive Episode (MDE) in the Past Year: Among Adults Aged 18 or Older; by Age Group, 2025

SUD or MDE	18 or Older	18 to 25	26 to 49	50 or Older
SUD or MDE	20.8 (0.33)	32.2 (0.68)	25.7 (0.50)	13.2 (0.48)
SUD but No MDE	13.4 (0.28)	18.0 (0.56)	16.6 (0.43)	9.2 (0.43)
MDE but No SUD	4.7 (0.16)	8.5 (0.36)	5.4 (0.25)	2.9 (0.22)
Co-Occurring SUD and MDE	2.8 (0.12)	5.7 (0.33)	3.7 (0.20)	1.1 (0.15)
Co-Occurring SUD and MDE with Severe Impairment ¹	2.1 (0.10)	4.4 (0.29)	2.9 (0.17)	0.7 (0.12)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: SUD estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on SUD.

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

¹ Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on an adult's life. Impairment is defined as the highest severity level of role impairment across four domains: (1) home management, (2) work, (3) close relationships with others, and (4) social life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains were considered severe impairment.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.42B Co-Occurring Substance Use Disorder (SUD) and Major Depressive Episode (MDE) or MDE with Severe Impairment in the Past Year: Among Adults Aged 18 or Older; by Age Group, 2021-2025

SUD and MDE	2021		2022		2023		2024		2025		Trend
Co-Occurring SUD and MDE, 18 or Older	3.2	(0.13)	3.6	(0.13)	3.4	(0.13)	3.4	(0.13)	2.8	(0.12)	Decreased
18 to 25	7.5	(0.39)	8.9	(0.41)	7.9	(0.37)	7.2	(0.33)	5.7	(0.33)	Decreased
26 to 49	4.1	(0.21)	4.2	(0.20)	4.4	(0.20)	4.4	(0.21)	3.7	(0.20)	No Change
50 or Older	1.3	(0.18)	1.7	(0.18)	1.4	(0.17)	1.4	(0.18)	1.1	(0.15)	No Change
Co-Occurring SUD and MDE with Severe Impairment,¹ 18 or Older	2.5	(0.12)	2.8	(0.12)	2.6	(0.11)	2.5	(0.10)	2.1	(0.10)	Decreased
18 to 25	5.7	(0.34)	7.1	(0.38)	5.8	(0.32)	5.6	(0.28)	4.4	(0.29)	Decreased
26 to 49	3.2	(0.19)	3.1	(0.17)	3.3	(0.18)	3.3	(0.17)	2.9	(0.17)	No Change
50 or Older	1.0	(0.16)	1.3	(0.17)	1.0	(0.15)	0.9	(0.15)	0.7	(0.12)	Decreased

Decreased = the linear trend test showed a statistically significant decrease from baseline year to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from baseline year to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from baseline year to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: SUD estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition (DSM-5). See the [2025 Methodological Summary and Definitions](#) for details on who was eligible to receive questions on SUD.

NOTE: MDE estimates are based on criteria from DSM-5, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

¹ Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on an adult's life. Impairment is defined as the highest severity level of role impairment across four domains: (1) home management, (2) work, (3) close relationships with others, and (4) social life. Ratings greater than or equal to 7 on a scale of 0 to 10 in any of the role domains were considered severe impairment.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.43B Substance Use in the Past Year or Past Month: Among Adults Aged 18 or Older; by Past Year Major Depressive Episode (MDE), 2025

Period/Substance	18 or Older		MDE		No MDE	
PAST YEAR USE						
Illicit Drugs ¹	25.3	(0.38)	49.6	(1.37)	23.3	(0.38)
Marijuana	22.4	(0.36)	43.8	(1.37)	20.7	(0.36)
Cocaine	1.8	(0.11)	4.8	(0.57)	1.6	(0.11)
Heroin	0.2	(0.04)	0.5	(0.21)	0.2	(0.04)
Hallucinogens	3.3	(0.14)	9.9	(0.80)	2.8	(0.12)
Inhalants ²	0.8	(0.07)	3.0	(0.53)	0.6	(0.06)
Methamphetamine	1.0	(0.09)	2.8	(0.46)	0.8	(0.08)
Misuse of Prescription Psychotherapeutics	4.6	(0.17)	12.0	(0.78)	4.0	(0.17)
Pain Relievers	2.5	(0.13)	6.2	(0.60)	2.3	(0.13)
Prescription Opioids ³	2.4	(0.12)	5.9	(0.57)	2.2	(0.12)
Stimulants	1.4	(0.08)	4.5	(0.48)	1.2	(0.07)
Tranquilizers or Sedatives	1.5	(0.11)	5.2	(0.53)	1.3	(0.11)
Misuse of Opioids ^{1,4}	2.5	(0.12)	6.1	(0.58)	2.2	(0.12)
Misuse of Central Nervous System Stimulants	3.5	(0.15)	9.2	(0.74)	3.0	(0.15)
PAST MONTH USE						
Nicotine Product Use ^{5,6}	23.6	(0.37)	33.0	(1.16)	22.8	(0.38)
Tobacco Products	17.5	(0.33)	22.2	(1.03)	17.1	(0.34)
Cigarettes	13.5	(0.30)	19.0	(0.99)	13.1	(0.30)
Nicotine Vaping ⁶	10.4	(0.24)	20.3	(0.93)	9.6	(0.25)
Alcohol	48.1	(0.47)	53.6	(1.29)	47.7	(0.48)
Binge Alcohol Use	21.1	(0.35)	25.9	(1.11)	20.7	(0.36)
Heavy Alcohol Use	5.5	(0.18)	7.8	(0.71)	5.3	(0.19)
Marijuana	16.0	(0.32)	31.2	(1.22)	14.8	(0.32)
Marijuana Vaping ⁷	5.8	(0.17)	14.4	(0.78)	5.1	(0.17)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

¹ These estimates do not include illegally made fentanyl.

² Changes were made to the inhalant questions in 2025. See Chapter 3 of the [2025 National Survey on Drug Use and Health: Methodological Summary and Definitions](#) for details.

³ Respondents who reported the misuse of only nonopioid pain relievers were not counted as having misused prescription opioids.

⁴ Estimates include the use of heroin or the misuse of prescription opioids in the past year.

⁵ Nicotine product use includes use of tobacco products (cigarettes, smokeless tobacco [such as snuff, dip, chewing tobacco, or snus], cigars, or pipe tobacco) or nicotine vaping. Use of tobacco products does not include nicotine vaping because people could have used a vaping device to vape nicotine-containing products other than tobacco.

⁶ Nicotine vaping refers to using an e-cigarette or other vaping device to vape nicotine or tobacco.

⁷ Marijuana vaping refers to using vape pens, dab pens, tabletop vaporizers, or portable vaporizers to vape marijuana.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.44B Level of Mental Illness in the Past Year: Among Adults Aged 18 or Older; by Age Group, 2021-2025

Mental Illness	2021		2022		2023		2024		2025		Trend
ANY MENTAL ILLNESS, 18 OR OLDER	21.0	(0.36)	21.3	(0.33)	20.9	(0.31)	21.5	(0.30)	20.6	(0.33)	No Change
18 to 25	33.2	(0.75)	35.2	(0.66)	32.7	(0.63)	31.9	(0.65)	28.6	(0.64)	Decreased
26 to 49	26.2	(0.51)	27.1	(0.50)	27.0	(0.43)	27.7	(0.46)	27.1	(0.51)	No Change
50 or Older	13.1	(0.52)	12.3	(0.49)	12.3	(0.46)	13.2	(0.47)	12.8	(0.48)	No Change
SERIOUS MENTAL ILLNESS, 18 OR OLDER	7.9	(0.21)	8.4	(0.21)	7.9	(0.20)	7.8	(0.18)	6.9	(0.18)	Decreased
18 to 25	16.8	(0.56)	17.6	(0.54)	15.3	(0.45)	14.1	(0.45)	12.1	(0.45)	Decreased
26 to 49	10.0	(0.32)	10.3	(0.35)	10.6	(0.30)	10.3	(0.31)	9.6	(0.32)	No Change
50 or Older	3.5	(0.28)	4.1	(0.30)	3.5	(0.27)	3.8	(0.28)	3.0	(0.22)	No Change

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Some 2021-2024 estimates may differ from previously published estimates due to updates that were made to the mental illness model beginning in 2025. For details, see the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Mental illness aligns with criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of serious mental illness (SMI) are a subset of estimates of any mental illness (AMI) because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.45A Substance Use Disorder (SUD) or Level of Mental Illness in the Past Year: Among Adults Aged 18 or Older; by Age Group, 2025

SUD/Level of Mental Illness	18 or Older	18 to 25	26 to 49	50 or Older
SUD or AMI	78,878 (1,454)	14,886 (431)	39,419 (845)	24,572 (879)
SUD but No AMI	24,246 (713)	4,556 (205)	10,927 (405)	8,764 (510)
AMI but No SUD	36,179 (892)	6,309 (245)	17,987 (502)	11,882 (610)
Co-Occurring SUD and AMI	18,452 (564)	4,022 (174)	10,505 (383)	3,926 (306)
SUD or SMI	53,096 (1,082)	10,997 (343)	26,930 (665)	15,170 (646)
SUD but No SMI	34,895 (858)	6,628 (258)	16,818 (503)	11,449 (571)
SMI but No SUD	10,397 (375)	2,419 (135)	5,498 (256)	2,480 (231)
Co-Occurring SUD and SMI	7,804 (345)	1,950 (118)	4,613 (247)	1,241 (173)

AMI = any mental illness; SMI = serious mental illness.

NOTE: Estimates shown are numbers in thousands with standard errors included in parentheses. Numbers may not add to totals due to rounding.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: SUD estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on SUD.

NOTE: Mental illness aligns with criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of SMI are a subset of estimates of AMI because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.45B Substance Use Disorder (SUD) or Level of Mental Illness in the Past Year: Among Adults Aged 18 or Older; by Age Group, 2025

SUD/Level of Mental Illness	18 or Older	18 to 25	26 to 49	50 or Older
SUD or AMI	29.8 (0.38)	41.2 (0.74)	37.4 (0.57)	19.9 (0.57)
SUD but No AMI	9.1 (0.24)	12.6 (0.48)	10.4 (0.35)	7.1 (0.38)
AMI but No SUD	13.6 (0.28)	17.5 (0.56)	17.1 (0.41)	9.6 (0.44)
Co-Occurring SUD and AMI	7.0 (0.19)	11.1 (0.42)	10.0 (0.33)	3.2 (0.24)
SUD or SMI	20.0 (0.32)	30.5 (0.67)	25.6 (0.50)	12.3 (0.46)
SUD but No SMI	13.2 (0.27)	18.4 (0.57)	16.0 (0.41)	9.3 (0.42)
SMI but No SUD	3.9 (0.14)	6.7 (0.35)	5.2 (0.24)	2.0 (0.18)
Co-Occurring SUD and SMI	2.9 (0.12)	5.4 (0.31)	4.4 (0.22)	1.0 (0.14)

AMI = any mental illness; SMI = serious mental illness.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: SUD estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on SUD.

NOTE: Mental illness aligns with criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of SMI are a subset of estimates of AMI because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.46B Co-Occurring Substance Use Disorder (SUD) and Level of Mental Illness in the Past Year: Among Adults Aged 18 or Older; by Age Group, 2021-2025

SUD/Level of Mental Illness	2021		2022		2023		2024		2025		Trend
Co-Occurring SUD and AMI, 18 or Older	7.4	(0.21)	8.0	(0.19)	7.6	(0.19)	7.7	(0.20)	7.0	(0.19)	No Change
18 to 25	13.3	(0.52)	14.7	(0.49)	13.7	(0.48)	13.0	(0.43)	11.1	(0.42)	Decreased
26 to 49	10.0	(0.32)	10.8	(0.35)	10.4	(0.30)	10.9	(0.33)	10.0	(0.33)	No Change
50 or Older	3.5	(0.30)	3.6	(0.26)	3.4	(0.25)	3.3	(0.26)	3.2	(0.24)	No Change
Co-Occurring SUD and SMI, 18 or Older	3.5	(0.13)	3.8	(0.14)	3.6	(0.13)	3.5	(0.13)	2.9	(0.12)	Decreased
18 to 25	7.6	(0.39)	8.5	(0.36)	7.6	(0.34)	6.9	(0.31)	5.4	(0.31)	Decreased
26 to 49	4.6	(0.22)	4.8	(0.22)	5.0	(0.22)	5.0	(0.22)	4.4	(0.22)	No Change
50 or Older	1.3	(0.18)	1.7	(0.19)	1.2	(0.16)	1.3	(0.18)	1.0	(0.14)	No Change

AMI = any mental illness; SMI = serious mental illness.

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Some 2021-2024 estimates may differ from previously published estimates due to updates that were made to the mental illness model beginning in 2025. For details, see the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: SUD estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 Methodological Summary and Definitions](#) for details on who was eligible to receive questions on SUD.

NOTE: Mental illness aligns with criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of SMI are a subset of estimates of AMI because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.47B Substance Use in the Past Year or Past Month: Among Adults Aged 18 or Older; by Level of Mental Illness in the Past Year, 2025

Period/Substance	18 or Older		Any Mental Illness		Serious Mental Illness		No Mental Illness	
PAST YEAR USE								
Illicit Drugs ¹	25.3	(0.38)	43.3	(0.81)	53.0	(1.36)	20.6	(0.39)
Marijuana	22.4	(0.36)	38.7	(0.80)	46.8	(1.36)	18.2	(0.37)
Cocaine	1.8	(0.11)	4.1	(0.31)	6.0	(0.62)	1.2	(0.11)
Heroin	0.2	(0.04)	0.6	(0.13)	0.7	(0.24)	0.1	(0.03)
Hallucinogens	3.3	(0.14)	7.6	(0.42)	11.5	(0.84)	2.2	(0.12)
Inhalants ²	0.8	(0.07)	2.0	(0.25)	3.4	(0.58)	0.4	(0.06)
Methamphetamine	1.0	(0.09)	2.5	(0.27)	3.9	(0.58)	0.6	(0.08)
Misuse of Prescription Psychotherapeutics	4.6	(0.17)	9.8	(0.49)	13.9	(0.92)	3.3	(0.16)
Pain Relievers	2.5	(0.13)	5.2	(0.34)	7.1	(0.70)	1.9	(0.13)
Prescription Opioids ³	2.4	(0.12)	5.1	(0.33)	7.0	(0.70)	1.8	(0.13)
Stimulants	1.4	(0.08)	3.5	(0.25)	5.4	(0.55)	0.9	(0.07)
Tranquilizers or Sedatives	1.5	(0.11)	4.0	(0.34)	6.1	(0.59)	0.9	(0.10)
Misuse of Opioids ^{1,4}	2.5	(0.12)	5.2	(0.33)	7.3	(0.71)	1.8	(0.13)
Misuse of Central Nervous System Stimulants	3.5	(0.15)	7.8	(0.42)	11.7	(0.88)	2.4	(0.14)
PAST MONTH USE								
Nicotine Products ^{5,6}	23.6	(0.37)	33.0	(0.83)	37.5	(1.24)	21.1	(0.40)
Tobacco Products	17.5	(0.33)	23.6	(0.75)	26.2	(1.14)	15.9	(0.36)
Cigarettes	13.5	(0.30)	19.6	(0.71)	22.3	(1.07)	11.9	(0.31)
Nicotine Vaping ⁶	10.4	(0.24)	18.7	(0.60)	22.6	(1.00)	8.3	(0.24)
Alcohol	48.1	(0.47)	50.9	(0.85)	53.0	(1.38)	47.4	(0.52)
Binge Alcohol Use	21.1	(0.35)	25.3	(0.70)	26.6	(1.14)	20.0	(0.39)
Heavy Alcohol Use	5.5	(0.18)	7.5	(0.45)	8.9	(0.78)	4.9	(0.20)
Marijuana	16.0	(0.32)	28.3	(0.72)	34.6	(1.29)	12.8	(0.32)
Marijuana Vaping ⁷	5.8	(0.17)	12.7	(0.48)	17.5	(0.93)	4.0	(0.16)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental illness aligns with criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of serious mental illness (SMI) are a subset of estimates of any mental illness (AMI) because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

¹ These estimates do not include illegally made fentanyl.

² Changes were made to the inhalant questions in 2025. See Chapter 3 of the [2025 National Survey on Drug Use and Health: Methodological Summary and Definitions](#) for details.

³ Respondents who reported the misuse of only nonopioid pain relievers were not counted as having misused prescription opioids.

⁴ Estimates include the use of heroin or the misuse of prescription opioids in the past year.

⁵ Nicotine product use includes use of tobacco products (cigarettes, smokeless tobacco [such as snuff, dip, chewing tobacco, or snus], cigars, or pipe tobacco) or nicotine vaping. Use of tobacco products does not include nicotine vaping because people could have used a vaping device to vape nicotine-containing products other than tobacco.

⁶ Nicotine vaping refers to using an e-cigarette or other vaping device to vape nicotine or tobacco.

⁷ Marijuana vaping refers to using vape pens, dab pens, tabletop vaporizers, or portable vaporizers to vape marijuana.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.48AB Suicidal Thoughts or Behaviors in the Past Year: Among Adults Aged 18 or Older; 2025

Suicidal Thoughts or Behavior	Number in Thousands¹		Percentage²	
HAD SERIOUS THOUGHTS OF SUICIDE, MADE ANY SUICIDE PLANS, OR ATTEMPTED SUICIDE	14,559	(512)	5.5	(0.18)
Had Serious Thoughts of Suicide	13,946	(500)	5.3	(0.18)
Made Any Suicide Plans	4,855	(287)	1.8	(0.11)
Attempted Suicide	2,283	(204)	0.9	(0.08)
HAD ONE TYPE OF SUICIDAL THOUGHTS/BEHAVIOR				
Had Serious Thoughts of Suicide (Did Not Make Any Suicide Plans or Attempt Suicide)	9,360	(394)	3.5	(0.14)
Made Any Suicide Plans (Did Not Have Serious Thoughts of Suicide or Attempt Suicide)	386	(100)	0.1	(0.04)
Attempted Suicide (Did Not Have Serious Thoughts of Suicide or Make Any Suicide Plans)	139	(46)	0.1	(0.02)
HAD TWO TYPES OF SUICIDAL THOUGHTS/BEHAVIORS				
Had Serious Thoughts of Suicide and Made Any Suicide Plans (Did Not Attempt Suicide)	2,529	(188)	1.0	(0.07)
Had Serious Thoughts of Suicide and Attempted Suicide (Did Not Make Any Suicide Plans)	204	(40)	0.1	(0.02)
Made Any Suicide Plans and Attempted Suicide (Did Not Have Serious Thoughts of Suicide)	88	(30)	<0.1	(0.01)
HAD ALL THREE TYPES OF SUICIDAL THOUGHTS/BEHAVIORS (Had Serious Thoughts of Suicide, Made Any Suicide Plans, and Attempted Suicide)	1,852	(196)	0.7	(0.07)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.49B Had Serious Thoughts of Suicide, Made Any Suicide Plans, or Attempted Suicide in the Past Year: Among Adults Aged 18 or Older; by Age Group, 2021-2025

Suicidal Thoughts or Behavior/Age Group	2021	2022	2023	2024	2025	Trend
HAD SERIOUS THOUGHTS OF SUICIDE, 18 OR OLDER	4.9 (0.16)	5.2 (0.16)	5.0 (0.15)	5.5 (0.16)	5.3 (0.18)	No Change
18 to 25	13.4 (0.49)	13.6 (0.46)	12.2 (0.41)	12.6 (0.44)	10.8 (0.43)	Decreased
26 to 49	5.5 (0.25)	5.5 (0.25)	5.9 (0.23)	6.1 (0.25)	6.2 (0.27)	Increased
50 or Older	2.0 (0.20)	2.4 (0.23)	2.1 (0.21)	2.9 (0.22)	2.9 (0.25)	Increased
MADE ANY SUICIDE PLANS, 18 OR OLDER	1.4 (0.08)	1.5 (0.07)	1.4 (0.07)	1.8 (0.10)	1.8 (0.11)	Increased
18 to 25	5.2 (0.37)	4.9 (0.27)	4.2 (0.24)	4.2 (0.24)	4.0 (0.26)	Decreased
26 to 49	1.4 (0.14)	1.3 (0.10)	1.6 (0.13)	1.8 (0.13)	2.0 (0.15)	Increased
50 or Older	0.3 (0.08)	0.6 (0.09)	0.5 (0.09)	1.1 (0.15)	1.1 (0.17)	Increased
ATTEMPTED SUICIDE, 18 OR OLDER	0.7 (0.06)	0.6 (0.05)	0.6 (0.04)	0.8 (0.07)	0.9 (0.08)	Increased
18 to 25	2.8 (0.29)	2.1 (0.17)	2.0 (0.16)	2.0 (0.16)	1.9 (0.18)	Decreased
26 to 49	0.7 (0.10)	0.5 (0.06)	0.6 (0.07)	0.8 (0.10)	0.9 (0.12)	Increased
50 or Older	0.2 (0.06)	0.3 (0.08)	0.2 (0.06)	0.6 (0.11)	0.5 (0.12)	Increased

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.50AB Suicidal Thoughts or Behaviors in the Past Year: Among Adolescents Aged 12 to 17; 2025

Suicidal Thoughts or Behavior	Number in Thousands¹		Percentage²	
HAD SERIOUS THOUGHTS OF SUICIDE, MADE ANY SUICIDE PLANS, OR ATTEMPTED SUICIDE	2,772	(128)	10.9	(0.45)
Had Serious Thoughts of Suicide ³	2,625	(126)	10.3	(0.44)
Made Any Suicide Plans ³	1,288	(87)	5.1	(0.33)
Attempted Suicide ³	738	(66)	2.9	(0.25)
HAD ONE TYPE OF SUICIDAL THOUGHTS/BEHAVIOR				
Had Serious Thoughts of Suicide (Did Not Make Any Suicide Plans or Attempt Suicide)	1,378	(83)	5.4	(0.31)
Made Any Suicide Plans (Did Not Have Serious Thoughts of Suicide or Attempt Suicide)	113	(23)	0.4	(0.09)
Attempted Suicide (Did Not Have Serious Thoughts of Suicide or Make Any Suicide Plans)	24	(9)	0.1	(0.03)
HAD TWO TYPES OF SUICIDAL THOUGHTS/BEHAVIORS				
Had Serious Thoughts of Suicide and Made Any Suicide Plans (Did Not Attempt Suicide)	543	(54)	2.1	(0.21)
Had Serious Thoughts of Suicide and Attempted Suicide (Did Not Make Any Suicide Plans)	82	(19)	0.3	(0.07)
Made Any Suicide Plans and Attempted Suicide (Did Not Have Serious Thoughts of Suicide)	11	(4)	<0.1	(0.02)
HAD ALL THREE TYPES OF SUICIDAL THOUGHTS/BEHAVIORS (Had Serious Thoughts of Suicide, Made Any Suicide Plans, and Attempted Suicide)	622	(63)	2.4	(0.24)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates that round to 0.0 percent are presented as <0.1.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

³ Percentages and standard errors in these rows may differ slightly from the estimates for “yes” in [Table A.51B](#) because the denominator for this table includes all adolescents aged 12 to 17. [Table A.51B](#) excludes respondents with unknown information on suicidal thoughts and behaviors from the denominator.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.51B Had Serious Thoughts of Suicide, Made Any Suicide Plans, or Attempted Suicide in the Past Year: Among Adolescents Aged 12 to 17; 2025

Suicidal Thoughts or Behavior	12 to 17	
HAD SERIOUS THOUGHTS OF SUICIDE		
Yes	10.4	(0.44)
No	75.9	(0.63)
Not Sure/Don't Know	7.2	(0.41)
Don't Want to Answer/Refuse	6.6	(0.38)
MADE ANY SUICIDE PLANS		
Yes	5.1	(0.33)
No	86.3	(0.49)
Not Sure/Don't Know	3.0	(0.25)
Don't Want to Answer/Refuse	5.6	(0.33)
ATTEMPTED SUICIDE		
Yes	2.9	(0.25)
No	90.3	(0.41)
Not Sure/Don't Know	1.8	(0.22)
Don't Want to Answer/Refuse	5.0	(0.29)

NOTE: Estimates shown are percentages with standard errors included in parentheses. Percentages may not add to 100 percent due to rounding.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Respondents with unknown information on suicidal thoughts and behaviors other than the categories shown in this table were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.52B Had Serious Thoughts of Suicide, Made Any Suicide Plans, or Attempted Suicide in the Past Year: Among Adolescents Aged 12 to 17; 2021-2025

Suicidal Thoughts or Behavior	2021	2022	2023	2024	2025	Trend
Had Serious Thoughts of Suicide	12.9 (0.49)	13.4 (0.44)	12.3 (0.47)	10.1 (0.40)	10.4 (0.44)	Decreased
Made Any Suicide Plans	6.2 (0.37)	6.5 (0.34)	5.6 (0.32)	4.6 (0.26)	5.1 (0.33)	Decreased
Attempted Suicide	3.6 (0.29)	3.7 (0.28)	3.3 (0.23)	2.7 (0.20)	2.9 (0.25)	Decreased

Decreased = the linear trend test showed a statistically significant decrease from 2021 to 2025 at the .05 level;

Increased = the linear trend test showed a statistically significant increase from 2021 to 2025 at the .05 level;

No Change = the linear trend test showed no statistically significant change from 2021 to 2025 at the .05 level;

Not Tested = trend testing was not conducted because estimates were suppressed for 1 or more years, or 4 years of comparable data were not available.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates for 2021 may differ from previously published estimates because the 2021 analysis weights were updated to facilitate between-year comparisons. For details, see the [2022 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#).

NOTE: Respondents with unknown information on suicidal thoughts and behaviors were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2021-2025.

Table A.53B Engaged in Nonsuicidal Self-Harm in the Past Year: Among Adolescents Aged 12 to 17; 2025

Nonsuicidal Self-Harm	12 to 17	
Yes	11.2	(0.43)
No	80.3	(0.59)
Not Sure/Don't Know	2.9	(0.27)
Don't Want to Answer/Refuse	5.6	(0.34)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Respondents with unknown information on nonsuicidal self-harm other than the categories shown in this table were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.54AB Need for Substance Use Treatment or Receipt of Substance Use Treatment in the Past Year: Among People Aged 12 or Older; by Age Group, 2025

Needed/Received Substance Use Treatment	Aged 12 or Older, Number ¹		Percentage among People Aged 12 or Older ²		Aged 12 to 17, Number ¹		Percentage among Adolescents Aged 12 to 17 ²		Aged 18 to 25, Number ¹		Percentage among Young Adults Aged 18 to 25 ²		Aged 26 or Older, Number ¹		Percentage among Adults Aged 26 or Older ²	
Needed Substance Use Treatment ³	47,231	(1,009)	16.3	(0.28)	2,061	(117)	8.1	(0.42)	8,782	(302)	24.3	(0.63)	36,388	(900)	15.9	(0.33)
Received Substance Use Treatment	7,554	(376)	2.6	(0.12)	470	(62)	1.8	(0.24)	845	(77)	2.3	(0.21)	6,238	(365)	2.7	(0.15)
Received Substance Use Treatment among People Who Needed Substance Use Treatment ³	7,554	(376)	16.0	(0.69)	470	(62)	22.8	(2.44)	845	(77)	9.6	(0.87)	6,238	(365)	17.1	(0.87)
Received Substance Use Treatment among People Who Had an SUD in the Past Year ^{3,4}	4,898	(309)	11.0	(0.61)	286	(46)	15.3	(2.15)	640	(69)	7.5	(0.79)	3,972	(298)	11.6	(0.77)
Received Substance Use Treatment among People Who Had a Mild SUD in the Past Year ^{3,4}	980	(143)	4.1	(0.57)	75	(24)	8.1	(2.46)	115	(27)	2.7	(0.63)	790	(138)	4.2	(0.69)
Received Substance Use Treatment among People Who Had a Moderate SUD in the Past Year ^{3,4}	1,017	(131)	9.7	(1.14)	78	(19)	16.2	(3.63)	117	(21)	5.1	(0.93)	823	(128)	10.7	(1.51)
Received Substance Use Treatment among People Who Had a Severe SUD in the Past Year ^{3,4}	2,901	(239)	28.9	(1.91)	134	(30)	28.5	(5.15)	408	(52)	19.8	(2.30)	2,359	(232)	31.5	(2.45)
Received Substance Use Treatment among People without an SUD in the Past Year ⁴	2,655	(213)	1.1	(0.09)	184	(34)	0.8	(0.14)	205	(38)	0.7	(0.14)	2,266	(207)	1.2	(0.11)

SUD = substance use disorder.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used alcohol or drugs in their lifetime. These estimates include data from respondents who reported that they received any substance use treatment but did not report the substance for which they received treatment.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

³ Respondents were classified as needing substance use treatment if they met the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition (DSM-5), criteria for an SUD or received treatment in the past year for their alcohol or drug use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

⁴ SUD estimates are based on criteria from DSM-5. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on SUD.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.55AB Types and Locations of Substance Use Treatment in the Past Year: Among People Aged 12 or Older; 2025

Type/Location of Treatment ¹	Aged 12 or Older, Number ²		Percentage among People Aged 12 or Older ³	
SUBSTANCE USE TREATMENT	7,554	(376)	2.6	(0.12)
Inpatient ⁴	2,177	(194)	0.7	(0.07)
Outpatient ⁵	4,416	(270)	1.5	(0.09)
Outpatient, Other Than General Medical Clinic or Doctor's Office ⁵	4,073	(255)	1.4	(0.08)
Medications for Alcohol Use Disorder ⁶	1,141	(126)	0.4	(0.04)
Among Those with an Alcohol Use Disorder ⁷	679	(108)	2.6	(0.41)
Medications for Opioid Use Disorder ⁶	2,132	(209)	0.7	(0.07)
Among Those with an Opioid Use Disorder ⁷	623	(92)	15.7	(2.17)
Telehealth Treatment ⁸	3,631	(260)	1.2	(0.09)
Prison, Jail, or Juvenile Detention Center	649	(107)	0.2	(0.04)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used alcohol or drugs in their lifetime. These estimates include data from respondents who reported that they received any substance use treatment but did not report the substance(s) for which they received treatment.

NOTE: People were assumed to have received medications for opioid use disorder if they used prescription pain relievers but not heroin in their lifetime.

¹ Respondents could indicate multiple types/locations for receiving substance use treatment; thus, these response categories are not mutually exclusive.

² Estimates shown are numbers in thousands with standard errors included in parentheses.

³ Estimates shown are percentages with standard errors included in parentheses.

⁴ Inpatient treatment locations were places where people stayed overnight or longer to receive substance use treatment, including hospitals where people stayed as inpatients, residential drug or alcohol rehabilitation or treatment centers, residential mental health treatment centers, or some other place they stayed overnight or longer to receive treatment.

⁵ Outpatient treatment locations were places where people received substance use treatment without needing to stay overnight, including drug or alcohol rehabilitation or treatment centers; mental health treatment centers; the office of a therapist, psychologist, psychiatrist, or substance use treatment professional; general medical clinics or doctor's offices; hospitals where people received treatment as outpatients; school health or counseling centers; or some other place where people received treatment as outpatients.

⁶ Questions for the receipt of medications for alcohol use disorder or opioid use disorder were asked only if respondents reported lifetime use of alcohol or lifetime use of heroin or prescription pain relievers, respectively.

⁷ Alcohol use disorder estimates and opioid use disorder estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on alcohol use disorder and opioid use disorder.

⁸ Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.56AB Received Substance Use Treatment through Telehealth in the Past Year: Among People Aged 12 or Older and among People Aged 12 or Older with a Past Year Substance Use Disorder; by Age Group, 2025

Received Substance Use Treatment through Telehealth	Aged 12 or Older, Number ¹	Percentage among People Aged 12 or Older ²	Aged 12 to 17, Number ¹	Percentage among Adolescents Aged 12 to 17 ²	Aged 18 to 25, Number ¹	Percentage among Young Adults Aged 18 to 25 ²	Aged 26 or Older, Number ¹	Percentage among Adults Aged 26 or Older ²
Received Substance Use Treatment through Telehealth	3,631 (260)	1.2 (0.09)	238 (42)	0.9 (0.16)	374 (47)	1.0 (0.13)	3,019 (256)	1.3 (0.11)
Received Substance Use Treatment through Telehealth among People with a Substance Use Disorder ³	2,526 (222)	5.7 (0.46)	167 (34)	8.9 (1.68)	308 (43)	3.6 (0.50)	2,052 (215)	6.0 (0.59)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

³ Substance use disorder estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.57AB Received Other Services in the Past Year to Help with Alcohol or Drug Use: Among People Aged 12 or Older or People Who Received Other Services and among People Aged 12 or Older with a Past Year Substance Use Disorder (SUD) or People with a Past Year SUD Who Received Other Services; 2025

Group/Services	Aged 12 or Older, Number ¹		Percentage among All People Aged 12 or Older ²		Percentage among People Who Received Other Services ²	
TOTAL AGED 12 OR OLDER						
Any Receipt of Other Services ³	7,914	(407)	2.7	(0.13)	100.0	(0.00)
Received SUT and Other Services ⁴	4,467	(305)	1.5	(0.10)	56.4	(2.56)
Received Other Services Only	3,447	(271)	1.2	(0.09)	43.6	(2.56)
PAST YEAR SUBSTANCE USE DISORDER, AGED 12 OR OLDER						
Any Receipt of Other Services ³	4,265	(283)	9.6	(0.57)	100.0	(0.00)
Received SUT and Other Services ⁴	3,093	(257)	6.9	(0.53)	72.5	(2.44)
Received Other Services Only	1,171	(109)	2.6	(0.24)	27.5	(2.44)

SUT = substance use treatment.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Other Services to help with alcohol or drug use include receiving support services from a support group or from a peer support specialist or recovery coach, services in an emergency room, withdrawal management services, or treatment with overdose reversal medicine.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses. Numbers may not add to totals due to rounding.

² Estimates shown are percentages with standard errors included in parentheses. Percentages may not add to totals due to rounding.

³ Any Receipt of Other Services is with or without the receipt of SUT.

⁴ SUT includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. SUT questions are asked of respondents who used alcohol or drugs in their lifetime. These estimates include data from respondents who reported that they received any SUT but did not report the substance(s) for which they received treatment.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.58A Received Specific Other Services in the Past Year to Help with Alcohol or Drug Use: Among People Aged 12 or Older or People Who Received Specific Other Services and among People Aged 12 or Older with a Past Year Substance Use Disorder (SUD) or People with a Past Year SUD Who Received Other Services; 2025

Group/Specific Other Service	Among All People Aged 12 or Older	Among People Who Received Specific Other Services	
	Any Receipt of Other Services ¹	Received SUT and the Specific Other Service ²	Received the Specific Other Service but Not SUT
TOTAL AGED 12 OR OLDER			
Support Group	5,749 (340)	3,155 (226)	2,594 (242)
Peer Support Specialist or Recovery Coach	2,261 (204)	2,003 (198)	258 (44)
Emergency Room/Department	1,718 (169)	1,100 (136)	619 (99)
Withdrawal Management Services	1,137 (154)	1,096 (154)	40 (13)
Overdose Reversal Medicine	668 (111)	* (*)	* (*)
PAST YEAR SUBSTANCE USE DISORDER, AGED 12 OR OLDER			
Support Group	2,866 (200)	2,086 (175)	780 (93)
Peer Support Specialist or Recovery Coach	1,559 (183)	1,441 (180)	118 (32)
Emergency Room/Department	1,258 (136)	915 (125)	343 (50)
Withdrawal Management Services	989 (149)	962 (149)	27 (9)
Overdose Reversal Medicine	406 (77)	* (*)	* (*)

* Low precision; no estimate reported.

SUT = substance use treatment.

NOTE: Estimates shown are numbers in thousands with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

¹ Any Receipt of Other Services is with or without the receipt of SUT.

² SUT includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. SUT questions are asked of respondents who used alcohol or drugs in their lifetime. These estimates include data from respondents who reported that they received any SUT but did not report the substance(s) for which they received treatment.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.58B Received Specific Other Services in the Past Year to Help with Alcohol or Drug Use: Among People Aged 12 or Older or People Who Received Specific Other Services and among People Aged 12 or Older with a Past Year Substance Use Disorder (SUD) or People with a Past Year SUD Who Received Other Services; 2025

Group/Specific Other Service	Among All People Aged 12 or Older		Among People Who Received Specific Other Services			
	Any Receipt of Other Services ¹		Received SUT and the Specific Other Service ²		Received the Specific Other Service but Not SUT	
TOTAL AGED 12 OR OLDER						
Support Group	2.0	(0.11)	54.9	(2.83)	45.1	(2.83)
Peer Support Specialist or Recovery Coach	0.8	(0.07)	88.6	(1.98)	11.4	(1.98)
Emergency Room/Department	0.6	(0.06)	64.0	(4.63)	36.0	(4.63)
Withdrawal Management Services	0.4	(0.05)	96.5	(1.19)	3.5	(1.19)
Overdose Reversal Medicine	0.2	(0.04)	*	(*)	*	(*)
PAST YEAR SUBSTANCE USE DISORDER, AGED 12 OR OLDER						
Support Group	6.4	(0.42)	72.8	(2.88)	27.2	(2.88)
Peer Support Specialist or Recovery Coach	3.5	(0.39)	92.4	(2.09)	7.6	(2.09)
Emergency Room/Department	2.8	(0.30)	72.7	(3.89)	27.3	(3.89)
Withdrawal Management Services	2.2	(0.33)	97.3	(0.97)	2.7	(0.97)
Overdose Reversal Medicine	0.9	(0.17)	*	(*)	*	(*)

* Low precision; no estimate reported.

SUT = substance use treatment.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

¹ Any Receipt of Other Services is with or without the receipt of SUT.

² SUT includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. SUT questions are asked of respondents who used alcohol or drugs in their lifetime. These estimates include data from respondents who reported that they received any SUT but did not report the substance(s) for which they received treatment.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.59AB Did Not Receive Substance Use Treatment or Other Services in the Past Year to Help with Alcohol or Drug Use: Among People Aged 12 or Older with a Past Year Substance Use Disorder; by Age Group: 2025

No Receipt of Substance Use Treatment or Other Services/Age Group	Aged 12 or Older, Number ¹		Percentage among People Aged 12 or Older ²	
PAST YEAR SUBSTANCE USE DISORDER, AGED 12 OR OLDER	38,506	(872)	86.4	(0.65)
12 to 17	1,511	(90)	80.5	(2.37)
18 to 25	7,768	(291)	90.6	(0.82)
26 or Older	29,227	(774)	85.7	(0.81)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used alcohol or drugs in their lifetime. These estimates include data from respondents who reported that they received any substance use treatment but did not report the substance(s) for which they received treatment.

NOTE: Other Services to help with alcohol or drug use include receiving support services from a support group or from a peer support specialist or recovery coach, services in an emergency room, withdrawal management services, or treatment with overdose reversal medicine.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.60AB Perceptions of Unmet Need for Substance Use Treatment in the Past Year: Among People Aged 12 or Older with a Past Year Substance Use Disorder Who Did Not Receive Substance Use Treatment; by Age Group, 2025

Perceived Unmet Need for Substance Use Treatment	Aged 12 to 17, Number ¹		Percentage among Adolescents Aged 12 to 17 ²		Aged 18 or Older, Number ¹		Percentage among Adults Aged 18 or Older ²	
Past Year Substance Use Disorder and Did Not Receive Substance Use Treatment	1,591	(93)	100.0	(0.00)	38,087	(870)	100.0	(0.00)
Any Perceived Unmet Need³	74	(18)	4.9	(1.11)	2,038	(174)	5.5	(0.45)
Sought Treatment ³	11	(5)	0.7	(0.31)	187	(50)	0.5	(0.13)
Did Not Seek Treatment but Thought Should Get Treatment ³	63	(17)	4.2	(1.07)	1,851	(167)	5.0	(0.43)
Did Not Perceive Need for Substance Use Treatment³	1,446	(86)	95.1	(1.11)	34,911	(817)	94.5	(0.45)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used alcohol or drugs in their lifetime. These estimates include data from respondents who reported that they received any substance use treatment but did not report the substance(s) for which they received treatment.

NOTE: Substance use disorder estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses. Percentages may not add to totals due to rounding.

³ Respondents with unknown information for perceptions of need for substance use treatment were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.61B Detailed Reasons for Not Receiving Substance Use Treatment in the Past Year: Among People Aged 12 or Older with a Past Year Substance Use Disorder and a Perceived Unmet Need for Substance Use Treatment in the Past Year; by Age Group, 2025

Reason for Not Receiving Substance Use Treatment ¹	12 to 17		18 or Older	
Thought It Would Cost Too Much	*	(*)	39.2	(4.15)
Did Not Have Health Insurance Coverage for Alcohol or Drug Use Treatment	*	(*)	28.8	(4.05)
Health Insurance Would Not Pay Enough of Costs for Treatment	*	(*)	30.4	(4.18)
Did Not Know How or Where to Get Treatment	*	(*)	40.5	(4.16)
Could Not Find Treatment Program or Healthcare Professional They Wanted to Go to	*	(*)	32.7	(4.05)
No Openings in Treatment Program or with Healthcare Professional They Wanted to Go to	*	(*)	10.6	(2.64)
Had Problems with Things Like Transportation, Childcare, or Getting Appointments at Times That Worked for Them	*	(*)	21.5	(3.75)
Did Not Have Enough Time for Treatment	*	(*)	54.3	(4.23)
Worried That Information Would Not Be Kept Private	*	(*)	37.4	(4.62)
Worried about What People Would Think or Say if They Got Treatment	*	(*)	41.4	(4.49)
Thought That if People Knew They Were in Treatment, Bad Things Would Happen, Like Losing Their Job, Home, or Children	*	(*)	34.9	(4.42)
Not Ready to Start Treatment	*	(*)	67.7	(4.06)
Not Ready to Stop or Cut Back on Using Alcohol or Drugs	*	(*)	68.4	(3.88)
Thought They Should Have Been Able to Handle Their Alcohol or Drug Use on Their Own	*	(*)	82.5	(2.97)
Thought Their Family, Friends, or Religious Group Would Not Like It if They Got Treatment	*	(*)	13.2	(2.84)
Thought They Would Be Forced to Stay in Rehab or Treatment against Their Will	*	(*)	17.0	(2.81)
Did Not Think Treatment Would Help Them	*	(*)	31.5	(3.95)
Thought No One Would Care if They Got Better	*	(*)	17.3	(2.87)

* Low precision; no estimate reported.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used alcohol or drugs in their lifetime. These estimates include data from respondents who reported that they received any substance use treatment but did not report the substance(s) for which they received treatment.

NOTE: Substance use disorder estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

NOTE: Respondents with a perceived unmet need did not receive substance use treatment in the past year.

NOTE: Respondents with unknown information for perceived unmet need for substance use treatment were excluded.

¹ Respondents could indicate multiple reasons for not receiving treatment; thus, these response categories are not mutually exclusive.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.62B Types and Locations of Mental Health Treatment in the Past Year: Among Adolescents Aged 12 to 17 and Adolescents Aged 12 to 17 with a Major Depressive Episode (MDE) or an MDE with Severe Impairment in the Past Year; 2025

Type/Location of Treatment	12 to 17		MDE ¹		MDE with Severe Impairment ^{1,2}	
MENTAL HEALTH TREATMENT³	27.6	(0.70)	57.7	(1.99)	61.7	(2.28)
Inpatient ⁴	2.5	(0.23)	7.4	(1.01)	9.5	(1.33)
Outpatient ⁵	20.3	(0.61)	48.4	(1.92)	52.4	(2.28)
Office of a Therapist, Psychologist, Psychiatrist, or Mental Health Professional	14.0	(0.53)	36.9	(1.90)	40.7	(2.23)
General Medical Clinic or Doctor's Office	5.3	(0.32)	16.5	(1.50)	19.4	(1.86)
School Health or Counseling Center	11.4	(0.47)	31.6	(1.81)	35.8	(2.26)
Prescription Medication	13.3	(0.52)	28.7	(1.78)	32.0	(2.17)
Telehealth Treatment ⁶	13.0	(0.58)	32.8	(1.92)	37.1	(2.31)
Prison, Jail, or Juvenile Detention Center	1.1	(0.17)	2.2	(0.64)	3.0	(0.87)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Respondents could indicate multiple treatment or other service types/locations; thus, these response categories are not mutually exclusive.

¹ MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. Respondents with unknown information for past year MDE or past year MDE with severe impairment were excluded.

² Impairment is based on the Sheehan Disability Scale role domains, which measure the impact of a disorder on an adolescent's life. Impairment is defined as the highest severity level of role impairment across four domains: (1) chores at home, (2) school or work, (3) close relationships with family, and (4) social life. Ratings greater than or equal to 7 on a scale from 0 to 10 in any of the role domains were considered severe impairment. Respondents with unknown impairment data were excluded.

³ Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

⁴ Inpatient treatment locations were places where people stayed overnight or longer to receive mental health treatment, including hospitals where people stayed as inpatients, residential mental health treatment centers, residential drug or alcohol rehabilitation or treatment centers, or some other place where people stayed overnight or longer to receive treatment.

⁵ Outpatient treatment locations were places where people received mental health treatment without needing to stay overnight, including outpatient mental health treatment centers; outpatient drug or alcohol rehabilitation or treatment centers; the office of a therapist, psychologist, psychiatrist, or mental health professional; general medical clinics or doctor's offices; hospitals where people received treatment as outpatients; school health or counseling centers; or some other place where people received treatment as outpatients.

⁶ Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.63AB Perceived Unmet Need for Mental Health Treatment in the Past Year: Among Adolescents Aged 12 to 17 with a Past Year Major Depressive Episode (MDE) Who Did Not Receive Mental Health Treatment; 2025

Perceived Unmet Need for Mental Health Treatment	Aged 12 to 17, Number ¹		Percentage among Adolescents Aged 12 to 17 ²	
Past Year MDE and Did Not Receive Mental Health Treatment	1,569	(95)	100.0	(0.00)
Any Perceived Unmet Need³	651	(63)	41.7	(3.04)
Sought Treatment ³	107	(20)	6.8	(1.25)
Did Not Seek Treatment but Thought Should Get Treatment ³	544	(58)	34.8	(2.95)
Did Not Perceive Need for Mental Health Treatment³	910	(72)	58.3	(3.04)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. Respondents with unknown past year MDE data were excluded.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

³ Respondents with unknown information for perceptions of need for mental health treatment were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.64AB Received Other Services in the Past Year to Help with Mental Health: Among Adolescents Aged 12 to 17 or Adolescents Who Received Other Services and among Adolescents Aged 12 to 17 with a Past Year Major Depressive Episode (MDE) or Adolescents with a Past Year MDE Who Received Other Services; 2025

Group/Services	Aged 12 to 17, Number ¹		Percentage among All Adolescents Aged 12 to 17 ²		Percentage among Adolescents Who Received Other Services ²	
TOTAL AGED 12 TO 17						
Any Receipt of Other Services ³	2,504	(127)	9.8	(0.46)	100.0	(0.00)
Received MHT and Other Services ⁴	1,906	(108)	7.5	(0.40)	76.1	(2.03)
Received Other Services Only	597	(60)	2.3	(0.23)	23.9	(2.03)
PAST YEAR MDE, AGED 12 TO 17 ⁵						
Any Receipt of Other Services ³	822	(68)	22.2	(1.60)	100.0	(0.00)
Received MHT and Other Services ⁴	744	(67)	20.1	(1.60)	90.5	(2.31)
Received Other Services Only	78	(19)	2.1	(0.52)	9.5	(2.31)

MHT = mental health treatment.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Other Services to help with mental health include receiving support services from a support group or from a peer support specialist or recovery coach, or services in an emergency room.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

³ Any Receipt of Other Services is with or without the receipt of MHT.

⁴ MHT includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

⁵ MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. Respondents with unknown information for past year MDE were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.65A Received Specific Other Services in the Past Year to Help with Mental Health: Among Adolescents Aged 12 to 17 or Adolescents Who Received Specific Other Services and among Adolescents Aged 12 to 17 with a Past Year Major Depressive Episode (MDE) or Adolescents with a Past Year MDE Who Received Other Services; 2025

Group/Specific Other Service	Among All Adolescents Aged 12 to 17	Among Adolescents Who Received Specific Other Services			
	Any Receipt of Other Services ¹	Received MHT and the Specific Other Service ²		Received the Specific Other Service but Not MHT ²	
TOTAL AGED 12 TO 17					
Support Group	1,883 (111)	1,379 (93)		504 (56)	
Peer Support Specialist or Recovery Coach	679 (60)	587 (57)		92 (21)	
Emergency Room/Department	576 (57)	524 (56)		52 (14)	
PAST YEAR MDE, AGED 12 TO 17 ³					
Support Group	603 (59)	544 (58)		59 (18)	
Peer Support Specialist or Recovery Coach	292 (39)	267 (39)		25 (9)	
Emergency Room/Department	231 (34)	229 (34)		1 (1)	

MHT = mental health treatment.

NOTE: Estimates shown are numbers in thousands with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

¹ Any Receipt of Other Services is with or without the receipt of MHT.

² MHT includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

³ MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. Respondents with unknown information for past year MDE were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.65B Received Specific Other Services in the Past Year to Help with Mental Health: Among Adolescents Aged 12 to 17 or Adolescents Who Received Specific Other Services and among Adolescents Aged 12 to 17 with a Past Year Major Depressive Episode (MDE) or Adolescents with a Past Year MDE Who Received Other Services; 2025

Group/Specific Other Service	Among All Adolescents Aged 12 to 17	Among Adolescents Who Received Specific Other Services	
	Any Receipt of Other Services ¹	Received MHT and the Specific Other Service ²	Received the Specific Other Service but Not MHT ²
TOTAL AGED 12 TO 17			
Support Group	7.4 (0.41)	73.2 (2.48)	26.8 (2.48)
Peer Support Specialist or Recovery Coach	2.7 (0.24)	86.4 (2.89)	13.6 (2.89)
Emergency Room/Department	2.3 (0.22)	90.9 (2.32)	9.1 (2.32)
PAST YEAR MDE, AGED 12 TO 17 ³			
Support Group	16.3 (1.47)	90.2 (2.87)	9.8 (2.87)
Peer Support Specialist or Recovery Coach	7.9 (1.03)	91.5 (3.08)	8.5 (3.08)
Emergency Room/Department	6.2 (0.86)	99.4 (0.39)	0.6 (0.39)

MHT = mental health treatment.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

¹ Any Receipt of Other Services is with or without the receipt of MHT.

² MHT includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

³ MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. Respondents with unknown information for past year MDE were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.66AB Did Not Receive Mental Health Treatment or Other Services in the Past Year to Help with Mental Health: Among Adolescents Aged 12 to 17 with a Past Year Major Depressive Episode (MDE): 2025

No Receipt of Mental Health Treatment or Other Services	Aged 12 to 17, Number ¹	Percentage among Adolescents Aged 12 to 17 ²
PAST YEAR MDE, AGED 12 TO 17	1,491 (94)	40.2 (2.01)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: Other Services to help with mental health include receiving support services from a support group or from a peer support specialist or recovery coach, or services in an emergency room.

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. Respondents with unknown information for past year MDE were excluded.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.67B Detailed Reasons for Not Receiving Mental Health Treatment in the Past Year: Among Adolescents Aged 12 to 17 with a Past Year Major Depressive Episode (MDE) and a Perceived Unmet Need for Treatment in the Past Year; 2025

Reason for Not Receiving Mental Health Treatment ¹	MDE	
Thought It Would Cost Too Much	26.9	(3.82)
Did Not Have Health Insurance Coverage for Mental Health Treatment	10.7	(2.28)
Health Insurance Would Not Pay Enough of Costs for Treatment	9.0	(2.24)
Did Not Know How or Where to Get Treatment	43.2	(4.25)
Could Not Find Treatment Program or Healthcare Professional They Wanted to Go to	25.4	(3.91)
No Openings in Treatment Program or with Healthcare Professional They Wanted to Go to	7.0	(1.99)
Had Problems with Things Like Transportation, Childcare, or Getting Appointments at Times That Worked for Them	14.7	(2.78)
Did Not Have Enough Time for Treatment	24.3	(3.51)
Worried That Information Would Not Be Kept Private	57.2	(4.50)
Worried about What People Would Think or Say if They Got Treatment	62.8	(4.29)
Thought That if People Knew They Were in Treatment, Bad Things Would Happen, Like Losing Their Job, Home, or Children	10.8	(2.31)
Not Ready to Start Treatment	41.1	(4.20)
Thought They Should Have Been Able to Handle Their Mental Health, Emotions, or Behavior on Their Own	87.4	(2.95)
Thought Their Family, Friends, or Religious Group Would Not Like It if They Got Treatment	41.7	(4.62)
Afraid of Being Committed to Hospital or Forced into Treatment against Their Will	34.5	(3.93)
Thought They Would Be Told They Needed to Take Medication	34.4	(4.27)
Did Not Think Treatment Would Help Them	53.9	(4.70)
Thought No One Would Care if They Got Better	41.4	(4.54)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: Respondents with a perceived unmet need did not receive mental health treatment. Respondents with unknown past year perceived unmet need data were excluded.

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. Respondents with unknown past year MDE data were excluded.

¹ Respondents could indicate multiple reasons for not receiving treatment; thus, these response categories are not mutually exclusive.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.68B Types and Locations of Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older; by Age Group, 2025

Type/Location of Treatment	18 or Older		18 to 25		26 to 49		50 or Older	
MENTAL HEALTH TREATMENT¹	21.6	(0.36)	24.5	(0.57)	25.9	(0.53)	17.1	(0.55)
Inpatient ²	1.2	(0.09)	2.0	(0.18)	1.5	(0.14)	0.7	(0.12)
Outpatient ³	12.3	(0.27)	15.8	(0.51)	15.5	(0.42)	8.6	(0.41)
Mental Health Treatment Center	2.7	(0.14)	3.3	(0.22)	3.2	(0.20)	2.2	(0.25)
Office of a Therapist, Psychologist, Psychiatrist, or Mental Health Professional	9.6	(0.24)	12.8	(0.45)	12.5	(0.38)	6.2	(0.36)
General Medical Clinic or Doctor's Office	4.6	(0.16)	5.1	(0.28)	5.9	(0.25)	3.3	(0.25)
Prescription Medication	16.2	(0.32)	16.8	(0.52)	19.0	(0.46)	13.8	(0.50)
Telehealth Treatment ⁴	12.3	(0.28)	15.1	(0.47)	16.4	(0.43)	8.0	(0.41)
Prison, Jail, or Juvenile Detention Center	1.1	(0.10)	0.6	(0.11)	1.2	(0.13)	1.1	(0.19)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Respondents could indicate multiple treatment types/locations; thus, these response categories are not mutually exclusive.

¹ Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

² Inpatient treatment locations were places where people stayed overnight or longer to receive mental health treatment, including hospitals where people stayed as inpatients, residential mental health treatment centers, residential drug or alcohol rehabilitation or treatment centers, or some other place where people stayed overnight or longer to receive treatment.

³ Outpatient treatment locations were places where people received mental health treatment without needing to stay overnight, including outpatient mental health treatment centers; outpatient drug or alcohol rehabilitation or treatment centers; the office of a therapist, psychologist, psychiatrist, or mental health professional; general medical clinics or doctor's offices; hospitals where people received treatment as outpatients; school health or counseling centers; or some other place where people received treatment as outpatients.

⁴ Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.69B Types and Locations of Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with a Past Year Major Depressive Episode (MDE); by Age Group, 2025

Type/Location of Treatment	18 or Older		18 to 25		26 to 49		50 or Older	
MENTAL HEALTH TREATMENT¹	65.9	(1.20)	59.1	(1.72)	68.6	(1.48)	67.6	(3.15)
Inpatient ²	6.2	(0.70)	6.8	(0.88)	6.7	(1.01)	4.8	(1.64)
Outpatient ³	47.6	(1.25)	45.7	(1.70)	49.9	(1.66)	45.2	(3.34)
Mental Health Treatment Center	12.0	(0.85)	10.4	(1.01)	13.8	(1.37)	10.0	(1.83)
Office of a Therapist, Psychologist, Psychiatrist, or Mental Health Professional	38.9	(1.19)	39.3	(1.66)	43.1	(1.66)	30.2	(2.93)
General Medical Clinic or Doctor's Office	22.7	(1.14)	17.8	(1.33)	24.3	(1.46)	24.6	(2.99)
Prescription Medication	51.7	(1.26)	42.8	(1.78)	53.9	(1.60)	56.9	(3.37)
Telehealth Treatment ⁴	44.7	(1.31)	41.9	(1.76)	50.7	(1.61)	36.0	(3.41)
Prison, Jail, or Juvenile Detention Center	2.5	(0.45)	0.7	(0.24)	2.6	(0.64)	4.2	(1.31)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Respondents could indicate multiple treatment types/locations; thus, these response categories are not mutually exclusive.

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

¹ Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

² Inpatient treatment locations were places where people stayed overnight or longer to receive mental health treatment, including hospitals where people stayed as inpatients, residential mental health treatment centers, residential drug or alcohol rehabilitation or treatment centers, or some other place where people stayed overnight or longer to receive treatment.

³ Outpatient treatment locations were places where people received mental health treatment without needing to stay overnight, including outpatient mental health treatment centers; outpatient drug or alcohol rehabilitation or treatment centers; the office of a therapist, psychologist, psychiatrist, or mental health professional; general medical clinics or doctor's offices; hospitals where people received treatment as outpatients; school health or counseling centers; or some other place where people received treatment as outpatients.

⁴ Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.70B Types and Locations of Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with Any Mental Illness (AMI) in the Past Year; by Age Group, 2025

Type/Location of Treatment	18 or Older		18 to 25		26 to 49		50 or Older	
MENTAL HEALTH TREATMENT¹	50.9	(0.84)	49.7	(1.26)	52.8	(1.07)	48.1	(1.99)
Inpatient ²	4.0	(0.34)	4.7	(0.49)	4.3	(0.45)	3.1	(0.72)
Outpatient ³	34.2	(0.78)	36.0	(1.24)	35.7	(1.02)	30.4	(1.83)
Mental Health Treatment Center	9.0	(0.49)	8.2	(0.62)	9.2	(0.65)	9.2	(1.18)
Office of a Therapist, Psychologist, Psychiatrist, or Mental Health Professional	27.6	(0.73)	30.3	(1.18)	29.6	(0.98)	22.2	(1.63)
General Medical Clinic or Doctor's Office	14.9	(0.58)	12.9	(0.79)	16.0	(0.74)	14.1	(1.32)
Prescription Medication	39.5	(0.83)	35.4	(1.25)	40.9	(1.03)	39.7	(1.97)
Telehealth Treatment ⁴	32.8	(0.81)	33.2	(1.21)	36.1	(1.02)	26.6	(1.84)
Prison, Jail, or Juvenile Detention Center	2.6	(0.31)	0.9	(0.26)	2.5	(0.35)	4.0	(0.86)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Respondents could indicate multiple treatment types/locations; thus, these response categories are not mutually exclusive.

NOTE: AMI aligns with criteria from the 5th edition of the *Diagnostic and Statistical Manual of Mental Disorders* and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

¹ Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

² Inpatient treatment locations were places where people stayed overnight or longer to receive mental health treatment, including hospitals where people stayed as inpatients, residential mental health treatment centers, residential drug or alcohol rehabilitation or treatment centers, or some other place where people stayed overnight or longer to receive treatment.

³ Outpatient treatment locations were places where people received mental health treatment without needing to stay overnight, including outpatient mental health treatment centers; outpatient drug or alcohol rehabilitation or treatment centers; the office of a therapist, psychologist, psychiatrist, or mental health professional; general medical clinics or doctor's offices; hospitals where people received treatment as outpatients; school health or counseling centers; or some other place where people received treatment as outpatients.

⁴ Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.71B Types and Locations of Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with Serious Mental Illness (SMI) in the Past Year; by Age Group, 2025

Type/Location of Treatment	18 or Older		18 to 25		26 to 49		50 or Older	
MENTAL HEALTH TREATMENT¹	67.7	(1.17)	63.0	(1.90)	68.5	(1.51)	71.2	(3.32)
Inpatient ²	7.9	(0.80)	8.6	(1.04)	7.4	(0.97)	8.6	(2.55)
Outpatient ³	50.1	(1.33)	49.2	(1.90)	50.6	(1.70)	49.7	(3.82)
Mental Health Treatment Center	13.9	(0.93)	12.9	(1.22)	14.5	(1.31)	13.3	(2.55)
Office of a Therapist, Psychologist, Psychiatrist, or Mental Health Professional	42.2	(1.30)	43.0	(1.86)	43.3	(1.66)	38.1	(3.71)
General Medical Clinic or Doctor's Office	24.4	(1.10)	20.5	(1.46)	25.5	(1.46)	25.8	(3.16)
Prescription Medication	54.1	(1.26)	46.9	(1.96)	55.5	(1.66)	58.4	(3.65)
Telehealth Treatment ⁴	46.0	(1.33)	43.7	(1.94)	49.6	(1.64)	39.2	(3.86)
Prison, Jail, or Juvenile Detention Center	2.9	(0.51)	0.9	(0.32)	2.9	(0.65)	5.0	(1.68)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Respondents could indicate multiple treatment types/locations; thus, these response categories are not mutually exclusive.

NOTE: SMI aligns with criteria from the 5th edition of the *Diagnostic and Statistical Manual of Mental Disorders* and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of SMI are a subset of estimates of any mental illness (AMI) because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

¹ Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

² Inpatient treatment locations were places where people stayed overnight or longer to receive mental health treatment, including hospitals where people stayed as inpatients, residential mental health treatment centers, residential drug or alcohol rehabilitation or treatment centers, or some other place where people stayed overnight or longer to receive treatment.

³ Outpatient treatment locations were places where people received mental health treatment without needing to stay overnight, including outpatient mental health treatment centers; outpatient drug or alcohol rehabilitation or treatment centers; the office of a therapist, psychologist, psychiatrist, or mental health professional; general medical clinics or doctor's offices; hospitals where people received treatment as outpatients; school health or counseling centers; or some other place where people received treatment as outpatients.

⁴ Respondents who reported that they received telehealth treatment (i.e., over the phone or through video) were not asked for the type or location of providers for the telehealth treatment they received.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.72AB Received Other Services in the Past Year to Help with Mental Health: Among Adults Aged 18 or Older or Adults Who Received Other Services, among Adults Aged 18 or Older with a Past Year Major Depressive Episode (MDE) or Adults with a Past Year MDE Who Received Other Services, among Adults Aged 18 or Older with Any Mental Illness (AMI) in the Past Year or Adults with AMI in the Past Year Who Received Other Services, and among Adults Aged 18 or Older with Serious Mental Illness (SMI) in the Past Year or Adults with SMI in the Past Year Who Received Other Services; 2025

Group/Services	Aged 18 or Older, Number ¹	Percentage among Adults Aged 18 or Older ²	Percentage among Adults Who Received Other Services ²
TOTAL AGED 18 OR OLDER			
Any Receipt of Other Services ³	15,498 (562)	5.8 (0.19)	100.0 (0.00)
Received MHT and Other Services ⁴	10,943 (449)	4.1 (0.16)	70.6 (1.61)
Received Other Services Only	4,555 (312)	1.7 (0.11)	29.4 (1.61)
PAST YEAR MDE, AGED 18 OR OLDER⁵			
Any Receipt of Other Services ³	3,688 (230)	18.7 (1.01)	100.0 (0.00)
Received MHT and Other Services ⁴	3,404 (217)	17.3 (0.97)	92.3 (1.78)
Received Other Services Only	284 (69)	1.4 (0.35)	7.7 (1.78)
AMI IN THE PAST YEAR, AGED 18 OR OLDER⁶			
Any Receipt of Other Services ³	8,118 (385)	14.9 (0.62)	100.0 (0.00)
Received MHT and Other Services ⁴	6,784 (341)	12.4 (0.56)	83.6 (1.95)
Received Other Services Only	1,333 (177)	2.4 (0.32)	16.4 (1.95)
SMI IN THE PAST YEAR, AGED 18 OR OLDER⁶			
Any Receipt of Other Services ³	3,840 (231)	21.1 (1.08)	100.0 (0.00)
Received MHT and Other Services ⁴	3,593 (227)	19.7 (1.08)	93.6 (1.11)
Received Other Services Only	247 (43)	1.4 (0.23)	6.4 (1.11)

MHT = mental health treatment.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Other Services to help with mental health include receiving support services from a support group or from a peer support specialist or recovery coach, or services in an emergency room.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

³ Any Receipt of Other Services is with or without the receipt of MHT.

⁴ MHT includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

⁵ MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

⁶ Mental illness aligns with criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of SMI are a subset of estimates of AMI because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.73A Received Specific Other Services in the Past Year to Help with Mental Health: Among Adults Aged 18 or Older or Adults Who Received Specific Other Services, among Adults Aged 18 or Older with a Past Year Major Depressive Episode (MDE) or Adults with a Past Year MDE Who Received Other Services, among Adults Aged 18 or Older with Any Mental Illness (AMI) in the Past Year or Adults with AMI in the Past Year Who Received Other Services, and among Adults Aged 18 or Older with a Serious Mental Illness (SMI) in the Past Year or among Adults with SMI in the Past Year Who Received Other Services; 2025

Group/Specific Other Service	Among Adults Aged 18 or Older		Among Adults Who Received Specific Other Services			
	Any Receipt of Other Services ¹		Received MHT and the Specific Other Service ²		Received the Specific Other Service but Not MHT ²	
TOTAL AGED 18 OR OLDER						
Support Group	12,305	(498)	8,360	(387)	3,945	(289)
Peer Support Specialist or Recovery Coach	4,091	(279)	3,855	(266)	236	(59)
Emergency Room/Department	3,924	(253)	2,783	(212)	1,141	(136)
PAST YEAR MDE, AGED 18 OR OLDER ³						
Support Group	2,788	(203)	2,556	(190)	232	(67)
Peer Support Specialist or Recovery Coach	1,029	(108)	979	(107)	50	(20)
Emergency Room/Department	1,198	(120)	1,145	(119)	53	(21)
AMI IN THE PAST YEAR, AGED 18 OR OLDER ⁴						
Support Group	6,274	(339)	5,144	(294)	1,129	(171)
Peer Support Specialist or Recovery Coach	2,529	(219)	2,437	(216)	93	(33)
Emergency Room/Department	2,354	(172)	1,970	(160)	385	(64)
SMI IN THE PAST YEAR, AGED 18 OR OLDER ⁴						
Support Group	2,916	(204)	2,737	(200)	178	(37)
Peer Support Specialist or Recovery Coach	1,128	(114)	1,084	(112)	44	(19)
Emergency Room/Department	1,479	(139)	1,373	(137)	105	(28)

MHT = mental health treatment.

NOTE: Estimates shown are numbers in thousands with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

¹ Any Receipt of Other Services is with or without the receipt of MHT.

² MHT includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

³ MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

⁴ Mental illness aligns with criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of SMI are a subset of estimates of AMI because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.73B Received Specific Other Services in the Past Year to Help with Mental Health: Among Adults Aged 18 or Older or Adults Who Received Specific Other Services, among Adults Aged 18 or Older with a Past Year Major Depressive Episode (MDE) or Adults with a Past Year MDE Who Received Other Services, among Adults Aged 18 or Older with Any Mental Illness (AMI) in the Past Year or Adults with AMI in the Past Year Who Received Other Services, and among Adults Aged 18 or Older with a Serious Mental Illness (SMI) in the Past Year or among Adults with SMI in the Past Year Who Received Other Services; 2025

Group/Specific Other Service	Among Adults Aged 18 or Older		Among Adults Who Received Specific Other Services			
	Any Receipt of Other Services ¹		Received MHT and the Specific Other Service ²		Received the Specific Other Service but Not MHT ²	
TOTAL AGED 18 OR OLDER						
Support Group	4.6	(0.18)	67.9	(1.83)	32.1	(1.83)
Peer Support Specialist or Recovery Coach	1.5	(0.10)	94.2	(1.36)	5.8	(1.36)
Emergency Room/Department	1.5	(0.09)	70.9	(2.91)	29.1	(2.91)
PAST YEAR MDE, AGED 18 OR OLDER ³						
Support Group	14.2	(0.93)	91.7	(2.27)	8.3	(2.27)
Peer Support Specialist or Recovery Coach	5.2	(0.53)	95.1	(1.87)	4.9	(1.87)
Emergency Room/Department	6.1	(0.58)	95.6	(1.72)	4.4	(1.72)
AMI IN THE PAST YEAR, AGED 18 OR OLDER ⁴						
Support Group	11.5	(0.57)	82.0	(2.39)	18.0	(2.39)
Peer Support Specialist or Recovery Coach	4.6	(0.38)	96.3	(1.30)	3.7	(1.30)
Emergency Room/Department	4.3	(0.31)	83.7	(2.56)	16.3	(2.56)
SMI IN THE PAST YEAR, 18 OR OLDER ⁴						
Support Group	16.0	(1.01)	93.9	(1.27)	6.1	(1.27)
Peer Support Specialist or Recovery Coach	6.2	(0.60)	96.1	(1.66)	3.9	(1.66)
Emergency Room/Department	8.1	(0.71)	92.9	(1.88)	7.1	(1.88)

MHT = mental health treatment.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

¹ Any Receipt of Other Services is with or without the receipt of MHT.

² MHT includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

³ MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

⁴ Mental illness aligns with criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of SMI are a subset of estimates of AMI because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.74AB Did Not Receive Mental Health Treatment or Other Services in the Past Year to Help with Mental Health: Among Adults Aged 18 or Older with a Past Year Major Depressive Episode (MDE), Any Mental Illness (AMI) in the Past Year, or Serious Mental Illness (SMI) in the Past Year; by Age Group: 2025

No Receipt of Mental Health Treatment or Other Services	Aged 18 or Older, Number ¹		Percentage among Adults Aged 18 or Older ²	
PAST YEAR MDE, AGED 18 OR OLDER³	6,428	(287)	32.7	(1.18)
18 to 25	2,010	(119)	39.3	(1.75)
26 to 49	2,934	(176)	30.5	(1.45)
50 or Older	1,485	(172)	30.0	(3.05)
AMI IN THE PAST YEAR, AGED 18 OR OLDER⁴	25,517	(679)	46.7	(0.84)
18 to 25	4,973	(214)	48.1	(1.30)
26 to 49	12,790	(428)	44.9	(1.08)
50 or Older	7,754	(436)	49.0	(1.99)
SMI IN THE PAST YEAR, AGED 18 OR OLDER⁴	5,634	(252)	31.0	(1.16)
18 to 25	1,552	(106)	35.5	(1.92)
26 to 49	3,042	(176)	30.1	(1.48)
50 or Older	1,040	(144)	27.9	(3.30)

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: Other Services to help with mental health include receiving support services from a support group or from a peer support specialist or recovery coach, or services in an emergency room.

¹ Estimates shown are numbers in thousands with standard errors included in parentheses.

² Estimates shown are percentages with standard errors included in parentheses.

³ MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

⁴ Mental illness aligns with criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of SMI are a subset of estimates of AMI because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.75A Perceived Unmet Need for Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with a Past Year Major Depressive Episode (MDE) Who Did Not Receive Mental Health Treatment; by Age Group, 2025

Perceived Unmet Need for Mental Health Treatment	18 or Older		18 to 25		26 to 49		50 or Older	
Past Year MDE and Did Not Receive Mental Health Treatment	6,712	(297)	2,091	(118)	3,022	(179)	1,600	(182)
Any Perceived Unmet Need¹	2,402	(166)	989	(81)	1,028	(100)	385	(106)
Sought Treatment ¹	328	(52)	124	(27)	174	(39)	30	(20)
Did Not Seek Treatment but Thought Should Get Treatment ¹	2,073	(159)	865	(75)	854	(88)	355	(105)
Did Not Perceive Need for Mental Health Treatment¹	4,102	(232)	1,066	(85)	1,864	(141)	1,172	(150)

NOTE: Estimates shown are numbers in thousands with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

¹ Respondents with unknown information for perceptions of need for mental health treatment were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.75B Perceived Unmet Need for Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with a Past Year Major Depressive Episode (MDE) Who Did Not Receive Mental Health Treatment; by Age Group, 2025

Perceived Unmet Need for Mental Health Treatment	18 or Older		18 to 25		26 to 49		50 or Older	
Past Year MDE and Did Not Receive Mental Health Treatment	100.0	(0.00)	100.0	(0.00)	100.0	(0.00)	100.0	(0.00)
Any Perceived Unmet Need¹	36.9	(2.03)	48.1	(2.90)	35.5	(2.82)	24.7	(5.77)
Sought Treatment ¹	5.0	(0.77)	6.0	(1.26)	6.0	(1.30)	1.9	(1.29)
Did Not Seek Treatment but Thought Should Get Treatment ¹	31.9	(2.04)	42.1	(2.78)	29.5	(2.61)	22.8	(5.73)
Did Not Perceive Need for Mental Health Treatment¹	63.1	(2.03)	51.9	(2.90)	64.5	(2.82)	75.3	(5.77)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: MDE estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms.

¹ Respondents with unknown information for perceptions of need for mental health treatment were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.76A Perceived Unmet Need for Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with Any Mental Illness (AMI) in the Past Year Who Did Not Receive Mental Health Treatment; by Age Group, 2025

Perceived Unmet Need for Mental Health Treatment	18 or Older		18 to 25		26 to 49		50 or Older	
Past Year AMI and Did Not Receive Mental Health Treatment	26,850	(703)	5,196	(215)	13,457	(438)	8,197	(459)
Any Perceived Unmet Need¹	5,613	(255)	1,833	(117)	2,924	(173)	857	(151)
Sought Treatment ¹	780	(83)	221	(35)	460	(79)	98	(36)
Did Not Seek Treatment but Thought Should Get Treatment ¹	4,834	(244)	1,611	(110)	2,463	(154)	759	(146)
Did Not Perceive Need for Mental Health Treatment¹	20,642	(645)	3,270	(170)	10,187	(393)	7,185	(446)

NOTE: Estimates shown are numbers in thousands with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: AMI aligns with criteria from the 5th edition of the *Diagnostic and Statistical Manual of Mental Disorders* and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

¹ Respondents with unknown information for perceptions of need for mental health treatment were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.76B Perceived Unmet Need for Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with Any Mental Illness (AMI) in the Past Year Who Did Not Receive Mental Health Treatment; by Age Group, 2025

Perceived Unmet Need for Mental Health Treatment	18 or Older		18 to 25		26 to 49		50 or Older	
Past Year AMI and Did Not Receive Mental Health Treatment	100.0	(0.00)	100.0	(0.00)	100.0	(0.00)	100.0	(0.00)
Any Perceived Unmet Need¹	21.4	(0.92)	35.9	(1.84)	22.3	(1.22)	10.7	(1.82)
Sought Treatment ¹	3.0	(0.31)	4.3	(0.68)	3.5	(0.59)	1.2	(0.44)
Did Not Seek Treatment but Thought Should Get Treatment ¹	18.4	(0.90)	31.6	(1.75)	18.8	(1.11)	9.4	(1.77)
Did Not Perceive Need for Mental Health Treatment¹	78.6	(0.92)	64.1	(1.84)	77.7	(1.22)	89.3	(1.82)

NOTE: Estimates shown are percentages with standard errors included in parentheses. Percentages may not add to totals due to rounding.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: AMI aligns with criteria from the 5th edition of the *Diagnostic and Statistical Manual of Mental Disorders* and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

¹ Respondents with unknown information for perceptions of need for mental health treatment were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.77A Perceived Unmet Need for Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with Serious Mental Illness (SMI) in the Past Year Who Did Not Receive Mental Health Treatment; by Age Group, 2025

Perceived Unmet Need for Mental Health Treatment	18 or Older		18 to 25		26 to 49		50 or Older	
Past Year SMI and Did Not Receive Mental Health Treatment	5,881	(257)	1,618	(106)	3,190	(182)	1,073	(145)
Any Perceived Unmet Need¹	2,321	(152)	889	(77)	1,131	(96)	*	(*)
Sought Treatment ¹	362	(55)	129	(28)	196	(41)	36	(22)
Did Not Seek Treatment but Thought Should Get Treatment ¹	1,960	(141)	760	(71)	935	(85)	*	(*)
Did Not Perceive Need for Mental Health Treatment¹	3,417	(213)	704	(74)	1,961	(154)	*	(*)

* Low precision; no estimate reported.

NOTE: Estimates shown are numbers in thousands with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: SMI aligns with criteria from the 5th edition of the *Diagnostic and Statistical Manual of Mental Disorders* and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of SMI are a subset of estimates of any mental illness (AMI) because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

¹ Respondents with unknown information for perceptions of need for mental health treatment were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.77B Perceived Unmet Need for Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with Serious Mental Illness (SMI) in the Past Year Who Did Not Receive Mental Health Treatment; by Age Group, 2025

Perceived Unmet Need for Mental Health Treatment	18 or Older		18 to 25		26 to 49		50 or Older	
Past Year SMI and Did Not Receive Mental Health Treatment	100.0	(0.00)	100.0	(0.00)	100.0	(0.00)	100.0	(0.00)
Any Perceived Unmet Need¹	40.5	(2.23)	55.8	(3.35)	36.6	(2.79)	*	(*)
Sought Treatment ¹	6.3	(0.92)	8.1	(1.70)	6.3	(1.29)	3.4	(2.01)
Did Not Seek Treatment but Thought Should Get Treatment ¹	34.1	(2.14)	47.7	(3.22)	30.2	(2.55)	*	(*)
Did Not Perceive Need for Mental Health Treatment¹	59.5	(2.23)	44.2	(3.35)	63.4	(2.79)	*	(*)

* Low precision; no estimate reported.

NOTE: Estimates shown are percentages with standard errors included in parentheses. Percentages may not add to totals due to rounding.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: SMI aligns with criteria from the 5th edition of the *Diagnostic and Statistical Manual of Mental Disorders* and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of SMI are a subset of estimates of any mental illness (AMI) because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

¹ Respondents with unknown information for perceptions of need for mental health treatment were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.78B Detailed Reasons for Not Receiving Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with Any Mental Illness (AMI) in the Past Year and a Perceived Unmet Need for Treatment in the Past Year; 2025

Reason for Not Receiving Mental Health Treatment ¹	AMI	
Thought It Would Cost Too Much	61.4	(2.24)
Did Not Have Health Insurance Coverage for Mental Health Treatment	39.0	(2.21)
Health Insurance Would Not Pay Enough of the Costs for Treatment	40.3	(2.49)
Did Not Know How or Where to Get Treatment	44.9	(2.27)
Could Not Find Treatment Program or Healthcare Professional They Wanted to Go to	43.2	(2.37)
No Openings in Treatment Program or with Healthcare Professional They Wanted to Go to	15.5	(1.71)
Had Problems with Things Like Transportation, Childcare, or Getting Appointments at Times That Worked for Them	27.3	(1.84)
Did Not Have Enough Time for Treatment	48.3	(2.38)
Worried That Information Would Not Be Kept Private	24.5	(2.12)
Worried about What People Would Think or Say if They Got Treatment	26.3	(1.96)
Thought That if People Knew They Were in Treatment, Bad Things Would Happen, Like Losing Their Job, Home, or Children	11.7	(1.40)
Not Ready to Start Treatment	47.7	(2.36)
Thought They Should Have Been Able to Handle Their Mental Health, Emotions, or Behavior on Their Own	72.9	(2.30)
Thought Their Family, Friends, or Religious Group Would Not Like It if They Got Treatment	11.0	(1.13)
Afraid of Being Committed to Hospital or Forced into Treatment against Their Will	23.5	(1.83)
Thought They Would Be Told They Needed to Take Medication	34.9	(2.29)
Did Not Think Treatment Would Help Them	36.0	(2.14)
Thought No One Would Care if They Got Better	20.1	(1.71)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: AMI aligns with criteria from the 5th edition of the *Diagnostic and Statistical Manual of Mental Disorders* and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

NOTE: Respondents with unknown past year perceived unmet need data were excluded.

NOTE: Respondents with a perceived unmet need did not receive mental health treatment.

¹ Respondents could indicate multiple reasons for not receiving treatment; thus, these response categories are not mutually exclusive.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.79B Received Substance Use Treatment or Mental Health Treatment in the Past Year: Among Adolescents Aged 12 to 17 with Past Year Substance Use Disorder (SUD) and Major Depressive Episode (MDE); 2025

Receipt of Treatment	Co-Occurring SUD and MDE	
No Substance Use Treatment OR Mental Health Treatment	24.6	(3.38)
Substance Use Treatment OR Mental Health Treatment	75.4	(3.38)
Substance Use Treatment BUT NOT Mental Health Treatment	0.9	(0.65)
Mental Health Treatment BUT NOT Substance Use Treatment	60.2	(4.31)
Both Substance Use Treatment AND Mental Health Treatment	14.3	(3.38)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used alcohol or drugs in their lifetime.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: SUD estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition (DSM-5). See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

NOTE: MDE estimates are based on criteria from the DSM-5, which specifies a period of at least 2 weeks when a person experienced a depressed mood or loss of interest or pleasure in daily activities and had a majority of specified depression symptoms. Respondents with unknown past year MDE data were excluded.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.80B Received Substance Use Treatment or Mental Health Treatment in the Past Year: Among Adults Aged 18 or Older with a Past Year Substance Use Disorder (SUD) and Any Mental Illness (AMI) or Serious Mental Illness (SMI) in the Past Year; by Age Group, 2025

Co-Occurring SUD, Level of Mental Illness, and Age Group	No Substance Use Treatment OR Mental Health Treatment	Substance Use Treatment OR Mental Health Treatment	Substance Use Treatment BUT NOT Mental Health Treatment	Mental Health Treatment BUT NOT Substance Use Treatment	Both Substance Use Treatment AND Mental Health Treatment
CO-OCCURRING SUD AND AMI					
18 or Older	42.6 (1.29)	57.4 (1.29)	2.8 (0.45)	41.8 (1.29)	12.7 (0.96)
18 to 25	43.9 (1.96)	56.1 (1.96)	1.6 (0.46)	44.6 (2.05)	9.9 (1.39)
26 to 49	41.5 (1.63)	58.5 (1.63)	3.4 (0.67)	41.9 (1.60)	13.2 (1.07)
50 or Older	44.3 (3.84)	55.7 (3.84)	2.5 (0.99)	39.0 (3.58)	14.2 (3.09)
CO-OCCURRING SUD AND SMI					
18 or Older	28.7 (1.71)	71.3 (1.71)	3.0 (0.78)	51.9 (1.93)	16.4 (1.57)
18 to 25	34.5 (2.91)	65.5 (2.91)	1.7 (0.73)	51.5 (3.03)	12.3 (1.90)
26 to 49	26.2 (2.02)	73.8 (2.02)	3.9 (1.22)	52.6 (2.37)	17.3 (1.79)
50 or Older	* (*)	* (*)	* (*)	* (*)	* (*)

* Low precision; no estimate reported.

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Substance use treatment includes treatment for drug or alcohol use through inpatient treatment/counseling; outpatient treatment/counseling; medications for alcohol use disorder or opioid use disorder; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center. Substance use treatment questions are asked of respondents who used alcohol or drugs in their lifetime.

NOTE: Mental health treatment includes treatment/counseling received as an inpatient or as an outpatient; use of prescription medication to help with mental health; telehealth treatment; or treatment received in a prison, jail, or juvenile detention center.

NOTE: SUD estimates are based on criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details on who was eligible to receive questions on substance use disorder.

NOTE: Mental illness aligns with criteria from the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, and is defined as having a diagnosable mental, behavioral, or emotional disorder, other than a developmental or substance use disorder. Estimates of SMI are a subset of estimates of AMI because SMI is limited to people with AMI that resulted in serious functional impairment. These mental illness estimates are based on a predictive model and are not direct measures of diagnostic criteria.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.81B Perceived Ever Having Had a Substance Use Problem or a Mental Health Issue: Among Adults Aged 18 or Older; by Age Group, 2025

Characteristic	Ever Had a Substance Use Problem ¹	Ever Had a Mental Health Issue ²
TOTAL	11.6 (0.26)	24.3 (0.36)
AGE GROUP		
18 to 25	8.0 (0.36)	35.5 (0.66)
26 or Older	12.2 (0.30)	22.5 (0.39)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates in this table exclude a subset of respondents who did not complete the questionnaire. The analysis weights and estimates were adjusted for the reduced sample size. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details.

¹ Respondents were excluded if they had missing data for ever having a problem with their drug or alcohol use.

² Respondents were excluded if they had missing data for ever having a problem with their mental health.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

Table A.82B Considered Themselves To Be in Recovery from a Substance Use Problem: Among Adults Aged 18 or Older Who Perceived Ever Having Had a Substance Use Problem and Considered Themselves To Be in Recovery from a Mental Health Issue among Adults Aged 18 or Older Who Perceived Ever Having Had a Mental Health Issue; by Age Group, 2025

Characteristic	Considered Themselves To Be in Recovery from a Substance Use Problem ¹	Considered Themselves To Be in Recovery from a Mental Health Issue ²
TOTAL	73.0 (0.97)	69.4 (0.68)
AGE GROUP		
18 to 25	63.4 (2.20)	66.4 (1.04)
26 or Older	74.0 (1.04)	70.2 (0.79)

NOTE: Estimates shown are percentages with standard errors included in parentheses.

NOTE: Additional estimates may be found in [Results from the 2025 National Survey on Drug Use and Health: Detailed Tables](#). Measures and terms are defined in Appendix A of the 2025 Detailed Tables.

NOTE: Estimates in this table exclude a subset of respondents who did not complete the questionnaire. The analysis weights and estimates were adjusted for the reduced sample size. See the [2025 National Survey on Drug Use and Health \(NSDUH\): Methodological Summary and Definitions](#) for details.

¹ Respondents were asked if they considered themselves to be in recovery or to have recovered from a substance use problem only if they reported ever having a drug or alcohol use problem. Respondents were excluded if they had missing data for ever having a substance use problem or missing data for ever having considered to be in recovery from their substance use problem.

² Respondents were asked if they considered themselves to be in recovery or to have recovered from a mental health issue only if they reported ever having a mental health issue. Respondents were excluded if they had missing data for ever having a mental health issue or missing data for ever having considered themselves to be in recovery from their mental health issue.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2025.

HHS Publication No. PEP26-07-010
2026

U.S. Department of Health and
Human Services

Substance Abuse and Mental Health
Services Administration

Center for Behavioral Health
Statistics and Quality

SAMHSA

Substance Abuse and Mental Health
Services Administration

*SAMHSA's mission is to lead public
health and service delivery efforts
that promote mental health, prevent
substance misuse, and provide
treatments and supports to foster
recovery while ensuring access and better
outcomes for all.*

1-877-SAMHSA-7 (1-877-726-4727)
1-800-487-4889 (TDD)

www.samhsa.gov